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Abstract 
Background 
There is increasing evidence demonstrating that lifestyle interventions of 
exercise and diet may represent a useful supportive therapy for men with 
prostate cancer, improving physiological and psychosocial outcomes. There 
has been limited investigation of the effects of such interventions in men with 
castrate resistant prostate cancer (CRPC), the terminal phase of the disease.  
It is not clear how exercise has been implemented in the prostate cancer 
care pathway and what a successfully implemented exercise programme 
might look like. Furthermore, the specific treatment and disease related 
barriers men with CRPC might face engaging in exercise is not documented, 
particularly when considering their advanced stage of disease. 
This work described in this thesis covers an exploration of the feasibility and 
acceptability of an exercise and dietary intervention to improve outcomes in 
men with CRPC.  
Methods 
A healthcare professional survey was conducted to assess the extent to 
which NHS trusts are meeting the NICE guidelines (CG175, 1.4.19) for 
exercise training for men with prostate cancer on androgen deprivation 
therapy (ADT). 
Semi-structured interviews of UK healthcare professionals, specialising in 
prostate cancer care and based in UK National Health service (NHS) trusts 
were conducted. These explored underlying reasons behind the variability in 
NHS trusts in delivering exercise training programmes and probed the views 
of the HCPs regarding exercise training, including the acceptability of 
concurrent use of an anabolic agent for men with CRPC. 
A feasibility randomised controlled trial (RCT) of an exercise and dietary 
intervention in CRPC patients was conducted (COMRADE). Men with CRPC 
recruited to the RCT were randomised on a 1:1 ratio to either the intervention 
or usual care for 16 weeks. Men allocated the intervention received up to 
24 
 
three sessions of supervised resistance exercise a week; supplemented with 
whey protein and creatine monohydrate; and given dietary advice. They were 
also asked to partake in at least one independent moderate intensity aerobic 
activity lasting at least 30 minutes a week. 
Following the RCT, post study participant focus groups addressed patients’ 
views on aspects of the study, particularly with regards to acceptability of trial 
procedures, barriers and facilitators to exercise training and the impact of 
living with CRPC. 
Results 
The healthcare professional survey demonstrated significant variability 
between NHS trusts in the UK in delivering the NICE guidelines and that a 
supervised exercise training programme is not currently embedded within 
"usual care" for prostate cancer.  
The healthcare professional interviews (n=12) demonstrated support for an 
individualised and adaptable exercise programme for men with CRPC which 
could improve fitness and mitigate some of the long term effects of their 
cancer/cancer therapy. Their opinions reflected that comorbidities and 
disease/treatment specific barriers to exercise must be taken into account to 
support better adherence. 
In the feasibility RCT, n=31 men were recruited from a total of n=3607 
screened (recruitment rate=13.6%). There were eighteen in the intervention 
and thirteen randomised to the control group. The attrition rate was 16%, 
with n=4 dropping out of the intervention and n=1 death in the control. 
Adherence to the supervised and independent exercise sessions was 69% 
and 78% respectively. The adherence to the whey protein was 68% and 
creatine was 71%. There were 4 AEs associated with trial procedures, none 
of which were serious. 
Three primary themes were identified from the participant focus groups 
(n=3); these included 1) living with CRPC, 2) experience and opinions of the 
trial, 3) attitudes and experiences of exercise training and physical activity. 
The findings demonstrated that the study procedures were well received by 
25 
 
the participants, including the trial assessments and format of the 
intervention. Valuable insights were gained for implementing future exercise 
intervention studies - providing participant perspectives for the success of a 
lifestyle behaviour study such as COMRADE. 
Conclusions 
The findings suggest that it is feasible to randomise and retain men with 
CRPC to an exercise and diet intervention, however there was a high rate of 
attrition in the study, due to the complex nature of the disease in these men. 
Further work is required to address the barriers related to implementation of 
exercise in the prostate cancer pathway for men with CRPC.  
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Chapter 1 Introduction 
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1. Prostate cancer 
1.1 A brief history of prostate cancer: The evolution of our 
understanding and treatment  
Since Huggins and Hodges demonstrated that hormone manipulation was 
effective in alleviating symptoms of metastatic prostate cancer more than 70 
years ago, androgen deprivation therapy (ADT) has been the cornerstone for 
the treatment for advanced prostate cancer (Huggins, Stevens et al. 1941). 
However, men with metastatic prostate cancer eventually relapse:, if he lives 
long enough, despite castrate blood serum levels of androgens a man with 
prostate cancer will develop disease progression, referred to as castrate-
resistant prostate cancer (CRPC). Up until 2010, docetaxel, a taxane-based 
antimitotic agent was the only agent that had demonstrated an overall 
survival (OS) benefit in CRPC (Petrylak, Tangen et al. 2004, Berthold, Pond 
et al. 2008). Since then, there has been an introduction into clinical practice 
of five other therapeutic options which have shown a survival benefit in 
phase III trials: carbazitaxel, sipuleucel-T, radium-223, abiraterone and 
enzalutamide. This has led to a dramatic change in how CRPC is treated 
(Kantoff, Higano et al. 2010, de Bono, Logothetis et al. 2011, Oudard 2011, 
Scher, Fizazi et al. 2012, Parker, Nilsson et al. 2013). The landscape 
continues to evolve rapidly with ever-changing indications and introduction of 
new therapies directed at castrate-resistant prostate cancer (Nuhn, De Bono 
et al. 2018). 
Regardless of this expanding armamentarium for CRPC, therapies are not 
curative and therefore essentially palliative for these men. CRPC is still the 
terminal phase of the disease and those with metastatic disease (mCRPC) 
are expected to live <19 months (Heidenreich, Pfister et al. 2013). These 
men are faced not only with the burden of advanced disease but also of 
many years of cancer treatment, with attendant adverse events. For this 
reason, when a clinician is faced with a treatment decision, considerations of 
preservation of quality of life (QoL) become paramount as men enter this 
phase of the disease. Treating clinicians often face a difficult trade-off 
between treating with the intention to improve overall survival (OS) and the 
associated treatment adverse events (AEs) impacting on QoL. In comparison 
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to men at earlier stages of disease, many men with CRPC are elderly and 
have competing comorbidities (Scosyrev, Messing et al. 2012). In this case, 
there is further complication as to whether the primary risk to survival is 
indeed the disease, and therefore treatment may be unnecessary. To date, 
there is no comprehensive management strategy demonstrated to improve 
or sustain good QoL among these men (Rosario, Greasley et al. 2016). 
1.2 Androgens, the androgen receptor and the prostate 
In men, androgens are involved in male sexual differentiation and 
reproductive organ growth in embryogenesis (Murashima, Kishigami et al. 
2015). The prostate gland also forms during embryogenesis, and develops 
from multiple buds that grow out of the proximal urethra into the surrounding 
connective tissue where 5α reductase (5αR) is expressed in epithelial cells 
(Wilson 2011). These organs mature during early post-natal puberty where 
there is a peak in circulating androgens known as a "mini puberty" 
(Pasterski, Acerini et al. 2015). In "mini puberty", testosterone levels peak 
between one to three months. The early periods of androgen production are 
necessary for the formation and development of the urogenital tract and 
external genitalia (Pasterski, Acerini et al. 2015). Post "mini puberty", 
androgen levels remain relatively constant up until adrenarche, puberty and 
adulthood. The usual age of adrenarch is 6 to 8 years which precedes and 
can occur independently of puberty. Adrenarch, results from increased 
androgen secretion from the adrenal glands, independent of gonadal 
androgen secretion. Adrenal androgen levels will continue to increase until 
the third decade of life, thereafter a continuous and variable decrease is 
present (Hiort 2002). During normal male puberty gonadotrophin stimulates 
the gonads increasing levels of testosterone. Changes start with the 
enlargement of the testes and penis in addition to increases in muscle and 
bone mass, enlargement of the larynx (resulting in deepening of the voice), 
secondary hair changes including increased trunk hair growth, skin thickens, 
a growth spurt occurs and erythrocyte cell mass increases (Hiort 2002). 
Furthermore, testosterone may alter behaviour, these effects include 
stimulation of sexual libido and aggressiveness (Hiort 2002).  
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Whereas androgens are clearly involved in the development of the prostate 
and other male reproductive glands (Wilson 2011), the exact interplay 
between androgenic activity and the aetiology and evolution of prostate 
cancer remains uncertain. In men, androgens are synthesised primarily in 
the testes under the regulation of luteinizing hormone (LH) released from the 
anterior pituitary gland. LH release is regulated by gonadotrophin releasing 
hormone (GnRH; also known as luteinizing hormone-releasing hormone) 
from the hypothalamus. Androgens control normal prostate cell growth by 
regulating the ratio of cells proliferating to those undergoing apoptosis 
(Minutoli, Rinaldi et al. 2016). Testosterone is the main circulating androgen 
in males and is normally produced by Leydig cells in the testes (Feldman and 
Feldman 2001). Testosterone circulates in the blood where it is 
predominantly in a protein-bound state to either albumin or sex-hormone 
binging globulin (SHBG), with only a small proportion circulating free in the 
blood (Feldman and Feldman 2001). Also synthesised in the testes is 5α-
reductase (5α-R), an enzyme responsible for the conversion of testosterone 
to 5α-dihydrotestosterone (DHT), a more active metabolite of testosterone 
with a five-fold higher affinity for the androgen receptors (AR) (Heinlein and 
Chang 2004, Wilson 2011). Testosterone and DHT exhibit their effects on 
the prostate by binding to the AR in prostate cells resulting in transcriptional 
activity. This includes prostate cell differentiation, proliferation and apoptosis, 
necessary to complete prostate formation and maturation (Heinlein and 
Chang 2004, Attar, Takimoto et al. 2009). AR activity is mediated by 
androgens and regulates the biological activity of the prostate, with the 
exception of dysfunctional AR activity which can occur independent of 
androgens as can be the case in prostate cancer. As apoptosis in prostate 
cells can be hormone regulated, the removal of gonadal androgens can 
cause normal prostate and prostate cancer cells to undergo apoptosis, 
demonstrated in early preclinical studies (Kyprianou and Isaacs 1988, 
English, Kyprianou et al. 1989, Kyprianou, English et al. 1990, Colombel, 
Olsson et al. 1992).  
Benign prostatic hyperplasia (BPH) is the most common benign proliferative 
disease among men (Wei, Calhoun et al. 2005). The histological prevalence 
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of BPH has been estimated at 8%, 50%, and 80% in the 4th, 6th, and 9th 
decades of life, respectively (Lim 2017). Men with BPH commonly 
experience lower urinary tract symptoms (LUTS), resulting in the need for 
medical or surgical treatment (Izumi, Mizokami et al. 2013). A common 
treatment for BPH is the use of 5αR inhibitors, which suppress testosterones 
conversion to DHT and suggest the androgen and androgen receptor 
signalling play a key role in the development of BPH (Izumi, Mizokami et al. 
2013). 
1.2 Epidemiology of prostate cancer 
1.2.1 Incidence and mortality 
There are significant geographical variations in the incidence of prostate 
cancer with over 70% of diagnoses made in the most developed regions of 
the world. Amongst the highest rates are Australia/New Zealand and the 
United States (US) with 111.6 and 97.2 cases per 100,000, respectively 
(GLOBOCAN 2012). Incidence in Asian countries is much lower and in some 
parts of China, it’s a relatively rare disease. 
In the United Kingdom (UK), prostate cancer is the most common cancer in 
men with 47,151 new cases reported in 2015 (Office of National Statistics 
2015), putting the UK incidence rate 17th highest in Europe. It accounts for 
around 26% of cancer diagnoses in men and around 84% of men diagnosed 
with prostate cancer can expect to live 10 or more years (Office of National 
Statistics 2015). In Europe, around 417,000 new cases of prostate cancer 
were estimated to have been diagnosed in 2012. 
Prostate cancer is the 5th leading cause of cancer death in men worldwide. 
(GLOBOCAN 2012). An estimated 1.1 million men diagnosed with prostate 
cancer in 2012 (GLOBOCAN 2012). There is significant difference in the 
distribution of mortality and incidence rates of prostate cancer worldwide 
:less than 10% of those in the US die of their disease comparative to over a 
third in the Caribbean nations (GLOBOCAN 2012). What is evident is that 
although the incidence of prostate cancer varies more than 25-fold across 
the globe, there is only a 10-fold difference in mortality. Furthermore, 
relatively speaking, the prognosis of prostate cancer remains worst in the 
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less-developed areas, whereas incidence has risen in more developed. 
Much of this variation is likely to be related to the prevalence of opportunistic 
prostate specific antigen (PSA) screening in the more developed countries. 
In addition, the disparity between mortality between developing countries 
compared to more developed regions such as Europe and North America 
can possibly be attributed to the higher total expenditures on health/gross 
product (GDP), with more favourable outcomes associated with greater 
spend on cancer care (Chen, Wang et al. 2017). 
1.2.2 Risk factors for prostate cancer 
As there is some difficulty in establishing the raw incidence of prostate 
cancer due to the disparities in PSA testing in different regions, there is some 
uncertainty regarding the incidence of significant prostate cancer impacting 
survival and of prostate cancer mortality. As a result there is limited 
consistent risk factor data for prostate cancer with the exception of three 
non-modifiable factors: age, race and family history. 
Prostate cancer incidence increases with age, the incidence rate of prostate 
cancer is 9.2/100,000 for men aged 40–44 years, this increases to 
984.8/100,000 in men aged 70–74 years, after which it slightly decreases 
(Leitzmann and Rohrmann 2012). 
Prostate cancer is most common in black males, followed by white males 
and least common in Asian men in the UK (Lloyd, Hounsome et al. 2015). 
Black men are 2-3 times more likely to be diagnosed with prostate cancer 
compared to white men of the same age in the UK, furthermore black men 
are more likely to be diagnosed earlier than white men (Ben-Shlomo, Evans 
et al. 2008). 
There are risk factors associated with having a family history of prostate 
cancer (Albright, Stephenson et al. 2015). If one first-degree relative has 
prostate cancer, such as father or brother, the risk is at least doubled. The 
risk increases further, to 5–11 times when two or more first-line relatives are 
affected (Albright, Stephenson et al. 2015). The risk also increases based on 
earlier age at diagnoses, where risk increases by 6 times for one or more 
first-degree relatives diagnosed before age 50 years. Less than 10% of men 
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with prostate cancer have hereditary disease associated with a mutation, 
which is associated with an earlier onset (around 6-7 years). Carriers of the 
breast cancer 1, early onset (BRCA1) and breast cancer 2, early onset 
(BRCA2) mutations are at a higher risk of developing more aggressive 
phenotypes of prostate cancer (Mitra, Fisher et al. 2008, Castro, Goh et al. 
2013). For men carrying the mutations rate of both metastatic disease and 
death from prostate cancer are significantly higher (Castro, Goh et al. 2013). 
The findings of a UK BRCA screening study (IMPACT) showed positive 
predictive value for biopsy using a PSA threshold of 3.0 ng/ml in BRCA2 
mutation carriers was double the positive predictive value reported in 
population screening studies, furthermore there was a significant difference 
in detecting intermediate-high risk disease observed in BRCA2 carriers 
(Bancroft, Page et al. 2014). However, further research is needed to 
determine the possible differences between the impact of the two BRCA 
mutations however the findings do indicate germline genetic markers can be 
used to identify men at higher risk of prostate cancer (Bratt and Loman 
2015). 
There are other lifestyle related factors associated with prostate cancer. 
There is strong evidence to suggest a link between some prostate cancers 
and being overweight or obese, being tall and a high consumption of beta-
carotene (WCRF-CUP 2014). Furthermore, obesity is linked with elevated 
incidence of aggressive disease, increased risk of biochemical failure 
following radical prostatectomy and external-beam radiotherapy, higher 
frequency of complications following ADT, and increased prostate cancer 
mortality (Allott, Masko et al. 2013). There is some evidence to suggest a link 
between prostate cancer risk and sedentary behaviour, a higher 
consumption of dairy products, diets high in calcium, low plasma alpha-
tocopherol concentration (vitamin E) and low plasma (blood) selenium 
concentrations (WCRF-CUP 2014).  
In England, it is also less common in men in the most deprived areas 
(Tweed, Allardice et al. 2018). However, this is likely linked to the rise in 
incidence rates since the introduction of PSA testing, where those who are in 
more affluent areas are more likely to have greater exposure to testing 
33 
 
(Shafique, Oliphant et al. 2012). This reflects the disparities of prostate 
cancer incidence worldwide mentioned previously.  
The link between hypogonadism and the risk of prostate cancer is 
contentious, but there is some evidence to suggest a link with an increased 
risk of developing more aggressive prostate cancer with hypogonadism 
(Morgentaler and Rhoden 2006). 
1.3 Evolution and clinical staging 
A large population of men with prostate cancer are asymptomatic until the 
late stages of their disease. Once the prostate has enlarged to where it 
obstructs the urethra, known as bladder outlet obstruction, men may 
experience typical lower urinary tract symptoms (LUTS) (Rosier and de la 
Rosette 1995). This includes micturition hesitancy, nocturnal polyuria, urinary 
retention and haematuria. For more advanced disease where metastasis is 
present bone pain is a frequent symptom, particularly in the spine and pelvis.  
1.3.1 Diagnostic and staging procedures  
Prostate cancer screening, using blood PSA levels, has dramatically shifted 
the stage at which the disease is diagnosed with fewer men diagnosed 
showing radiographical evidence of metastasis since its introduction. There 
is no formal widespread population screening programme for PSA as there 
exists no evidence for it but the topic remains one of the most controversial 
in uro-oncology (Mottet, Bellmunt et al. 2017).  
The European Randomised Study of Screening for Prostate Cancer study of 
162,388 men with a 13 year follow up demonstrated a small absolute 
reduction in prostate cancer mortality (Schroder, Hugosson et al. 2009). In 
the screening group the relative risk (RR) of death was reduced to 0.79, an 
absolute risk reduction of 0.128% or 13 lives saved per 10 000 men invited 
for screening. 
However, the Prostate, Lung, Colorectal, and Ovarian Cancer Screening 
Trial, which involved 76 685 men also with a 13 year follow up, concluded 
that the prostate cancer specific mortality in screen detected individuals very 
low and not significant (Andriole, Crawford et al. 2009). In addition, both of 
these large scale RCTs demonstrated not only a substantial risk of over 
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diagnosis with PSA screening but also of a lack of benefit to all-cause 
mortality. As a result, widespread PSA screening programmes have not been 
adopted. However, targeting those men who are considered at risk of 
developing prostate cancer such as those with a family history of those of 
African American origin may be appropriate (Mottet, Bellmunt et al. 2017).  
PSA is a continuous parameter where a higher PSA is indicative of an 
increasing likelihood of prostate cancer. A PSA is accompanied with a digital 
rectal examination (DRE) where the prostate is felt for an abnormal 
morphology. Currently, the optimal intervals for PSA testing and DRE follow-
up vary dependant on the individual, such as the presence of prostate cancer 
risk factors (e.g. family history), age and life expectancy being taken into 
account.  
Where blood serum PSA levels or an abnormal DRE may be indicative of the 
presence of prostate cancer, it should be confirmed by histological 
assessment of a prostate biopsy. At this stage a grading system, previously 
the Gleason score and now Gleason grade, is used to determine the 
presence of prostate cancer cells defined on the histological appearance 
(uniformity, size and differentiation). The Gleason score is calculated 
according to the image (figure 1.1) below between 1 and 5 for the most 
prevalent pattern (primary grade), then between 1 and 5 again for the next 
most prevalent (secondary grade). If a small area of high grade is present, 
this will be attributed a tertiary grade. The primary and secondary grades are 
added together to provide a sum score e.g. 3+3 = 6 or 4+3 = 7 
(Rezaeilouyeh and Mahoor 2016). Men with a sum score ranging from 6 to 7 
have the higher chances of survival, whereas men with scores from eight to 
ten have the highest mortality rate (Gleason and Mellinger 1974). The 
development of the Gleason grading system stratifies patients in to "groups" 
based on the histological definitions of the original Gleason scoring system.  
The Gleason grading system (Epstein, Zelefsky et al. 2016): 
 Grade group 1 (Gleason score 3 + 3 ≤6): Only individual discrete well-
formed glands. 
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 Grade group 2 (Gleason score 3 + 4 = 7): Predominantly well-formed 
glands with lesser component of poorly formed/fused/cribriform 
glands. 
 Grade group 3 (Gleason score 4 + 3 = 7): Predominantly poorly 
formed/fused/cribriform glands with lesser component of well-formed 
glands. 
 Grade group 4 (Gleason score 8)  
- Only poorly formed/fused/cribriform glands or 
- Predominantly well-formed glands and lesser component 
lacking glands 
- Predominantly lacking glands and lesser component of well-
formed gland 
 Grade group 5 (Gleason scores 9–10): Lack of gland formation (or 
with necrosis) with or without poorly formed/fused/cribriform glands. 
 
 
Figure 1.1 The Gleason score, the higher scores are indicative of a greater 
malignancy. Taken from the National Cancer Institute website 
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<https://training.seer.cancer.gov/prostate/abstract-code-stage/morphology.html> 
public domain 
Upon the histological confirmation of prostate cancer, further radiographical 
assessment is undertaken, inclusive of skeletal x-rays, computed 
tomography (CT) scanning or magnetic resonance imaging (MRI). 
Additionally, isotope bone scans are used to determine the extent of bone 
metastasis, such as Tc99 bone scan.  
The most widely used staging classification is the TNM staging system. The 
system assesses the extent of the primary tumour (T), regional lymph nodes 
(N), and distant metastases (M) and provides a “stage grouping” based on T, 
N, and M (Edge and Compton 2010). The TNM staging system is detailed 
below. 
Table 1.1 TNM staging of prostate cancer 
TNM staging of prostate cancer  
Localised  
Tx Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
T1 Clinically apparent tumour neither palpable or visible by 
imaging 
T1a Tumour incidental histologic finding in ≤5% of tissue 
resected 
T1b Tumour incidental histologic finding in >5% of tissue 
resected 
T1c Tumour identified by needle biopsy 
T2 Tumour confined within prostate 
T2a Tumour involves one half of one lobe or less 
T2b Tumour involves more than one-half of one lobe but not 
both lobes 
T2c Tumour involves both lobes 
Locally advanced  
T3a Extracapsular extension (unilateral or bilateral) 
T3b Tumour involves seminal vesicles 
T4 Bladder invasion, fixed to pelvic side of wall, or invasion 
of adjacent structures 
Metastatic   
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N1 Positive regional lymph nodes 
M1 Distant metastasis 
 
Dependant on a combination of PSA, Gleason score and TNM staging the 
EAU risk group classification can be used to determine the risk of 
reoccurrence after radical local treatment for prostate cancer (table 1.2).  
Table 1.2 Risk groups for biochemical reoccurrence of localised and locally 
advanced prostate cancer taken from (Mottet, Bellmunt et al. 2017) with 
permission.  
 Low risk Intermediate 
risk 
Intermediate 
- high risk 
High risk 
PSA <10 ng/ML 10-20 ng/ML >20ng/ML any PSA 
Gleason 
score 
AND <7 OR 7 OR >7 any Gleason 
score 
TNM staging AND T1-2a  OR T2b OR T2c T3-4 OR N+ 
 
1.4 Prostate cancer treatment  
For disease localised to the prostate gland, a clinician with their patient will 
most likely choose to not treat at all or treatment with curative intent, opting 
for surgery known as radical prostatectomy or radical radiotherapy (NICE 
2014). In general, surgery is more commonly adopted by North America and 
Europe. For more advanced disease there are a multitude of therapies which 
are summarised in figure 1.2 (NICE 2014). However, the cornerstone therapy 
for advanced, or inoperable, disease is hormone manipulation or ADT. This 
can be achieved with orchidectomy or the pharmacological agents - 
gonadotrophin-releasing hormone (GnRH) analogues. ADT manipulates 
circulating levels of testosterone to near negligible levels, essentially 
achieving castration.  
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Figure 1.2 Prostate cancer treatments with advancing disease  
1.4.1 Localised prostate cancer 
Decisions on treatments for localised prostate cancer depend on patient 
fitness, comorbidities, life-expectancy and patient preference. The disease 
will also be risk assessed based on the Gleason score, stage and PSA. 
Crucially, active treatment is performed with curative intent unlike prostate 
cancer which is at more advanced stages.  
1.4.1.1 Active surveillance and watchful waiting 
Active surveillance is reserved for patients with the lowest risk prostate 
cancers (Gleason score 6 or 7) where it is expected that their disease will not 
progress to a higher grade. Active surveillance is a programme of quarterly 
PSA monitoring to detect a PSA doubling time of less than 3 years and 
planned repeat biopsies at 6–12 months from diagnosis (and thereafter 3–4 
yearly), with the aim of early intervention for those who progress (Duchesne 
2011, Lane, Donovan et al. 2014).  
Active surveillance is not to be confused with watchful waiting, which is also 
a programme that omits active treatment but is reserved for those who are 
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considered too high risk for active treatment, such as multiple comorbidities. 
Older men (60-70 and older) with a higher numbers of existing comorbidities 
(n≥3) are more likely to die of other causes than of their prostate cancer and 
treatment may actually cause more harm (Lane, Donovan et al. 2014, 
Daskivich, Fan et al. 2015). In this case, it is unlikely that the presence of 
prostate cancer is going to affect OS.  
1.4.1.2 Surgery 
Radical prostatectomy is surgical resection of the prostate and is usually 
offered for the younger fitter patients. Older patients are at higher risk of 
incontinence with this procedure. It is conducted via an open retropubic or 
laparoscopic  approach with or without robotic surgery (Duchesne 2011).  
1.4.1.3 External bean radiotherapy 
The technique for prostate radiotherapy in the UK is intensity modulated 
radiotherapy with image guided radiotherapy. Radiotherapy is used in both 
localised and locally advanced disease (Duchesne 2011). 
1.4.1.4 Brachytherapy 
Brachytherapy is an alternative radiation therapy which can be delivered 
directly into the prostate by transperineal implantation of permanent 
radioactive seeds (usually iodine-125, low dose rate brachytherapy), or with 
a temporary implant (high dose rate brachytherapy) (Duchesne 2011). A 
predominant advantage of this method is the low dose of radiation to the 
surrounding tissues. Brachytherapy can be used in conjunction with external 
beam radiation therapy where very high doses of radiation are warranted.  
1.4.1.5 Exercise 
Exercise is a promising emerging supportive therapy for cancer. This 
includes emerging data in localised and locally advanced prostate cancers. 
This is covered in more detail in the proceeding sections however a recently 
published multi-site feasibility RCT of aerobic exercise in men with locally 
advanced disease, the PANTERA trial, demonstrated that men in the 
intervention group had a reduction in body mass (although body composition 
was not measured), systolic and diastolic blood pressure and improved QoL 
(Bourke, Stevenson et al. 2018). However, as this study was a feasibility 
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study, there was no indication to the statistical significance of these findings 
as primary outcomes were feasibility measures. 
1.4.2 Advanced prostate cancer: Androgen deprivation therapy 
Hormone manipulation, or ADT, is the principle therapy for inoperable or 
metastatic disease. As mentioned previously, this can be achieved by either 
medical (GnRH analogues) or surgical castration (orchidectomy). As most 
prostate cancers are initially dependant on androgenic stimulation, both 
methods of ADT downregulate the level of prostate cancer cell proliferation 
compared to the rate of cell apoptosis and therefore tumour regression is 
achieved. About 80-90% of prostate cancers at initial diagnosis are sensitive 
to androgens and androgen ablation is effective at inducing regression of the 
disease (Heinlein and Chang 2004). 
Orchidectomy is a relatively simple surgical procedure with minor surgical 
risks. However, despite its low physical morbidity, the development of 
pharmacological agents to achieve castration and the associated 
psychological effects of orchidectomy means it has fallen out of favour 
(Sharifi, Gulley et al. 2005). Medical castration has evolved from using 
oestrogens, to GnRH agonists and later the use of GnRH antagonists. 
Oestrogens work predominantly by having anti-gonadotrophic effects 
however direct effects on the tumour leading to regression, including 
increased synthesis of SHBG, inhibition of 5α-R, and direct effects on Leydig 
cell function, have all been reported (Cox and Crawford). GnRH receptor 
agonists include drugs such as leuprolide, bruserelin and goserelin. The 
agonists work to inhibit LH production from the pituitary, which in turn causes 
a suppression of testosterone and DHT (Cook and Sheridan 2000). 
However, when first administered GnRH agonists can cause a surge in the 
release of LH, and in turn a surge in testosterone and DHT; around 5-12 
days before the inhibition of LH. This surge in LH presents clinically as 
"tumour flare" where symptoms such as bone pain, compression of a nerve 
root, spinal cord compression and ureter constriction can worsen (Cook and 
Sheridan 2000). Tumour flare can be extremely dangerous and often leads 
to clinical emergencies. GnRH antagonists and anti-androgens such as 
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flutamide or cyproterone acetate, have been demonstrated to reduce the 
flare reaction and can be used instead of GnRH agonists (Cook and 
Sheridan 2000, Sharifi, Gulley et al. 2005). 
GnRH antagonists, such as degarelix, may also be used as an alternative for 
medical castration. GnRH antagonists work by binding to the GnRH 
receptors without eliciting a response, competing with endogenous GnRH. 
The antagonists block GnRH and inhibits LH production, which in turn 
causes a suppression of testosterone and DHT (Drudge-Coates 2010). 
Degarelix was compared to leuprolide for achieving and maintaining 
testosterone suppression in a 1 year phase III trial of 610 prostate cancer 
patients (Klotz, Boccon-Gibod et al. 2008). The study demonstrated that 
degarelix was as effective as leuprolide in maintaining low testosterone 
levels throughout the treatment period and that it achieved testosterone and 
PSA suppression significantly faster than leuprolide. PSA suppression was 
also maintained throughout the study. Degarelix is recommended for treating 
advanced hormone-dependant prostate cancer in people with spinal 
metastasis (NICE 2016). 
1.5 The prostate cancer care pathway 
Established healthcare pathways are essential to facilitate the structured, 
multidisciplinary and high quality care of a patient from the point of diagnosis. 
Such pathways ensure a translation of national guidelines to implementation 
in local protocols and subsequently practice. Prostate cancer is no different, 
and The National Institute for Health and Care Excellence (NICE) have 
continued to provide the UK with national guidelines on how these men 
should be effectively managed. These recommendations are based on 
systematic reviews of the current evidence regarding prostate cancer 
treatments and cost effective data (Graham, Kirkbride et al. 2014). 
As discussed earlier, there are many challenges faced when deciding on the 
most appropriate and effective care for a patient. Clinicians are faced with 
balancing the perceived benefits to the potential harm when deciding the 
optimal treatments, where policy makers and governing bodies must decide 
on the cost effectiveness of treatments. Where multiple treatment options 
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exist, management of patients becomes ever more complex. Such is the 
case in the prostate cancer care pathway. The care of men with prostate 
cancer is multidisciplinary spanning both urology and oncology departments. 
The decision making on treatments for these men becomes a team 
approach, crucially involving the patient themselves. The aim of this clinical 
pathway, like all pathways, is to ensure continuity, increase multidisciplinary 
integration and facilitate appropriate patient education, treatment and care 
for cancer patients (de Vries, van Weert et al. 2007).  
Details on the treatment options for the different stage of disease have been 
described; however the schematic below (figure 1.3) gives a very brief 
indication of the prostate cancer care pathway. The boxes marked in blue 
indicate where a man's care will be predominantly overseen by a urologist 
and those in red indicate where his care is overseen by an oncologist in the 
UK, with the exception of radiotherapy which is overseen by a clinical 
oncologist. This section details the prostate cancer care pathway with a 
focus for men with advanced metastatic disease.  
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Figure 1.3 The prostate cancer care pathway. Developed from the NICE guidelines 
(NICE 2014) 
1.6 Therapeutic changes to the pathway 
The treatment of prostate cancer poses unique problems when compared to 
other neoplastic diseases. The natural history of prostate cancer can be very 
long, with some men surviving with their disease for over two decades. Men 
can therefore have aggressive therapies over very long periods of time and 
the AEs of these therapies as a result could cause more harm than good.  
1.6.1 Pathway changes for hormone sensitive advanced prostate cancer 
Since the development of PSA testing, 5 year survival statistics for prostate 
cancer have significantly increased since the early 1990s. As a result, the 
diagnosis of prostate cancer was occurring at much earlier stages and 
survival was therefore better where treatment could be offered with curative 
intent, but this could be due to the "lead time bias" and stage infiltration. 
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For advanced disease however, ADT, either alone or in combination, 
remains the cornerstone of treatment. However, in 2015 improvements in 
survival of men with the use of docetaxel at earlier (hormone sensitive) 
stages of metastatic (M1) prostate cancer were demonstrated in the 
multicentre RCTs STAMPEDE and CHAARTED (James, Spears et al. 2015, 
Sweeney, Chen et al. 2015). The STAMPEDE trial also evaluated two other 
agents, zolendronic acid and celecoxib as well as combination of the three 
agents in different arms (James Nicholas, Sydes Matthew et al. 2009, 
James, Sydes et al. 2012). Both trials demonstrated a survival benefit with 
the introduction of docetaxel upon initiation of ADT when compared to the 
ADT group alone (or standard care).  
In the CHAARTED trial, in patients with hormone sensitive but higher volume 
disease, a survival benefit of 57.6 vs 44.0 months (docetaxel + standard care 
vs standard care only) (hazard ratio (HR) 95% confidence interval (CI) 0.47 
to 0.81; p <0.001) (Sweeney, Chen et al. 2015). In the STAMPEDE study, 
men with newly diagnosed M1 hormone sensitive disease had a greater 
failure free survival 37 vs 20 months (docetaxel + standard care vs standard 
care only) (HR 0.61, 95% CI 0.53-0.70; p =0.413 × 10-13), median failure-free 
survival 37 months (HR 0.61, 95% CI 0.53-0.70; p =0.413 × 10-13) (James, 
Sydes et al. 2016). The study also addressed the use of zoledronic acid 
alone or in combination with docetaxel (plus standard care) and found no 
overall improvement in survival outcomes compared to docetaxel alone (plus 
standard care).  Consequentially, in 2015 changes in clinical practice 
followed and an increasing number of men received docetaxel chemotherapy 
earlier in their prostate cancer care pathway (figure 1.3).  
The implication of this pathway change however is yet to be evaluated. 
Furthermore, the predominant benefits of chemohormonal therapy was 
observed in those with higher volume disease in both trials, therefore the role 
of chemohormonal therapy for patients with N0/1 and M0 disease is still 
being evaluated and the benefits (or risks) of the treatment for this group is 
less clear. There were reports of increased fatigue and neutropenic fever 
observed in the CHAARTED trial although overall docetaxel plus standard 
care was well tolerated in both studies. However, the long-term effects of 
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early chemohormonal therapy have yet to be elucidated, and it is not clear 
how such treatments may impact on QoL, tolerance to later therapy, 
subsequent optimal treatment sequencing and/or cross-resistance with later 
treatments. 
More recently, the second generation anti-androgens have been of great 
interest for their use earlier in the pathway where previously they have been 
used for castrate sensitive disease. Several new arms to the STAMPEDE 
have been introduced to assess the efficacy of enzalutamide and abiraterone 
in hormone naïve men initiating ADT (standard care) with M1 advanced 
prostate cancer (Attard, Sydes et al. 2014). At the point of writing this thesis 
the results for the enzalutamide + ADT arm in the STAMPEDE trial have not 
yet been published. However, in 2017 the study demonstrated that in the 3 
year follow up period the failure-free survival was 75% in the abiraterone + 
ADT group and 45% in the ADT-alone group (HR for treatment failure, 0.29; 
95% CI, 0.25 to 0.34; p <0.0001).  The mean failure-free survival time was 
43.9 months in the abiraterone + ADT group and 30.0 months in the ADT-
alone group in the first 54 months after randomisation, a difference of 13.9 
months (95% CI, 12.3 to 15.4) (James, de Bono et al. 2017).  
These findings however did bring about a problem; there is no direct 
comparative data of docetaxel + ADT vs abiraterone + ADT. However, a sub 
analysis was later conducted which demonstrated no significant difference in 
survival between the two treatment modalities. Early measures of failure free 
survival, freedom from metastatic disease progression and freedom from 
symptomatic skeletal events favoured abiraterone, but the data was 
underpowered (Sydes, Mason et al. 2017, Wallis, Klaassen et al. 2017). 
Toxicity profiles for either regimen were similar. This may go some way to 
explaining why abiraterone + ADT has not been adopted in clinical practice 
in the NHS, more robust comparative data is needed. Once more, 
abiraterone is approved for use in later stages of disease (in CRPC), and the 
long-term effects of abiraterone will be of significant importance if its use is 
shifted to earlier in the pathway, similar to the concerns described for 
docetaxel. This too could result in problems with determining optimal 
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treatment sequencing at later stages of disease and potential cross-
resistance of subsequent therapies.  
2. Castrate resistant prostate cancer 
2.1 Definition, diagnosis and prevalence 
CRPC is progression of prostate cancer (clinically, biochemically or 
radiographically) despite the removal of testosterone of gonadal origin via 
ADT. Clinically, this might present as a symptomatic progression, 
biochemically this will present as a rise in PSA and radiographically this 
presents as the appearance of new metastasis or visceral disease (via 
imaging from computed tomography, magnetic resonance imaging, or 
radionuclide bone scintigraphy) or lymphadenopathy. Although other terms 
have been used for this stage of disease, such as hormone refractory or 
hormone resistant, CRPC has been adopted from the understanding that 
prostate cancer cells maintain androgen sensitivity via a number of 
mechanisms (Mostaghel, Page et al. 2007). To determine the presence of 
castrate resistant disease, it is imperative that testosterone levels are 
determined and shown to be at castrate levels (<50 ng/dl (1.73 nmol/l)), only 
then can a diagnosis of CRPC be made (Hotte and Saad 2010, Nishiyama 
2014). 
The incidence of men diagnosed with prostate cancer developing CRPC is 
approximately 10-20% within 5 years (Kirby, Hirst et al. 2011, Scher, Solo et 
al. 2015). For men diagnosed with CRPC without metastasis, about 33% will 
develop metastasis within 2 years (Smith, Kabbinavar et al. 2005, Kirby, Hirst 
et al. 2011). The epidemiological data on CRPC is spare and inconsistent but 
a review in 2012 estimated the mean survival time of men with CRPC at 13.5 
months in the UK (Hirst, Cabrera et al. 2012). It's been estimated that about 
17.8% of men with prostate cancer have castrate resistant disease (Ritch 
and Cookson 2016) but again these figures can vary wildly. 
2.2 Pathophysiology and clinical manifestation 
Clinical response to ADT, castrate responsive disease, occurs in around 
80% of cases, with the remaining 20% or so of men being deemed castrate 
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resistant from the outset (Greasley, Khabazhaitajer et al. 2015). Where 
tumour regression is initially achieved, and potentially could last for several 
years, the disease will inevitably relapse. However the exact process by 
which prostate cancer cell proliferation becomes independent of ADT is 
unclear but several few mechanisms have been identified.  
 It was previously thought that the development of CRPC was due to a loss 
of responsiveness of the AR however it has been demonstrated that the 
signalling of the AR is almost never lost but in fact is maintained despite low 
level circulating androgens through a variety of proposed mechanisms 
(Feldman and Feldman 2001). These include intratumoral production of 
androgens via increased expression of steroidogenic enzymes, apoptosis 
evasion, altered AR transcriptional coregulator expression, AR 
posttranslational modification (phosphorylation), ligand-independent 
pathways activating AR, amplification, and selection of genetically modified 
AR with constitutive active AR splice variants summarised in figure 1.4 (Hotte 
and Saad 2010, Greasley, Khabazhaitajer et al. 2015).  As a result, whilst 
androgen deprivation ceases to control disease progression, the androgen 
receptor remains an important target in castrate resistant prostate cancer 
therapies.  
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Figure 1.4  Proposed mechanisms contributing to the development of castrate 
resistant prostate cancer taken from (Greasley, Khabazhaitajer et al. 2015) with 
permission. 
Unfortunately, around 90% of patients with CRPC will develop bone 
metastasis which can present as a bone pain, a pathological fracture or bone 
marrow failure (Hotte and Saad 2010). 
2.3 Treatments for castrate resistant prostate cancer 
2.3.1 Changing treatment paradigms in castrate resistant prostate cancer 
Therapies used to treat CRPC are not curative but palliative however these 
agents have demonstrated not only to improve OS but also disease 
symptoms (table 1.3). Prior to 2010, therapeutic options for men with CRPC 
aimed at prolonging life remained limited to chemotherapy, specifically 
docetaxel,  which demonstrated a significant survival benefit (18.9 months vs 
16.5 months in the docetaxel groups vs mitoxantrone group) (Petrylak, 
Tangen et al. 2004, Tannock, de Wit et al. 2004). Previous to docetaxel, 
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treatments included maximum androgen blockade (MAB; using bicalutamide, 
nilutamide, flutamide and/or surgical castration) and oestrogens (Group. 
1984, Crawford, Eisenberger et al. 1989, Dijkman, Janknegt et al. 1997). 
Another first generation CRPC treatment includes oral ketoconazole, which 
was used to suppress gonadal, as well as adrenal, androgen synthesis via 
inhibition of enzymes in the steroidogenesis pathway (Sanford, Drago et al. 
1976).  
Post 2010, great improvements in the treatment of CRPC were seen with the 
introduction of several new treatments (cabazitaxel, abiraterone, 
enzalutamide, and radium-223) (Kantoff, Higano et al. 2010, de Bono, 
Logothetis et al. 2011, Oudard 2011, Scher , Fizazi  et al. 2012, Scher, Fizazi 
et al. 2012, Parker, Nilsson et al. 2013). Sipuleucel-T was also shown to 
demonstrate a survival benefit in phase III trials however its recommended 
use by NICE was withdrawn in 2015 (Lovett, George et al. 2015).  
This surge in CRPC therapies brought uncertainties around the optimal 
sequencing of such agents. Prior to the pathway change in 2015 for men 
with hormone sensitive disease, there were three treatment spaces for drug 
development in CRPC: pre-docetaxel; docetaxel combinations; and post-
docetaxel (Omlin, Pezaro et al. 2013). Since this pathway change there is a 
lack of data for treatments in the post-docetaxel setting. It is now the case 
that more men relapsing after initial ADT treatment will also have had a 
docetaxel regimen and therefore data on optimal treatment regimens 
becomes pivotal.  
Unfortunately, preclinical data suggest that use of additional treatments 
might confer resistance to further therapies where they allow expansion of 
prostate cancer clones with resistant mutations (Baca, Prandi et al. 2013). 
Details on the incremental survival benefits of further post docetaxel + ADT 
treatment as well as toxicity profiles and QoL benefits are critical. Although 
there are a number of approved agents in CRPC post docetaxel, we do not 
know how the timing of the docetaxel regimen at much earlier stages of 
disease will affect the disease evolution. At such a late and advanced stage 
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of disease, treatment decisions aimed to balance survival and the 
maintenance of QoL are paramount. 
The severity of disease symptoms and the AEs which can impede QoL are 
essential considerations when considering the initiation and sequencing of 
treatment. In trials which addressed newer agents such as abiraterone, 
enzalutamide and sipuleucel-T, these men were minimally symptomatic with 
a good performance status (PS) (Kantoff, Higano et al. 2010, de Bono, 
Logothetis et al. 2011, Scher, Fizazi et al. 2012). In these trials the above 
agents were very well tolerated and therefore it is the case that the use of 
these agents is in patients with minimal symptoms or a good performance 
status (PS 0-1). For patients with symptomatic disease or with a poorer 
performance status it is less clear how these agents may be tolerated and 
therefore the direct impact to QoL. Therefore treatment options for this group 
remain limited. 
2.4 Treatments for castrate resistant prostate cancer: Adverse 
events and quality of life 
Improvement or the maintenance of QoL is of fundamental importance to 
men with CRPC. Multiple studies have addressed the impact of the 
pharmacological agents used to treat CRPC on QoL. The four predominant 
treatments for CRPC in the UK are discussed. 
2.4.1 Docetaxel 
Docetaxel has been associated with numerous AEs known to negatively 
impact QoL and is one of the most commonly used agents in CRPC (Al-
Batran, Hozaeel et al. 2015). Studies which have evaluated the impact of 
docetaxel on QoL have suggested that minimally symptomatic patients with 
good QoL scores at baseline tended to respond better to treatment (Caffo, 
Sava et al. 2011). The landmark study of docetaxel for advanced prostate 
cancer reported ≥ 1 serious adverse events (SAEs) occurred in 26% of the 
patients that received three weekly docetaxel and two treatment related 
deaths (Tannock, de Wit et al. 2004). Furthermore, grade 3/4 neutropenia 
was significantly more common those who received three weekly docetaxel 
(32%) than for those patients receiving weekly docetaxel or mitoxantrone 
(2% and 22%). In addition, nausea and vomiting were common with all 
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regimens but diarrhea was significantly more frequent in the docetaxel 
schedules. Discontinuation of treatment with docetaxel was due to fatigue, 
musculoskeletal events, nail changes, sensory neuropathy, and infection. 
However this study showed when compared to the mitoxantrone and 
standard care, the HR for death in the three weekly docetaxel arm was 0.76 
(95% CI 0.62 to 0.94, p =0.009) indicating a statistically significant 
improvement in OS (Tannock, de Wit et al. 2004). A cochrane review 
demonstrated that overall, studies which evaluated the OS benefit of a 
docetaxel regimen compared to best standard care in men with CRPC was 
<2.5 months, however the review evaluating these landmark studies was 
published in 2006 and the standard of care has evolved since then as 
discussed (Shelley, Harrison et al. 2006). 
2.4.2 Enzalutamide 
The AFFIRM trial, one of the landmark phase III trials evaluated 
enzalutamide in men with CRPC post-chemotherapy in 1199 men. The study 
showed the incidence of grade≥ 3 AEs was lower in the enzalutamide group 
(45.3%) than in the placebo group (53.1%) (Scher, Fizazi et al. 2012). In the 
enzalutamide group, AEs included fatigue (34%), diarrhea (21%), hot flashes 
(20%), musculoskeletal pain (14%), headache (12%), cardiac disorder (6%), 
seizure (<1%), and myocardial infarction (<1%). AEs leading to death 
occurred in 3% (n =23) of the patients in the enzalutamide group. 
Enzalutamide was superior to a placebo in terms of QoL measured by the 
FACT-P questionnaire (43% in the enzalutamide group vs 18% in placebo 
arm had a 10 point improvement in FACT-P scores). 
However, in the PREVAIL phase III study of 1,717 CRPC randomly assigned 
to receive enzalutamide or a placebo, toxicity profiles were not quite as good 
compared to placebo (Beer , Armstrong  et al. 2014). Grade≥ 3 AEs occurred 
in 43% of the patients in the enzalutamide group vs 37% of those in the 
placebo group. Common AEs experienced in the enzalutamide group 
included fatigue (36%), back pain (27%) and constipation (22%). AEs leading 
to death occurred were similar in each group (4%). 
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2.4.3 Abiraterone 
The double-blind phase III trial of abiraterone plus prednisolone (n =791) and 
a placebo plus prednisolone (n =394) demonstrated that both groups had a 
similar toxicity profiles (de Bono, Logothetis et al. 2011). The most common 
AE of was fatigue (abiraterone plus prednisolone: 44% vs placebo plus 
prednisolone: 43%). The other common AEs were back pain, nausea, 
constipation, bone pain, and arthralgia which were similar across both 
groups. In another study, AEs were more common in the abiraterone plus 
prednisolone group for fluid retention/edema, and hypokalemia (31 and 17% 
vs Placebo: 22 and 8% respectively). Mortality was also similar in both 
groups (abiraterone group: 13% vs placebo group: 16%) (Fizazi, Tran et al. 
2017). Although both studies assessed QoL using the FACT-P 
questionnaire, neither reported on changes in scoring for men in the studies. 
2.4.4 Carbazitaxel  
The phase III study a large-scale compared cabazitaxel plus prednisone (n 
=371) to mitoxantrone plus prednisolone (n =371) (the TROPIC trial) (de 
Bono, Oudard et al. 2010). The most common grade≥ 3 AEs described in the 
cabazitaxel arm were neutropenia (82%), leukopenia (68%), anaemia (11%), 
and thrombocytopenia (4%). The most common non-haematological AE was 
diarrhoea (47% for all grades). 5% patients in the cabazitaxel group died due 
to AEs.  
Unfortunately the above study also failed to report on QoL outcomes. 
Another study addressed the safety of carbazitaxel and its impact on QoL 
(Bahl, Masson et al. 2015). QoL was measured using the EQ-5D-3L 
questionnaire and the visual analogue scale, the study showed a trend 
towards improvement in QoL and in pain scores during treatment however 
neither of these findings were significant (Bahl, Masson et al. 2015). 
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Table 1.3 Current treatment options for CRPC taken from (Greasley, Khabazhaitajer et al. 2015) with permission 
Therapeutic agent Mechanism of action Clinical trial status Therapeutic efficacy 
Docetaxel Stabilization of tubulin, induction 
of cell cycle arrest and inhibition of 
cell proliferation 
FDA approved Overall survival benefit vs mitroxantrone (2.0–2.9 
month) and palliation of cancer-associated 
symptoms 
Cabazitaxel Stabilization of tubulin, induction 
of cell cycle arrest and inhibition of 
cell proliferation 
FDA approved for men after failure of 
docetaxel 
Overall survival benefit vs mitroxantrone (2.3 
months) and palliation of cancer-associated 
symptoms. 
Sipuleucel-T (provenge) Enhancement of men’s 
autologous antigen-presenting 
cells to induce cytotoxic response 
against prostate cancer cells 
FDA approved Increase in overall survival (4.4 months) but not 
progression-free survival 
Abiraterone acetate Irreversible inhibition of CYP17 
and subsequent androgen 
synthesis 
FDA approved in the pre- and post-docetaxel 
settings 
Increase in overall survival (almost 4 months), 
radiographic progression-free survival, time to PSA 
progression, and palliation of cancer- associated 
symptoms 
MDV3100 (enzalutamide) AR antagonist preventing nuclear 
translocation and binding to 
chromatin 
FDA approved in the post-docetaxel setting 
Phase III clinical trial in comparison with 
placebo in chemotherapy-naïve men 
Increase of overall survival (4.8 months), 
radiographic progression-free survival and time to 
PSA progression. 
Similar benefits reported 
BEZ235 Inhibition of PI3K Phase I/II clinical trials in combination with Results pending 
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Abiraterone acetate (NCT01717898) 
RAD001 (everolimus) Inhibition of mTOR Phase II clinical trial in combination with 
bicalutamide (NCT00630344) 
Failure to show increase in time to progression 
Alpharadin (Radium-223)50 An alpha emitter which selectively 
targets bone metastases with 
alpha particles 
Phase III clinical trial in men who had 
received, were not eligible to receive, or 
declined Docetaxel 
Increase of overall survival (median, 14.0 months 
vs 11.2 months [placebo]; HR 0.70). 
Dovitinib (TK1258) Inhibition of FGFR Phase II clinical trial in men after failure of 
docetaxel-based chemotherapy 
(NCT01741116) 
Results pending 
Cabozantinib (XL184) Inhibition of c-MET Phase II clinical trial in men with mCRPC 
(NCT01428219) 
Phase III clinical trial in comparison with 
prednisone in men previously treated with 
docetaxel and abiraterone or MDV3100 
(COMET-1, NCT01605227) 
Phase III clinical trial in comparison with 
mitoxantrone and prednisone (COMET-
2, NCT01522443) 
Reduction of soft tissue lesions, resolution of bone 
scans, increase of progression-free survival 
Results pending 
Abbreviations: CRPC, castration resistant prostate cancer; FDA, Food and Drug Administration; PSA, prostate-specific antigen; mCRPC, 
metastatic castration resistant prostate cancer; PSA, prostate-specific antigen; AR, androgen receptor; vs, versus. 
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2.5 Treatment decisions: balancing quality of life and survival 
The debate regarding sequencing of treatment is weighted heavily in 
prolonging OS. However, CRPC patient preferences regarding treatments 
have shown a greater concern for the potential loss of QoL due to treatment 
AEs than the prolonging of survival (Uemura, Matsubara et al. 2016). In 
addition, the relationship between disease progression and the emergence of 
worsening symptoms is not well defined and there is limited data on 
predicting worse outcomes for patients with progressive disease. Given the 
AEs associated with treatments for CRPC, balancing QoL and survival is a 
pivotal issue. 
ADT has long been associated with detrimental effects to QoL (Lubeck, 
Grossfeld et al. 2001, Green, Pakenham et al. 2002, Dacal, Sereika et al. 
2006). As these men will have remained on ADT for a number of years they 
are a risk of developing significant AEs, worsening with time. Studies have 
demonstrated that for some of these men, there is significant regret in 
treatment choices made at earlier stages of their disease  due to the 
significant impact on their QoL (Clark, Wray et al. 2001). Some of this is 
associated with problematic communication with the treating clinician.  
Although QoL is of fundamental importance to these men there appears to 
be a significant lack of data in research with a large amount of clinical studies 
failing to report QoL outcomes. Clinicians are therefore faced with the difficult 
task of balancing unknown effects on QoL with survival benefit, which as 
discussed can also be uncertain. This can be compounded further by the fact 
these men are faced with more complications and comorbidities. In addition, 
shared decision making on therapy is a very individual approach, with some 
patients desiring minimal input, delegating this to the clinician, and others 
wanting to take the reigns over their care (Edwards and Elwyn 2009).   
It is clear however that as a key aspect of patient and clinician decisions on 
treatment, maintenance of QoL throughout prostate cancer care becomes 
integral to successful outcomes. Interventions involving the maintenance or 
improvement in QoL for men with CRPC are therefore essential. 
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2.5.1 Hypogonadism: A therapeutic minefield 
The landmark publication by Huggins and Hodges stated there was a 
symptomatic relief in patients with clinical prostate cancer (Huggins, Stevens 
et al. 1941). The study led to the widespread use of bilateral orcidectomy and 
acceptance of the androgen hypothesis, which supports the role of 
androgens in prostate cancer growth, proliferation, and progression; however 
the ADT palliative effects were confused with cure or permanent cancer 
control. The androgen hypothesis was further supported by animal studies 
which demonstrated induced prostate tumours with testosterone 
administration (Pollard, Luckert et al. 1982). Two historical studies in prostate 
cancer patients with metastatic or advanced prostate cancer reported tumour 
growth and/or recurrence (Prout and Brewer 1967, Fowler and Whitmore 
1981).  
Since, ADT achieved through surgery or from pharmacological agents, has 
demonstrated to result in numerous significant physiological and 
psychological AEs. Physiological AEs include a loss of muscle mass, 
increasing fat mass, hot flashes, fatigue, sexual dysfunction, insulin 
resistance, increased cardiovascular disease (CVD) and detrimental effects 
to bone mineral density (BMD) increasing bone fracture risk (Basaria, Lieb et 
al. 2002, Galvão, Spry et al. 2008, Bagrodia, DiBlasio et al. 2009, 
Sountoulides and Rountos 2013, Cheung, Zajac et al. 2014). QoL is greatly 
affected by this and is compounded by the negative psychological effects 
also associated with treatment (Green, Pakenham et al. 2002, Dacal, 
Sereika et al. 2006). A summary of the AEs of ADT is given in table 1.4. 
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Adverse 
effect 
Type of study Measures Findings Conclusion Evidence 
Sexual 
function 
Potosky 2002:  A population-
based random sample of 661 
men undergoing ADT. 
Elliot 2010:  A multidisciplinary 
working group (21 clinicians and 
researchers). 
Potosky 2002:  Medical 
Outcomes Study 36-
item generic health 
status questionnaire 
Elliot 2010:  Expert 
opinion of the side 
effects of ADT that 
affect the QoL of men 
with prostate cancer and 
their partners. 
Potosky 2002:  Decline in multiple attributes of 
sexual function, including libido, erectile function, and 
frequency of sexual activity in men receiving ADT 
Elliot 2010:  Side effect identified included body 
feminization (gynecomastia, weight gain and loss of 
muscle mass, genital shrinkage, hot flashes), sexual 
changes (erectile dysfunction, loss of sexual desire, 
absent orgasm, infertility). 
Castration levels 
of circulating 
testosterone 
results in a loss of 
potency, 
decreased genital 
size, sexual 
dysfunction and 
loss of libido. 
(Potosky, 
Reeve et al. 
2002, Elliott, 
Latini et al. 
2010) 
 
Fatigue Stones 2000: population based 
study of 62 men starting ADT. 
Pirl 2008: Cohort of men with 
advanced or recurrent prostate 
cancer (n =52) were randomly 
assigned to receive either 
leuprolide or bicalutamide. 
Cherrier 2009: A cohort of (n-
=20) hormone naïve men with 
prostate cancer were treated 
with intermittent ADT. 
Stone 2000:  Fatigue 
Severity Scale  (FSS) 
Pirl 2008:  Fatigue 
Severity Scale 
questionnaire. 
Cherrier 2009:  Profile 
of Mood States 
questionnaire. 
Stone 2000: A significant increase in subjective 
fatigue in patients with prostate cancer after 
treatment with LHRH analogues. Overall 66% of men 
reported an increase in fatigue severity. 
Pirl 2008:  Mean FSS scores increased significantly 
from baseline (μ:24.43, SD:11.75) to 6 months 
(μ:27.93, SD:13.52) remaining steady at 12 months. 
Cherrier 2009:  A significant increase fatigue in the 
ADT group at month 9 compared to baseline, and a 
trend for increased fatigue in month three compared 
to baseline (p <0.08). 
Fatigue worsens 
over time following 
ADT initiation after 
only a short period 
of treatment, as 
little as 3 months. 
As many as 66% 
of men treated with 
ADT have been 
reported to 
experience 
clinically significant 
fatigue. 
(Stone, Hardy 
et al. 2000, 
Pirl, Greer et 
al. 2008, 
Cherrier, 
Aubin et al. 
2009) 
 
Body 
composition 
Basaria 2002: cross-sectional 
study: 20 men undergoing 
medical castration for at least 12 
months prior to the onset of the 
study (ADT group); 18 men with 
non-metastatic disease who 
were post prostatectomy and/or 
radiotherapy but had not 
undergone ADT (non-ADT 
Basaria 2002: DEXA 
Berutti 2002: DEXA 
Smith 2002: DEXA 
Basaria 2002:  BMD was significantly lower in men 
on ADT. The ADT group had higher fat mass 
compared to the other groups (p = 0·0001) and 
significantly reduced upper body strength (p = 0·001). 
Berutti 2002:  At baseline 46% (at spine) and 40% 
(at hip) of cases were classified as osteopenic and 
14% (at spine) and 4% (at hip) as osteoporotic. ADT 
significantly decreased BMD either at the lumbar 
spine or the hip.  Lean body mass decreased 
ADT is associated 
with significant 
decreases in LBM 
and increases in 
visceral and total 
body fat mass. 
This also 
associated with a 
decline in muscle 
(Basaria, Lieb 
et al. 2002, 
Berruti, 
Dogliotti et al. 
2002, Smith, 
Finkelstein et 
al. 2002) 
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group); and 20 age-matched 
normal men (control group). 
Berutti 2002: Prospective 
cohort study of 35 patients with 
prostate cancer who received 
ADT for 12 months. 
Smith 2002: RCT of men with 
prostate cancer (n =40) locally 
advanced, node-positive or 
biochemically recurrent prostate 
cancer and no prior ADT  were 
treated with leuprolide or  
leuprolide and pamidronate 
(plus biclutamide).  
whereas fat body mass consistently increased with 
ADT. 
Smith 2002:  Weight increased by μ=2.4%. 
Percentage fat body mass increased by μ=9.4%, and 
percentage lean body mass decreased by μ=2.7%. 
Cross-sectional paraspinal muscle area decreased 
by μ=3.2%. 
strength, fitness 
and physical 
function. The 
increase in fat 
mass is associated 
with increasing 
body weight, BMI, 
increased insulin 
resistance and 
metabolic 
dysfunction. 
Cardiovascul
ar morbidity 
Keating 2006: Observational 
study of a population-based 
cohort of 73,196 diagnosed with 
locoregional prostate cancer 
treated with GnRH agonists or 
orchiectomy. 
Saigal 2007: A cohort of newly 
diagnosed men (n = 22,816 
subjects). 
Tsai 2007:  Data from the 
Cancer of the Prostate Strategic 
Urologic Research Endeavor 
database of 3262 patients 
treated with radical 
prostatectomy and 1630 patients 
treated with external beam 
radiation therapy, 
brachytherapy, or cryotherapy 
for localized prostate cancer. 
Jespersen 2014:  A national 
Keating 2006: 
Surveillance, 
Epidemiology and End 
Results Medicare data 
was used for analysis. 
Saigal 2007: Using a 
multivariate model, the 
risk of subsequent 
cardiovascular morbidity 
in men with prostate 
cancer who were treated 
with ADT was 
calculated. 
Tsai 2007:  Risk 
regression analyses 
assessed whether use 
of ADT was associated 
with a shorter time to 
death from 
cardiovascular causes. 
Keating 2006:  GnRH agonist use was associated 
with significant increased risk of incident diabetes 
(HR: 1.44), coronary heart disease (HR: 1.16), 
myocardial infarction (HR: 1.11), and sudden cardiac 
death (HR, 1.16). 
Saigal 2007: Newly diagnosed prostate cancer 
patients who received ADT for at least 1 year were 
found to have a 20% higher risk of serious 
cardiovascular morbidity compared with similar men 
who did not receive ADT. Subjects began incurring 
this higher risk within 12 months of treatment.  
Tsai 2007: ADT use (HR: 2.6) was associated with 
statistically significant increased risk of death from 
cardiovascular causes in patients treated with radical 
prostatectomy. Among patients 65 years or older 
treated with radical prostatectomy, the 5-year 
cumulative incidence of cardiovascular death was 
5.5% in those who received ADT and 2.0% in those 
who did not. Among patients 65 years or older 
treated with external beam radiation therapy, 
ADT is associated 
with an increased 
risk of myocardial 
infarction with HR 
of 1.09. CVD is still 
the most common 
cause of death in 
men diagnosed 
with prostate 
cancer and men 
are 2.6 times more 
likely to die from a 
cardiovascular 
event then men not 
receiving ADT. 
Some evidence 
suggests that men 
on ADT have a 20-
25% higher risk of 
coronary artery 
(Keating, 
O'malley et 
al. 2006, 
Saigal, Gore 
et al. 2007, 
Tsai, D’Amico 
et al. 2007, 
Jespersen, 
Norgaard et 
al. 2014) 
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cohort study of all patients with 
incident prostate cancer 
registered in the Danish Cancer 
Registry from January 1, 2002, 
through 2010 (n = 31,571). 
Jespersen 2014:  Cox 
regression analysis to 
estimate HR of 
myocardial infarction 
and stroke for ADT 
users. 
brachytherapy, or cryotherapy, ADT use was 
associated with a higher cumulative incidence of 
death from cardiovascular causes. 
Jespersen 2014:  Men treated with ADT had an 
increased risk for mycocardial infarction and stroke 
with adjusted HRs of 1.31 and 1.19 respectively, 
compared with nonusers of ADT. 
disease compared 
to men not 
receiving ADT. 
Risk factors for 
CVD are metabolic 
syndrome, 
diabetes and 
sarcopenic obesity. 
Bone health Morote 2007:  A cross-sectional 
study that included 390 patients 
with prostate cancer who were 
free of bone metastases. 
Hamilton 2010: 12 month 
prospective observational study 
of 26 men with  non-metastatic 
prostate cancer during the first 
year of ADT. 
Beebe-Dimmer 2012: Data 
from a cohort of the  
Surveillance, Epidemiology, and 
End Results–Medicare linked 
database,  for fracture incidence 
related to the exposure and 
dose among prostate cancer 
patients of GnRH. 
Morote 2007: DEXA 
Hamilton 2010:  High-
resolution peripheral 
quantitative computed 
tomography. 
Beebe-Dimmer 2012:  
Adjusted HRs using 
time-dependent Cox 
regression  
Morote 2007: The osteoporosis rate was 35.4% in 
hormone-naive patients, 42.9% after 2 years of ADT, 
49.2% after 4 years, 59.5% after 6 years, 65.7% after 
8 years, and 80.6% after 10 or more years. 
Conversely, the rate of normal BMD decreased from 
19.4% in hormone-naive patients to 17.8% after 2 
years of ADT, 16.4% after 4 years, 10.8% after 6 
years, 5.7% after 8 years, and 0% after 10 or more 
years of ADT 
Hamilton 2010:  After 12 months of ADT, total bone 
density decreased by 5.2% at the distal radius and 
4.2% at the distal tibia. Total testosterone levels were 
independently associated with decreased total and 
corrected cortical volumetric BMD at the tibia. 
Beebe-Dimmer 2012: ADT was associated with an 
increased rate of fracture in both non-metastatic 
patients (HR: 1.34) and metastatic patients (HR: 
1.51). Fracture rates increased with increasing 
cumulative GnRH dose but decreased with 
increasing number of months since last use in each 
dose category. The mortality rate doubled for men 
experiencing a fracture after their diagnosis 
compared with that for men who did not experience a 
fracture (HR: 2.05). 
Within the first year 
of ADT, absolute 
BMD loss is ≈5%. 
The temporal 
relationship of ADT 
and incidence of 
osteoporosis is 
demonstrated over 4 
and 10 years at 
49.2% and 80.6%, 
respectively. In a 
large observational 
study, ADT was 
associated with 
increased rate of 
fracture (HR, 1.34), 
and mortality risk 
doubled after a 
fracture. 
(Morote, 
Morin et al. 
2007, 
Hamilton, 
Ghasem-
Zadeh et al. 
2010, 
Beebe-
Dimmer, 
Cetin et al. 
2012) 
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Quality of 
Life 
Green 2002:  RCT or men with 
extraprostatic prostate cancer (n 
=82) assigned to receive 
continuous leuprorelin, 
goserelin, cyproterone acetate 
or close clinical monitoring. 
Llorente 2005: A population-
based, retrospective cohort 
review age 65 and older, 
residing in South Florida 
between 1983 and 1993. 
Cherrier 2009: A cohort of (n-
=20) hormone naïve men with 
prostate cancer were treated 
with intermittent ADT. 
Green 2002:  cognitive 
assessments measuring 
memory, mood, 
attention and executive 
function. 
Llorente 2005: Average 
annual suicide rate was 
calculated for prostate 
cancer-related suicides 
Cherrier 2009:  Profile 
of Mood States 
questionnaire. 
Green 2002: Men receiving ADT per- 
formed worse in two of  12 tests of  attention and 
memory; 24 of  50 men randomized to active 
treatment and assessed 6 months later had a 
clinically significant decline in one or more cognitive 
tests but not one 
patient randomized to close monitoring showed a 
decline in any test performance. 
Burke 2005:  Of 667 completed suicides, 20 were 
prostate cancer-related (3% of the total male suicide 
sample). The risk of suicide in men with prostate 
cancer was 4.24 times that of an age- and gender-
specific cohort. 
Cherrier 2009: A significant decline in spatial 
reasoning, spatial abilities and working memory 
during treatment for men on ADT. Significant 
changes in self-rated mood such as increased 
depression, tension, anxiety, fatigue and irritability 
were evident during treatment compared with 
baseline. 
In a survey of men 
newly diagnosed 
with metastatic 
disease, about a 
third of patients 
were identiﬁed as 
highly distressed 
increasing over the 
ﬁrst 12 months 
with a 4 fold risk of 
suicide compared 
to controls. ADT 
has been found to 
impair memory, 
attention and 
executive functions 
resulting in a 
decline of cognitive 
performance in as 
little as 6 months 
from initiating ADT. 
(Green, 
Pakenham et 
al. 2002, 
Llorente, 
Burke et al. 
2005, 
Cherrier, 
Aubin et al. 
2009) 
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2.5.2 The Saturation Model 
More recently, the widespread acceptance of the "androgen hypothesis" has 
been challenged, arguing the link between Huggins’ castrated men over 70 
years ago and current hypogonadal men treated with ADT is tenuous, with 
no direct evidence of increased risk of recurrence for men successfully 
treated for primary prostate cancer (Morgentaler 2008, Morgentaler 2008, 
Isbarn, Pinthus et al. 2009). There exists an argument to move beyond the 
historical data given the profound AEs of hypogonadism resulting from ADT. 
The saturation model is an alternative to the androgen hypothesis. It 
suggests that physiological concentrations of testosterone provide an excess 
of testosterone and of DHT for optimal prostatic proliferation. By reducing 
testosterone concentrations to below a critical concentration threshold (the 
saturation point) it creates a intracellular milieu and the availability of 
androgens becomes rate limiting to prostate tissue growth (Morgentaler and 
Traish 2009). This model accounts for the observation that prostate cancer 
growth is extremely sensitive to blood testosterone concentrations at or 
below the castrate level (<50 ng/dl (1.73 nmol/l)). In an in vitro cell model of 
prostate cancer cells in a study by Bologna demonstrated that testosterone 
and DHT were able to stimulate growth in prostate cancer cells (LnCaps) in 
only the lowest tested concentrations of testosterone and DHT (0.001 μM). 
At higher concentrations, they show a moderate inhibition effect, but was is 
most cases is not statistically significant (Bologna, Muzi et al. 1995). The 
saturation model could also explain why at peak lifetime level of testosterone 
young men do not develop BPH or prostate cancer despite the presence of 
prostate cancer microfoci (Sakr, Grignon et al. 1994). This study showed 
frequency of cancer in prostates without high grade prostatic intraepithelial 
neoplasia (HGPIN) was 24%. HGPIN was found in 0, 5, 10, 41 and 63% of 
men in the 3rd, 4th, 5th and 7th decades of life, respectively (Sakr, Grignon 
et al. 1994). In addition, it offers an explanation for the lack of an increased 
rate of prostate cancer or significant changes in PSA in testosterone therapy 
trials (Morgentaler 2008). Some of the most compelling evidence for the 
saturation model came in a trial published in 2012 which demonstrated no 
association between prostate cancer and testosterone and DHT (Muller, 
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Gerber et al. 2012). The Reduction by Dutasteride of Prostate Cancer Events 
trial of 8122 men showed that prostate cancer detection was similar among 
men with low compared with normal baseline testosterone levels (25.5% and 
25.1%; p =0.831). Prostate cancer risk was unrelated to testosterone and 
DHT levels. However, among men with low baseline testosterone levels (n 
=596; 18%), those with the lowest baseline testosterone had the lowest 
prostate cancer risk. This risk increased as baseline testosterone levels 
approached normal levels; thereafter, prostate cancer risk stabilized 
regardless of higher testosterone levels. At the higher end of baseline 
testosterone levels, prostate cancer detection decreased (Muller, Gerber et 
al. 2012).  
Furthermore, prostate cancer appears to be more prevalent in hypogonadal 
men (Morgentaler and Rhoden 2006, Shin, Hwang et al. 2010). The 
Morgentaler et al study involved 345 men diagnosed with hypogonadism and 
showed cancer was detection was higher in men in the lowest tertile 
compared with the highest tertile for total testosterone (OR: 2.15; 95% CI 
1.01 - 4.55) and for free testosterone (OR: 2.26; 95% CI 1.07 - 4.78). The 
Shin et al observational study involved a slightly larger cohort of 568 men, 
and showed a low serum testosterone level was associated with a higher risk 
of prostate cancer (OR=1.99, 95% CI=1.25-3.16, p =0.001) but had no 
association with the risk of high grade prostate cancer.  However, both of 
these studies were observational studies within select populations of men. 
Conversely, another study found men with higher Gleason scores ranging 
from 7 to 10 had lower serum testosterone levels at baseline with respect to 
men with lower Gleason scores (2 to 6) (Garcia-Cruz, Piqueras et al. 2012). 
However this study was a retrospective cohort study of 183 men and was 
therefore lower level evidence. A published abstract of 671 hypogonadal 
men also showed that those who had received testosterone had a lower 
incidence of prostate cancer than those men who did not, however the full 
manuscript data was not available for this study (Haider and Haider 2017). In 
contrary to the androgen hypothesis, these studies potentially evidence the 
saturation model proposed. 
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2.5.3 Hormone replacement therapy 
2.5.3.1 Hypogonadism: Testosterone replacement therapy 
Physiological hypogonadism, which is circulating androgens below 
normophysiological levels not resulting from ADT, is associated with 
decreased muscle mass, decreased energy, depressed mood, decreased 
libido, gynecomastia and erectile dysfunction (Bhasin, Cunningham et al. 
2010, Basaria 2014). Physiological hypogonadism can result from impaired 
testosterone production and in rare cases mutations of the androgen 
receptor. Testosterone replacement therapy has been used to treat the 
secondary effects of hypogonadism (Byrne and Nieschlag 2003, Kalra, 
Agrawal et al. 2010). A 2016 systematic review suggested that testosterone 
replacement therapy in four RCTs (involving 1779 participants) improved 
libido, erectile function and sexual satisfaction (Ponce, Spencer-Bonilla et al. 
2018).  
Despite the potential  therapeutic benefits, its use is not recommended in 
men with prostate cancer; men with a palpable prostate nodule or PSA 
greater than 4 ng/ml; or in men at high risk for prostate cancer (Bhasin, 
Cunningham et al. 2010). This is due to predominantly historical data 
supporting the "androgen hypothesis" stating: androgens play a key role in 
the etiology of prostate cancer; high testosterone levels is a risk factor for 
prostate cancer; low levels of testosterone are protective against prostate 
cancer; and administering testosterone to men with existing prostate cancer 
universally causes rapid tumour growth (Gravina, Di Sante et al. 2015). 
Furthermore, concerns over the potential promotion of prostate cancer with 
testosterone replacement therapy have led to reservations in prescribing in 
hypogonadal individuals. Despite this, three RCTs which have addressed 
testosterone replacement therapy on normal prostate tissue have shown no 
increase in PSA, prostate tissue levels or in dihydrotestosterone (Cooper, 
Perry et al. 1998, Marks, Mazer et al. 2006, Bhasin, Cunningham et al. 
2010). These studies were all conducted in normal healthy men and the 
study by Marks et al evaluated testosterone replacement in hypogonadal 
men. As a result, the saturation theory described is the proposed model 
offering to explain these lack of prostate cancer progression in these trials, 
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which contradict what would be expected based on the androgen hypothesis 
(Warburton, Hobaugh et al. 2015). 
However, all of these studies have been conducted in very small numbers of 
men (between 31 and 44 participants), and so the conclusions regarding 
testosterone administration and prostate safety are limited and further large 
scale studies are needed. Furthermore, a systematic review of the use of 
testosterone in hypogonadal men determined that there was a lack of 
evidence demonstrating therapeutic effects on cardiovascular outcomes, 
erectile dysfunction, libido, physical function and psychological wellbeing, in 
contrast to previous studies (Huo, Scialli et al. 2016). The findings of the 
review did suggest however, there to be improvements in muscle strength 
(Huo, Scialli et al. 2016).  
2.5.3.2 Testosterone replacement and prostate cancer 
As one might expect, the controversy surrounding the use of testosterone 
replacement therapy for men with treated or untreated prostate cancer has 
led to a lack of research. But in 2009 a case study was published which 
demonstrated treatment with testosterone for two years in a hypogonadal 
men with untreated prostate cancer (but without HGPIN) resulted in a drop in 
PSA with no prostate cancer progression reported (Rhoden and Morgentaler 
2003). However, this study was a small cohort intervention study of 75 men 
with only a small follow up period of 1 year. As a result, the level of evidence 
is limited from this study, and data on long-term safety was not obtained.  
Another study in 2004 documented that testosterone therapy for 
hypogonadal men who had been previously treated with curative radical 
prostatectomy had no evidence of biochemical or clinical evidence of cancer 
recurrence (Kaufman and Graydon 2004). This study was a small 
retrospective review of 7 hypogonadal men, so once more definitive 
conclusions from this limited level of evidence cannot be drawn. 
Furthermore, the study determined further cautious use of testosterone in a 
carefully selected population given the study limitations.  
Similarly, a study in 2008 demonstrated that testosterone therapy in 
hypogonadal men who had undergone radical prostatectomy or radical 
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radiotherapy for localised prostate cancer had no significant difference in 
PSA compared to the control and that symptoms of hypogonadism had 
improved (Davilla, Arison et al. 2008). Like previous studies, this study was 
limited by a small sample size of 20 men who were retrospectively studied in 
a cohort study and therefore no determinant conclusions can be drawn.  
 A larger and more recent study involving 103 hypogonadal men with 
prostate cancer treated with testosterone after prostatectomy too 
demonstrated that although a rise in PSA was observable, no clinical signs of 
cancer reoccurrence were reported even for those with high risk disease 
(Pastuszak, Pearlman et al. 2013). Although there was a small but 
statistically significant increase in PSA was observed in the high risk and 
non-high risk treatment groups, the increase was not supportive of prostate 
cancer recurrence, i.e. no consecutive increases in PSAs and patient referral 
for salvage radiotherapy. In addition, the biochemical reoccurrence rate in 
the high risk men treatment with testosterone remained lower than in the 
high risk men not treated (Pastuszak, Pearlman et al. 2013). Another study in 
2014 involving 1181 men received exogenous testosterone following a 
prostate cancer diagnosis which was not associated with increased overall or 
cancer-specific mortality (Kaplan, Trinh et al. 2014). Both of these studies 
were retrospective cohort studies therefore the data is limited to the 
population of men studied, which lacked randomisation and therefore a 
selection bias exists. Given both trials did not have placebo groups it is not 
possible to objectively compare those who had not received testosterone 
replacement therapy in the same time frame.  
The lack of clinical disease progression demonstrated in these studies 
suggests that the use of testosterone replacement therapy may be of 
therapeutic benefit where symptoms of hypogonadism have been alleviated. 
The data conflicts with the "androgen hypothesis" where you would expect a 
progression of prostate cancer with the reintroduction of androgens. 
However, there is a significant lack of high level evidence pertaining to 
placebo controlled RCTs of large cohorts in the given data. Much of the data 
is in small cohort and retrospective studies which limits the conclusions 
which can be drawn given the lack of high quality evidence. 
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2.5.3.3 Castrate resistant prostate cancer and androgen replacement 
therapy (clinical and preclinical) 
In vitro CRPC cell models involving prostate cancer cells (LnCap) cultured in 
androgen free medium for 2 years resulted in progression to a different 
phenotype of cell, with slow growing and fast growing characteristics 
(Kokontis, Hay et al. 1998). The new phenotype was not responsive to the 
anti-androgen therapy Casodex. In fact the proliferation of the androgen-
deprived cells was mitigated by the addition of androgens. The cells when 
continuously passed through androgen rich growth medium actually reverted 
cells back to the androgen dependant phenotype (Kokontis, Hay et al. 1998). 
Another study used the same cell phenotype, cultured the cells similarly and 
implanted them into castrated mice models where tumours were allowed to 
form. When treated with testosterone, LnCap cell proliferation was mitigated 
and tumour regression was observed (Umekita, Hiipakka et al. 1996). This 
effect was not observed however in tumours derived from LnCap cells which 
were not androgen deprived or from androgen receptor negative prostate 
cancer (PC3) cell lines. In addition, the removal of testosterone or 
implantation of finasteride, a 5α-R inhibitor, caused regrowth of these 
tumours in these mice (Umekita, Hiipakka et al. 1996). A very similar study in 
mice models demonstrated similar effects and testosterone treatment 
resulted in tumour regression. The suppression of LnCap proliferation was 
caused by G1 cell cycle arrest via reduction of Skp2 and c-Myc and induction 
of p27Kip1 (Chuu, Kokontis et al. 2011). 
One of the few studies to address the use of high dose exogenous 
testosterone in men with CRPC was conducted in 2009 (Morris, Huang et al. 
2009). The trial took small cohorts of patients and administered testosterone 
for a week (cohort 1), a month (cohort 2) or until disease progression (cohort 
3). The trial found that even at supraphysiologal levels of testosterone, its 
administration was safe. One participant achieved a >50% drop in PSA and 
the median time on testosterone treatment was 84 days (range: 23–247 
days) for cohort 3 (Morris, Huang et al. 2009). Interestingly, the exogenous 
testosterone levels given were three times the normophysiological levels but 
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despite this replacement dose, blood testosterone levels did not exceed 
normal levels.  
Another phase I study treated 15 men with endogenous testosterone doses 
of 2.5, 5.0, or 7.5 mg/day with discontinuation of treatment for significant 
toxicity, clinical progression, or a 3-fold increase in PSA (Szmulewitz, Mohile 
et al. 2009). The study demonstrated that testosterone was well tolerated 
and the median time to progression was 9 weeks (range: 2-96 weeks). The 
AEs included one discontinuation of the study due to grade 4 cardiac toxicity 
at 53 weeks and minimal grade 2 toxicities. Symptomatic progression was 
seen in one patient and 20% (n =3) of patients had a decrease in PSA. 
The preclinical studies to exogenous testosterone have demonstrated the 
potential for testosterone to have a therapeutic effect. In addition, the safety 
of testosterone treatment has been demonstrated in early clinical studies 
however there is a significant lack of evidence in human studies for its use 
therapeutically. Although the use of testosterone in symptomatic 
hypogonadal men with or cured of their prostate cancer is theoretically 
underpinned, there is still a reluctance to explore its use in research where 
historically it has always been contraindicated. There is a huge void of 
evidence and a need for larger scale, multi-arm RCT to establish the 
potential therapeutic benefit of testosterone and therefore challenge the 
androgen hypothesis. It may be the case that we have the potential to 
alleviate some of the highly detrimental effects of ADT for these men, and 
this question is fundamentally worth investigating. 
2.6 Summary: Prostate cancer and castrate resistant prostate cancer 
Prostate cancer is the most common malignancy amongst men in the UK. 
CRPC is defined by disease progression despite ADT. Men with CRPC are 
an extremely complex and heterogenous population, potentially with a very 
long history of disease.  
ADT has long been the cornerstone of therapy for men with advanced 
prostate cancer and men with CRPC can remain on ADT for over a decade. 
ADT is associated with a tirade of adverse effects which can significantly 
impact on QoL including detrimental effects to sexual function, body 
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composition, cardiovascular (CV) morbidity, bone health and increased 
fatigue. Furthermore the advancement and development in treatments for 
CRPC has presented further difficulty. Since the introduction of docetaxel, 
numerous other agents have been introduced and have significantly changed 
the treatment landscape for CRPC such as Enzalutamide and Abiraterone. 
The data surrounding the optimum sequencing of these therapies however is 
lacking with no consensus on the optimal sequencing of approved agents for 
CRPC and the potential for cross resistance of pharmacological agents. 
Furthermore, there is some doubt over the tolerability and impact on these 
treatments in men with symptomatic disease or with a poorer performance 
status. 
There is critical debate over the widespread use of ADT as a treatment for 
prostate cancer, with doubt over the accepted "androgen hypothesis". Some 
emerging data is suggested to support and alternative model, the "saturation 
model", whereby androgens such as testosterone are no longer thought to 
be the driving force in prostate cancer progression in androgen sensitive 
disease. This is supported by the lack of disease progression observed in 
men with prostate cancer treated with testosterone replacement therapy. 
There is some suggestion that testosterone replacement therapy could be 
used in men with prostate cancer to alleviate symptoms of hypogonadism, 
although extremely controversial.  
3. Muscle matters: conditions causing skeletal muscle loss  
Whole lean body mass (LBM) contributes to around 30-40% and 20-30% of a 
healthy adult male and female body mass respectively (Nedergaard, Karsdal 
et al. 2013).  Skeletal muscle functions not only to enable locomotion, 
ventilation and prevention against trauma; it critically acts as the main 
glycogen store in humans and mammals, therefore regulating glucose 
metabolism and energy utilization (LeBrasseur, Walsh et al. 2010, Jensen, 
Rustad et al. 2011). For this reason skeletal muscle is implicated in critical 
homeostatic and physiological mechanisms such as insulin sensitivity as well 
as providing the key amino acids for cellular and neuronal development (Wai 
and Langer 2016).  
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A significant loss in LBM can have catastrophic effects not only on 
functionality but on general health and wellbeing. The primary causes of LBM 
loss are natural processes such ageing, starvation or inactivity; however, it 
can also be a common comorbidity accelerated in chronic disease (Evans 
2010, Nedergaard, Karsdal et al. 2013). It results from the imbalance in 
protein metabolism to favour more catabolic than anabolic processes and is 
an accurate predictor of a poorer QoL and an increased risk of morbidity and 
mortality (Mei, Batsis et al. 2016, Vanhoutte, van de Wiel et al. 2016).  
The nature of LBM loss can be complex and multifactorial making it 
increasingly difficult to determine the origin. As a result, particularly in chronic 
disease, there has been great difficulty in accurately defining and recognising 
it's causation in both the clinic and in research. Often terminology is 
incorrectly used to define LBM loss in these conditions; such as sarcopenia 
(which is accelerated LBM loss associated with ageing) a term often used 
regardless of the age and disease status of the individual (Hepple 2012). 
There is an ongoing need to have a wide-spread acceptance of the correct 
terms for these conditions in order for the development of accurate 
diagnostic criteria as well as effective treatments, particularly as we risk the 
false impression that all muscle atrophy is mediated by the same processes. 
In addition to this, the lack of clear definitions or understanding of these 
conditions can hinder the ability to gain epidemiological information and 
recruit to clinical trials (Vanhoutte, van de Wiel et al. 2016).  
In research, progress has been made in determining the pathophysiology 
behind chronic disease associated with LBM loss and this has subsequently 
fed into the development of tools to help accurately screen, diagnose and 
treat. However, both recognition and treatment or prevention of LBM loss is 
still a clinically unmet need. It is vastly underestimated as a driving factor in 
numerous pathologies accelerating metabolic dysfunction and bone loss.  
3.1 Cancer related muscle loss  
A multitude of studies have demonstrated increased treatment toxicity and 
poorer OS with a decline in LBM in cancer patients (and its association with 
a decline in PS). In some cases, dose limiting toxicities can lead to 
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compromising therapy. The findings associating a decline in both LBM and 
PS and the associated detrimental treatment and survival effects are detailed 
in table1.5. 
3.2 Chemotherapy and muscle loss  
Cancer therapeutics have been associated with muscle wastage contributing 
to LBM loss and cancer cachexia (section 3.1.3)  (Barreto, Mandili et al. 
2016). Although the association of chemotherapy with cancer cachexia is not 
completely clear, there are profound side effects associated with 
chemotherapy are thought to be contributory to cachexia such as nausea, 
diarrhoea, anorexia and fatigue (Barreto, Mandili et al. 2016). There is 
evidence to suggest that chemotherapy promotes the onset of cachexia 
regardless of tumour growth (Garcia, Garcia-Touza et al. 2005, Damrauer, 
Stadler et al. 2008). Some studies have shown that where 
chemotherapeutics have been able to indeed reduce the tumour burden the 
symptoms of cachexia persist, in one study this was attributable to the 
induction of NF-κB activity (Damrauer, Stadler et al. 2008). 
3.3 ADT and body composition 
The effect of testosterone in promoting muscle protein synthesis is well 
established (Griggs, Kingston et al. 1989). In hypogonadal men, testosterone 
replacement results in an increase in fat-free mass (predominantly 
associated with increased skeletal muscle mass) and a decrease in fat mass 
(FM) (Brodsky, Balagopal et al. 1996).  
Smith et al demonstrated that within 48 weeks of treatment with ADT for men 
with locally advanced non-metastatic prostate cancer, men experienced a 
2.4% ±0.8% increase in body weight and an increase in FM by 9.4% ±0.4% 
(Smith, Finkelstein et al. 2002). In addition, LBM decreased by 2.7% ±0.5% 
and cross-sectional paraspinal muscle area decreased by 3.2% ±1.3% 
(Smith, Finkelstein et al. 2002). 
In a retrospective analysis conducted by Boxer et al, men who had received 
6 months of ADT were compared to age-matched controls. The study 
showed that men who had received ADT had a higher body FM vs controls 
(29.8 ± 6.3 vs 26.3 ± 4.6, respecively). Men on ADT also had a lower 
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appendicular skeletal muscle mass compared to controls, where skeletal 
muscle mass decreased from baseline to by 2.3%(± 0.03; p ⩽0.001) (Boxer, 
Kenny et al. 2005). 
A cross-sectional study assessed three patient groups; men with prostate 
cancer on ADT for at least 12 months, age‐matched men with non-metastatic 
prostate cancer who were post prostatectomy and/or radiotherapy with no 
previous ADT and age‐matched healthy normal men (control group). The 
study showed the long-term ADT group had a lower BMD (lumbar spine 
BMD (p ≤ 0·0001) and total body BMD (p =0·03), a higher FM and a reduced 
upper and lower body strength (although lower body strength did not reach 
statistical significance, p =0.022) (Basaria, Lieb et al. 2002).There was 
however no statistically significant difference in LBM between the groups.  
A multisite study also followed men with stage M0 prostate cancer initiating 
ADT to 12 months follow up. With the concurrent fall in blood testosterone 
levels (79.7% ± 3.0%) a decrease in LBM of 3.8% ± 0.6% and increase in 
FM 11.0% ± 1.7% was observed (Smith 2004).  
Galvao also demonstrated upper limb, lower limb, trunk and whole-body LM 
decreased by a mean (standard error, SE) of 5.6 (0.6)%, 3.7 (0.5)%, 1.4 
(0.5)% and 2.4 (0.4)% (p <0.01), respectively in men after 36 weeks of ADT 
(Galvão, Spry et al. 2008). Indeed, FM had also significantly increased 
(upper limb 20.7 (3.3)%, lower limb 18.7 (2.7)%, trunk 12.0 (2.5)% and total 
13.8 (2.3)% (p <0.001)). Hip, spine, whole-body and upper limb BMD 
decreased by 1.9 (0.3)%, 3.3  (0.4)%, 1.6  (0.3)% and 1.3 (0.3%) (p <0.001) 
respectively.  
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Author  Type of study Patient 
population 
N Median 
age 
Performance status 
outcomes  
LBM 
outcomes 
Treatment and survival outcomes 
(Wu, Liu et 
al. 2015) 
 
Retrospective 
review 
Prostate cancer, 
Docetaxel 
333 60-70 for 
different 
chemo 
regimens 
 CT: iSKM Those with a high skeletal muscle index (iSKM) had 
a median survival of 5.4 months longer than those 
with a low iSKM. 
(Antoun, 
Baracos et 
al. 2010) 
 
RCT phase III Renal cell 
carcinoma, 
sorafenib 
55 - 
sorafeni
b; 41 – 
placebo 
59  CT: iSKM 8 males with dose limiting toxicity (DLT) had a iSKM 
index 48.6 vs no DLT 54.1 [0.02, SS] and 4 females 
with DLT iSKM 38.4 vs no DLT 38.0 (Not significant). 
None significant association for iSKM DLT for all 
participants. 
(Prado, 
Lieffers et al. 
2008) 
Cross-
sectional study 
Solid tumours of 
the respiratory 
and 
gastrointestinal 
tract 
250 63.9 ECOG scores of >2 median 
survival 13·7 months [1·7–
15·8] vs scores of 0–1 24·0 
months 
[16·1–32·5] 
CT: iSKM 15% of obese patients had sarcopenia (iSKM 43·3 
(6·3) vs non-sarcopenic (iSKM =56·4 (9·9). 
Sarcopenic obesity vs non-sarcopenic survival HR = 
2·4 [SS] Median 10.3 longer survival for non-
sarcopenic.  
(Aslani, 
Smith et al. 
1999) 
 
Longitudinal Breast cancer; 
cyclophosphamid
e, methotrexate, 
and 5-fluorouracil 
based 
chemotherapy 
31 47  Total body 
Nitrogen 
and total 
body 
protein 
A nitrogen index of <0.89 was associated 
significantly with risk for neutropenia (85% of 
courses of chemotherapy in populations with 
<0.089 lead to neutropenia) RR = 1.14 
Table 1.5 Treatment and survival outcomes associated with performance status and lean body mass 
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(Prado, 
Baracos et 
al. 2009) 
 
Prospective 
study 
Metastatic breast 
cancer resistant 
to anthracycline 
and/or taxane 
treatment; 
capecitabine 
55 54.8 ECOG 0-1 vs ECOG >2 was not 
significantly different 
between  sarcopenic and 
non-sarcopenic 
CT: SKM 
and LBM 
(kg) 
25.5% were sarcopenic and 74.5% were non-
sarcopenic. DLT present in 50% of sarcopenic vs 
20% of non-sarcopenic individuals (p = 0.03). 
Lumbar iSKM in sarcopenic individuals was lower 
(35.0 vs non-sarcopenic 47). Whole LBM in 
sarcopenic individuals was lower (34.0 vs non-
sarcopenic 42.5). The dose of mg capecitabine/kg 
LBM in sarcopenic individuals was 104.2 vs non-
sarcopenic 86.9 . Diarrhoea and stomatitis was 
significantly worse in the sarcopenia group. RR of 
Time to progression in sarcopenic individuals 1.9. 
(Prado, 
Baracos et 
al. 2007) 
 
Prospective 
study 
Stage II/III colon 
cancer patients; 
5-FU and 
leucovorin. 
62 60.3  CT: LBM Patients who had DLT had a mean of 5-FU/kg LBM 
of 17.9 versus 16.3 mg/kg in patients who did not 
have any DLT. Neutropenia was the most common 
toxicity. Women with 5-FU/kg LBM >20 mg/kg had a 
statistically significant lower total muscle cross-
sectional area and LBM (-15%) and higher 5-FU/kg 
LBM (+ 24%) compared with women <20 mg/kg. 
Logistic regression showed that 20 mg/kg as cut-off 
for 5-FU/kg LBM was a significant predictor of 
overall toxicity OR = 16.73 for women. 
(Barret, 
Antoun et al. 
2014) 
Prospective, 
cross-sectional 
study 
metastatic 
colorectal cancer; 
oxaliplatin, 
irinotecan, 
fluoropyrimidine 
51 65 WHO score, n (%)  
0: 13 (25.5) 
1: 31 (60.8)  
2:  5 (9.8) 
3: 2 (3.9) 
CT: iSKM Sarcopenia [n (%)] women [5 (38.5)] Men [31 
(81.6)]. In multivariate logistic regression analysis 
the only factor associated with Grade 3-4 toxicity 
was sarcopenia: OR = 13.55. 
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(Cousin, 
Hollebecque 
et al. 2014) 
 
Prospective 
study 
various cancer 
types and stages 
93 57 ECOG: n (%) 
0: 32 (34) 
1: 59 (64) 
≥2 : 2 (2) 
CT: iSKM 10% of patients experienced DLT and had a lower 
iSKM: 40.8±4.6 vs. 48.1±9.6 cm2 /m2 (p =0.01). 
Severe toxicity events (STE) occurred in 14 %. STE 
was associated with low iSKM: 42.4±5.8 vs. 48.4±9.7 
cm2/m2 (p =0.02). 
(Huillard, 
Mir et al. 
2013) 
 
 Retrospective 
review  
Metastatic renal 
cell carcinoma; 
sunitinib 
61 60 ECOG: n (%) 
0: 19 (31.2 
1: 31 (50.8) 
≥2: 11 (18) 
CT: iSKM 
and LBM 
Sarcopenic patients with a BMI <25kgm2 
experienced more DLTs (p = 0.01; OR = 4.1), more 
cumulative grade 2 or 3 toxicities (p = 0.008), more 
grade 3 toxicities (p = 0.04) and more acute vascular 
toxicities (p = 0.009). LBM of those with early DLT = 
37.7 (9.7) vs those without early DLT = 45.6 (9.4). 
iSKM of those with early DLT = 43.5 (10.3) vs those 
without 48.7 (8.2) [SS, P = 0.02]. 
(Choi, Oh et 
al. 2015) 
 
 Retrospective 
review  
Pancreatic 
cancer; palliative 
chemotherapy 
484 60.4 ECOG: n (%) 
0–1: 393 (81.2) 
≥2: 91 (18.8) 
CT: iSKM Sarcopenia and low iSKM during chemotherapy 
were poor prognostic factors for OS. While the OS 
of male patients was affected with sarcopenia and 
decreased iSKM, the OS of female patients was 
influenced with overweight at diagnosis, decreased 
BMI and decreased iSKM. 
(Massicotte, 
Borget et al. 
2013) 
Phase III RCT Advanced 
medullary thyroid 
cancer. 
33 54  CT:iSKM Without DLT vs with DLT had lower iSKM (37.2 vs 
44.3 cm2/m2) and a higher blood vandetanib level 
(1091 vs 739 ng/mL). Lower BMI and low muscle 
mass may be associated with vandetanib toxicity; 
83% of the patients with normal or low BMI and low 
muscle mass experienced DLT. Normal or low BMI 
and low muscle mass had a higher probability of DLT 
(10 of 12, 83%) vs patients with BMI > 25 or SM 
index > 43.1 (3 of 17, 18%). 
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(Tan, 
Brammer et 
al. 2015) 
 
 oesophago-
gastric cancer; 
neoadjuvant 
chemotherapy 
89 65.8  CT: iSKM DLT occurred in 37 (41.6%) undergoing 
chemotherapy. Sarcopenia (OR: 2.95; p = 0.015) 
was associated with DLT. Median OS for patients 
who were sarcopenic was 569 days vs. 1013 days 
for patients who were not sarcopenic (p = 0.04).  
(Iwase, 
Sangai et al. 
2016) 
Retrospective 
study 
Advanced breast 
cancer; 
neoadjuvant 
chemotherapy 
172 54 Whole group ECOG of 0−1 CT:iSKM No significant relation between muscle mass and 
survival. May result from the threshold value for 
iSKM being higher than previous studies, ranging 
from 38.5 to 41.0 cm2/m2. 
iSKM - Skeletal muscle mass; OR - Odds ratios; DLT - dose limiting toxicity; STE - Severe toxicity events 
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3.4 Cancer Cachexia:  Definition, diagnosis and prevalence 
3.4.1 Definition 
Cachexia is defined as "a complex metabolic syndrome associated with 
underlying illness and characterized by a loss of muscle with or without loss 
of FM"(Evans, Morley et al. 2008). It is a multifactorial syndrome with a 
complex pathology and clinical presentation making it difficult to accurately 
diagnose. There is no single adopted operational definition to characterise 
cachexia in patients and, almost self-fulfilling, is therefore infrequently 
identified, diagnosed and treated (Fox, Brooks et al. 2009). This lack of 
definition is equally problematic for healthcare professionals in that they are 
therefore unable to adequately plan appropriate resources and treatment for 
the cachectic patient. It is important that cachexia is not to be confused with 
simple starvation or sarcopenia, an age related loss of lean body mass. 
There are a few hallmark symptoms associated with cancer cachexia and 
include anorexia, fatigue, metabolic and endocrine alterations, and loss of 
LBM. 
The National Cancer Institute has graded cancer cachexia via the common 
toxicity criteria: Grade 1 is defined as 5% loss from baseline body weight; 
Grade 2 is a 10% weight loss; Grade 3 is a 20% weight loss; Grade 4 is 
defined as life threatening (Gullett, Mazurak et al. 2011). The criteria is 
limited with its predominant focus on weight loss without any evaluation of 
inflammation, fatigue, weakness or the loss of muscle mass which are 
predominant detrimental effects of cancer cachexia.  
 
Recent efforts in the scientific and clinical community to properly define 
cachexia have developed a three stage classification: pre-cachexia, cachexia 
and refractory cachexia (Fearon, Strasser et al. 2011). The classification 
aimed to aid healthcare providers in the recognition and therefore correct 
diagnosis and treatment of the syndrome. Conflicting and varying definitions 
underline the importance of working on the diagnostic framework for 
cachexia in order to allow not only a true representation of the prevalence of 
the condition but equally to aid in the development of therapeutics. 
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3.4.2 Clinical manifestation and diagnosis 
There is indeed a spectrum in cancer cachexia, ranging from non-
symptomatic alterations with minimal weight and muscle loss at early stages, 
to severe muscle wasting and poor PS in more advanced stages (Madeddu, 
Maccio et al. 2012).  
In 2006, a meeting organised by Society for Cachexia and Wasting 
Disorders, saw a consensus group made up of international experts 
conclude the agreed definition of cachexia which has predominantly been 
adopted (Evans, Morley et al. 2008). The consensus group agreed that a 
diagnosis of cachexia can be made on the following criteria: "a weight loss of 
at least 5% or more in 12 months or less (or BMI <20 kg/m2) in the presence 
of underlying illness, plus three of the following criteria: decreased muscle 
strength, fatigue, anorexia, low fat-free mass index, abnormal biochemistry 
(increased inflammatory markers (C-reactive protein >5.0 mg/l), IL-6 >4.0 
pg/ml), anaemia (<12 g/dl), and low blood albumin (<3.2 g/dl)) (Evans, 
Morley et al. 2008). Other diagnostic modalities such as physical 
performance can also be very valuable. 
However, this has not been consistently translated in research. Fox et al, 
demonstrated that the proportion of cancer patients with cachexia, from 8541 
cancer patients identified from a retrospective database study, varied 
between 0.8% and 25.5% (for various cancer types) dependant on which of 
four possible definitions of cachexia were employed (table 1.6) (Fox, Brooks 
et al. 2009). For prostate cancer specifically, 3354 patients were identified 
from the study and proportions varied from 0.8% to 15.1% (Fox, Brooks et al. 
2009). 
It has been recognised that there is a need for a robust set of clinical 
identifiers by which patients can be successfully classified in to cachectic 
stages and therefore receive the necessary and effective treatments. A few 
attempts have been made to address this gap (Muscaritoli, Anker et al. 2010, 
Fearon, Strasser et al. 2011, Blum, Stene et al. 2014). More recently Argilés 
et al put forth a model which not only addressed the issue surrounding 
identification and diagnosis of pre-cachexia but equally defined the 
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classification domains within cancer cachexia (Figure 1.5) which is termed 
"The cachexia score" (CASCO) (Argilés, López-Soriano et al. 2011). 
Although issues with diagnosis and identifying the different stages of 
cachexia are recognised internationally, it is likely that even whilst attempts 
are made to rectify this by researchers, it will take significantly longer for new 
approaches in diagnosis to be adopted routinely in clinics. Patients are 
therefore still at risk of going unrecognised and not receiving the best care 
available. 
 
 
Figure 1.5 The CASCO staging scale: BWC body weight loss and composition, IMD 
inflammation/metabolic disturbances/immunosupression, PHP physical 
performance, ANO anorexia, QOL quality of life.  Taken from (Argilés, López-
Soriano et al. 2011) 
3.4.3 Prevalence 
Cachexia is thought to be experienced by up to 80% of advanced stage 
cancer patients and estimated to be responsible for 20-40% of immediate 
cancer related death (Fox, Brooks et al. 2009, Gullett, Mazurak et al. 2011). 
As previously discussed, a lack of standard definition of cachexia has made 
it increasingly difficult to estimate the prevalence of the condition, and 
therefore to accurately plan appropriate resources and treatments for 
patients (table 1.6).  
However, more recently von Haehling and Ankler estimated that around 1 
million of cancer patients within Europe had cachexia, stating that these 
figures were in fact most likely an underestimate (von Haehling and Anker 
2014). Details of the estimated clinical impact are given in table 1.7. These 
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estimates are based on the cachexia criteria determine by the consensus 
group. 
Unfortunately, until a standard definition is routinely adopted internationally 
there can be no accurate data on prevalence.  
Table 1.6 Proportion of cancer patients with cachexia by cancer type. Adapted from 
(Fox, Brooks et al. 2009) 
Cancer type Cancer 
patients 
with 
cachexia 
ICD-9 code 
only 
Cancer 
patients with 
cachexia ICD-
9 code only 
Cancer 
patients 
taking 
prescription 
medication 
indicative of 
cachexia 
Cancer 
patients 
with ≥5% 
weight loss 
Cancer 
patients with 
any one of 
the cachexia 
definitions 
Breast, n =2112 0.80% 3.10% 5.30% 18.60% 24.80% 
Colorectal, n =905 2.50% 6.10% 6.20% 16.40% 25.50% 
Oesophagus, n 
=117 
12.80% 20.50% 13.70% 16.20% 41.90% 
Gastric, n =142 8.40% 15.50% 19.00% 19.70% 41.50% 
Head/neck, n 
=246 
6.10% 17.10% 6.10% 19.90% 37.00% 
Liver, n =153 3.30% 6.50% 3.90% 17.00% 24.20% 
Lung, n =1291 6.40% 9.70% 14.20% 15.20% 31.10% 
Pancreas, n =221 3.60% 7.20% 19.50% 12.70% 34.80% 
Prostate, n =3354 0.80% 3.20% 2.60% 11.00% 15.10% 
 
Table 1.7 The Estimated clinical impact of cachexia in cancer in Europe 2014. 
Estimates are assumed to be rather conservative. Adapted from (von Haehling and 
Anker 2014) 
 
 
  
Prevalence 
in population 
(%) 
Patients at 
risk (%) 
Prevalence 
in patients at 
risk (%)  
Absolute 
number of 
patients with 
cachexia* 
1-year 
mortality of 
patients with 
cachexia (%) 
Cancer, All 
types 
0.5 90 30 1.0m 20-60 
*assupmtions are based on a total population of 742 million in Europe. 
 
3.5 Cancer Cachexia: Pathophysiology and aetiology 
Significant weight loss through the catabolism of skeletal muscle and 
adipose tissue leads to increased morbidity, loss of muscle function, fatigue, 
impaired QoL and ultimately death occurring with 25-30% of total body mass 
loss from baseline pre-treatment weight. The respiratory failure from 
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hypostatic pneumonia is the consequence of loss of respiratory muscle 
function, i.e. the degradation of the diaphragm (Windsor and Hill 1988).  
The degradation of proteins and decreased protein synthesis contributes to 
catabolism of skeletal muscle while loss of adipose tissue results mainly from 
enhanced lipolysis. These mechanisms are most likely predominantly 
mediated through systemic inflammation and involve both interactions of the 
host and the tumour.  
The host hepatic acute phase protein response (APPR) is stimulated by an 
increase in inflammatory cytokines, predominantly IL-6 but others such as  
Tumour necrosis factor-α (TNF-α), Interleukin-2 (IL-2), IL-8, interferon-γ IFN-
γ and parathyroid hormone related peptide (PTHrP), can play an important 
role in the pathophysiology of cachexia (Moshage 1997). It encompasses a 
variety of pathophysiological responses such as pyrexia, leukocytosis, 
hormone alterations, and muscle protein depletion in an attempt to minimize 
tissue damage while enhancing the repair process. It consequentially leads 
to a multitude of metabolic abnormalities, including increased insulin 
resistance, elevated synthesis of acute phase proteins and altered nutrient 
utilization (Ladner, Caligiuri et al. 2003, Figueras, Busquets et al. 2005, 
Skipworth, Stewart et al. 2007). 
The tumour contributes by increasing the local secretion of pro-inflammatory 
cytokines that then lead to the initiation of the APPR by activating the host 
inflammatory cells as they pass through the tumour (Deans, Wigmore et al. 
2006, Deans, Tan et al. 2009). This subsequently leads host cells initiating or 
triggering their own cytokine cascade and therefore the production of pro-
cachectic factors that have direct catabolic effects on host tissues e.g 
proteolysis inducting factor (PIF) and lipid mobilising factor (LMF) (Todorov, 
Cariuk et al. 1996, Hirai, Hussey et al. 1998). Both the systemic inflammatory 
response and the neuroendocrine response become activated.  
Although a variety of mechanisms leading to the development of cachexia 
are likely to exist, its full nature is not well understood. However, some of  the 
predominant processes which are established in research are described in 
further detail.  
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3.5.1 Muscle metabolism 
Reductions in muscle mass are as a result of a whole body net increase in 
protein catabolism. This is not always purely a result of processes increasing 
protein catabolism, decreased protein anabolic processes result from 
decreased plasma insulin levels and insulin sensitivity in the skeletal muscle. 
The metabolism of amino acids is altered from the reduction in insulin 
sensitivity reducing their movement into striated muscle promoting protein 
synthesis and inhibiting degradation (Manchester and Wool 1963, Gelfand 
and Barrett 1987, Ardies 2002).   
The proteolytic pathways are numerous and complex, however the 
predominant pathway implicated in cancer cachexia is the ubiquitin 
proteasome pathway (UPP). 
3.5.1.1 Ubiquitin-proteasome pathway 
Muscle proteolysis in cancer cachexia is predominantly attributed to the 
UPP, occurring as the muscle atrophies and is dependent on ATP to 
dissemble and degrade muscle myofilaments (Lecker, Solomon et al. 1999). 
Proteins are marked for degradation by ubiquitin chained molecules via 
covalent bonds, or polyubiquitination (figure 1.6). Polyubiquitination requires 
the action of the ubiquitin-activating enzyme (E1), ubiquitin-conjugated 
enzyme (E2) and ubiquitin protein ligase (E3) where E3 is the key enzyme in 
the process (Lecker, Solomon et al. 1999, Wing 2005).  
E1 has a relatively low expression in skeletal muscle; E2 expressed in 
multiple mammalian cells, although only a few are expressed in muscle 
wasting, and interacts with E3, which recognises specific protein substrates 
and forms the largest family (although a limited number are upregulated in 
muscle wasting) (Burckart, Beca et al. 2010). The target protein is 
subsequently degraded by a large tube like proteasome, 26S proteasome 
(figure 1.6).Two specific genes encoding E3s have been found to be 
upregulated in catabolic conditions: atrogin-1/MAFbx (muscle atrophy F-box 
protein) under control of FoxO- forkhead box O and MuRF-1 (muscle specific 
ring-finger) under transcription of NF-KB. Studies have demonstrated that 
mice lacking either of these ligases are resistant to proteolysis suggesting it 
as a potential target in the UPP (Bodine, Latres et al. 2001).  
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Figure 1.6 Ubiquitin proteasome pathway. The protein is tagged for degradation by 
an ubiquitin molecule via covalent attachments. The protein is subsequently 
polyubiquitinated by a chain of ubiquitin molecules (conjugation) which is then 
recognised by the 26S proteasome (a large multi-subunit catalytic complex). The 
proteasome then degrades the protein into peptide fragments. 
 
3.5.1.2 TNF-alpha 
TNF-α is one of the first known mediators of cancer cachexia and is 
produced by the host immune system and some tumours. As well as being 
implicated in the UPP, it is also thought to reduce muscle uptake of glucose 
and amino acids key to reducing insulin sensitivity (Tuca, Jimenez-Fonseca 
et al. 2013). 
3.5.1.3 IL-6 
Blood serum IL-6 levels 7 pg/mL or greater was associated with a reduction 
in total protein, albumin, and cholesterol levels, haemoglobin levels, and 
body mass index in one study involving prostate cancer patients (Kuroda, 
Nakashima et al. 2007).  IL-6 was also associated with increased tumour 
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size, greater weight loss and poorer prognosis (Kuroda, Nakashima et al. 
2007). Anti-IL-6 antibodies were effective in attenuating cachectic response 
(Strassmann, Fong et al. 1993). 
3.5.1.4 Autophagic-lysosomal System 
More recently, the autophagic-lysosomal pathway has demonstrated its 
increasing importance in cancer cachexia. In autophagy small ubiquitin like 
molecules are involved in the formation of a double membrane vesicle. This 
vesicle engulfs cellular constituents (autophagosome) and then fuses with 
lysosomes where there content is degraded (figure 1.7) (Sandri 2010).  
Cathepsins (B, L, D, and H) are proteolytic enzymes present within the 
lysosomes which determine its proteolytic capacity (Bechet, Tassa et al. 
2005).The level of lysosomal protease cathepsin B was found upregulated in 
patients with lung cancer and suggested an inverse relationship with fat free 
mass (Jagoe, Redfern et al. 2002). 
 
Figure 1.7 Autophagic-lysosomal System. The autophagosome engulfs the cellular 
components when it then fuses with the lysosome and degrades its contents. 
3.5.1.5 Calcium Dependant (Calpain) Pathway 
Cytosolic calcium derived system can be activated by PIF. Calpains are 
cysteine proteases and are activated by calcium. They are implicated in 
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muscle wasting by initiating digestion of individual myofibrillar proteins 
(Huang and Forsberg 1998).  PIF was first identified as glycosylated 
polypeptide isolated from mice models transplanted with the MAC16 
adenocarcinoma (McDevitt, Todorov et al. 1995). It has been detected in the 
urine of cachexia patients which demonstrates a significantly greater weight 
loss than those whose urine does not contain PIF (Cariuk, Lorite et al. 1997). 
Additionally, injection of PIF which was isolated from the urine of cachectic 
cancer patients into mice induced cachexia (Cariuk, Lorite et al. 1997). 
3.5.2 Adipose metabolism 
Unlike muscle and protein metabolism in cachexia, the factors relating to 
adipose tissue loss have been much less well researched. Studies into the 
mechanisms underlying adipose tissue loss have led to the discovery of a 
LMF, which was purified from the urine of cachectic patients (Masuno, 
Yamasaki et al. 1981, Masuno, Yoshimura et al. 1984). LMF is a tumour 
induced catabolic factor, working on adipose tissue to release free fatty acids 
and glycerol via oxidation (Rydén, Jocken et al. 2007). LMF also binds with 
high affinity to β3-adrenergic receptor which is thought to play a key role in 
the regulation of lipolysis, energy expenditure and triglyceride-fatty acid 
cycling (Russell, Hirai et al. 2002). 
As mentioned previously, cancer induces an upregulation of pro-
inflammatory cytokines which stimulates the APPR. This can reduce 
lipogenesis and circulating lipid uptake whilst also activating lipolysis and 
triglyceride mobilisation by inhibiting lipoproteinlipase (Tuca, Jimenez-
Fonseca et al. 2013).  
3.5.3 Neuroendocrine response 
When it comes to homeostasis, the hypothalamus is the principle co-
ordinator and is fine tuned in energy balance. Therefore, it is only logical that 
it is critically implicated in functions relating to the development of cachexia, 
stimulating or repressing food intake and energy expenditure. The 
hypothalamus is constituted by neurons that co-ordinately secrete 
anorexigenic or orexigenic neuropeptides to control food intake with different 
lesions of hypothalamus, such as ventromedial and lateral regions, inducing 
either hyperphagia or promoting anorexia (Anand and Brobeck 1951, Hervey 
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1959). Research has implicated the melanocortin system as a key driver in 
the development of cancer cachexia. The system primarily consists of pro-
opiomelanocortin neurons that exert anorexigenic effects (Balthasar, 
Dalgaard et al. 2005, Cone 2005, Silva, de Almeida et al. 2014). 
3.5.4 Patient demographic 
It may also be the case that the individual patient demographic plays an 
important role in the development of cachexia as well as the response (and 
therefore reversibility of the condition) to therapeutics. Age, level of physical 
activity and specific patterns of metabolism of ingested protein are likely to 
have an effect (Skipworth, Stewart et al. 2007). Elderly muscle appears to be 
less anabolically sensitive to amino acids, which are key to protein synthesis 
via post-prandial increase in plasma amino acid concentration (Tessari, 
Inchiostro et al. 1987).  
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3.6 Treatments for cancer cachexia 
The multi-faceted aetiology of cancer cachexia makes it a complex and 
difficult disorder to treat and requires a multimodal approach. In early stage 
or pre-cachexia, therapy is primarily prophylactic, and it is generally accepted 
that the only way to completely cure cachexia is to cure the cancer (Suzuki, 
Asakawa et al. 2013). At advanced stages of cancer, usually the time at 
which patients have evolved in to cachexia and refractory cachexia stages, 
the treatments predominantly palliative (Suzuki, Asakawa et al. 2013). In 
addition, the classifications of cachexia are not adequately described in most 
trials which aim to assess the effectiveness of treatments, preventing the 
graded recommendations for the different stages and dimensions of 
cachexia.  
Physiotherapy, psychological and nutritional support is a part of the 
management of cachexia in patients; however table 1.8 predominantly 
focuses on the pharmacological approach to cachexia treatment. 
Pharmacological treatment may be inappropriate in contexts where therapy 
offers more of a burden than relief, particularly for patients at end stages of 
disease. Treatments are focused on alleviating the consequences of 
cachexia and their risk may outweigh the potential benefit. Equally, 
treatments which may take weeks for effect will likely be inappropriate where 
patients may have an extremely poor prognosis and short life expectancy. 
For these reasons, a comprehensive patient assessment and ensuring the 
patient is well informed is key to determine the most effective treatment, if 
any treatment at all.  
The tolerance of chemotherapy and radiation therapy can be dramatically 
affected by weight loss and therefore impact on a patients survival benefit. 
Sub-optimal dosage of anti-cancer therapies and a greater number of AEs 
have been associated with cachexia (Andreyev, Norman et al. 1998, 
O'Gorman, McMillan et al. 1998). Refractory cachexia is characterised by a 
poor performance score (PS; WHO 3-4) (Radbruch L 2010) and at this stage, 
men with prostate cancer would not be eligible to receive either ADT or 
chemotherapy for their disease. Currently, there is no globally effective or 
accepted treatment for cachexia; however there are multiple therapies 
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currently under investigation. The data is lacking however, and as a result 
oncologists may find themselves reluctant to prescribe pharmacological 
agents without further research.  
Table 1.8 highlights the use of novel, emerging and established cachexia 
therapeutics, with detail of their use for men with prostate cancer where data 
is available. This includes a description of whether the agents have 
androgenic activity, indicated by androgen receptor activity. Many of the 
agents have androgenic activity, indicative of the therapeutic role of 
androgens in the mitigation of LBM loss and maintenance of LBM. In 
addition, the studies below have demonstrated other therapeutic benefits in 
reducing symptoms of hypogonadism such as improvements bone health, 
libido, decreased FM, the reduction of hot flashes and improvements in QoL 
for example. Treatments such as testosterone have also been shown to have 
increased efficacy when used alongside exercise (Lenehan 2003, 
Kanayama, Hudson et al. 2008). 
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Table 1.8 Cachexia treatments  
Type of 
agent 
Name of 
agent  
Mode of action and metabolic 
effects 
AR+ Physiological effect Benefits  Harms and Disadvantages Cancer risks Evidence 
SERM Gtx-758 Selective oestrogen receptor 
(ER) alpha agonist: Rapidly 
increases sex hormone binding 
globulin (SHBG) and reduces 
circulating free testosterone 
N Suppress secretion of luteinizing 
hormone (LH) by feedback 
inhibition on the pituitary, 
thereby inhibiting the production 
of androgens by the testes. 
The potential to prevent and/or 
ameliorate bone loss and hot 
flashes in men on ADT. 125 mg 
and 250 mg doses have 
demonstrated dose dependent 
increases in s SHBG, reductions 
in free testosterone, and a 
reduction in PSA. 
Phase 2 clinical trials in men 
with CRPC was terminated.  
Higher incidence of venous 
thromboembolic events vs 
placebo. 
none 
recorded  
(Clinicaltrials
.gov 2011, 
GTx 2012, 
Yu, 
Getzenberg 
et al. 2015) 
 
SARM Gtx-024 Tissue selective anabolic and 
androgenic activity: Binds with 
high affinity and selectivity to 
the AR, does not bind the ER, 
and cannot be converted to 
estrogenic metabolites. 
Y Tissue selective anabolic effects 
on muscle and bone whilst 
sparing androgenic tissue related 
to hair growth in women and 
prostate effects in men.  
Statistically significant increase 
in lean body mass, improved 
physical function, enhanced 
libido, decrease in bone 
turnover (potentially resistant 
to metastasis), decreased total 
FM and increased QoL. 
Reduction in blood insulin. 
In development, was not FDA 
approved for treatment of 
wasting diseases.  AE include 
nausea, alopecia, anaemia and 
vomiting. Decreases in HDL in a 
dose dependant manner.  
none 
recorded  
(Dalton, 
Barnette et 
al. 2011, 
Dobs, 
Boccia et al. 
2013) 
 
SARM MK-4541 Tissue selective anabolic and 
androgenic activity: Gene 
selective agonist that induces 
AR-conformations results in a 
ligand that maintains some of 
the actions of DHT such as 
musculoskeletal anabolic 
activities but lack effects on 
skin and prostate. 
Y Inhibit proliferation and induce 
apoptosis of AR+ prostate cancer 
cell line that grows in an 
androgen-independent manner. 
Inhibits the growth of the 
prostate in rats and mice while 
maintaining significant anabolic 
activity of androgens on bone 
and muscle. Reduction in 
seminal vesicle weight by 96%. 
Induced bone formation. 
Maintains some of the 
beneficial anabolic activity such 
as musculoskeletal benefits. 
Reduced prostate tumour size 
in animal models. 
Only studied in animal models. 
No change in LBM in animal 
models. 
none 
recorded 
(Schmidt, 
Meissner et 
al. 2014) 
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A highly 
selective 
ghrelin 
receptor 
agonist 
Anamore
lin 
Non-peptidic, orally-active, 
centrally-penetrant, selective 
agonist of the ghrelin/growth 
hormone: Increases plasma 
levels of growth hormone (GH), 
IGF-1, and IGF-binding protein 3 
(IGFBP-3) in humans. 
N Appetite-enhancing and anabolic 
effects with significant increases 
in overall body weight, LBM, and 
muscle strength. 
Improves appetite and body 
mass in patients with advanced 
lung cancer who are suffering 
cancer anorexia and cachexia. 
Improvements in LBM. 
 Most frequently occurring AEs 
were hyperglycaemia and 
nausea. Patients did not 
experience improvements in 
their muscle strength in phase 2  
and 3 trials . 
none 
recorded  
(Garcia, 
Boccia et al. 
, Temel, 
Abernethy et 
al.) 
 
Polypepti
de 
hormone 
GH/IGF-1 Hepatic/extra hepatic target 
tissues: stimulates release of 
IGF-1.  Anabolic effects on 
protein synthesis. 
Insulin-like properties: 
increased glucose uptake and 
protein synthesis (particularly in 
liver and muscles) and 
inhibition of lipolysis in adipose 
tissue.  Retention of nitrogen 
and improved nitrogen balance 
increasing protein synthesis. 
N Longitudinal growth of bones. 
Stimulation of myoblast 
differentiation, increases in 
muscle mass and glomerular 
filtration rate. Mobilisation of 
lipids from adipose tissue and 
increases oxidation, sparing 
muscle glycogen improving body 
composition. 
Sustained increases in LBM and 
weight. Decrease in fat mass. 
Improvements in physical 
functioning. Well tolerated in 
HIV wasting .  AEs resolve with 
symptomatic treatment or dose 
reduction. Improvements not 
seen in patients <90% of ideal 
body weight. Benefits can be 
transient. 
Hypoglycaemia, intracranial 
hypertension, myalgia, visual 
changes, headache, nausea, 
vomiting, peripheral oedema, 
carpal tunnel syndrome, 
arthralgia, myalgia, acromegalic 
features, hypertension, 
cardiomegaly, cardiovascular 
risk, glucose intolerance and 
diabetes. 
IGF-1 
implicated in 
cell 
proliferation, 
apoptosis 
angiogenesis
, metastasis 
and chemo 
resistance 
Some 
evidence 
connecting it 
to 
leukaemia. 
(Cohen, 
Clemmons 
et al. 2000, 
Mulligan and 
Schambelan 
2002, 
Lenehan 
2003) 
 
Testostero
ne 
Propionat
e 
Testoster
one 
Propiona
te 
Androgenic, anabolic: Bind to 
the androgen receptor or is 
converted to DHT by 5α- 
reductase activating gene 
expression. 
Y  Shorter duration of action than 
testosterone cypionate. 
Protein anabolic effects may 
be augmented with resistance 
exercise training, efficacy in 
women uncertain. Significant 
gains in LBM, weight, muscle 
mass and muscle strength. 
Improvement in QoL and 
indices of depression. 
Decreased HDL cholesterol. 
Fluctuations in circulating levels 
of testosterone. Lower anabolic 
effects in comparison to 
anabolic steroids. 
Tumours on 
liver and 
kidneys in 
animal 
models given 
doses 
equivalent to 
body-
builders/athl
etes. 
 
(Lenehan 
2003, 
Kanayama, 
Hudson et 
al. 2008) 
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Testostero
ne 
Cypionate 
Testoster
one 
Cypionat
e 
Androgenic, anabolic: Bind to 
the androgen receptor or is 
converted to DHT by 5α-R 
activating gene expression. 
Y  Protein anabolic effects may be 
augmented with resistance 
exercise training, efficacy in 
women uncertain. 
Decreased HDL cholesterol. Can 
aromatise easily (high doses): 
gynaecomastia. Fluctuations in 
circulating levels of 
testosterone. Lower anabolic 
effects in comparison to 
anabolic steroids 
Tumours on 
liver and 
kidneys in 
animal 
models given 
doses 
equivalent to 
body-
builders/athl
etes. 
(Lenehan 
2003, 
Kanayama, 
Hudson et 
al. 2008) 
 
Cannabin
oid 
Dronabin
ol 
Partial agonist activity at the 
cannabinoid receptor CB1, 
located mainly in the central 
nervous system, and the CB2 
receptor, expressed in cells of 
the immune system. 
Psychoactive effects mediated 
by its activation of CB1G-
protein coupled receptors, 
which result in a decrease in 
the concentration of the second 
messenger molecule cAMP 
through inhibition of adenylate 
cyclase. 
N Antiemetic and appetite 
stimulant. 
Improvements in mood and 
appetite. 
Common AE: tiredness, 
dizziness, cardiovascular and 
psychoactive effects. Overdose 
usually presents with lethargy, 
decreased motor coordination, 
slurred speech, and postural 
hypotension. Politically and 
socially controversial. 
none 
recorded 
(Gullett, 
Mazurak et 
al. 2011, 
Tuca, 
Jimenez-
Fonseca et 
al. 2013) 
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Steroidal 
Progestin 
Megestr
ol 
Acetate 
Anti-anabolic effects, the 
mechanism of action of 
progestagens in cachexia has 
not been completely 
elucidated. Agonist of the 
progesterone receptor. Behaves 
as an anti-androgen no affinity 
for the ER.  Antigonadotropic 
effects at sufficient doses, 
decreasing circulating androgen 
and oestrogen concentrations 
to castrate levels in both sexes. 
Y Appetite stimulant. Appetite stimulation, increased 
fat deposition and weight gain. 
Improved wellbeing and QoL. 
Lower circulating levels of IL-1α, 
IL-1β and TNF-α . 
Ankle oedema, mild 
hyperglycaemia, 
thrombophlebitis (doses 
exceeding 800mg/d). Little or 
no improvement in LBM. 30% 
of patients treated experience 
short-term appetite 
stimulation, although weight 
and appetite improve, there is 
no demonstrated improvement 
in QoL or OS. 
none 
recorded 
(Gullett, 
Mazurak et 
al. 2011) 
 
Corticoste
roid 
Prednisol
one 
Synthetic glucocorticoid, a 
derivative of cortisol. Agonist of 
the progesterone receptor. 
Behaves as an anti-androgen no 
affinity for the ER.  
Antigonadotropic effects at 
sufficient doses, decreasing 
circulating androgen and 
oestrogen concentrations to 
castrate levels in both sexes. 
Y Appetite stimulant Improves appetite and QoL 
compared with placebo. 
Long-term use: progressive 
muscle wasting and weakness, 
especially in proximal gravity 
opposing muscles. Mental 
status changes, diabetes, 
osteoporosis, cataract 
formation and 
immunosuppression. It has 
been shown that prednisolone 
plasma levels in patients with 
CRPC were sufficiently high to 
activate mutant AR. 
none 
recorded 
(Richards, 
Lim et al. 
2012) 
 
Fish oil 
suppleme
nt 
Eicosape
ntanoic 
acid 
Omega-3 fatty acid that acts as 
a precursor for prostaglandin-3 
(which inhibits platelet 
aggregation), thromboxane-3, 
and leukotriene-5 eicosanoids. 
May support the anabolic 
potential of muscle through 
sensitising skeletal muscle to 
insulin. May  inhibit several 
catabolic stimuli that promote 
N May decrease muscle breakdown 
via a protective role in skeletal 
muscle differentiation. Immune: 
down-regulate acute phase 
response. 
Significant gains in LBM, weight 
gain, appetite and QoL. 
Phase III clinical trials reported 
minimal benefits of 
supplementation. Previous 
studies were small, non-
randomised and uncontrolled.  
none 
recorded 
(Gullett, 
Mazurak et 
al. 2011, 
Murphy, 
Yeung et al. 
2011) 
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AR+: Y- Indicates the agent as an effect on the androgen receptor; N- the agent has no effect on the androgen receptor.  
muscle degradation during the 
cachectic process 
Anabolic 
steroid 
Oxymeth
olone 
Anabolic agent: Block tumour 
necrosis factor alpha. Nitrogen 
balance is improved. Enhances 
the production and urinary 
excretion of erythropoietin. 
Y Increased LBM  via protein 
anabolism 
Orally available.  Weight gain 
and improvements in LBM. Self-
reported appetite and QoL 
improved. 
 
Elevations in liver enzymes.  
Potential liver toxicity. At higher 
doses: depression, lethargy, 
headache, swelling, rapid 
weight gain, priapism, changes 
in skin colour, urination 
problems, nausea, vomiting, 
stomach pain (if taken on an 
empty stomach), loss of 
appetite, jaundice, breast 
swelling in men, feeling restless 
or excited, insomnia, and 
diarrhoea. No studies 
performed for treatment of 
PCa). Gains not possible 
without weight/resistance 
training and better with 
strenuous exercise. 
Liver cell 
tumours are 
also 
reported. 
Most often 
these 
tumours are 
benign and 
androgen-
dependent, 
but fatal 
malignant 
tumours 
have been 
reported. 
Withdrawal 
of drug often 
results in 
regression or 
cessation of 
progression 
of the 
tumour. 
(Hengge, 
Baumann et 
al. 1996, 
Kanayama, 
Hudson et 
al. 2008) 
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3.6.1 Protein and creatine supplementation, and changes in lean body 
mass 
The effect of protein in promoting the maintenance or gain in LBM is well 
established, including in ageing or chronically ill populations (Burke, 
Chilibeck et al. 2001, Frestedt, Zenk et al. 2008, Gullett, Mazurak et al. 2011, 
Chalé, Cloutier et al. 2012). Protein supplementation has also been shown to 
be useful in mitigating some of the effects of cancer cachexia by preserving 
LBM (Fearon, von Meyenfeldt et al. 2003, Fearon 2008, Gullett, Mazurak et 
al. 2011). In addition it has been shown to improve total energy expenditure 
and physical activity in cachectic patients with pancreatic cancer (Fearon, 
von Meyenfeldt et al. 2003). In breast cancer, a higher protein intake has 
also been associated with better survival (Borugian, Sheps et al. 2004). 
Protein supplementation has also been demonstrated to have greater gains 
in LBM in combination with resistance exercise vs resistance exercise alone 
in frail elderly adults (Tieland, Dirks et al. 2012). 
A combination of protein and creatine supplementation has been 
demonstrated to further increase LBM gains (Burke, Chilibeck et al. 2001). 
Creatine alone has also demonstrated to have beneficial effects on LBM 
such as improved performance and strength, LBM gains and changes in 
GLUT-4, a marker of insulin sensitivity (Burke, Chilibeck et al. 2001, Derave, 
Eijnde et al. 2003, Cermak, Res et al. 2012). In parallel to exercise training, 
creatine supplementation in older adults has been reported in a meta-
analysis to improve both total body mass, fat-free mass, upper and lower 
body muscle strength and functional outcomes such as the 30 second chair 
sit-to-stand test, compared with exercise training without creatine. (Devries 
and Phillips 2014) 
3.7 Summary 
LBM loss is associated with a tirade of poor outcomes for patients with 
cancer. This includes reduced treatment tolerability from increased dose 
limiting toxicities, poorer survival, poorer PS and increased morbidity. In 
addition, a low LBM is associated with increased metabolic disorders such as 
decreased insulin sensitivity. In addition, prostate cancer treatments 
including chemo and ADT can contribute to LBM loss.  
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Cancer cachexia is a multifactorial syndrome with a complex pathology and 
clinical presentation making it difficult to accurately diagnose. Therefore, the 
true data on the prevalence and incidence of cachexia is not clear. However, 
it is estimated to be prevalent in about 80% of all advanced cancer patients 
at varying stages of cachexia. Some data suggest the proportion of cachexia 
in prostate cancer patients can be up to 15%. 
So far treatments for cachexia have been palliative and there are no known 
cures for cachexia, unless the cancer itself is cured. However, therapeutics 
for cachexia have the potential to be of greater benefit if cachexia is caught 
at earlier stages. 
Many of the therapeutics have some androgen receptor activity, which 
further demonstrates the potential therapeutic role of androgens. This 
includes not only the alleviation or mitigation of LBM loss, but also of other 
hypogonadal symptoms such as decreased hot flashes, improved bone 
health and increased libido in some agents. Given that testosterone 
replacement therapy has not been shown to result in disease progression, 
further detail is given in section 2.5, there could be a rationale the use of 
agents with androgenic activity for men with significant side effects from ADT 
detrimental to QoL. Furthermore, nutritional intervention with 
supplementation of protein and creatine has also demonstrated success in 
the preservation and improvement in LBM, including for that of cachexia 
patients. Both whey and creatine supplementation and testosterone 
replacement therapy have also demonstrated superior effects when 
combined with exercise training. 
A combination of a nutritional/pharmacological intervention alongside 
exercise training has the potential to improve symptoms of hypogonadism 
such as LBM loss, declining bone health and increased fat mass. This is of 
particular significance for men with CRPC, who have a long history of 
disease and a poor QoL. 
3.7.1 ADT body composition and cancer cachexia 
LBM loss and its associated skeletal dysfunction as a result of ADT has also 
been suggested to potentially exacerbate cachexia in men with prostate 
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cancer, facilitating a proinflammatory state and decreasing survival (Del 
Fabbro, Hui et al. 2010). The patient demographic described in section 3.3.4 
in this chapter describes how factors such as inactivity, age and patterns of 
metabolism may potentiate cachexia in cancer patients. Given the known 
metabolic effects of ADT, and the some evidence with demonstrates a link 
with hypogonadism in cachexia, there may potentially be a mechanism as to 
ADT predisposing these men at later stages in disease to developing 
cachexia (Wiechno, Poniatowska et al. 2017). Furthermore, hypogonadism 
has also been associated with appetite loss and thus potentially forming a 
vicious circle and exacerbating the cachexia (Garcia, Li et al. 2006, Wiechno, 
Poniatowska et al. 2017). At present however, there exists no established 
mechanism for this.  
Furthermore, the prevalence of cachexia is in fact lower in prostate cancer 
than other cancers given the data in table 1.6, which would suggest that ADT 
does not predispose these men to the onset of cachexia. However, given the 
associated LBM loss with ADT, and potentially pre-existing sarcopenia (given 
that this population of men is older) it may be that cachexia remains 
undiagnosed in this cohort, and is in fact mistaken for LBM loss associated 
with cancer treatments. As described in section 3.2 in the present chapter, 
there are ongoing difficulties with the diagnosis of cachexia in all cancer 
types, and therefore a missed diagnosis of cachexia could be possible. 
Furthermore, ADT could potentially mask the development of cachexia due 
to adverse effects such as increased central obesity. Equally, the lower 
numbers of cachexia in men with prostate cancer may indicate a potentially 
protective effect of ADT. Regardless, it is clear that the accurate diagnosis, 
prevalence and clinical significance of cachexia in men with prostate cancer 
requires further research. 
Subsequently, interventions aimed in men who are undergoing or continue to 
undergo long-term ADT may gain significant benefit from interventions to 
promote LBM accrual. Such interventions may include exercise and/or 
dietary programmes with an aim to improve or maintain LBM whilst these 
men continue through their cancer journey. The following chapter includes a 
literature review to address the current body of evidence surrounding 
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exercise and dietary interventions for men with CRPC with the aim to 
improve outcomes in these men.  
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Chapter 2 Literature review of 
exercise and dietary 
interventions as a supportive 
therapy for cancer and thesis 
overview 
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1. Introduction 
With an expanding cancer population expected to live 5 years or longer 
(White, Holman et al. 2014), the adoption of healthy lifestyle behaviours to 
reduce all cause morbidity and mortality have become increasingly 
important. A cancer diagnosis has long been regarded as "a teachable 
moment" by which cancer patients are motivated to make behaviour changes 
associated with a healthy lifestyle to reduce their risk of adverse health 
outcomes. This encompasses a "self-help" approach to mitigating the long 
and short term effects of cancer and its treatments. This approach can 
include adopting regular exercise and a healthy diet, maintaining a healthy 
weight and other practices such as attending support groups and 
undertaking mindfulness training for example (Jones and Demark-
Wahnefried 2006). Adoption of such lifestyle behaviours has been 
demonstrated to improve QoL and physical function in cancer patients 
(Morey, Snyder et al. 2009, Demark-Wahnefried, Morey et al. 2012). 
As discussed previously, the AEs associated with the treatment of prostate 
cancer can be debilitating. As a result, healthy lifestyle behaviours have the 
potential to help alleviate some of these debilitating effects unique to these 
men.  
2. Cancer and diet 
There are dual concerns when it comes to cancer patients and maintaining a 
healthy weight and diet. As previously discussed, cancer patients can be 
faced with anorexia and/or cachexia as a result of their cancer therapy and 
disease (in advanced cancer) and this is of significant concern. But much 
more prevalent in cancer populations is obesity and overweight problems 
(Brown Jean, Byers et al. 2009, Rock, Doyle et al. 2012). Obesity is an 
established risk factor for cancer such as breast, oesophagus, colon, 
prostate and kidney cancer (Bianchini, Kaaks et al. 2002, Vucenik and Stains 
2012). In addition, excess weight has been associated with increased cancer 
mortality (Calle, Rodriguez et al. 2003). For this reason, changes in body 
composition during the natural history of cancer can be convoluted and 
complex to treat but the metabolic effects can be devastating. Therefore, 
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establishing a nutritional balance is a clinical need in cancer patients to 
ensure favourable body composition and therefore reduce the risk of 
functional decline, comorbidity, and cancer recurrence.  
Multiple pre-clinical and clinical studies, including observational cohort 
studies, have demonstrated anti-tumour effects of a low carbohydrate and 
high protein diet (Slattery, Benson et al. 1997, Terry, Jain et al. 2003, Fung, 
Hu et al. 2011, Ho, Leung et al. 2011, Fokidis, Yieng Chin et al. 2015). A 
high fibre diet has also been associated with chemoprotective effects, 
lowering the risk of colorectal cancer (Bingham, Day et al. 2003, Peters, 
Sinha et al. 2003). 
2.1 Prostate cancer and diet 
In prostate cancer, there are some studies which suggest a link between 
certain food groups and increased cancer risk or chemopreventative effects. 
However, there is great complexity surrounding studies which demonstrate a 
causal relationship with isolated foods or food groups due to the highly 
variable nature of the human diet.  
2.1.1 Eggs 
A meta-analysis of nine cohort studies and 11 case-control studies has 
demonstrated there is no association with prostate cancer incidence or 
mortality and egg consumption (Xie and He 2012). This meta-analysis 
included 5791 cases of prostate cancer, and most studies suggested a non-
significant relationship.  
However, a prospective cohort study (Cancer of the Prostate Strategic 
Urologic Research Endeavor) by Richman et al of 1294 men with prostate 
cancer also showed a greater consumption of eggs was associated with 2-
fold increases in risk of prostate cancer recurrence or progression in a 
comparison of extreme quantiles (HR: 2.02; 95% CI: 1.10, 3.72; p =0.05) 
(Richman, Stampfer et al. 2010). Furthermore, in the Health Professional 
Follow-up study, involving 27,607 men followed from 1994–2008, men who 
consumed 2.5 or more eggs per week had an 81% increased risk of lethal 
prostate cancer compared with men who consumed less than 0.5 eggs per 
week (HR: 1.81; 95% CI: 1.13-2.89; p =0.01) (Richman, Kenfield et al. 2011). 
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Therefore, the data suggests that although egg consumption may not 
increase the risk of developing prostate cancer, there is an associated risk of 
a more aggressive prostate cancer phenotype, prostate cancer reoccurrence 
or progression. 
2.1.2 Fish 
Fish consumption has been associated with a lower risk of death from 
prostate cancer. A meta-analysis of cohort studies demonstrated that for 
men with the highest consumption of fish a there was a 63% reduction in 
prostate cancer-specific mortality [4 cohort studies (n =49,661), RR: 0.37; 
95% CI: 0.18, 0.74] (Szymanski, Wheeler et al. 2010). The meta-analysis did 
not demonstrate an association with a reduction in prostate cancer 
incidence. In particular, fish that is high in omega-3 such as salmon, sardines 
and mackerel, may reduce risk of clinically significant prostate cancer. 
Furthermore, the study of 1294 men by Richman et al did not find an 
association with fish consumption and prostate cancer recurrence or 
progression (Richman, Stampfer et al. 2010). But the findings did show that 
men who consumed the highest levels of fish also consumed more 
cruciferous vegetables and tomato products and less processed meat. 
These findings suggest that although consumption of fish products does not 
affect the incidence of prostate cancer, there may be a lower risk of prostate 
cancer mortality with high levels of fish consumption. However, it may be that 
these findings reflect overall healthier dietary behaviours in those who eat 
larger amounts of fish than those who do not. 
2.1.3 Poultry 
Studies suggest that skinless poultry is not associated with prostate cancer 
progression but poultry with skin has shown some association (Richman, 
Kenfield et al. 2011). The 2010 study by Richman et al did  demonstrate that 
poultry with skin (about 3 servings/week) after prostate cancer diagnosis had 
a 2.26-fold increased risk of recurrence compared with men who consumed 
0 servings/week (Richman, Stampfer et al. 2010). Conversely, poultry intake 
was inversely associated with advanced prostate cancer risk (p =0.009), with 
an odds ratio of 0.7 (95% CI: 0.6–1.0) for highest versus lowest quartile of 
intake for poultry that was baked (Joshi, Corral et al. 2012). This study 
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included 1096 controls, 717 localised and 1140 advanced prostate cancer 
cases from the California Collaborative Prostate Cancer Study. 
The findings suggest that there is tentative evidence a relationship between 
prostate cancer risk and poultry consumption. However, there may be an 
association in how poultry is prepared and prostate cancer risk. 
2.1.4 Processed and red meat 
There have been several reports highlighting processed and/or meat 
increases prostate cancer risk. A large cohort study of 175,343 US men 
demonstrated an increased risk with red and processed meat consumption 
for total (red meat: HR: 1.12, 95% CI: 1.04-1.21; processed meat: HR: 1.07, 
95% CI: 1.00-1.14) and advanced (red meat: HR: 1.31, 95% CI: 1.05, 1.65; 
processed meat: HR: 1.32, 95% CI: 1.08, 1.61) prostate cancer (Sinha, Park 
et al. 2009). The CLUE II study, involving 3892 men, demonstrated that 
processed meat (but not red meat or total meat consumption) was 
associated with a non-statistically significant higher risk of total (5+ vs. ≤1 
servings/week: HR: 1.53, 95% CI: 0.98–2.39) and advanced (HR: 2.24; 95% 
CI: 0.90–5.59) prostate cancer (Rohrmann, Platz et al. 2007).  
However, a meta-analysis published in 2010 demonstrated that no significant 
association between red meat or processed meat and prostate cancer was 
observed (Alexander, Mink et al. 2010). This meta-analysis included 
prospective cohort studies; 15 studies of red meat and 11 studies of 
processed meat were included in the analyses, which included the CLUE II 
study but not the Sinha et al 2009 study. The summary results for processed 
meat were slightly elevated however, the association across the more 
recently published studies that were adjusted was attenuated and not 
statistically significant. The authors concluded there was evidence of 
publication bias across the cohort studies of processed meat. Despite this, 
this study and the authors of this meta-analysis were partially funded by the 
Cattlemen's Beef Board, through the National Cattlemen's Beef Association 
which presents a serious conflict of interest. 
The findings suggests that while some large scale studies do report an 
association between red and processed meat and prostate cancer the data is 
102 
 
tentative with a meta-analysis data of complied studies suggesting no 
association (although this meta-analysis had a serious conflict of interest). 
Furthermore, the World Cancer Research Fund - Continuous Update Project 
(WCRF-CUP) has determined that there is inconclusive evidence of the 
relationship between red and processed meat and prostate cancer, however 
the authors still recommended to limit the consumption of red and processed 
meat (WCRF-CUP 2014). 
2.1.5 Cruciferous vegetables 
The greater consumption of cruciferous vegetables is associated with a lower 
risk of developing aggressive prostate cancer. In one study, risk of prostate 
cancer (stage III or IV tumours) decreased with increasing vegetable intake 
(RR: 0.41, 95% CI: 0.22-0.74, for high versus low intake; p =0.01). The study 
demonstrated this association was considered to be predominantly explained 
by intake of cruciferous vegetables (RR: 0.60, 95% CI: 0.36-0.98, for high 
versus low intake; p =0.02) (Kirsh, Peters et al. 2007).  Similarly, a 2000 
study of 1619 cases of prostate cancer demonstrated the inverse relationship 
(Kolonel, Hankin et al. 2000). 
Overall the studies suggest there to be an inverse relationship with the 
consumption of cruciferous vegetables and prostate cancer risk.  
Furthermore, the WCRF-CUP suggest a diet high in fruit, vegetables and 
legumes as part of cancer prevention recommendations (WCRF-CUP 2014). 
2.1.6 Dairy products 
The Prostate Cancer Systematic Literature Review (SLR) 2014 by the 
WCRF-CUP identified a total of 21 studies which addressed the association 
of dairy products and prostate cancer risk (WCRF-CUP 2014).  
Of 15 studies examining total prostate cancer incidence, 13 reported a 
positive association with dairy products, four of which were significant. Two 
studies reported a non-significant inverse association. Fifteen of the 21 
studies were included in the dose-response meta-analysis, which showed a 
statistically significant 7% increased risk per 400 g of dairy products per day 
(RR 1.07). However, when stratified by prostate cancer type, there was no 
significant association for non-advanced, advanced, or fatal prostate cancer. 
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The report concluded that for a higher consumption of dairy products, the 
evidence suggesting an increased risk of prostate cancer is limited. 
2.2 Supplementation and cancer 
Similarly, with specific food groups, decades of extensive research has 
attempted to clarify the role of dietary supplementation in cancer groups. In 
the previous chapter the effect of whey protein and creatine supplementation 
on LBM in cancer and non-cancer populations was discussed. However, 
there are a number of other dietary supplements which have been studied in 
cancer populations. The primary aim of many of these studies has been to 
demonstrate some level of anti-tumour effect of dietary supplementation as a 
complementary therapy alongside usual cancer treatments. In general, these 
studies have demonstrated limited effects, and the role of dietary 
supplements in cancer is still contentious. This is in part due to the difficultly 
in conducting robust research studies relating to diet. Most of the evidence 
which exists is in retrospective, case control and prospective cohort studies 
as RCTs are much more difficult to perform but provide the most robust level 
one data. However, some RCT studies and their findings have been 
summarized in table 2.1 reproduced from (Vernieri, Nichetti et al. 2018).  
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Table 2.1 RCTs testing supplements for cancer prevention. In the column “Results”, 
relative change in tumour incidence in the intervention arm compared with the 
control arm of each trial is indicated. * indicates statistically significant results (p 
<0.05). Reproduced from (Vernieri, Nichetti et al. 2018) with permission (23 May 
2018; licence 4354810177315) 
Study Participant group Tumour Supplement Results 
(Incidence) 
CARET (Omenn, 
Goodman et al. 1996) 
High risk of 
developing lung 
cancer 
Lung Beta-carotene 
plus retinyl 
palmitate 
+28%* 
The Alpha-
Tocopherol, Beta 
Carotene Cancer 
Prevention Study 
Group (1994) 
Male smokers Lung Beta carotene +18%* 
SELECT (Lippman, 
Klein et al. 2009) 
Men Prostate Vitamin E +17% 
Linxian (Blot, Li et al. 
1993) 
Men/women 
Chinese, including 
poorly nourished 
All tumors Molibden plus 
vitamin C 
+6% 
SELECT (Lippman et 
al., 2009) 
Men Prostate Selenium +4% 
SU.VI.MAX. (Hercberg, 
Galan et al. 2004) 
Healthy French 
adults 
All tumors 
(women) 
Low-dose vitamin 
plus mineral mix 
+4% 
Linxian (Blot et al., 
1993) 
Men/women 
Chinese, including 
poorly nourished 
All tumors Zn plus retinol No 
difference 
The Alpha-
Tocopherol, Beta 
Carotene Cancer 
Prevention Study 
Group (1994) 
Male smokers Lung Vitamin E −1% 
PHS (Hennekens, 
Buring et al. 1996) 
Male U.S. physicians All tumors Beta carotene −2% 
WHI (Cauley, 
Chlebowski et al. 
2013) 
Postmenopausal 
Women 
Colorectal Ca2+ plus vit D −5% 
Linxian (Blot et al., 
1993) 
Men/women 
Chinese, including 
poorly nourished 
All tumors Selenium plus 
Beta carotene 
plus vitamin E 
−7% 
SU.VI.MAX. (Hercberg 
et al., 2004) 
Healthy French 
adults 
All tumors 
(men) 
Low-dose vitamin 
plus mineral mix 
- 31%  
 
2.2.1 Prostate cancer and dietary supplementation 
The data presented below has been taken from the WCRF-CUP meta-
analysis (Prostate Cancer SLR 2014) of the evidence for supplements for 
prostate cancer (WCRF-CUP 2014). 
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2.2.1.1 Calcium supplementation 
The Prostate Cancer SLR 2014 included a total of nine cohort studies in the 
CUP on calcium supplements. Dose-response meta-analysis of four studies 
on total, advanced, and non-advanced prostate cancer showed no significant 
association to prostate cancer risk (Ahn, Albanes et al. 2007, Park, Murphy 
et al. 2007, Park, Mitrou et al. 2007, Kristal, Arnold et al. 2010). Two studies 
were included in the dose-response meta-analysis on fatal prostate cancer 
and calcium supplements, which showed a significant positive effect (RR: 
1.27) (Giovannucci, Liu et al. 2006, Park, Mitrou et al. 2007). One RCT was 
included in the CUP, which showed a non-significant inverse association to 
prostate cancer risk (Kristal, Arnold et al. 2010). The report findings 
suggested that no conclusion could be drawn for calcium supplements. 
2.2.1.2 Beta-carotene supplementation 
The Prostate Cancer SLR 2014 identified five cohort studies (three articles) 
(Cook, Stampfer et al. 2000, Wu, Erdman et al. 2004, Kirsh, Hayes et al. 
2006, Ahn, Moslehi et al. 2008, Ambrosini, de Klerk et al. 2008, Roswall, 
Larsen et al. 2013). All five studies reported no significant association 
between beta-carotene supplements and total prostate cancer. The report 
concluded that consuming beta-carotene in supplements is unlikely to have a 
substantial effect on the risk of prostate cancer. 
2.2.1.3 Vitamin E 
The Prostate Cancer SLR 2014 conducted dose-response meta-analyses for 
vitamin E supplements, and total prostate cancer. No significant associations 
were found at a dose of 100 IU/day (RR 1.00 95% CI 0.99-1.01) from seven 
studies in 21,862 cases (WCRF-CUP 2014). This meta-analysis included the 
findings mentioned in table 2.1 of the SELECT study which did demonstrate 
an association, however when the evidence was compiled with other studies 
no associations were found.  
2.2.1.4 Selenium 
The Prostate Cancer SLR 2014 included a total of five studies in the CUP on 
selenium supplements, but no meta-analysis was possible. The SELECT trial 
reported that selenium supplements, taken alone or with vitamin E, did not 
reduce risk of prostate cancer (Stratton and Godwin 2011). The findings of 
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the SELECT trial relating to selenium exposure given in table 2.1 were not 
related to selenium supplementation but other exposures (such as diet). 
3. Physical activity, exercise and cancer 
The goal of a sustained exercise programme is that over time cardiovascular, 
musculoskeletal, respiratory, neurophysiological and metabolic adaptations 
occur. For cancer patients living with or beyond the disease, there is sound 
theoretical rationale that such adaptations have the potential to confer a 
range of benefits specific to this population. Increasing evidence 
demonstrates that exercise may represent a useful stand alone or supportive 
therapy for the treatment of cancer, improving physiological and 
psychosocial outcomes (Segal, Reid et al. 2003, Knols, Aaronson et al. 
2005, Ornish, Weidner et al. 2005, Galvao, Nosaka et al. 2006, Courneya, 
Segal et al. 2007).   
This thesis refers to the terms "physical activity" and "exercise" throughout 
and are defined below, as has previously been described in (Caspersen, 
Powell et al. 1985): 
"Physical activity is defined as any bodily movement produced by skeletal 
muscles that results in energy expenditure…Physical activity in daily life can 
be categorized into occupational, sports, conditioning, household, or other 
activities. Exercise is a subset of physical activity that is planned, structured, 
and repetitive and has as a final or an intermediate objective the 
improvement or maintenance of physical fitness." 
The current UK public health physical activity recommendations for adults 
states, weekly activity should add up to at least 150 minutes of moderate 
intensity physical activity, undertaken in bouts of 10 minutes or longer or 75 
minutes of vigorous intensity activity a week (Rock, Doyle et al. 2012, 
Sparling, Howard et al. 2015). Compared to healthy adults,  cancer patients 
are more likely to be inactive (defined as not meeting these 
recommendations) as well as being more sedentary after a cancer diagnosis, 
rarely returning to pre-diagnosis activity levels (Brown Jean, Byers et al. 
2009).  
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In this body of work, sedentary was determined as less than 90 minutes of 
moderate intensity exercise per week. This criterion was chosen because 
less than this refers to under three 30-minute exercise sessions or less per 
week, which is substantially less than the Centre for Disease Control and 
Prevention (CDC) and the American College of Sports Medicine (ACSM) 
recommendation (Bennett, Wolin et al. 2009) and therefore those men would 
be considered sedentary or inactive. This criteria has also been described as 
sedentary in a previous systematic review of exercise interventions in 
sedentary cancer patients (Bourke, Homer et al. 2013). However, in research 
any definitions of sedentary have been adopted; furthermore many studies 
have failed to report on what was deemed as sedentary (Pate, O'Neill et al. 
2008, Tremblay, Aubert et al. 2017). 
In comparison to that of studies which focus on early stage cancer, the effect 
of exercise on advanced cancer is less understood except  the need to 
adequately adapt exercise programmes on an individual basis for these 
patients (Brown Jean, Byers et al. 2009). These patients are faced with a 
different set of clinical problems in comparison to those at earlier stages of 
disease. They tend to be older and can have bone disease or signiﬁcant 
impairments such as arthritis or peripheral neuropathy, where there may be a 
higher risk of falls and injures as a result. Equally, there may be occasions 
where the disease or treatment necessitates periods of bed rest, such as 
major surgery, and a result a reduced fitness and strength may follow. As 
discussed previously, for these patients, LBM loss and a gain in visceral FM 
can also be of significant clinical concern. This is compounded with being on 
long-term anti-neoplastic therapies. However, exercise is a promising 
intervention strategy for these patients given its ability to reduce 
inflammation, increase protein anabolism and protein synthesis and 
decrease fatigue (Gould, Lahart et al. 2013) and the beneficial effects of 
exercise training for improving or preserving LBM are well established 
(Galvao, Nosaka et al. 2006, Galvão, Taaffe et al. 2010, Hvid, Winding et al. 
2013). Studies investigating the effectiveness of resistance training and 
cancer have shown positive effects demonstrating an increase in 
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chemotherapy completion rate (Courneya, Segal et al. 2007, van Waart, 
Stuiver et al. 2015).   
3.1 Prostate cancer and exercise  
Multiple systematic reviews have demonstrated that exercise interventions 
have a beneficial effect specific to improving outcomes in men with prostate 
cancer. These results have been summarised in table 2.2. The studies 
represented in the systematic reviews and single meta-analysis represent 
effects of exercise on prostate cancer patients at a range of stages in their 
treatment from interventions during irradiation, ADT and with inpatients prior 
to and/or shortly after surgery. 
The findings of the reviews and meta-analysis suggest that exercise for men 
with prostate cancer is safe and can alleviate some of the symptoms of ADT. 
This includes potential benefits to QoL, fatigue, functional performance and 
muscle strength. In addition, the findings suggest that resistance exercise 
(with or without aerobic training) in particular potentially confers a greater 
benefit for outcomes such as QoL, muscle strength/endurance and LBM.  
However, the strength of this evidence varied between reviews dependant on 
the quality of the trials. Where some reviews excluded based on trial design, 
such as the inclusion of only RCTs, others included non-randomised trials 
and cohort studies. This meant that there were differing levels of evidence 
between studies. Studies which included solely RCT, or stratified studies for 
higher level evidence, found little or no evidence of benefit for disease 
progression, cardiovascular health, or sexual function. There was also 
inconclusive evidence for blood lipids, BMD and immune response. 
There is a stronger body of evidence, from the most robust studies (RCTs 
with a low risk of bias) to suggest improvements in QoL, fatigue and 
muscular strength and endurance. There is moderate level evidence to 
suggest improvements in body composition, sexual function and functional 
performance. Overall it was clear that the most promising results were from 
studies which involved supervised exercise as opposed to home-based 
programmes. In addition, the evidence suggested that group-based 
programmes were also more effective. It was also felt that a mix of both 
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aerobic and resistance exercise was most likely to confer the largest 
beneficial effects. One review assessed studies which examined whether 
trials involving resistance exercise (Hasenoehrl, Keilani et al. 2015) which 
demonstrated beneficial effects on muscle strength and performance (more 
strongly correlated with resistance exercise only studies) and QoL, however 
there were inclusive results on body composition and BMD.  
Only one review conducted a meta-analysis which determined no significant 
effect of exercise to QoL in contrast to the other reviews (Bourke, Smith et 
al. 2015). However, the authors concluded this was potentially due to the 
poor adherence reported in the trials. This was predominantly due to the 
finding that those trials with poor adherence did not find clinically significant 
changes in trial outcomes. In addition there was no significant effect of 
exercise on disease progression, cardiovascular health, or sexual function 
where other systematic reviews had suggested a beneficial effect.  
Observational data and early pilot trials  have linked exercise behaviour after 
diagnosis to favourable disease progression and cancer specific mortality 
outcomes in men with prostate cancer (Ornish, Weidner et al. 2005, 
Frattaroli, Weidner et al. 2008, Kenfield, Stampfer et al. 2011, Richman, 
Kenfield et al. 2011, Magbanua, Richman et al. 2014). However, the findings 
from the study by Bourke et al did not determine an association with exercise 
and disease progression in a meta-analysis data of only RCTs, which 
considers only higher level evidence (Bourke, Smith et al. 2015). Given the 
limitations described in the Bourke et al study (i.e. low adherence) the data 
regarding disease progression and mortality is not conclusive. 
However, due to the level one evidence in multiple published RCTs, special 
recommendations for prostate cancer patients, have been published. NICE in 
the UK (NICE-CG175) and the European Association of Urology (EAU) have 
both recommended supervised exercise training as part of standard 
treatment for men with prostate cancer on long-term ADT (NICE 2014). The 
NICE guidance states to offer men who are starting or having ADT 
supervised resistance and aerobic exercise at least twice a week for 12 
weeks to reduce fatigue and improve QoL. EAU guidelines recommend to 
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offer men on ADT, 12 weeks of supervised (by trained exercise specialists) 
combined aerobic and resistance exercise. 
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Author Review  Quality of studies Findings Conclusions 
(Baumann, 
Zopf et al. 
2012) 
A systematic review of RCTs in 
men with prostate cancer 
including 25 studies involving 
2590 patients. The trials involved 
both supervised and unsupervised 
exercise studies published up until 
2010 
Most studies ranked evidence 
level “2b.” Only four studies, 
all conducted during medical 
treatment, reached the level 
“1b.” 
Supervised exercise was deemed more effective 
than non-supervised exercise. Resistance 
training during irradiation showed significant 
improvement in fatigue, aerobic fitness, muscle 
strength, and quality of life. Similar results could 
be observed in prostate cancer patients 
performing aerobic endurance training during 
irradiation. Toxicity scores also decreased. 
However, resistance training brings about more 
positive effects than endurance training. 
Significant improvements in quality of life, fatigue, 
and fitness seem to only be accomplished by 
isolated resistance training during ADT. 
The data suggested that 
incontinence, fitness, 
fatigue, body 
composition and QoL 
can be improved by 
exercise in patients 
during and after prostate 
cancer.  
(Bourke, 
Smith et al. 
2015) 
A systematic review and meta-
analysis of 16 RCTs involving 
1574 men with prostate cancer 
published up to March 
2015.Studies included aerobic 
and/or resistance exercise.  
Level 1 evidence.  Sensitivity 
analysis of studies that were 
judged to be of high quality 
indicated a moderate positive 
effect estimate (standardised 
mean differences (SMD) 0.33, 
95% CI 0.08-0.58; median 
follow-up 12 wk). The most 
common issues effecting high 
risk of bias that would impact 
on study quality were level of 
study attrition during at least 
one follow-up point, poor 
intervention adherence, lack 
of investigator blinding, and 
selective reporting bias. 
Analysis of the 7 trials which measured QoL 
revealed no significant effect (SMD 0.13, 95% 
confidence interval [CI] -0.08 to 0.34, median follow-
up 12 wk). Similar beneficial effects were seen for 
cancer-specific fatigue, submaximal fitness, and 
lower body strength. There was no evidence of 
benefit for disease progression, cardiovascular 
health, or sexual function. 
These results supported 
the hypothesis that 
exercise interventions 
improve cancer-specific 
quality of life, cancer-
specific fatigue, 
submaximal fitness, and 
lower body strength. 
(Gardner, 
Livingston 
et al. 2014) 
A systematic review of 10 studies 
published between January 1980 
and June 2013. Studies involved 
Risk of bias was addressed 
from the downs and black 
checklist of methodological 
Exercise training demonstrated benefits in muscular 
strength, cardiorespiratory fitness, functional task 
performance, lean body mass, and fatigue, with 
Among patients with 
prostate cancer treated 
with androgen-
Table 2.2 Prostate cancer and exercise interventions reviews  
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men on ADT with prostate cancer. 
Studies included both aerobic 
and/or resistance exercise. 10 
studies were included involving a 
total of 565 patients. 5 studies 
were RCTs and 5 studies were 
uncontrolled trials.  
quality. All studies ranked 
good or excellent for risk of 
bias (>20). 
inconsistent effects observed for adiposity. 
However, the impact of exercise on bone health, 
cardiometabolic risk markers, and quality of life are 
currently unclear. 
deprivation therapy, 
appropriately prescribed 
exercise is safe and may 
ameliorate a range of 
treatment-induced 
adverse effects.  
(Hasenoehrl, 
Keilani et al. 
2015) 
A systematic review of studies 
published between 1966 and 
September 2014 involving 
resistant exercise in men 
undergoing adjuvant therapy and 
rehabilitation of prostate cancer. 
The study included 13 studies 
involving 876.  
Of the 13 studies 2 studies 
were categorized Leve IIb 
and the remainder at level Ia. 
Risk of bias was measured by 
the downs and black 
checklist. The scores of the 
rated studies ranged good to 
excellent (23-30 of a 
maximum of 32 points). The 
study subjects could not be 
blinded to the interventions. In 
7 of the 13 studies, no 
attempt was made to blind 
those measuring the main 
outcomes. 
The majority of studies demonstrated resistance 
exercise as an effective and safe intervention to 
improve muscular strength and performance, 
fatigue and QoL. There is inconclusive evidence 
concerning cardiovascular performance, body 
composition, blood lipids, BMD and immune 
response. 
Resistance exercise  
appears to be  safe  in 
prostate cancer patients 
with beneficial effects on 
physical performance 
capacity and QoL.  
(Keogh and 
MacLeod 
2012) 
A systematic review of 12 studies 
including 8 RCTs and 4 non-RCTs 
in men with prostate cancer. 
Studies included aerobic and/or 
resistance exercise.  
Of the 12 eligible studies, 
three were categorized as 
being Level I, five as Level II, 
and four as Level III–V. 
The most common issues 
effecting high risk of bias that 
would impact on study quality 
were level of study attrition 
and lack of investigator 
blinding. 
High level evidence was observed for the benefits 
of exercise in improving muscular endurance, 
aerobic endurance, and overall QoL, as well as 
reducing fatigue. Moderate level evidence also 
suggested that exercise may improve muscle mass, 
muscular strength, functional performance (walking 
and sit to stand speed), as well as health-related, 
social and physical QoL. These effects appeared 
greater for group, rather than home-based, 
exercise, especially if these programs included 
resistance training. 
It is recommended that 
most prostate cancer 
patients be encouraged 
to exercise regularly by 
their clinicians and 
significant others. Where 
possible, this exercise 
should be group-based 
and include some 
resistance training. 
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3.2 Men on androgen deprivation therapy and exercise 
Reviews have demonstrated that men on long-term ADT with prostate cancer will gain 
specific benefit from interventions of aerobic and/or resistance exercise related to their 
treatment and therefore hypogonadal state. A summary of the available evidence 
which has evaluated exercise in these men are given below.  
3.2.1 Body composition 
Galvao et al demonstrated an increased in LBM in a combined programme of aerobic 
and resistance exercise of 1% to 5% vs usual care (Galvão, Taaffe et al. 2010). 
However, his earlier 2006 study of resistance exercise showed no significant benefit 
(Galvao, Nosaka et al. 2006).  Although both studies had a 12-week intervention 
period, the 2006 study did involve only 10 men compared to the 57 men recruited in 
the 2010 study, which is likely to account for the inconsistencies in these findings.  
Similarly, Segal et al showed a 12-week resistance exercise intervention did not 
improve body composition significantly including body weight, BMI, waist 
circumference, or subcutaneous skinfolds (Segal, Reid et al. 2003). Conversely, his 
later study showed that whilst both control and aerobic exercise arms showed no 
effect on body fat percentage over 24 weeks only the resistance exercise arm was 
able to prevent increases in body fat (Courneya, Segal et al. 2007). 
Hanson et al also reported a significantly increased total body muscle mass of 2.7% 
and thigh muscle volume 6.4% with a 12-week resistance exercise intervention in 
black African men (Hanson, Sheaff et al. 2013). The study also demonstrated a 
significant decreased percentage body fat by 2.2% but not in subcutaneous or 
intermuscular fat. 
3.2.2 Bone health  
Of the RCTs mentioned in the reviews, Galvao et al investigated whole-body bone 
mineral calcification and hip BMD in 10 men over 20 weeks of resistance exercise and 
found no significant change (Galvao, Nosaka et al. 2006). However, the intervention 
may have mitigated further detrimental changes to bone health as opposed to 
increasing BMD. 
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3.2.3 Physical function 
Numerous studies have demonstrated a significant beneficial change in physical 
performance defined as cardiorespiratory fitness, muscular outcomes and functional 
tasks. Bourke et al showed significant improvements in cardiorespiratory fitness with a 
12-week aerobic and resistance exercise intervention which was maintained at six 
months of follow up (Bourke, Doll et al. 2011). The Hanson et al study demonstrated 
strength training significantly increased chair sit to stand tests and six-minute walk test 
(6MWT) (p <0.001) as well as timed up and go, stair climbs and 400m walk (p <0.05) 
(Hanson, Sheaff et al. 2013). However another study involving a 16-week physical 
activity intervention showed no significant changes in 6MWT or the sit and reach test 
(Culos-Reed, Robinson et al. 2010) but did show improvements in systolic and 
diastolic blood pressure.  
A 2012 study by Alberga et al failed to demonstrate significant changes in V˙O2 peak 
in the aerobic and resistance exercise group in a 24-week intervention, although 
aerobic fitness decreased in the control group (p =0.044) (Alberga, Segal et al. 2012). 
3.2.4 Fatigue 
Both the 2011 study by Bourke and the 2003 study by Segal showed significant 
reductions in fatigue with exercise training (Segal, Reid et al. 2003, Bourke, Doll et al. 
2011). The Segal 2003 study, involved 155 men in a 16-week resistance exercise trial. 
However the trial by Bourke et al involved 50 men undertaking a programme of 
aerobic activity so the findings are limited by a small sample size. The later study by 
Segal in 121 patients showed only a borderline significant improvement in fatigue with 
the resistance training group and no difference in the aerobic training group (Segal, 
Reid et al. 2009). Furthermore, the study demonstrated greater long-term 
improvements in fatigue in the resistance exercise group (Segal, Reid et al. 2009). 
Culos-Reed et al showed no benefit to fatigue with a home-based exercise 
intervention vs control (Culos-Reed, Robinson et al. 2010). The Culos-Reed study 
involved 100 men and included a mix of aerobic and some light resistance training. 
This may indicate that a 16-week programme of resistance exercise confers a more 
robust beneficial effect on fatigue when compared to aerobic training.  
3.2.5 Cardiovascular health 
ADT is associated with significant cardiovascular morbidity and mortality (Zhao, Zhu et 
al. 2014). This has been evidenced by the reduction in flow-mediated dilatation (FMD) 
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of the brachial artery in men treated with long-term ADT (Gilbert, Tew et al. 2013). An 
inverse relationship between relative FMD and the risk of future cardiovascular events 
exists. It has been suggested that a reduced cardiovascular risk of 13% per 1% higher 
relative FMD in individuals with any pre-existing cardiovascular risk factor (Ras, 
Streppel et al. 2013).  
Gilbert et al demonstrated an improvement in FMD in a 12-week supervised exercise 
intervention of aerobic, resistance and balance exercises (Gilbert, Tew et al. 2016). At 
12 weeks, the difference in FMD was 2.2% favouring the intervention group. The study 
estimated that the changes in FMD could translate clinically to a significant risk 
reduction in cardiovascular events by 39%, with a 4.1% absolute risk reduction.  
Galvao et al showed a decrease in C-reactive protein after a 12-week supervised 
exercise intervention, but the findings were not supported by any other improvements 
in cardiovascular health outcomes (Galvão, Taaffe et al. 2010). Another study of a 
home based exercise programme, by Culos-Reed et al, failed to show any clinically 
significant change in systolic and diastolic blood pressure, although there was a 
reduction in both the non-exercising and exercising groups (Culos-Reed, Robinson et 
al. 2010). 
3.2.6 Quality of life 
A number of studies have reported on QoL outcomes. Cormie et al there was a 
significant improvement in perceived general health, vitality and physical health 
composite domains of the Short-Form Health Survey (SF-36) (Cormie, Newton et al. 
2013). The 2003 and 2009 Segal studies too showed significant benefits of resistance 
exercise training to QoL measures (Segal, Reid et al. 2003, Segal, Reid et al. 2009). 
Conversely, a non-significant improvement in the Functional Assessment of Cancer 
Therapy- Prostate (FACT-P) QoL questionnaire score was demonstrated in the Bourke 
study (Bourke, Doll et al. 2011). The Culos-Reed study also demonstrated no 
significant benefit of the home based exercise intervention vs control in the QoL 
measures (Culos-Reed, Robinson et al. 2010). 
3.3 Supplementation and exercise in men with prostate cancer 
There is evidence to suggest that supplements taken alongside a programme of 
exercise is of some therapeutic benefit regarding LBM loss associated with cancer, 
either from the disease itself or from its associated treatments (Fearon 2008, Penna, 
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Busquets et al. 2011, Madeddu, Maccio et al. 2012). Exercise, whey protein and 
creatine supplementation to promote muscle protein synthesis through stimulation of 
anabolic processes in men with castrate levels of testosterone is therefore an 
attractive therapeutic choice. 
Two studies published recently have evaluated the effect of dietary supplementation 
and resistance exercise on musculoskeletal health for men with prostate cancer on 
long-term ADT (Hanson, Nelson et al. 2017, Dawson, Dorff et al. 2018).  
Hanson et al examined the effect of whey supplementation and resistance exercise on 
acute muscle protein synthesis response for men undergoing ADT for advanced 
prostate cancer (Hanson, Nelson et al. 2017). The findings demonstrated that men on 
ADT are still able to initiate a robust response increasing muscle protein synthesis 
following resistance exercise and whey protein supplementation, despite basal protein 
synthesis being compromised by ADT. The study involved 18 participants, 8 men 
undergoing treatment for prostate cancer and 10 healthy age-matched controls. The 
average duration of ADT in these men was 18 months. The resistance exercise 
consisted of unilateral knee exercises followed immediately by consuming 40g of whey 
protein isolate; the unilateral model enabled the participants to serve as their own 
resting controls (where one leg was not performing any knee exercise). The findings 
suggest that men on ADT for prostate cancer had a reduced basal and protein induced 
rises in muscle protein synthesis. However, when the protein ingestion followed 
resistance exercise, the increase in muscle protein synthesis exceeded that of the 
protein alone (resting leg), with the magnitude of the increase not statistically 
significantly different to that of the healthy age-matched controls.  
A pilot four arm RCT assessed the effect of protein supplementation, resistance 
exercise or the combination of both vs control in men with advanced prostate cancer 
undergoing ADT (Dawson, Dorff et al. 2018). The study involved 32 prostate cancer 
patients over a 12-week period and the aim was to counter obesity associated 
sarcopenia and cardiometabolic markers in men on current or adjuvant ADT. Individual 
resistance exercise was undertaken with a personal trainer, three times per week 
lasting approximately 45 minutes and the supplementation was 50g a day of whey 
protein isolate. The study demonstrated that 12 weeks of resistance exercise training 
significantly countered ADT related LBM loss and fat gain. Approximately 44% of the 
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participants in this study were classified as sarcopenic at baseline (appendicular 
skeletal mass (kg)/height (m2)) < 7.26 kg/m2, no differences between the groups at 
baseline) with the prevalence increasing in the non-exercising groups vs a significant 
reduction in the exercising groups. However, a comparison between the groups 
receiving protein demonstrated the protein did not enhance the effects of resistance 
training.  
4. Castrate resistant prostate cancer and exercise: A systematic review 
of the literature 
4.1 Methods 
A literature search was carried out to describe the current knowledge base for CRPC 
and exercise interventions. The search engines used were Web of Science, Medline 
via EBSCO, Scopus and SportsDiscus. The key search terms are given in table 2.3 
and literature was filtered by human studies and English language. Papers were 
assessed at abstract and title and subsequently full text. Exclusions were made if the 
papers were reviews, not specific to men with CRPC or non-primary literature (ie, 
study or trials). Figure 2.1 summarises the search strategy. 
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Table 2.3 Search terms and the number of literature retrieved from the databases (Search 
date: 23/06/2018) 
Search 
term 
number 
Medline Scopus Web of Science SportsDiscus 
1 "castrat* resistant" 
6152 8083 7845 22 
2 "hormone refractory" 
2753 3161 3189 13 
3 "prostate cancer" 
99828 156,345 174873 1244 
4 prostat* N3 neoplasm* 
114738 1058411 73542 7 
5 prostat* N3 carcinoma* 
18037 266764 194493 23 
6 physical* N3 activ* 
106441 1678446 1838725 57495 
7 "motor activity" 
100656 109941 15200 1338 
8 physical* N3 exercis* 
21904 207348 344227 10069 
9 "aerobic exercis*" 
7972 15698 12486 9513 
10 "resistance training" 
10056 15090 8048 6856 
11 lifestyle 
81369 103508 87833 18087 
12 walking 
69954 141284 164202 21482 
13 kinesi* 
39389 53068 15561 29541 
14 "strength training" 
4356 6539 5521 9180 
15 "exercise therap*" 
35928 34231 3365 6197 
16 1 OR 2 
8763 10992 10891 34 
17 3 OR 4 OR 5 
224283 190486 188238 57521 
18 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 
392525 605014 462995 140631 
19 16 AND 17 
6987 10890 10723 0 
20 17 AND 18 
107198 3280 2650 57497 
21 19 AND 18 
23 56 33 0 
1 "prostat* neoplasm*"; 2 prostat* NEAR neoplasm*; 3 prostat* NEAR carcinoma*; 4 
"prostat* carcinoma*"; 5 physical* NEAR activ*; 6 "physical* activ*"; 7 physical* NEAR 
exercis*; 8 "physical* exercis*" 
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Figure 2.1 Summary of literature review search strategy 
4.2 Results 
Post exclusion, only two texts were available an abstract and a protocol, both for the 
ongoing INTERVAL‐MCRPC (ClinicalTrials.gov Identifier: NCT02730338) (Newton, 
Hart et al. 2017, Newton, Kenfield et al. 2018). The phase III RCT will determine if 
supervised high-intensity aerobic and resistance exercise with psychosocial support 
increases OS compared with printed exercise recommendations (self-directed 
exercise) with psychosocial support in men with CRPC. The study aims to recruit 866 
men with no prior chemotherapy or evidence of progression of their disease at 
enrollment. After written informed consent, confirmation of clinical eligibility and 
successful completion of screening assessments, men will be randomised on a 1:1 
ratio to either the supervised exercise or self-directed exercise.  
Secondary endpoints include time to disease progression, occurrence of a skeletal-
related event or progression of pain, and degree of pain, opiate use, physical and 
emotional quality of life, and changes in metabolic biomarkers (Newton, Kenfield et al. 
2018). 
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This study has extensive exclusion criteria, however such exclusions could lead to 
poor recruitment. Given that some clinicians may preferentially treat with docetaxel 
early whilst men have good PSs, such exclusion criteria including no previous 
docetaxel regimen for metastatic disease will likely limit the timeframe by which men 
can be eligible for recruitment. In addition, another exclusion is the presence of 
progressive disease whilst undergoing treatment with enzalutamide or abiraterone. 
These exclusion criteria will exclude a proportion of patients who otherwise may be 
very keen to take part in the study. Men must also have a good PS (ECOG ≤ 1). Given 
that these men have a long history of disease and treatment, many suffer with adverse 
effects which impact on PS. In addition, the proportion of men at such advanced 
stages of disease who have maintained a good PS is not clear, but it is likely to be 
much less compared to earlier stages of disease where the literature for exercise 
interventions for prostate cancer patients exists.  
The need for a good PS in these men may be explained by the intensity of the 
supervised exercise programme proposed. The period of the study intervention period 
is 2 years (24 cycles with each cycle spanning 28 days). Given that upon the diagnosis 
of CRPC life expectancy in the UK is around 13.5 months, to ensure the participants 
have the best chance of completing the intervention it would be necessary to choose 
those with the best PS at baseline. However, a long period of intervention and the 
reported 3 year follow up, would give a great deal of data on survival and disease 
progression for those recruited. The applicability of these findings on the CRPC 
population however may be brought into question as those with the best PSs are 
recruited and therefore reflect only a select population. 
The programme consists of structured resistance exercise and combinations of high-
intensity interval training and moderate-intensity continuous training aerobic exercise. 
Although, the programme is stated to be "individualised, periodised, progressive and 
autoregulated" there may be issues with adherence with exercise of high-intensity, 
particularly with consideration to adverse effects such as fatigue. However, once more 
such criteria risk the exclusion of a large proportion of CRPC and therefore may bring 
into question the applicability of the findings of this study.  
The study offers a gradual tapered transition to self-management, with the subsequent 
48 weeks of the programme (year 2) self-managed with one exercise visit required. 
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Such an approach could be a successful way to empower these men to a "self-care" 
approach to managing the symptoms of their cancer. In addition, the trial includes 
behavioral and psychological support which could improve adherence and long-term 
behavior change.  
Finally, the study also encompasses both patient and public involvement. Such data 
will provide a unique viewpoint and experience of participants to ensure that the study 
protocol engages participants and addresses the needs of men with CRPC. In 
addition, the study also includes urologists and medical oncologists as part of the 
research team who work with men with CRPC on a daily basis. The inclusion of these 
clinicians will help inform the study of patient priorities, experience and preferences to 
help inform the development of the research questions and outcome measures. 
4.3 Castrate resistant prostate cancer and exercise: Unmet supportive care 
needs 
The significant lack of data suggests that there is an unmet clinical need for supportive 
interventions of exercise in men with CRPC. It is likely that due to the advanced stage 
at which these men present they have been negated in their inclusion to the plethora 
of exercise intervention studies that exist for men with prostate cancer. However, the 
advanced stage at which these men present mean they indeed stand to gain a great 
deal from such interventions. The associated benefits of exercise to LBM, BMD, QoL, 
fatigue and physical function to name a few are the heavily burdened by this 
population of men. Their long-term ongoing cancer therapies involving ADT and 
chemotherapy mean a potential specific benefit to treatment based outcomes, such as 
increased chemotherapy completion rate and reduced dose-limiting toxicity. Due to the 
nature of complex lifestyle intervention studies, such complex men with multiple 
comorbidities are likely to be seen as less desirable when looking for evidence of 
efficacy. Therefore, there is a significant gap in the research for such beneficial 
supportive programmes in men with CRPC. 
Although the ongoing INTERVAL‐MCRPC is a supervised exercise intervention for 
men with CRPC with an aim to improve survival, it replicates the limitations of previous 
cancer and exercise studies in some aspects (Newton, Hart et al. 2017, Newton, 
Kenfield et al. 2018). The study negates the inclusion of men with a poorer 
performance status, those with progressing disease on second line ADT as well as 
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those who have received a previous docetaxel regimen for metastatic CRPC. Such 
exclusions will likely mean that a very large proportion of men with CRPC will not be 
eligible for the study and therefore, those who although may have complex needs and 
potentially stand to gain a great deal from supportive interventions are neglected.  
5. Thesis overview 
The current prostate cancer treatment pathway is evolving and therefore so is the care 
of these men; the effects of new therapies, changes to treatment sequencing and 
access to treatments are unclear. Subsequently, with such uncertainties, it is not 
known how exercise may be feasible in the current treatment pathway. Despite the 
existing NICE recommendations for exercise training for men undergoing or initiating 
ADT, there is a significant lack of data as to show how exercise has been implemented 
and what a successfully implemented exercise programme may look like. It is also 
clear that given the severe and detrimental effects of long-term ADT, there is a clinical 
need for such interventions. Such lifestyle interventions have the potential to improve 
both physical and psychological wellbeing in men with CRPC; reducing the burden of 
treatment and disease. Furthermore, the specific barriers these men may face 
engaging in exercise given their advanced stage of disease, both treatment and 
disease related, is not documented. No studies exist which have evaluated an RCT of 
a lifestyle intervention of resistance exercise alone or in combination with a 
dietary/nutritional intervention for men with CRPC.  Despite the theoretical rationale for 
such a study, this group of men have remained neglected in research studies of 
lifestyle interventions for prostate cancer. 
A lifestyle intervention of resistance exercise, whey protein and creatine 
supplementation in men with CRPC has the potential not only to confer some of 
prostate specific benefits (such as QoL, fatigue, sexual function, muscle strength and 
endurance demonstrated in previous studies) but also offer a supportive therapy 
where currently nothing is offered. In addition, LBM loss associated with long-term 
ADT and advanced cancer could be mitigated or potentially reversed with such an 
intervention. A lifestyle intervention to alleviate some of the symptoms of 
hypogonadism and advanced cancer could significantly improve outcomes in these 
men and therefore QoL but at present, no such intervention has been conducted.  
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For the reasons described, the following body of work in this thesis is presented. This 
includes a national survey and interviews of healthcare professionals involved in 
prostate cancer care (chapter 3); a feasibility RCT of a lifestyle intervention involving 
exercise, whey protein and creatine supplementations for men with CRPC (chapter 4) 
and finally post-study focus groups of the RCT participants (chapter 5). This body of 
work is proposed to address the following research question. 
Research question: Can a lifestyle intervention of resistance exercise, dietary 
supplementation and dietary guidance improve outcomes in men with CRPC? 
5.1 Objectives 
 Describe exercise in the usual care pathway for men in the UK with prostate 
cancer who have undergone ADT; including if, how and in which trusts exercise 
is part of "usual care". 
 Explore the perspectives of health care professionals (HCP) on the use of 
exercise training for the management of CRPC. 
 Determine the feasibility and participant acceptability of a 16-week programme 
of resistance exercise training, dietary supplementation and dietary guidance as 
a novel supportive therapy in men with CRPC. 
5.2 Choice of methods 
5.2.1 A multi-method approach 
The importance of drawing on multiple sources of evidence to provide public health 
guidance, using a spectrum of sources and methodologies is widely recognised in 
healthcare research (Pawson 2006). Although, RCTs are considered the optimal study 
design giving an accurate estimate of the effect of an intervention (Craig, Dieppe et al. 
2008); both NICE and The Medical Research Council (MRC) recognise the need for 
qualitative methods to support and inform guidance for complex health interventions 
and development of public health guidance (NICE 2012, Craig, Dieppe et al. 2013). In 
public health, it is no longer enough to identify the efficacy of a prescribed intervention 
with only quantitative methods, the complexity of healthcare pathways and causal 
chains in public health means that often RCTs must be enhanced by qualitative 
studies to further understand the context, mechanisms underpinning their external 
validity. Multiple methodological designs provide robust evidence which enable the 
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implementation of such interventions successfully in real-life situations (Webber 2014). 
Furthermore, it may not be possible or ethical to undertake an RCT alone to test 
theory in complex interventions inclusive of multiple social interactions (Hawkins 2016) 
or where interventions are too large to implement or where it is impossible to 
manipulate exposure to the intervention.  
In public health, there is more than just the need for recommendations on what may be 
effective and/or cost effective. Social scientific, epidemiological and clinical evidence is 
needed to examine the context, process and implementation of an intervention and 
how this may affect outcomes. Essentially this multi-focus approach enables 
researchers to address when, why, how and for whom an approach does work 
(Pawson 2006). For example, the method of using interviews to obtain practitioners' 
views, experiences and working methods (including any barriers and facilitators to 
supporting implementation of the intervention) was fundamental to the development 
and design of the feasibility study of a complex lifestyle intervention (NICE 2012). 
Therefore, a multi-method approach to collecting evidence should be utilised and 
findings synthesised to comprehensively answer the research aims of complex 
interventions.  
5.3 Philosophical approaches 
This research in this thesis is based on the pragmatic paradigm using abductive 
processes that combine both qualitative and quantitative methods driven by the 
research questions (Neuman 2013). The range of methodological approaches routed 
in different philosophical positions overcomes the limitations of using a single 
methodological approach. Methods such as the RCT are routed in more positivist 
philosophical underpinnings, where positivist social science is deemed: 
"an organised method for combining deductive logic with precise empirical 
observations of individual behaviour in order to discover and confirm a set of 
probabilistic causal laws that can be used to predict general patterns of human 
activity" - (Neuman 2013) Chapter 4 page 95.  
However, realism assumes the existence of an empirical world outside of our inner 
thoughts and perceptions of it, which refers to underlying processes and mechanisms, 
and therefore the "real world" exists regardless of whether or not it is observed (Bonell, 
Fletcher et al. 2012, Neuman 2013). Qualitative methods are tools which can provide 
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emphasis and value on the human experience of the social world and the significance 
of both the participant and investigator interpretations. A realist approach can utilise 
these methods to explore the mechanism of change, the aspects of the intervention 
components and how pathway variables mediate intervention effects (Bonell, Fletcher 
et al. 2012).   
5.4 Summary 
Despite the evidence for the benefits of exercise and dietary interventions in men with 
prostate cancer or those with advanced cancer of any type, to the authors knowledge 
there have been no studies which have explored the effects of such interventions to 
improve outcomes in men with CRPC. Particularly as these men are afflicted with the 
AEs of long-term castration, they have the potential to gain specific health benefits 
from a supportive lifestyle intervention, such as improvements in LBM, physical fitness 
and physical performance. The following body of work was conducted to investigate if 
supportive resistance exercise training, dietary supplementation and dietary guidance 
intervention would be feasible for men with CRPC using the research methods 
described. 
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Chapter 3 Exercise training 
provision for prostate cancer 
patients - a survey and interviews 
of healthcare professionals in the 
UK 
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1. Introduction 
NICE published a set of guidelines (CG175, 1.4.19) around diagnosis and treatment of 
prostate cancer stating specifically to "Offer men who are starting or having androgen 
deprivation therapy (ADT) supervised resistance and aerobic exercise at least twice a 
week for 12 weeks to reduce fatigue and improve quality of life" (NICE 2014). There is 
very little known about the current provision of exercise services in the NHS and how 
(if at all) exercise programmes or referral schemes have been provided. This includes 
information on whether current provision for exercise support is integrated as part of 
current prostate cancer care, who it is delivered by and how men are referred to 
supportive exercise services. 
National campaigns aimed to improve physical activity and exercise behaviour in 
cancer patients run by cancer charities such as Macmillan’s “Move More” and “Active 
Everyday” working alongside local authorities and in some cases community based 
local referral programmes have been implemented (Macmillan 2018). Although it is not 
clear exactly what is available for these patients and what these referral programmes 
are offering. Both Macmillan and Prostate Cancer UK (PCUK) have  recommendations 
on physical activity for all cancer and prostate cancer patients respectively (Prostate 
Cancer UK 2015, Macmillan Cancer Support 2018). However, whilst both 
organisations recognise the importance of an active lifestyle, neither offered specific 
guidelines on the type, frequency, volume or intensity of activity. Furthermore, this 
results in a lack of clarity as to whether the aim of such programmes are to improve 
physical activity or to promote exercise training which is goal orientated and possibly 
disease specific. Cancer patients are an extremely heterogeneous population and 
therefore a safe and effective programme for one individual can look very different for 
another. For some, a community based programme may not be appropriate and 
therefore maintenance or increased activity or encouraging those to engage in an 
exercise training programme remains a challenge.  
In addition, guidelines set out by The American College of Sports Medicine (ACSM) 
recommend that cancer survivors should be supervised with a certified exercise 
professional when undertaking a new exercise programme (Wolin, Schwartz et al. 
2012).  Yet the ASCM recognised that circumstances such as finance and location 
could pose significant barriers. Where this is the case the key take home message 
from the ACSM was "avoid inactivity", a far cry from what the recommendations are 
128 
 
actually advocating i.e. 150 minutes of aerobic activity with at least 2 sessions of 
resistance exercise a week (Wolin, Schwartz et al. 2012), guidelines similar to those 
set out by NICE. 
The variability on available information, established programmes and advice for 
exercise in prostate cancer patients risks a significant lack of consistency of exercise 
advice present between clinicians and patients. In the UK, The National Cancer 
Survivorship Initiative (NCSI) recognised in 2011 that health and social care 
professionals are likely to need support to help cancer survivors to make lifestyle 
changes which will optimise their health and wellbeing (National Cancer Survivourship 
Initiative 2013).  It has been demonstrated that endorsement by HCPs to participate in 
physical activity is key to improving physical activity behaviours in patients (Craike, 
Livingston et al. 2011) and that a clinician referral into an exercise programme 
significantly improves exercise levels (Damush, Perkins et al. 2006, Livingston, Craike 
et al. 2015). However, despite evidence to suggest that there are benefits associated 
with structured exercise for men with prostate cancer, such supportive exercise 
programmes nor lifestyle advice is routinely discussed at follow-up appointments 
(Bourke, Sohanpal et al. 2012). The study by Bourke et al showed that none of the 
men with advanced prostate cancer who took part in an exercise trial had been offered 
information on lifestyle changes during their standard care. 
While a lack of available exercise referral schemes may be a barrier, for some HCPs 
there might also be concerns regarding safety to exercise, inhibiting the discussion of 
physical activity and exercise training with cancer patients. A survey of 102 oncologists 
and surgeons found that 55.9% did not discuss physical activity with their patients 
routinely (Daley, Bowden et al. 2008). However, the survey also demonstrated a 
strong association between the physical activity status of the clinician and the 
likelihood of such discussions taking place with their patients, where those who 
participated in more physical activity themselves were more likely to discuss (Daley, 
Bowden et al. 2008). Furthermore, those HCPs with more experience of dealing with 
potential contraindications (such as fatigue, anaemia or risk of infection) have higher 
levels of physical activity recommendations in patients undergoing cancer treatment 
(Tsiouris, Ungar et al. 2018).   
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For survivors who require supervision or who may need guidance on how to exercise 
safely, referral to an exercise programme under the supervision of an exercise 
specialist may help. There is evidence to suggest that a clinician referral and 12‐week 
exercise programme significantly improved vigorous exercise levels and had a positive 
impact on mental health outcomes for men living with prostate cancer (Livingston, 
Craike et al. 2015). 
The implementation of physical activity guidelines in the UK poses a challenge given 
the ever evolving pathway as described in chapter 1. A better understanding of the 
clinical pathways patients follow provides timely and accurate information as to how an 
exercise programme may be successfully implemented into the care pathway with the 
support of key stakeholders, such as clinicians, allied HCPs, CCGs and local 
authorities. Without the adequate support of key stakeholders for exercise 
programmes it is unlikely that exercise support services can be successfully 
implemented within the care pathway. 
In order to better understand the context for implementing exercise programme as part 
of the prostate cancer care pathway, it is important to establish what is currently being 
offered across the UK, defining what exercise support as part of "usual care" looks 
like. For this reason, a survey of UK HCPs involved in prostate cancer care was 
conducted. Interviews were undertaken with clinicians to establish their views on 
embedding a supervised, individually tailored exercise intervention in the prostate 
cancer care pathway for men with CRPC. It was important to understand the 
perspective of clinicians regarding roles, responsibilities and training needs associated 
with providing supervised exercise programmes for men with CRPC to inform the 
design and conduct of the feasibility study (COMRADE) (Chapter 4).  
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Aims:  
1) To describe what exercise referral is currently available for men on ADT as provided 
by the NHS and if a supervised, individually-tailored exercise training package (as per 
the national NICE guidelines CG175, 1.4.19) is available in usual care for prostate 
cancer. 
2) To explore the opinions of clinicians involved in prostate cancer care regarding the 
management of men with CRPC with particular emphasis on treatment timing and 
sequencing since the earlier introduction of chemohormonal therapy and treatment 
adverse-effects. 
3) To explore opinions of clinicians regarding the clinical significance of LBM loss in 
men with advanced prostate cancer. 
4) To explore opinions of clinicians regard to exercise without the use of an anabolic 
agent as a supportive therapy; to inform the design of a future RCT. 
2. Methods: Healthcare professional survey 
Clinicians were surveyed regarding the optimum sequencing of therapies and standard 
care for men with advanced prostate cancer in the care pathway; this also included 
any established supportive programmes for men with CRPC. In addition, questions 
regarding LBM loss or "muscle wastage" were asked with the objective to determine 
how clinically significant muscle wastage was considered, how it might be diagnosed 
or treated and how clinicians may distinguish muscle wastage from differing 
aetiologies (e.g. age related sarcopenia and cancer cachexia). Finally, the views and 
opinions of the exercise as a supportive therapy for men with prostate cancer were 
sought. This included exploring opinions on the combination of a structured exercise 
programme with or without anabolic pharmacological agents in with the aim to improve 
skeletal muscle mass.  
2. Methodology 
Survey methods are commonly used in health research to evaluate healthcare 
services. Unlike other qualitative methods such as focus groups and interviews, the 
predominant benefit of using quantitative survey methods are the number of 
respondents which can be reached. They are useful to obtain information for a 
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predetermined group of people and location. Although a relatively small amount of 
data can be obtained from the population, the geographical spread of data can be 
used to draw inferences on the wider population to an extent, providing information on 
a service "…in a snapshot of time" (Kelley, Clark et al. 2003). Other methods are often 
questioned on their representativeness of only nominal group views. Surveys are able 
to overcome these limitations and obtain such data from HCPs in a short period of 
time compared to other epidemiological study designs such as observational studies. 
As a key aim of this study was to determine the provision of exercise referral schemes 
across the UK in the NHS, it was important to obtain national representation and 
develop a consensus as to the definition of "usual care" for prostate cancer. In 
addition, the success of an established exercise referral scheme may be contingent on 
involving a number of different HCP's therefore it was considered important to have 
representation from all stakeholders involved in the clinical care of men with prostate 
cancer. This included primary and secondary care.  
The design of the survey and identification of survey respondents was undertaken by 
the researchers of the STAMINA1 programme (not the author). An independent, health 
services research consultancy service (Clinvivo) were contracted by the STAMINA 
programme development grant lead researchers to distribute the questionnaire 
(http://www.clinvivo.com/). Clinivivo collated the respondent survey responses into a 
data report, including the data analysis (appendix 1). The interpretation of the data 
from the questionnaire survey responses was conducted by the author (RG).  
2.1 Survey methods 
HCPs were identified and invited via professional bodies to take part in a 27-item 
electronic survey. The survey explored issues around delivering prostate cancer care 
in NHS practice and specifically to define if exercise referral schemes were available 
to men with prostate cancer.  
2.1.1 Research governance 
2.1.1.1 Ethics and research and development approval 
This study gained a favourable ethical opinion by NRES Committee South West - 
Cornwall & Plymouth (15/SW/0260) and in accordance with the Governance 
Arrangements for Research Ethics Committees and complied fully with the Standard 
Operating Procedures for Research Ethics Committees in the UK (appendix 2). All 
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Management permissions were sought from all NHS organisations involved in the 
study in accordance with NHS research governance arrangements.  
2.1.2 Respondent recruitment 
Survey respondents were identified via their professional bodies; British Association of 
Urological Nurses (BAUN), British Association of Urological Surgeons (BAUS), British 
Uro-Oncology Group (BUG), Primary Care Urology Society (PCUS); and invited by 
email or Twitter to participate. The respondents completed the survey through the 
online tool Clinvivo.  
2.1.2.1 Inclusion criteria 
Primary and secondary HCPs (e.g. general practitioners (GPs), urologists, oncologists, 
cancer nurse specialists (CNSs) who are actively involved in prostate cancer treatment 
OR Other specialist allied HCPs (i.e. physiotherapists, clinical exercise physiologists). 
UK based 
2.1.2.2 Exclusion criteria 
HCPs not involved in primary or secondary care and not involved in prostate cancer 
treatment. 
OR Not a specialist HCP  
Not UK based 
2.1.3 Survey items  
Full details of the 27 survey items are given in appendix 1.  
2.1.3.1 Respondent demographics/characteristics 
Questions one to two sought respondent's personal details, such as postcodes and job 
role. 
2.1.3.2 Prostate cancer care pathway 
Questions three to seven concern the prostate cancer care pathway. This included 
questions regarding the delivery and initiation of ADT alongside chemotherapy since 
the initiation of chemohormonal therapy for hormone sensitive disease.  
2.1.3.3 NICE guidelines 
Question eight asked respondents if they were aware of the NICE guidelines on 
prostate cancer (CG175). 
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Fourteen items explored the respondent's knowledge of exercise programmes/referral 
schemes, physical activity in their locality and awareness of the current NICE 
recommendation regarding delivery of supervised exercise to men initiating or 
undergoing ADT  (CG175, 1.4.19) (questions nine to 24 excluding question 20;  
appendix 1). Question ten asked respondents to subjectively score, their perceived 
ability to deliver the NICE recommendation on exercise for men on ADT.  
Question 20 requested the locality of the training schemes available for staff regarding 
exercise support for cancer populations if not provided by their own organisation.   
Question 25 asked the respondents if they felt charities had the capability to deliver 
the NICE recommendation 1.4.19 without the support of NHS resources.  
2.1.3.4 Further contact for research purposes 
Questions 26 and 27 enquired if respondents would be prepared to participate in 
future interviews and to provide their contact information. Those who consented to 
have further contact were used as a convenience sample for the proceeding HCP 
interviews. 
2.1.3.5 Item design 
Eleven of the questions were designed with "yes", "no" and "unsure" responses. Other 
items were multiple choice with the option to elaborate i.e. "other (please specify)". 
These questions related predominantly to HCP and allied HCP roles and regarding the 
format of exercise programmes (e.g. community/ hospital based programmes). 
Question ten asked the respondent to rate on a ten point score, scoring one indicating 
"extremely unlikely" and ten indicating "highly likely". Question five and three asked to 
provide a response via a slider which ranged from 0-100%.  
2.1.4 Procedure 
2.1.4.1 Sampling and recruitment 
Clinvivo provided details of sampling and respondent recruitment in a written report 
(appendix 1). To summarise, Clinvivo sent an invitation email to potential respondents, 
including professional organisations for circulation to their members, and one link to be 
shared by the investigators to their Twitter followers. Three hundred and ninety-two 
email invitations were sent on 26th November 2015 and email invitations for members 
of four professional organisations were sent to their contacts on 1st December 2015. A 
public Twitter link was shared by the investigators on 11th December 2015. The first 
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reminder email to invitees were sent on 10th December 2015 and the final reminders 
on 22nd December 2015.  
2.1.4.2 Data Analysis 
The results of the survey were summarised using descriptive statistics as provided by 
Clinvivo, appendix 1 The Clinvivo report.  The data was interpreted by the author (RG). 
3. Methods: Healthcare professional interviews 
There was specific interest in exploring the views of clinicians on embedding a 
supervised, individually tailored exercise intervention in the prostate cancer care 
pathway and to determine the feasibility of a full scale trial. It was important to explore 
the possibility if such programmes for men with castrate resistant disease would be 
acceptable to HCPs, with or without the use of an anabolic agent to increase or 
maintain LBM. There was also an exploration of emergent issues resulting from recent 
changes of the prostate cancer care pathway due to changes in treatment sequencing. 
One to one in-depth interviews were chosen as the most appropriate research method 
to explore motivations in decision making, processes, impacts and outcomes with a 
personal focus on the individual (Pope, Ziebland et al. 2007). Interviews are a more 
flexible research method where emergent themes can be explored as compared to the 
structure of a survey whereby the depth of data collated is usually limited (Pope, 
Ziebland et al. 2007). 
3.1 Research governance 
3.1.1 Ethics and research and development approval 
This study was approved by NRES Committee South West - Cornwall & Plymouth 
(15/SW/0260) and in accordance with the Governance Arrangements for Research 
Ethics Committees and complies fully with the Standard Operating Procedures for 
Research Ethics Committees in the UK (appendix 2). All management permissions 
were sought from the relevant NHS organisations involved in the study in accordance 
with NHS research governance arrangements. 
3.1.2 Informed consent 
Full informed consent was obtained from each participant before the commencement 
of interviews (appendix 3). 
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3.1.3 Confidentiality 
Interview transcripts were anonymised by allocating a participant number (e.g. 
RGUR0001/ RGONC0001, UR and ONC indicating a urologist and oncologist 
respectively) to protect the identity of all participants. All data was kept in a password 
protected drive or encrypted on a password protected USB. No identifiable information 
was released into the public domain or published. If a participant withdrew consent, 
their data would have been confidentially destroyed but no participants withdrew in this 
study. 
3.2 Sample and setting 
3.2.1 Sampling 
A convenience sample was obtained from the survey of HCPs described in section 1. 
This was used to identify clinicians (urologists, medical oncologists and clinical 
oncologists) responsible for prostate cancer management and follow-up whom were 
practicing in the NHS in the UK.  
3.2.2 Inclusion criteria 
 Urologist, medical oncologist or clinical oncologist responsible for the 
management and follow-up of prostate cancer. 
 Permanently based in an England NHS trust. 
3.2.3 Exclusion criteria 
 Clinicians not regularly involved in the care, management or follow-up of 
prostate cancer patients. 
 Non-permanently based in England or in the NHS. 
 Unable to give or failure to provide full informed consent. 
 Previously interviewed as part of the STAMINA1 programme development grant. 
3.3 Recruitment and data collection 
3.3.1 Recruitment 
The clinicians were identified through data obtained from the survey where they had 
expressed a willingness for further contact in question 26 and question 27 (appendix 
1). The clinicians were initially contacted via email and if expressed an interest were 
                                            
1 Sustained exercise TrAining for Men wIth prostate caNcer on Androgen deprivation: the STAMINA 
programme development grant was a multi-centre investigation of current NHS care involving a web-
based survey of NHS prostate cancer care, five focus groups involving 26 men on ADT and 37 semi-
structured interviews with clinicians involved in the management of prostate cancer. 
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subsequently sent an invitation letter, participant information sheet and consent form 
via post (see appendix 3, 4 and 5). Once consent was returned, dates for interview 
were confirmed via email or a telephone call at a time convenient for both the clinician 
and researcher. 
3.3.2 Data collection 
Interviews were conducted either face to face or by telephone. The preferred method 
was face to face, however this was limited by geographical location and convenience. 
Interviews were conducted by one researcher (the author) guided by the interview 
schedule. As new insights were offered these topics were explored. The interviews 
were digitally recorded (encrypted Olympus DM-650 Digital Voice Recorder), and then 
anonymised. 
3.4 Interview schedule 
The interview schedule was designed based on the relevant literature and theory as 
well as recent changes in treatment paradigms to prostate cancer care. The schedule 
was semi-structured with open ended questions and prompts to allow interviewees to 
express their views and opinions. The interview schedule consisted of 20 questions 
which covered the STAMPEDE and CHAARTED trial data; the clinician's role and 
current pathway for men with CRPC, muscle loss and cachexia in CRPC, prostate 
cancer and exercise interventions and finally novel pharmacological agents in 
combination with exercise. The interview schedule was designed to be inductive with 
some deductive reasoning. The detailed interview schedule can be reviewed as 
appendix 6. 
3.5 Data analysis 
Digital recordings were transcribed verbatim by an independent transcription service 
(JHTS audio and transcription service, www.jhts.co.uk) and the data coded via 
Nvivo10 (Version 1.0, by the author). Familiarisation with the transcripts was first 
performed and then initial codes were generated (appendix 7). Initial codes were then 
related to final themes and sub-themes and analysed according to a thematic 
framework analysis (Gale, Heath et al. 2013).  Four transcripts (>20%) were double 
coded by a second researcher Rebecca Turner (RT) to ensure reliability and rigour of 
the analysis. Any differences in coding were discussed and a consensus was reached 
on how the data should be coded. This included either changing the name and context 
of the code or choosing one of the reviewer's original codes after a consensus was 
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reached from both researchers. This generated a total of 79 codes in 11 categories. 
These categories were formed of the superordinate themes and subordinate themes. 
The data were then charted into the framework matrix of superordinate themes 
mapped against verbatim quotes from each interviewee grouped via their profession 
(i.e. Urologist, Medical Oncologist or Clinical Oncologist). An example of an extract 
from the table is given in appendix 9. The analytical framework was then refined and 
codes grouped together where they were conceptually related. The framework was 
then verified by a third party researcher Karen Collins (KC).  
3.5.1 Qualitative data analysis options 
As the approach to the analysis of the data was deductive, framework analysis was 
seen as the most appropriate form of analysis because the objectives of the interviews 
were set in advance rather than emerging from a reflexive research process (Mays 
and Pope 2000). The overall analytical process however, resonates with the thematic 
approach, but with the framework approach it is more explicit and informed by a priori 
reasoning (Mays and Pope 2000).  
3.5.2 The framework approach 
Framework analysis is a systematic analytical approach to qualitative research. It is a 
matrix based method for ordering and synthesizing qualitative data and was developed 
by Jane Ritchie and Liz Spencer in the 1980s for large scale policy research (Ritchie 
and Spencer 2002) but is now widely used in health research (Gale, Heath et al. 
2013). In the context of these interviews framework analysis was chosen as it is a 
pragmatic approach to systematically facilitate rigorous and transparent data 
management without losing sight of the "raw data" and enabled the classification of the 
data into key themes and sub themes, judged comprehensively.  
3.5.3 The method of the framework approach 
The analysis was carried out in a 6 step approach including 1) familiarising with the 
data; 2) generating initial codes; 3) searching for themes; 4) reviewing themes; 5) 
devising and naming themes and 6) producing the report (Braun and Clarke 2006).  
3.5.3.1 Familiarisation 
Before any attempt to sort through the data was made, there was a process of data 
familiarisation.  Transcripts and observational field notes were read and re-read and 
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recordings were listened to in order to fully immerse oneself with the data in advance 
of any kind of analytical stage. 
3.5.3.2 Generating initial codes and identifying a thematic framework 
After initial familiarisation, a process of "open coding" was conducted. This included 
analysis of a small number of selected transcripts and the coding of data which was 
felt to have relevance to the research aims and objectives (such as opinions, attitudes, 
behaviours or views). Each of these initial codes was accompanied with a note to 
clarify its meaning. 
3.5.3.3 Indexing/coding 
Coding aims to classify all the data and enable a systematic comparison between the 
different data sets. Codes are grouped together in categories which are clearly defined 
to generate themes and subthemes (Gale, Heath et al. 2013). Indexing was conducted 
electronically using the programme Nvivo which is demonstrated in appendix 8. 
Indexing indicated which themes in the text were being discussed. Once data had 
been coded a thematic framework was developed consisting of themes and 
subthemes. Initial themes were more descriptive rather than analytical or abstract. 
3.5.3.4 Charting 
Once the main themes and subthemes had been identified, reviewed and finalised, a 
matrix was created to help delineate the data set. Each column of the matrix was 
headed with each theme and each row with each participant identifier demonstrated in 
appendix 9. The relevant sections from each coded transcript were then summarised 
and entered into the framework matrix so the text can easily be navigated and 
comparisons can be made between individuals. For each participant summary, 
selected information was taken from each participant's transcript in order to reflect 
meaning without losing content. The transcription conventions were:   
 Italics - Direct quote 
 … - Quote has been abridged 
 [word] - Where the author has clarified the meaning or phrase from the 
quotation 
3.5.3.5 Mapping and interpretation 
Once charting was complete a more refined analysis of the data set was possible with 
a deeper immersion into the content of the transcripts. Summaries of each theme were 
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made from identifying relationships between the quotes and links between the data as 
a whole, providing explanations for the findings and overarching themes (Ritchie and 
Spencer 2002). This included drawing comparisons between the transcripts 
highlighting any conflict/consistencies in key terms/ phrases/ descriptions/ views or 
explanations. Explanations and conclusions were drawn from the analysis, this can be 
explicit (originating from the participants descriptive statements) or implicit (identified 
by the analyst). After the final analysis the data were categorised into a priori themes 
or new themes were constructed as appropriate (Ritchie and Spencer 2002).  
3.5.4 Ensuring quality within qualitative research 
Quality in qualitative research is multifaceted and includes consideration of the 
importance of the research question, the rigor of the research methods, the 
appropriateness and salience of the inferences, and the clarity and completeness of 
reporting (Smith and McGannon 2018). Although there is much debate about 
standards for methodological rigor in qualitative research there is widespread 
agreement about the need for clear and complete reporting. High quality research 
which is conducted and assessed systematically would enable researchers to 
synthesise the data, critically appraise the data with greater ease due to transparency 
and therefore subsequently ensure reproducibility.  
To ensure quality, this qualitative research was conducted following the guidelines for 
standards for reporting, process and methods from the Consolidated criteria for 
reporting qualitative research (COREQ) criteria (Tong, Sainsbury et al. 2007). The 
checklist was used to ensure explicit and comprehensive reporting of the final analysis 
(appendix 10). The NICE public health development guidance and MRC guidance on 
the development and evaluation of complex health interventions were used to aid the 
design of the clinician interviews (NICE 2012, Craig, Dieppe et al. 2013). The quality of 
qualitative research is judged fundamentally differently to that of quantitative methods 
which predominantly look for internal validity, external validity, reliability and objectivity. 
This study sought to ensure rigour by the four criteria outlined by Shenton i.e. 
credibility, transferability, dependability and confirmability (Shenton 2004).  
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4. Survey results 
4.1 Survey respondent characteristics 
From the survey, there were 95 postcodes from respondents corresponding to sites 
across the UK (e.g. hospitals, community centres, local gyms). In total 79 different 
NHS trusts corresponded to the sites identified, with some sites corresponding to the 
same trust (appendix 11). The proportions of the mode of invitation of the 95 
respondents are described in table 3.1. 
Table 3.1 Mode of invitation received by respondents to the survey 
Referrer n % 
British Association of Urological Nurses 13 13.7 
British Association of Urological Surgeons 24 25.3 
British Uro-Oncology Group 4 4.2 
E-mail 42 44.2 
Primary Care Urology Society 4 4.2 
Twitter (STAMINA twitter account) 8 8.4 
Total 95 100 
 
The majority of the respondents were urologists n =35 (36.8%) and second largest 
proportion were nurses n =20 (21.1%). Respondents professional roles are provided in 
Table 3.2. 
Table 3.2 Professional roles of respondents 
Profession n % 
Allied Health Care Professional 3 3.2 
Cancer Care Commissioner 3 3.2 
Exercise Physiologist 3 3.2 
General Care Commissioner 1 1.1 
General Practitioner 7 7.4 
Nurse 20 21.1 
Oncologist 4 4.2 
Physiotherapist 3 3.2 
Urologist 35 36.8 
Other 16 16.8 
Total 95 100 
4.2 The prostate cancer care pathway and delivery of care 
4.2.1 Proportion of men receiving chemohormonal therapy 
In light of STAMPEDE and CHAARTED, respondents indicated that on average 23.3% 
of men currently commencing long-term ADT were also receiving docetaxel or a 
similar agent at initiation of ADT. The reasons for not giving chemohormonal therapy is 
provided in table 3.3. 
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Table 3.3 Reasons for not giving chemohormonal therapy 
Reason n % 
No funding 17 43.6 
Unconvincing evidence 3 7.7 
Updating guidelines 8 20.5 
Clinician resistance 5 12.8 
Patient resistance 5 12.8 
Patient unfit 19 48.7 
Other 10 25.6 
Number of responses (multiple selection allowed) 39  
 
4.2.2 ADT delivery 
Respondents were asked to indicate the proportion of men on long-term ADT receiving 
treatment in primary care in their area. A total of 64 respondents reported a mean 
percentage of 84.5%, ranging from zero to 100%. The HCPs involved in delivering 
ADT are described in table 3.4. 
 
Table 3.4 HCPs involved in initiating ADT. 
Profession n % 
Oncologist 51 77.2 
Urologist 62 93.9 
Clinical Nurse Specialist 42 63.6 
General Practitioner  13 19.7 
Outpatient Nurse 0 0.0 
Practice nurse 3 4.5 
District Nurse 0 0.0 
Other 0 0.0 
Number of responses (multiple selection allowed) 66  
 
4.3 The ability to deliver the NICE guidelines (CG175, section 1.4.19) 
Of the respondents, n =70 (73.6%) had knowledge of the new NICE guidelines for 
prostate cancer (CG175). Slightly fewer (61.1%, n =58) were aware of the 1.4.19 
recommendations.  The respondents were asked to rate on a scale of 10 (1 being 
extremely unlikely and 10 highly likely) their ability to deliver this recommendation in 
their locality (the self-rated score), the mean response was 4.87. 
N =47 (49.5%) of respondents indicated the existence of local exercise 
referral/prescription programmes for patients with cancer. Among these respondents, 
n =38 (80.6%) reported that there were programmes accessible to men with prostate 
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cancer on ADT with most of the exercise referral schemes being available in the 
community (n =25, 53.2%), local authority (n =16, 34.0%) and hospital (n =10, 21.3%). 
4.3.1 Specialist involvement in exercise programmes 
Nurses (n =28, 59.6%), GPs (n =20, 42.6%), physiotherapists (n =18, 38.3%) and 
hospital consultants (n =16, 34.0%) were the HCPS most commonly reported to be 
involved in the exercise referral pathways. Other non-clinical specialists involved, 
included gym instructors (n =21, 44.7%) and personal trainers (n =12, 25.5%). It was 
the non-clinical professionals, primarily gym instructors, who were reported to be 
responsible for setting the frequency, intensity and duration of the exercise programme 
(n =31, 66.0%), and for supervising the delivery of exercise and tailoring and 
monitoring individuals' programmes (n =32, 68.1%).  
Over half  of the 47 respondents (n =25, 53.2%) who knew about exercise referral 
programmes were not aware or were unsure of the existence of training schemes in 
their organisations for staff on exercise interventions for cancer populations. 
4.3.2 Existing programme details 
A third of these respondents who knew of an exercise referral programme (n =11, 
32%) reported that instead these facilities were based in the community or local 
authority, n =7 (20.6%) reported that they were available in primary care, secondary 
care or charities, while most (n =15, 44.1%) reported that these facilities were based in 
other places. A majority of exercise programmes were offered in group sessions (n 
=28, 59.6%). 
Approximately half of respondents (n =48, 50.3%) did not believe that charity services 
for lifestyle support without NHS resources would fulfil the NICE guidelines on exercise 
for men with prostate cancer. 
4.3.3 Future contact for an interview 
Approximately half of the respondents agreed to take part in a future interview (50.3%, 
n =48).  
5. Healthcare professional interview results 
Of the 35 clinicians initially contacted, nineteen expressed an interest being 
interviewed and of these, 12 were interviewed (63% of sample approached). The 
demographics of the clinicians interviewed are detailed in table 3.5. 
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Table 3.5 HCP demographics 
C
lin
ic
ia
n
 
d
em
o
gr
ap
h
ic
s 
City (UK) Profession Sex NHS Trust 
London = 5 Medical 
oncologist = 3 
Male = 5 Teaching hospitals = 
11 
Newcastle = 2 Clinical oncologist 
= 6 Sheffield = 3 Female = 7 Non-teaching 
hospitals = 1 Leeds = 1 Urologist = 3 
Kent = 1 
 
The size of interview samples typically relies on the concept of “saturation” – the point 
at which no new information or themes are observed in the data (Guest, Bunce et al. 
2006). In this case, saturation occurred at 12 interviews. 
Four primary themes were identified from the data (table 3.6). Due to the richness of 
the data "Variability in the cancer care pathway" was discussed as two primary themes 
"The prostate cancer care pathway" and "Uncertainty with treatment sequencing in 
CRPC". Verbatim quotes are provided in order to illustrate the findings. 
  
144 
 
Table 3.6 Primary and secondary themes  
 Primary themes Secondary themes 
 
Theme 1: Attitudes towards the 
implementation of an exercise 
intervention with or without a 
pharmacological agent for men with 
CRPC 
Assessment of physical fitness for 
treatment 
Anabolic agents in combination 
with an exercise intervention 
Exercise and prostate cancer 
 
Variability in 
the cancer 
care pathway 
for men with 
prostate 
cancer 
Theme 2: The prostate cancer care 
pathway 
 
Cancer care pathway 
Current supportive or palliative 
programmes 
Theme 3: Uncertainty with treatment 
sequencing in CRPC 
Changes to standard care 
Sequencing of therapies 
  Theme 4: Clinicians reporting and 
management of the adverse effects of 
standard treatments and advancing 
disease 
CRPC: adverse effects of disease, 
treatment and impact on QoL 
Treatment decisions 
  
Theme 5: Clinicians experience of 
managing muscle wasting comorbidity in 
men with prostate cancer 
Muscle wastage, aetiology, 
assessment and treatment 
Cancer cachexia 
The clinical significance of  muscle 
wastage 
5.1 Theme 1: Attitudes towards the implementation of an exercise 
intervention with or without an anabolic agent for men with castrate 
resistant prostate cancer 
5.1.1 Assessment of physical fitness for treatment  
When asked how physical fitness would be assessed, all clinicians described a 
subjective assessment. This usually entails basic medical physiology parameters and 
consideration to comorbidities and medications. Parameters included blood count, 
BMI, renal and liver function tests as well as a basic physical performance scored 
using Karnofsky or the Eastern Cooperative Oncology Group (ECOG). This would be 
taken at baseline, usually on diagnosis, and regularly monitored during treatment.  
 "…I will ask my patients, you know, how far can you walk on the flat, how do 
you get on going up a hill…what sort of exercise do you normally do..." Urologist 2 
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General mobility is taken into account and any relevant investigations (CT scanning, 
bone scanning, examination findings). Two interviewees talked a great deal about the 
importance of age when considering fitness for treatment, although there was 
acknowledgement that some older men can be very fit. 
 "…so it’s their performance status…well, we subconsciously do it automatically, 
ECOG status...Their age is a factor to an extent, but it’s not really a factor anymore 
because the reality is you can get 84-year-olds who are super fit and you can get 60-
year-olds who are very unfit, so I think their current quality of life and their performance 
status is, is really key." Urologist 2 
As mentioned previously, physical fitness was a crucial factor in decisions on 
treatment, particularly for chemotherapy. 
5.1.2 Anabolic agents in combination with an exercise intervention 
5.1.2.1 Perceived benefits and concerns 
There was consensus amongst the clinicians for the need of robust data on any 
anabolic agents, particularly novel agents in the treatment of muscle wastage in men 
with CRPC. Those discussed in the interviews were novel agents such as SARMS and 
anabolic steroids. "What is known in the early pre-clinical data?" - was a key question 
that was asked (n =8). Information regarding the side effects and safety profile were 
considered imperative. The impression given by the majority of the clinicians (n =10) 
was that there was a lack of knowledge regarding anabolic agents and therefore an 
inability to make an informed choice. Education and an opportunity to ask questions 
regarding these agents were considered essential before the clinicians would consider 
offering it to a patient.  
Effects on progression of malignancy associated with the potentially androgenic 
effects were mentioned by numerous clinicians although some described this as a 
lesser concern in this advanced stage of disease.  For these clinicians, they expressed 
that as these men are in the terminal phase of the disease, that disease progression 
and survival were subordinate to potential improvements in QoL. 
 "At that sort of stage most of the patients are at the terminal event of their life, 
so I think if you are going to try and gain a quality of life, even though you might 
arguably speed up the tumour, I don’t think I would have that many concerns about 
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that, as long as we achieved what we wanted to, the quality of life improvement." 
Urologist 1 
Contraindications with second line treatment remained one of the biggest concerns, 
particularly administration whilst on other drugs because of unknown drug interactions. 
 "…I’m not sure if we would want to be doing that in conjunction with second line 
treatment. If they’d had all of their treatment then yes, you could give them…the 
problem that we have is that we think we understand how a lot of things work and what 
the pathways within the adrenal gland are, etc. but there’s probably a lot more 
crossover and interaction than we realise or we know and I’m not sure how safe, from 
a disease control point of view, and if these men have other treatment options that can 
effectively treat their prostate cancer, I’m not sure we should be giving other things 
that may be detrimental when we don’t quite know either way." Clinical oncologist 4 
Most clinicians were only agreeable to the use of these agents in the context of a trial 
setting, both tightly controlled and well designed. More specifically, if it was shown to 
be economically viable, improved QoL, negated muscle wastage, did not compromise 
other therapeutic agents and weighed up favourably against potential risks and side 
effects of exercise. 
 "Yeah, I think if you could prove it convincingly of a positive outcome and not 
just, you know, not for that short period of time but, you know, longer term positive 
outcome, then that would be hard to argue against." Clinical oncologist 1 
5.1.3 Exercise and cancer 
5.1.3.1 Knowledge of the current NICE recommendations on exercise  
Almost all the clinicians seemed to have knowledge of the NICE recommendations for 
exercise for men with advanced prostate cancer. However, there was some confusion 
as to why, given that NICE has made the recommendations, action had not been 
taken nationally to implement them. One participant suggested it was due to a lack of 
robust clinical evidence. One participant did admit to not knowing a great deal about 
the recommendations and another spoke of them exclusively in the context of bone 
health. 
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 "Well I was surprised to find out that NICE’s has actually made 
recommendations and so usually when NICE makes a recommendation then it 
eventually happens because it means it’s going to be funded…" Medical oncologist 1 
 "Um, not an awful lot except I do know it’s recommended in the 2014 update 
that patients who are embarking on ADT should have a trial of, is it twice weekly 
supervised exercise programme for 12 weeks to make, to try and minimise the side 
effects of ADT? And it’s interesting that NICE recommend that when there’s not any 
randomised data…to show that and there’s some data looking at toxicity profiles, 
associated radiotherapy and as far as I’m aware there’s no difference." Medical 
oncologist 2 
5.1.3.2 Barriers to success and implementation of an exercise programme 
5.1.3.2.1 Patient barriers: Education and programme specifics 
Lack of patient education regarding the rationale for exercise was the most frequently 
perceived barrier reported by clinicians. It was suggested that there may be a lack of 
clarity amongst patients regarding what exercise, "physical activity" or "being active" 
encompasses. Education was considered key to encouragement and motivation for 
these men to participate in exercise. 
The environment in which the exercise is expected to take place seemed to be a 
crucial factor amongst the clinicians. It was suggested that men are less likely to want 
to engage in a more public gym setting due to anxiety of being out of their "comfort 
zone". The location of a programme and ease at which the men can access the facility 
was thought to encourage adherence. Equally, it was thought a programme where 
there is a real drive to get these patients recruited and undertaking a specific exercise 
prescription would be far more effective than simply offering a "walk around the block".  
Medical oncologist 3 felt that it was not appropriate to mix men at different stages of 
disease in a prostate cancer specific exercise programme (e.g. advanced and early 
stage). 
 "…they’ve got other things on, how are they going to get there, what sort of 
people would go there because if you had people who were in the early stages being 
mixed with people who were in the later stages, it wouldn’t be good for either group. 
148 
 
Because the first group would think oh my God, am I going to end up like that?" 
Medical oncologist 3 
5.1.3.2.2 Patient barriers: Age, fitness and comorbidity 
There were many comments regarding the recruitment of older men to an exercise 
programme, who may be frailer, and how they may have much more extensive needs 
for which proper information and appropriate guidance will be necessary.  
 "Frail patients won’t want to come out and go to a gym or anything like that." 
Medical oncologist 2 
One clinician felt that in advanced stages, as the men tend to be older, they are far 
less likely to express an interest in this type of intervention. 
 "…well until you try it you don’t know but I just see a lot of elderly men being 
invited to take part in a physical exercise programme regarding the whole thing as 
grotesque. Yeah, it’s just, you know, I’m managing very well as I am, but I may be 
wrong." Medical oncologist 1 
There was concern from six of the clinicians regarding an exercise programme for the 
more advanced men who are disabled by poor health and comorbidity. For some 
clinicians, there would be no consideration of exercise in men with a poor PS. 
Chemotherapy was also seen as a factor which may impede the success of the 
programme. It was thought that whilst on chemotherapy it would be more difficult to 
assess physical capacity to do exercise but also how appropriate exercise may be 
(particularly in more public areas such as gyms) whilst these men can have a high risk 
of infection. Equally, the risk of fracture was a general worry by the clinicians.  
 "I think doing it, assessing it during chemotherapy can also be quite tricky 
because you’ve got so many other things going on with all the side effects of treatment 
and risks of infection and weakness due to steroids. So there’s a lot of other things 
going on, that it’s possibly quite tricky to assess…Sadly probably, again I’m guessing 
now, 50 or 60% of the men are probably fairly disabled by the symptoms and their 
other comorbidities and therefore I’m not sure how much they would be able to even 
exercise at home a great deal." Clinical oncologist 1 
149 
 
5.1.3.2.3 Patient barriers: Motivation and behaviour change 
Men from lower socioeconomic backgrounds were also perceived as more likely to 
partake in unhealthy behaviours, such as smoking and drinking. This was seen as 
more of a cultural barrier, and therefore these men may be harder to confer long- term 
behaviour change. 
 "…there’s a lot of poverty in the North East and I think a number of our patients 
are quite happy sitting at home watching the telly, drinking beer and smoking, to be 
perfectly honest!" Clinical oncologist 2 
Conversely, a programme would perhaps be very well received by the highly 
motivated individuals. Men who undertake regular exercise would likely be very 
interested in such programmes but would not gain the most benefit. Emphasis was 
made on the need to have an individualised approach to engagement, where some 
men may not need much incentive others may need encouragement and a reiteration 
of information. 
 "…people may not feel like going to the gym and I think the people that are 
likely to benefit from it most are probably those people who have never really done any 
exercise all their lives and so suddenly they’re just going to be, oh well, I’m 67 and I 
don’t fancy doing a 12-week exercise [programme], so there is going to be that!" 
Clinical oncologist 3 
5.1.3.2.4 Finance and clinician capacity 
Clinicians were aware that despite of the NICE guidelines (section 1.4.19 in CG175) 
trusts had not changed practice in accordance and that exercise, as part of prostate 
cancer care, remained a low priority. However, some trusts had made some general 
considerations, such as advice and recommendations given in clinic appointments.  
Resources and finance were mentioned numerous times by the clinicians and the lack 
of facilities to carry out a programme on NHS sites. It was thought that for an exercise 
programme to be realistic the QoL benefit to patients would have to significantly 
outweigh the cost of implementing the programme.  
One oncologist suggested that in order to successfully implement a programme, a 
business plan would need to be put forward and that designing a very specific 
programme on a select cohort of patients (i.e. prostate cancer patients) would not be 
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financially viable and also not logical to exclude the majority of other disease groups 
who would also benefit. Two of the clinicians would consider such a programme in the 
NHS more of a luxury than anything else and that if funding was allocated to such a 
programme it might not entirely be fair when compared to funding needed elsewhere. 
Lack of current government funding was considered detrimental to the growth and 
development of overall cancer care, particularly in comparison to other European 
countries that have superior survival statistics.  
 "So to try and integrate a new service, we’d have to have a business plan and 
business case and that might be tricky to show in the void of decent quality 
[data/research]" Medical oncologist 2 
 "I don’t think it would be necessarily right to spend a lot of resource on a 
specific programme, say for men with localised disease on surveillance. Maybe we’ll 
find that it’s really useful, but I sometimes feel there’s a quite a sort of unfair allocation 
of resources to cancer versus other things." Urologist 3 
The lack of clinician time and capacity was a concern for most of the interviewees. It 
was felt that they did not have the specialist knowledge to design, facilitate and follow-
up a programme tailored to the complex needs of individuals and that this would be 
better suited to an exercise physiologist or physiotherapist to ensure success. 
However, it was also a concern that a job role dedicated to the programme in itself 
would be difficult to fund. 
 "Well, it’s difficult, because you just create more work for ourselves…so to be 
able to do that for all of our castrate-resistant or all of our metastatic patients who are 
on long-term hormone therapy, that’s a huge pile of work for somebody to do, which 
nobody has really got capacity to put into their job plan, which means you need 
another person to do it, which is, you know, not feasible in the current climate." 
Clinical oncologist 4 
5.1.3.1 Facilitators to an exercise programme and perceived benefits 
5.1.3.1.1 Facilitators to an exercise programme 
A good knowledge of the potential benefits to the patients' health and wellbeing 
aligned to their disease status was seen as integral to facilitating patient engagement 
in exercise. A dedicated individual, or group of individuals, who have the specialist 
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knowledge to tailor an exercise intervention to the needs of each man and monitor 
throughout the process was considered paramount. Clinical oncologist 6 suggested 
there should be an MDT approach --"So I think it, it needs to be individualised and the 
multidisciplinary team is there to support the patients depending on their individual 
needs." 
Almost all of the clinicians (n =11) suggested the need for a physiotherapist, CNS or 
allied clinician to facilitate an exercise programme and felt this was vital to adherence. 
There was a consensus for there to be a need for a flexible programme dependant on 
the patient's circumstances. It was recommended that an experienced physiotherapist 
should be involved in the programme to ensure the safety, particularly for the more 
complex patients.  
It was thought that a group setting could be very beneficial for some individuals who 
would benefit from peer to peer support. However, this was not the opinion of all of the 
interviewees, with some stating that some men would prefer one to one exercise 
sessions and would be put off by group exercise sessions.  
 "I think, you know, in terms of methods of supporting doing exercise, I think men 
benefit from peer to peer support and I think that they benefit from sharing their story 
with other people and doing things together in a way and they may not think they like 
that before they get there, but I can guarantee that when they do get there they do 
enjoy that, because that’s been our experience and it’s been the experience of other, 
of other programmes." Urologist 2 
One clinician also stated that he felt that a diagnosis of cancer was a very "teachable 
moment" and that these men would be more than willing to improve their potential 
outcomes.  Another clinician felt that it would help some patients to feel they have 
gained some control over their disease. Urologist 3 also mentioned that treating the 
exercise programme as a prescription would confer better adherence. 
 "…if people see it as a prescription from the hospital, like it’s a group support, if 
you say, this is your next appointment, rather than, this is a group…it gets much better 
uptake, so that’s something to consider." Urologist 3 
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5.1.3.1.2 Perceived benefits of an exercise programme 
There was consensus amongst clinicians that an exercise intervention would confer 
the most benefit when initiated as early as possible in the pathway (ideally at hormone 
sensitive stages) and continued throughout the course of the disease. It was 
recognised that at this stage men may be at their most active but, as their disease 
progresses, their needs will change and are likely to require more help from the 
physiotherapists. Initiation of a programme early on in the cancer care pathway would 
encourage continued adherence down the line where men are likely to experience 
more AEs and therefore may gain more benefit. It was felt that an exercise programme 
would be extremely beneficial and be well received amongst younger patients (i.e. 
those around 40-50) and those who may be asymptomatic without a great deal of 
disease burden. It was thought that initiation prior to ADT could help mitigate some of 
the long-term effects of castration.  
The psychological benefits, including beneficial effects to QoL outcomes, from an 
intervention were considered invaluable and this could gain favourable support from 
family. 
 "I’m sure the men would like it. The wives of the men would like it!" Medical 
Oncologist 3 
The potential physiological benefits of exercise, mentioned by the clinicians were the 
maintenance of muscle bulk and bone health which is often compromised on ADT, 
increased tolerance of treatment and a reduction in complications (surgical or 
medicinal).  
 "I think it’s, it’s beneficial for maintaining muscle strength, quality of life and 
exercise capacity, which I think is very important for them and it keeps some bone 
strength, you know, when on their long-term hormones, the more exercise they do the 
more they can maintain their bone strength, which is going to be a good thing, and it’s 
good psychologically, you know, if they can keep going out and playing golf or doing 
whatever they do, then I think that’s very important for them, so yes, it is." Clinical 
oncologist 4 
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There was also support for further studies to demonstrate the benefits of exercise 
training in CRPC from Medical Oncologist 2 who was sceptical of the current available 
data surrounding exercise for prostate cancer. 
 "I mean if you, if you can show a treatment works and it’s as simple as exercise, 
it improves energy levels, wellbeing, potentially decreased other side effects with 
muscle wasting that is, that is what they call a no-brainer" Medical oncologist 2 
5.2 Variability in the prostate cancer care pathway 
5.2.1 Theme 2: The prostate cancer care pathway 
5.2.1.1 The Cancer care pathway: continuity of care  
It was unanimously accepted amongst all 12 clinicians that the data from the 
STAMPEDE and CHAARTED trials has changed the prostate cancer pathway, where 
men with advanced hormone sensitive disease are now being offered chemotherapy 
alongside initiation of first line ADT (James, Spears et al. 2015, Sweeney, Chen et al. 
2015). Two oncologists (one clinical and one medical) stated that as a result they are 
experiencing an increased number of referrals of men with hormone sensitive disease 
and therefore the oncologists involvement in the cancer care pathway has increased, 
where previously they would treat men with CRPC with chemotherapy. This represents 
a dramatic increase in work load for oncologists and presents potential challenges that 
may not have been foreseen.  
 "Before [the] NHS agreed to fund [docetaxel for men with metastatic hormone 
sensitive disease] in January, we were just doing it based on the American study 
[CHAARTED], which was the more extensive group [higher volume metastatic 
disease], and not do the people with minimal disease. And we’re trying to still do that, 
just to keep the numbers down... well I’m in the process of being made to say that 
we’re going to have to have a, a waiting list for these patients…" Medical oncologist 
3 
Both the urologists and oncologists were clear and explicit when distinguishing their 
role from each other. The involvement of either clinician is based on an individual's 
disease stage or treatment. Those who are hormone sensitive are predominantly 
under the care of their urologists (except where they receive docetaxel from their 
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oncologist) and only when they progress to castrate resistant stages are they primarily 
under the care of oncology.  
 "So, I refer [castrate resistant men] to oncology!...I don't see that many castrate-
resistant men myself…so I may diagnose people, so I diagnose people presenting with 
metastatic disease just because I'm part of the diagnostics pathway, but usually 
they're already under the care of the oncologists and I don’t really get involved." 
Urologist 3 
However, the referral of care from urology to oncology appeared problematic in some 
cases. The pathway changes post 2015, and the ensuing change in current practice, 
appeared to introduce pressures on the cross-over period of a man's care from urology 
to oncology as it appears earlier in the pathway at hormone sensitive stages. Medical 
oncologist 3 talked specifically about the time constraints surrounding the 
simultaneous initiation of chemotherapy and ADT. The current recommendations 
(based on the trial data) state that docetaxel should be initiated within 90 
days.(Specialised Commissioning Team 2016)  
 "That has caused a problem, at an MDT, yesterday because they referred a 
patient who was five months out, four or five months out and then the patient got upset 
that they weren’t offered [docetaxel with ADT]...But then there’s no evidence for it, 
beyond for more than 90 days…surgeons would argue that if there’s no evidence you 
should give [docetaxel]. Whereas oncologists argue that if there’s no evidence you 
shouldn’t give [docetaxel]." Medical oncologist 3 
5.2.1.2 Current supportive programmes 
Professionals were not aware of any supportive programmes specifically targeted to 
men with CRPC. However, the supportive programmes mentioned which men with 
CRPC could access, aimed at general cancer populations, were charity funded 
programmes run by Macmillan and Prostate Cancer UK. This included support groups 
and wellness programmes offering psychological support for those living with and 
beyond cancer. No exercise/physical activity programmes embedded in the cancer 
care pathway were mentioned. Outside of this, palliative care (including hospice care) 
and alternative therapies, such as acupuncture, were mentioned as was routine 
support from the patient's cancer nurse specialist.  
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 "So for men in our Trust…they have Macmillan teams available, they have 
hospice care, we have specialist nurses who support them and we have a survivorship 
nurse specialist as well…so if a patient comes into hospital in extremis or as a new 
presentation then there is a palliative care team which is primarily nurse led..." 
Urologist 2 
 "… they have done things like, auricular acupuncture…they can kind of just 
direct them to other services." Clinical Oncologist 6 
5.2.2 Theme 3: Uncertainty with treatment sequencing in castrate resistant 
prostate cancer 
Almost all of the clinicians felt that changes to the pathway had resulted in dilemmas 
associated with the sequencing of treatment later on when men develop castrate 
resistant disease. Previous to the STAMINA and CHAARTED data, men with newly 
diagnosed castrate resistant disease would have been chemo-naïve. Now some men 
progressing to CRPC will have had a docetaxel regimen and it was understood 
amongst the clinicians that standard care would likely change. 
 "So a lot of it [treatment options] is individual…so [future treatment] will change 
somewhat because the use of chemotherapy may have happened earlier on for 
hormone sensitive disease…" Clinical oncologist 1 
There was a lack of clarity regarding sequencing second line anti-androgens and 
chemotherapy. Some of the interviewees indicated that men would need a better PS to 
receive second line ADT (enzalutamide and abiraterone) than to receive second line 
chemotherapy.  
 "So you can be fairly unfit to have hormones [ADT], but for the chemotherapy 
we’d only offer that to people who are fit basically, you know, at some level, able to 
withstand it anyway." Urologist 3 
 “Having said that, for people who are asymptomatic and haven’t got rapidly 
progressing disease then, you know, something like enzalutamide is relatively 
straightforward. So obviously if someone isn’t physically fit, you’re less likely to 
consider chemotherapy.” Clinical oncologist 1 
 "You could give it [enzalutamide or abiraterone] but you shouldn’t but I, I just 
suspect that some oncologists would give it…But you shouldn’t do it…according to 
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NICE or NHS, where the data was always in your healthy population. It was never in 
your poorly population and it shouldn’t really be given in the poorly population, but I’m 
sure some people do…"  
 “…to get enzalutamide or abiraterone they have to be performance status zero 
or one. And they have to have, be asymptomatic or minimally symptomatic. So they 
should be fit enough for chemo when they are fit enough for that.” Medical oncologist 
3 
5.3 Theme 4: Clinician's reporting and management of the adverse effects of 
standard treatments and advancing disease 
5.3.1 Castrate resistant prostate cancer: Adverse effects of disease and treatment 
and the impact on quality of life 
Bone metastasis and associated bone pain were considered the most commonly 
occurring AEs of advancing disease subsequently having the most impact on patient 
QoL. Clinician's frequently referred to it as the most common AE which was the most 
difficult to treat. The most common treatment mentioned was radium-223.  
 “So I think the biggest thing will be if they have, if they’ve got bone metastases 
and they’ve got pain and discomfort and reduced mobility.” Clinical oncologist 6 
 "…it tends to be a bony pain depending where their metastatic disease is. 
Commonly it might be in the back, the rib, the pelvis and typically they do get quite a, a 
chronic disabling quite painful problem which requires quite considerable quantities of 
pain relief." Urologist 1 
Other AEs frequently mentioned were spinal cord compression, fracture, neurological 
problems and lower urinary tract symptoms (LUTS). It was also noted that for 
progressing disease, men may not seek to have further systemic treatment until the 
point they become symptomatic.  
PSA progression was the predominant non-symptomatic factor mentioned indicative of 
advancing disease, and one of the main reasons to initiate second line therapy.  
Others, but less common, included imaging and biopsy. A pathological fracture might 
also be one of the ways in which advancing disease presents. Medical oncologist 2 
defined the confirmation of advancing disease: 
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 “…we would like to see…well two things out of three, so radiological change, 
symptomatic change or biochemical change, so we’re waiting for two, two out of those 
three.” Medical oncologist 2 
Clinician's reported the most common AEs associated with ADT were fatigue, weight 
gain, hot flashes, muscle weakness/ wastage (particularly worse when compounded 
with steroids), a decrease in sex drive and breast swelling (gynecomastia). The most 
commonly mentioned effects of chemotherapy were neutropenia (with a chronic worry 
of acute death), emesis (vomiting), peripheral neuropathy and fatigue. Sometimes the 
source of the AE was not always clear.  
 “…I think it’s, it’s difficult sometimes to determine which has been the cause 
and which is the effect, if that makes sense, of the treatments.” Urologist 2 
This was particularly relevant to the symptoms of muscle wasting where it can be 
difficult to determine the cause of significant muscle loss (see later sections).  
Given the impact of AEs on QoL, all clinician's reported that the preservation of 
patient's QoL was paramount even in this late stage of disease. 
 “Well, I think the benefits have to be twofold, don’t they…there are disease 
specific benefits and then there’s quality of life and they’re not necessarily aligned...” 
Urologist 2 
 “…really quality of life is a, it’s a huge issue and there’s no point in keeping 
people alive if we’re wrecking their lives.” Clinical oncologist 5 
5.3.2 Treatment decisions  
Clinician's perception of the AEs of second generation anti-androgens (Enzalutamide 
and Abiraterone) was variable reflecting differing patient reported treatment 
experiences and the clinician's preference for either drug.  
 “…although my experience of enzalutamide hasn’t been as good as my 
experience of abiraterone, so I am kind of swayed towards [abiraterone] still as my first 
line…That’s just, my own preference, because I’ve had, especially in the last few 
months, all the people I’ve got on enzalutamide seem to have problems on it” Clinical 
oncologist 4 
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 “…cognitive state, change in mood, change in energy level, sometimes with 
enzalutamide in particular, we have this global weakness and sometimes, the 
associated, neurology, twitching. So that’s, that’s happening more frequently than we 
could have anticipated” Medical oncologist 2 
Whilst some clinicians demonstrated a preference for either abiraterone or 
enzalutamide due to better tolerance, this was not the case for all. Medical oncologist 
3 also mentioned the lack of trial data comparing the two drugs. 
 Medical oncologist 3 "The nuisance is that there’s no evidence to compare 
them [Enzalutamide and Abiraterone]. 
 Interviewer “Oh OK because from speaking to some oncologists, they’ve said 
that they’ve actually found abiraterone is tolerated a lot better.” 
 Medical oncologist 3 “I don’t agree with that…I don’t because I would probably 
say most tolerate it pretty well.” 
All of the clinicians spoke of the choice of drug dependant on patient PS, comorbidity 
and therefore risk of complications. Diabetics and those with heart disease are offered 
enzalutamide, due to the cardiac risk and the need to take prednisolone with 
abiraterone; epileptics are offered abiraterone, due to the risk of fits associated with 
enzalutamide. These complications, although affecting treatment decisions, were 
rarely experienced by the clinicians interviewed.  
Chemotherapy was generally considered the treatment which was less well tolerated 
in comparison to ADT. As a result how a clinician would deem a man clinically suitable 
for chemotherapy became paramount.  
 “…they’d have to be PS 0 or 1 for me to give them docetaxel generally, with 
good renal function, and, you know, just generally a good performance status…with no 
other significant comorbidities.” Clinical oncologist 4 
Interestingly, aside from fitness to treat and tolerance of therapies, medical oncologist 
1 offers a more holistic view and mentions the importance of social support as another 
factor which is considered, emphasising the need for assistance and support from a 
partner or family member on "bad days". 
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 “I’m just going, going back thinking, it can be difficult giving chemotherapy to 
single men…Men who live, men who live alone…They, they’re a real worry.” Medical 
oncologist 1 
Six of the clinicians mentioned patient decision making in their interviews. It was 
reported that many men are happy as they are or have simply had enough of 
treatments. Some may only consider further treatment upon the development of 
symptoms from disease progression. There are also other factors such as pressure 
from family to pursue further treatment which men may take into account. 
 “…the patient-related factors, not wanting chemotherapy and some patients 
would, are keen not to go onto further endocrine therapy so that can cause some 
delay while we give them a bit of time to, to just confirm that their PSA is rising or their, 
their imaging is showing progressive disease.” Medical oncologist 2 
Men may prefer to accept alternative therapies such as palliative radiation and 
analgesia if they choose to avoid second line treatment. Patient treatment decisions 
are also dependant on their preferences around the monitoring involved with the 
individual treatments and the impact of such monitoring on day to day living. This in 
combination with the individual risks carried with treatments. 
 “…it’s difficult…the problem with abiraterone is they have to come fortnightly for 
bloods and blood pressure, for the first three months. So if you’ve got one, someone 
who’s active and wants to keep away from hospitals, they’ll often say no to that, and 
also the steroids with the abiraterone puts some patients off, even though you point 
out that they’ll get steroids with the docetaxel, so that sometimes puts them off. If 
they’re a patient who’s got, epilepsy or doesn’t fancy the chances of a fit they will 
choose the abiraterone or some patients like to be seen more frequently. They feel as 
if they’re being looked after and they will choose abiraterone…” Medical Oncologist 3  
5.4 Theme 5: Clinicians experience of managing muscle wasting comorbidity 
in men with prostate cancer 
5.4.1 Muscle wastage aetiology, assessment and treatment 
The types of muscle wastage referred to in the interviews were originating from ADT, 
physical inactivity, steroids (prednisone), sarcopenia (age related muscle wastage) 
and cachexia. 
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 "…and you’ve started the drug…and very often people will be saying to you, I 
was OK and then I started these hormones, …and patients say the same things, they 
can’t get up from squatting position, that sort of thing…" Clinical oncologist 5 
One example given by clinical oncologist 3 described how ADT was stopped due to 
extreme muscle wastage in one patient.   
 "...so I’ve seen muscle wasting that was quite significant that was stopping 
somebody from going out and doing their job…they worked in a shop and it was 
stopping them from doing that. So, although there was data for overall survival benefit 
in continuing the hormones, I stopped the hormones after discussion, because I felt 
that we’re going to leave him housebound at the end of this and I felt that that was a 
more, poor prognostic factor in his life…" Clinical oncologist 3 
Clinicians were unanimous (n =12) that there currently exists no robust diagnostic 
procedures when distinguishing muscle wastage of different aetiologies. For some, 
this meant that no official assessment for muscle wastage was made at any stage in 
the prostate cancer care pathway.  
A man who presents as being fairly well but has generalised weakness, ADT related 
muscle wastage (a common side effect) may be presumed. If however, he presents 
with proximal muscle wastage following the initiation of steroids, side effects of 
steroids may potentially be the cause. The interplay between the induced LBM loss 
associated with treatments and that associated with cachexia resulted in difficulty 
distinguishing the two. With a lack of clarity and a definitive diagnosis of muscle 
wastage, accordingly, treatments were the same regardless of aetiology; generally 
advocating exercise and a healthy diet.  
 "While I don’t have any method in clinic of assessing muscle wastage and I 
don’t, certainly don’t have time to sit measuring their muscle bulk...." 
 "...I probably should weigh them more often, but it depends what I’m going to do 
about it, I guess."  Clinical oncologist 4 
 "…I haven’t made a clear distinction between, muscle weakness because of 
ADT, muscle weakness because of steroids, muscle weakness because of cachexia, 
um, perhaps we should." Medical oncologist 2 
161 
 
 " I just advocate a healthy diet but mainly it’s the exercise that I think that is the 
most important…exercise I think is the most important thing to maintain muscle bulk." 
Clinical oncologist 5 
5.4.2 Cancer cachexia 
Most clinicians felt that recognising cachexia occurred upon the association of 
progressive disease accompanied with rapid muscle wasting rather than any sort of 
clinical diagnostic method and is generally identified towards the end of life. Therefore, 
an accurate patient history which demonstrates the onset of cachexia associated 
physiological symptoms from the patient's baseline physiological state, was felt to be 
attributable to the comorbidity. However, the use of long-term steroids, particularly for 
advanced patients, can also be the origin of muscle wastage. Furthermore, it was not 
clear how cachexia would be distinguished from muscle wastage associated with ADT. 
Therefore, the need for a robust diagnostic procedure was highlighted where clinicians 
can risk the cessation of steroids when the underlying cause is cachexia. Where 
cessation of steroids is inappropriate, there is a risk to further exacerbate the disease 
and disease symptoms. 
 "The cachexia is usually end stage and it’s, you know, and often they’re on 
steroids anyway for their disease control, so if you think its cancer related cachexia 
then it, it could be steroids." Clinical oncologist 6 
As well as nutritional interventions, steroids such as dexamethasone are often used to 
combat cachexia but this can in turn cause proximal muscle weakness. Cachexia's 
association with advanced stages of cancer meant exercise was considered 
inappropriate by one of the clinicians. 
 "I don’t think it would be appropriate to be telling a patient, you know, who’s 
losing weight because they’ve got advanced cancer that they should be taking 
exercise." Clinical oncologist 2 
5.4.3 Clinical significance of muscle wastage 
There was significant variation between the clinicians on how they viewed clinical 
significance of muscle wastage among men with prostate cancer. Whilst for most it 
was considered of clinical importance, for the urologists it was not seen very regularly 
or considered a primary concern. 
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 “…but I’d say for the majority of men, although it’s objectively there, I’m not sure 
subjectively it may make a great deal of difference to their quality of life.” Urologist 1 
However, five oncologists however did see muscle wastage as a significant 
comorbidity, although some alluded to the fact that men may not prioritize it amongst 
other concerning disease symptoms or survival. 
 "Yes it’s very clinically, very clinically important…the prevalence of the muscle 
wastage or weakness is… usually is probably quite high." Medical oncologist 2 
It was also clear that whilst a man may not give the direct complaint of muscle 
wastage, it may be the loss of mobility or vigour which he notices and this can have 
profound effect on his QoL. For those men who are more physically active however, 
they may notice a significant decrease in exercise tolerance and this can have a 
considerably deleterious effect on his wellbeing. 
 “…they come and they say, yeah, I feel really tired, I can’t play a round of golf 
anymore, I can’t walk as far as I did, so not specific muscle loss, but the 
consequences are the things that the men complain about.” Clinical oncologist 4 
 “…men who say they’re not as strong as what they used to be and they can’t, 
you know, do the amount of exercise that they used to do or, you know, find it difficult 
sort of maintaining their jobs if they’re still working.” Clinical oncologist 6 
6. Discussion 
6.1 The healthcare professional survey 
The 95 respondents represented a range of professions with experience of the 
prostate cancer pathway based throughout the UK and gave an insight into what could 
be described as "usual care". This included how exercise programmes which had the 
potential to meet the NICE guidelines were being delivered nationally.  
A clear understanding of the current prostate cancer pathway gives an insight into how 
changes to the pathway, such as the introduction of exercise as a complementary 
therapy, are successfully implementable. This is especially the case with prostate 
cancer where the care pathway is continuously evolving. Establishing a clear picture of 
key HCP roles within the prostate cancer care pathway in relation to the delivery and 
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initiation of ADT is paramount. As highlighted in the survey, there are a wide range of 
HCPs involved in the delivery of ADT but the planning and initiation of these therapies 
is predominantly the responsibility of urologists and oncologists which was an 
expected finding.  
Despite the survival benefit demonstrated in STAMPEDE and CHAARTED, the current 
survey revealed an unexpected finding that the average amount of men receiving 
docetaxel on ADT was as little as 23.3% (James, Sydes et al. 2012, James, Spears et 
al. 2015, Sweeney, Chen et al. 2015). Furthermore, the responses given ranged 
between 0-87% indicating that the low average may represent differences in care 
between trusts rather than a national picture of men receiving docetaxel.  
The most common barrier to chemohormonal therapy was "patient unfit" indicated by 
just under half of the respondents. This suggests that in order for patients to have the 
best possible chance of receiving the highest standard of care, fitness is at the core to 
accessing treatments. Patient fitness is a contentious issue, where it is very much 
subjective how a clinician may determine a patient as physically fit and whether such 
subjective assessments are adequate (Greasley, Turner et al. 2018).  
Previously it has been reported that HCPs experience significant barriers preventing 
the discussion of physical activity with their patients, including how it is not deemed to 
be a part of their role (Jones, Courneya et al. 2005, Karvinen, McGourty et al. 2012, 
Spellman, Craike et al. 2014). It was key to establish how supervised exercise 
programmes may or may not be embedded in the NHS despite the NICE 
recommendations. A large proportion of respondents (74%) indicated having 
knowledge of the NICE recommendations (CG175, 1.14.19). However, the average 
score for ability to deliver on these recommendations was only 4.87, indicating that 
despite knowledge of these recommendations, there remain barriers to 
implementation.  
The findings show that across the UK there is either very little to nothing being offered 
in the form of an exercise referral programme (for more than half the population) or 
some level of accessible exercise programme available for these men. This indicates a 
potential disparity between UK trusts, where some are failing to deliver NICE 
recommendations by simply not having any available programmes for men to access.  
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It is clear that there is huge variability nationally in what is being delivered to meet the 
NICE guidelines. Where trusts have attempted to put in place exercise programmes 
for cancer patients, there remains further variation. Although the majority indicated that 
these programmes would be accessible to prostate cancer patients on ADT and that 
the programmes predominantly run in a community setting, 20% of the respondents 
indicated that these programmes would not be available for these men, potentially 
indicating that the programmes are designed for other cancer types, such as 
breast/colorectal, although this was not clear. 
However, a positive finding was that of the programmes that exist the predominant 
HCPs involved are nurses and GPs indicating primary care and secondary care 
involvement in exercise referral in some trusts. In addition, gym instructors were 
primarily responsible for setting the frequency, intensity, and duration of exercise. 
However, a disappointing 53% of respondents reporting an exercise referral 
programme indicated that no staff training was provided for exercise programmes in 
cancer populations, or that they were unsure if such training existed. Without proper 
training for HCPs in the benefits of exercise programmes it is doubtful that 
conversations regarding exercise or physical activity in clinic with cancer patients will 
arise especially where time is often limited during appointments (Clark, McArthur et al. 
2017). In addition, without proper education, fears regarding advising physical activity 
due to issues of safety could prove a significant barrier (Tsiouris, Ungar et al. 2018). A 
training programme could help create clinician "buy in" to endorse exercise as a 
supportive therapy.  
Furthermore, issues regarding the cost of implementing physical activity guidelines 
and exercise programmes have been an established barrier (Nwosu, Bayly et al. 2012, 
Clark, McArthur et al. 2017). With half the respondents indicating the need for charity 
financial support to ensure the implementation of programmes which meet NICE 
guidelines for these men.  CRUK has recognised that health inequalities in cancer 
care span from information, support and cancer services all the way from provision to 
palliative care (CRUK 2006). The three factors presented in the survey (fitness, 
funding and updating guidelines) denoting substandard care can be summarised by 
what has been suggested as root causes in cancer care inequality nationally 
(Macmillan 2014). Profound changes in cancer care increases the risk of health 
inequalities where some services lack the capability to adapt successfully, there needs 
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to be a recognition that the support needs for trusts to undertake a rapid change in 
care to ensure the best outcomes of their patients likely differ for those trusts that lack 
the necessary resources and therefore are significantly challenged to adapt. Equally, 
as the aspects of care change and become more complex, some patients may lack the 
ability to confidentially act on the information regarding his care. Conversely those 
patients most capable of sharing decisions and self-manging are able to get the most 
out of their care. As cancer care pathways evolve and become more complex, 
services must act to prevent a variation in care quality. As Macmillan outlines in "The 
Dividing Line in Cancer Care for 2030"  
"…transfer power to the people who use services, enabling them to take greater 
control of their cancer team and their cancer journey…"  and with that enlisting 
patients in their own care (Macmillan 2014).  
 
Self-care is a critical dimension of healthcare and exercise programmes are a powerful 
self-care approach that have been demonstrated to be effective at managing side-
effects of disease and treatment. Despite the NICE recommendations, the variability in 
what is being delivered nationally demonstrates the need for a structured exercise 
referral pathway embedded into the care pathway. This would also require HCPs as 
key stakeholders for these men to champion this self-care approach and create an 
effective programme. 
6.2 The healthcare professional interviews 
6.2.1 Attitudes towards the implementation of an exercise intervention with a 
pharmacological agent for men with castrate resistant prostate cancer 
Views on the use of anabolic agents in men with CRPC alongside an exercise 
programme were varied. Clinicians were questioned about the use of widely available 
anabolic steroids as well as the more novel anabolic agents in combination with an 
exercise programme to enhance the effects. Although there was a positive feel 
towards the use of anabolic agents in a clinical trial there was some concern over the 
safety of such drugs. Few of the clinicians demonstrated a complete lack of support for 
the use of these drugs, for these clinician's the androgenic effects on the prostate were 
the primary concern and outweighed any potential benefits. Most of the clinicians 
stressed the need to see the preclinical research and be educated about the use of 
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such drugs in order to make an informed decision regarding their use in the context of 
a clinical trial.  
Medical oncologist 2 stated a lack of randomised data surrounding exercise as a 
therapeutic for men with prostate cancer. This was particularly interesting as to date 
there is level one evidence demonstrating improved outcomes in men with prostate 
cancer with exercise interventions in multiple reviews, systematic reviews and meta-
analysis of RCTs. These are highlighted in chapter 2. Importantly, Medical oncologist 2 
was recruited into this qualitative study via the recommendation of another participant 
and did not demonstrate a research interest in exercise for men with prostate cancer. 
It could be argued that medical oncologist 2's view was representative of some 
clinicians who have a lack of belief in exercise as a therapy; views which may have 
otherwise not have explored in this cohort.  
In qualitative research, a self-selection or non-response bias can result from 
participants declining to participate due to a lack of interest in the interview subject 
matter. As a result, the non-representative sample fails to capture some views and 
opinions. For this reason, medical oncologist 2 gave vital information for us to 
understand why exercise programmes may not be supported by clinicians. Medical 
oncologist 2 has demonstrated that this could be due to a lack of knowledge of the 
most current data supporting exercise interventions.  
However, largely there was support for the NICE guidelines recommending exercise 
for men with prostate cancer initiating ADT. Thus it could be argued that a combination 
of a lack of advocacy for such interventions by some clinicians and insufficient NHS 
funding are the reasons for why the guidelines have not been successfully 
implemented. Funding in the NHS, and lack thereof, was mentioned on several 
occasions in the interviews as a barrier to exercise programmes and cancer care in 
general. As well as this clinician capacity including time and specialist knowledge 
meant that programmes would likely be best placed to be facilitated by exercise 
specialists/physiotherapists with a good knowledge of the relevant individual medical 
conditions. This has previously been shown in other qualitative studies examining 
clinicians views on exercise referral schemes and for other chronic conditions (Din, 
Moore et al. 2015, Learmonth, Adamson et al. 2017). However, as demonstrated in 
the present study, clinicians are a patient's first point of contact regarding their health 
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and wellbeing and key drivers in patient based decision making (Bridges, Hughes et 
al. 2015) it is therefore key that they are campaigners for exercise as a fundamental 
aspect in cancer care. Currently, the data for the cost effectiveness of exercise 
programmes for advanced cancer populations undergoing palliative treatment is 
lacking (Santa Mina, Alibhai et al. 2012). However, these patients stand to gain a great 
deal of specific benefits relevant to their condition (Eyigor and Akdeniz 2014). 
Although expensive to implement initially, promoting habitual exercise in some cancer 
populations has been shown in to improve cost per QUALY, suggesting long-term 
financial benefits for the NHS (Haas and Kimmel 2011, May, Bosch et al. 2017). 
Lack of patient education and physical fitness were perceived by HCPs as significant 
barriers to exercise. In particular, men at advanced stages with potential multiple 
comorbidities, may be put off from exercise if they are not feeling well or physically 
capable. Similar findings have been demonstrated in clinician interviews regarding 
physical activity for lung cancer patients, stating the difficulty of "selling" physical 
activity at stages where there are symptoms and treatment side effects (Granger, 
Denehy et al. 2016). Educating patients and an individualised approach to the exercise 
programme was seen as paramount for successful engagement. Education would 
hopefully encourage the participation of those who are amongst the hardest to recruit, 
i.e. those who are from a lower socio-economic status and/or are older. Such an 
approach could help overcome some patient perceived barriers and fears regarding 
exercise. 
The timing of an exercise intervention was an essential consideration. The clinicians 
regarded a programme started as early as possible in the cancer care pathway would 
confer the most benefit i.e. at hormone sensitive stages where men are much "fitter". 
They did however feel that an opportunity to participate should be available at all 
stages in the cancer care pathway.  An intervention at earlier staged was felt to 
potentially confer long-term behaviour change and maintain levels of fitness. Rate of 
change of new therapeutics also means there potentiates a change in the history of 
disease. It is not clear how initiation of such treatments like docetaxel earlier in the 
pathway may affect a man's physical fitness and therefore perceived ability and 
motivations to undertaking exercise training. A previous qualitative study of HCPs has 
identified the perceived benefits of exercise interventions as early as possible, 
potentially mitigating the side effects of treatment and/or disease (Granger, Denehy et 
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al. 2016). Furthermore, initiating an exercise intervention as early as possible in the 
treatment pathway has been suggested to help mitigate muscle loss associated with 
cachexia (Bayly, Wilcock et al. 2017). At later stages it was felt that barriers such as 
advancing disease and comorbidity would present an issue. It was felt this could 
present some issues of safety. This was particularly the case during chemotherapy 
treatment and those who have advanced disease, and have remained on treatment for 
a number of years and therefore are likely to experience a number of side effects 
(Shapiro and Tareen 2012, Sountoulides and Rountos 2013). For example, the risk of 
infection in neutropenic patients, which can be fatal, due to chemotherapy in a gym 
environment was a primary concern. Concerns of exercise outside of cycles of 
chemotherapy or during ADT were not expressed by the HCPs. However, long-term 
effects of ADT were a consideration including patients experiencing a decline in bone 
health who potentially have osteoporosis or significant bone pain. They may be at 
significant risk of fracture, where fractures can result in significant morbidity and 
increased all-cause mortality (Van Hemelrijck, Garmo et al. 2013). Despite these 
concerns the clinicians still felt that an exercise programme would be accessible by the 
"fitter" patients with CRPC. 
It was therefore considered paramount that an exercise programme would be 
adaptable and flexible dependant on the individual and their stage of treatment and 
disease, both from a safety perspective and also from the perspective of patient 
engagement. This would likely be driven by the individual, giving them an option to 
"opt out" of a session where necessary and an understanding that these men will have 
"good weeks and bad weeks" was considered fundamental to better exercise 
compliance. 
It was also suggested that treating an exercise programme as a prescription would 
support better adherence. It was mentioned that men would likely prefer a programme 
where they did not mix with other men at other stages of the disease or where it is not 
necessarily within the community in a "typical" gym setting. But the clinicians in this 
study did not refer to exercise as a stand-alone treatment. In general, the clinicians 
spoke of exercise more as an adjunct to existing therapeutics, valuing it as a 
supportive therapy to help physical and psychological wellbeing. Overall, the clinicians 
were happy to advocate exercise and would support a trial for men with CRPC. 
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Exercise was seen as a valuable method for psychological benefit, including beneficial 
effects to QoL outcomes, the maintenance of muscle bulk and bone health, increased 
tolerance of treatment and a reduction in complications (surgical or medicinal). 
Although it was not recommended that exercise be used for those with advanced 
cachexia due to extremely poor PS', the use of exercise for LBM loss at earlier stages, 
such as pre-cachexia described in chapter 1, could be feasible. The potential for 
exercise to promote better tolerance to treatment is of particular value considering the 
importance of fitness for treatment and best treatment outcomes described in section 
6.2.2 and 6.2.3. All of the HCPs supported the use of a trial of resistance exercise as a 
supportive intervention for men with CRPC with an aim to LBM loss with long-term 
ADT, and the majority also supported it in combination with an anabolic agent. 
Overall, the HCPs showed support for an exercise intervention for men with CRPC, 
however the described barriers brought questions regarding its feasibility. Given the 
described issues regarding funding, comorbidities and patient pathway there would be 
challenges to an exercise programme for men with CRPC in the prostate cancer care 
pathway and the NHS. Logistical barriers include the lack of resource, the lack of 
clinician time and an ever evolving prostate cancer care pathway, including the 
changes in treatment sequencing. This could bring about barriers in terms of the 
optimal timing of an intervention. Despite the support for an exercise intervention for 
men with CRPC, most of the HCPs felt that the best time to introduce a man to an 
exercise intervention would be as early as possible, whilst maintaining the ability to be 
referred throughout his entire treatment pathway. This in part was due to concerns 
regarding the physical barriers which include progressive decline in health with 
ongoing long-term treatments and their side effects. Despite this, the HCPs were 
supportive of an exercise intervention for men with CRPC. 
Furthermore, an exercise intervention was viewed more as an addition, a supportive 
therapy, to standard treatment for men with prostate cancer rather than a stand-alone 
treatment. Physical fitness was described as a barrier to accessing treatments in both 
the survey and in the interviews, with the HCPs interviewed demonstrating its effect in 
treatment decision making. Given that physical fitness is a pivotal issue when 
prescribing therapeutics, exercise could be seen as a welcomed supportive therapy, 
improving or maintaining physical fitness and therefore granting access to treatments. 
This can be pivotal at later stages of disease where men have remained on treatments 
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for long periods of time. Exercise may be able to mitigate some of the functional 
decline experienced in these men. Furthermore, given that drugs such as 
enzalutamide and abiraterone have greater efficacy in men with a good performance 
status, these men may tolerate treatments better and get better outcomes. The 
difficultly would undoubtedly lie in determining who is fit enough to exercise but 
perhaps not fit enough for treatment, and potentially bringing those men to a fitness 
level good enough to receive further treatment should they want or require it. This area 
is yet to be explored in research. 
6.2.2 The prostate cancer care pathway: continuity of care 
Docetaxel is a widely used drug and a common therapy for CRPC. Its use has moved 
earlier in the prostate cancer pathway for suitable men upon the initiation of long-term 
ADT. It has been recognised that whilst the implementation of docetaxel earlier in the 
pathway is both recommended and feasible, there would be potentially adverse 
implications on the clinical pathway and resources (South, Burdett et al. 2015). The 
changes to the pathway have increased demand on oncology units and subsequently 
an additional workload to oncologists. Previous to such changes, oncologists would 
predominantly see men with CRPC, not hormone sensitive disease, when they are 
offered cytotoxic agents. As a result, any disjoint between urology and oncology may 
risk a delayed referral from one to the other. Ergo, if this falls outside of the 90 day 
window, a docetaxel regimen which can be offered to an eligible man is compromised.  
The findings of the present study suggest that for one oncologist, this has arguably 
risked sub-optimal patient care where the trust was challenged to accommodate the 
changes to the care-pathway by restricting the numbers of men referred for 
chemotherapy.    
The oncology team's involvement earlier in the pathway highlights the importance of a 
flexible integrated pathway of care between oncology and urology teams. Whether this 
is at the point where a man enters castrate resistant disease or where he is able to 
initiate docetaxel alongside ADT in hormone sensitive stages, a fractured pathway 
risks substandard care. An efficient and effective service would operationalise and 
adapt to changes in standard care to facilitate the best health outcomes for its users. 
Where the pathway lacks continuity, it is unlikely that trusts are able to implement 
additional supportive programmes for men across all stages of disease with prostate 
cancer. This may provide some evidence as to what was observed in the survey, 
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where there was significant variability across trusts in the implementation of exercise 
programmes for men with prostate cancer due to the NICE recommendations. 
It was clear that there was a distinct lack of embedded supportive programmes 
designed for the complex needs of men with CRPC. A 2013 survey suggested that 
81% of men with prostate cancer had some unmet supportive care need(s) (Cockle-
Hearne, Charnay-Sonnek et al. 2013). The clinicians mentioned that these men could 
access general psychological support programmes and palliative care programmes, 
both charity based and trust run; but whilst these men remain a part of the cancer 
pathway for a number of years, their needs differ significantly to those who may be at 
earlier stages of disease or those with other types of advanced cancer. So it is indeed 
surprising that there seemed to be a lack of guidance on how to specifically support 
these men through the terminal phase of their disease. These men are often 
signposted to generic "palliative" programmes as opposed to a programme which 
promotes more of a "self-care" approach. Such an approach is considered imperative 
to managing symptoms/AEs and promoting positive health outcomes (Cockle-Hearne 
and Faithfull 2010). Lifestyle changes, such as diet and exercise, have been 
demonstrated as an important, valued aspect of self-care in men with CRPC, 
promoting empowerment and a sense of control (Dodd and Miaskowski 2000, 
Miaskowski, Dodd et al. 2004, Street Jr, Makoul et al. 2009, O'shaughnessy, Laws et 
al. 2013). 
6.2.3 Treatment sequencing 
In addition to the immediate pressure of additional referrals to oncology units brought 
on by the change in the prostate cancer clinical pathway, it is important to consider 
how the introduction of docetaxel earlier will affect subsequent treatment sequencing. 
Some of the clinicians commented that second generation anti-androgens, abiraterone 
and enzalutamide, would be offered in the place of chemotherapy were it is felt men 
may not tolerate docetaxel due to a poorer PS. There was also a lack of clarity 
amongst clinician's in this study in how docetaxel and second generation anti-
androgens may be sequenced for men in the post-2015 pathway changes. 
The trials to date which have assessed the use of abiraterone and enzalutamide for 
men with CRPC were predominantly in men with no or mild symptoms (ECOG 0-1) 
(Danila, Morris et al. 2010, Scher , Fizazi  et al. 2012, Scher, Fizazi et al. 2012, Loriot, 
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Bianchini et al. 2013, Beer , Armstrong  et al. 2014). For the minority of men in these 
trials whom did have a poorer PS (ECOG ≥2) no significant OS benefit was 
demonstrated for either abiraterone or enzalutamide. Contraindications to docetaxel 
use are a poor PS (ECOG 3-4, caution for those with 2). This gives such men with a 
poorer PS few if not no treatment options. With these limitations we can conclude that 
fitness for treatment (and improved PS) can be the crux in treatment decision making 
by HCPs. 
Furthermore, the findings indicate some clinicians are treating men with abiraterone 
with poorer PSs’ preferentially over chemotherapy whilst there is a lack of data to 
support whether it may actually improve survival. The nature of high quality RCTs 
address the need for internal validity, but this may confound the "reach" within 
populations of patients recruited into these trials (Elting, Cooksley et al. 2006). 
Consequentially a selection bias exists in preference of men with better PSs (Elting, 
Cooksley et al. 2006, Geyer 2018, Gillessen, Attard et al. 2018).  Equally, recruiting 
such patients with poor PS whom have a significantly shorter survival time may lack 
relevancy in the "real world" when the approval of such drugs by NICE ultimately 
comes down to cost per quality adjusted life years (QUALY) (Elting, Cooksley et al. 
2006, Gillessen, Attard et al. 2018). With this exists a therapeutic quagmire with 
researchers and commissioners having to balance the need for data with clinical 
relevancy and economic viability. 
With a lack of trial data, clinical guidance and clarity within the cancer care pathway 
treating physicians face a major dilemma. They may have to make a treatment 
evaluation on a patient and potentially offer unsuitable treatments based on the 
premise that there is no suitable alternative. Furthermore, the optimum pre- or post-
docetaxel therapy is heavily debatable in CRPC given that there is no suitable 
comparison data, forcing physicians to make decisions based on assumptions and 
clinical experience rather than true "level one" data (Fitzpatrick and de Wit , van Soest, 
van Royen et al. , Sade, Baez et al. 2018).  
Therefore, if at present the available data for these treatments lack evidence for their 
efficacy in less fit populations with a poorer PS, interventions with an aim to improve 
and maintain of PSs and physical fitness in men with prostate cancer, introduced as 
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early as possible, would enable the best possible outcomes. Something which too was 
reflected in the opinions of the clinicians interviewed. 
6.2.4 Variability in the cancer care pathway and exercise implementation 
The variability in the care pathway and the problems faced with treatment sequencing 
can present significant barriers to the implementation of exercise programmes in the 
UK. This is further reflected in the findings of the survey, where less than half of UK 
trusts represented in the survey were able to offer an exercise programme to meet the 
NICE guidelines (section 1.4.19 in CG175).  
The lack of continuity between trusts in the cancer care pathway presents a structural 
barrier to the implementation of exercise interventions or programmes. Each trust is 
likely to have its own individual barriers which must be addressed, finance may be a 
problem for one, or the demographic of patients between trusts can be different and 
therefore differing social barriers may exist. Furthermore the lack of clinician time and 
capacity can differ between departments within the care pathway, as demonstrated in 
the oncologists interviews. Similar findings have been shown in other qualitative 
interview studies of healthcare professionals (Din, Moore et al. 2015, Granger, Denehy 
et al. 2016, Clark, McArthur et al. 2017). The difference in clinicians time and capacity 
will likely cause problems as to who is expected to facilitate conversations of exercise 
with the patient, and as demonstrated in the interviews, often it was felt to be the 
responsibility of the physiotherapist, CNS or allied clinician. However, it is 
recommended that for implementation of exercise requires a team approach at all 
points of contact a patient experiences in the cancer care pathway (Mina, Sabiston et 
al. 2018). 
Furthermore, issues surrounding the funding of such a programme were a primary 
concern. If there is no funding for a programme then despite the best intentions of a 
clinician, they are unable to refer these patients to the support which may help 
promote exercise behaviour. Furthermore, facilitating HCP and allied HCP training to 
increase "buy in" and create clinical champions for exercise as a part of clinical care to 
promote discussion physical activity and exercise with their patients will incur further 
cost. Referral schemes and supervised exercise have continually been demonstrated 
to promote exercise behaviour compared to home-based independent exercise. 
Therefore an established referral pathway is therefore considered the best evidence 
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based approach to encouraging exercise in cancer patients (Gaskin, Craike et al. 
2017, Yang, Hausien et al. 2017). However, given there are barriers to appropriate 
treatment to established cancer therapies described in the survey, and the findings in 
the present study demonstrating that some clinicians felt that an exercise programme 
would be considered more of "a luxury", the likelihood of increased specific funding for 
a programme could be problematic. Therefore there is a need for robust cost-effective 
data for implementation of exercise programmes in the NHS and, as one clinician had 
described, to generate a viable "business plan".  
6.2.5 Experience of the adverse effects of standard treatments and advancing 
disease 
Determining the root cause of an AE can have a profound impact on maintaining a 
patient's QoL whilst succeeding with the best possible treatment regimen to control 
disease. Dropping the dose, treatment breaks or switching to an alternate therapy can 
be an option, and so if a man's experience is such that the clinician regards this to be 
necessary then he/she must be sure of where the AE stems from to not compromise 
treatment. Dependant on the reaction to the previous treatments will also determine 
how the following treatment is offered. For example, if they have not tolerated first line 
ADT well, then new considerations need to be made for 2nd line ADT; and now 
considerations must be made for previous adjuvant chemo as the landscape has 
changed post STAMPEDE and CHAARTED. 
The interviews highlighted the importance of shared decision making for treatments 
between clinicians and patients. Shared decision making is preferred by a majority of 
patients and crucial in ensuring they feel fully informed and satisfied with their care 
(Blanchard, Labrecque et al. 1988, Joosten, DeFuentes-Merillas et al. 2008). Although 
it was highlighted that clinicians professional opinion on therapies are governed by a 
number of factors; such as the preference for a particular drug, comorbidity or 
contraindications and fitness for treatment; the maintenance of a man's QoL was 
always the primary concern. This would be guided by the patient's (and the patients 
family's) own preference a known key factor in decision making (Hobbs, Landrum et al. 
2015, Al-Bahri, Al-Moundhri et al. 2017). 
6.2.6 Experience of muscle wasting comorbidity in men with prostate cancer 
Fitness for treatment is a predominant factor in a clinicians treatment based decision 
making (Kelly and Shahrokni 2016). Treatment evaluation of a patient with CRPC 
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remains a significant issue given the predominance of muscle wasting and 
deterioration in bone health (Perlmutter and Lepor 2007). Further, retrospective data 
has associated better OS in men with metastatic prostate cancer receiving docetaxel 
with increased LBM (Wu, Liu et al. 2015). The overwhelming consensus amongst the 
clinicians was that both recognition and treatment or prevention of muscle wasting is a 
clinically unmet need but not necessarily one they feel they can address in practice.  
The findings highlight a lack of clarity over the origin of the muscle wastage and how 
these are to be subsequently assessed and treated. This is likely to reflect populations 
at different stages of disease but equally the complex nature of muscle wastage 
means there is greater difficulty in determining the aetiology. Given that the clinicians 
described a non-specific assessment for the diagnosis of cachexia; including a general 
functional decline of the patient, knowledge of their current treatments and disease 
stage and weight loss; very little preventative measures are put in place.  
There was an overwhelming view amongst clinicians that currently, very little is offered 
in the way of treatment to address muscle wastage. Generally, advocating a healthy 
diet and exercise was encouraged to treat the majority of muscle wastage seen in the 
clinic with the exception of cancer cachexia. Success from this approach was viewed 
as variable. This may be in part due to a lack of consistency from clinician to clinician 
in the subjective nature of general "exercise and diet advice". However, equally the 
"one size fits all" approach to tackling muscle wastage of differing aetiologies is 
unlikely to be efficacious.  Compromising treatment was also mentioned by some of 
the clinicians resulting in the cessation of ADT or restricting the use of steroids for men 
whom muscle wastage becomes a problem. Muscle wastage is particularly complex in 
its aetiology and therefore notoriously difficult to mitigate or treat. A huge challenge 
faced by clinicians is the lack of available therapeutic options for men where muscle 
wastage becomes a significant detriment to QoL, in some cases compromising 
treatment at the potential cost of a survival benefit (Andreyev, Norman et al. 1998, 
O'Gorman, McMillan et al. 1998). Equally, the effects of muscle wastage appear to 
have significant implications on the fitness and PS of a man, and therefore not only 
impacting his current therapy but also likely to affect future treatments he is offered as 
his disease progresses. 
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7. Study limitations  
It is important to acknowledge the limitations to these studies. The primary limitation of 
the survey was the number of respondents and the limit to the information gained. 
With surveys it is not possible to get in-depth detailed answers as is the case with 
interviews. Although interviews were subsequently conducted, this included only the 
limited professionals, i.e. medical and clinical oncologists and urologists. The views of 
other professionals which were identified in the survey such as CNSs, physiotherapists 
and gym instructors were not gained. Therefore the findings of these professionals 
were limited to the data in the survey.  
Furthermore, the HCP interviews did not include the views of men with CRPC.  They 
were an insight into the views and opinions of 12 clinicians and for this reason is 
limited in its generalisability. The interviews included the opinions of three urologists, 
three medical oncologists and six clinical oncologists. As the majority of interviewees 
were clinical oncologists the data may be more biased to the perspectives of this 
particular group of professionals. Due to the nature of how these participants were 
recruited into the study, it is acknowledged that a self-selection bias may also exist. Of 
the 35 clinicians contacted 54% (n =19) expressed an interest in the research themes 
(12 subsequently interviewed); the sampling of the participants in this study failed to 
address the views of those who did not express an interest. Some of these invited 
HCPs also expressed that they could not participate due to time-constraints, which 
indeed is a finding of the present study. The thematic framework approach to 
analysing the data was used, although commonly used in healthcare research; this 
form of analysis is more deductive and therefore stays strongly informed by a priori 
reasoning (Mays and Pope 2000).  
Finally, it is important to recognise that this work was the first qualitative work 
undertaken by the author (RG). Therefore, it should be noted that whilst the interviews 
provided some insights into the HCPs views and opinions, there was a limitation in the 
lack of experience of the author. Given that these HCPs were senior clinicians, the 
authors experience of the interviews was very different, in terms of both content, 
rapport and power dynamic than that of the focus groups described in chapter 5. 
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8. Conclusion 
The provision of exercise nationally was widely variable between trusts represented in 
this survey. Irrespective of the 2014 NICE recommendation (section 1.4.19 in CG175) 
there are inconsistencies in the NHS in how men initiating or undergoing ADT are 
offered supervised resistance and aerobic exercise. These inconsistencies were not 
only amongst all 79 trusts identified in the present study but also amongst the 47 sites 
determined by us as having an exercise programme or exercise referral scheme which 
had potential to meet the NICE recommendations. There is a need to standardise 
exercise programmes which can be fully integrated into the cancer care pathway and 
therefore consistently be available for all men initiating or undergoing ADT. 
Fitness for treatment in advanced prostate cancer remains a significant barrier for 
access to the available therapies in those with a poor PS. This has become even more 
pressing since changes in the current pathway. Given that men will have already 
received a docetaxel chemotherapy regimen, it is less clear how this may affect future 
treatment options and their physical fitness due to long-term effects of chemotherapy. 
In addition, muscle wastage is too of significant clinical impact, affecting fitness for 
treatment and in some cases compromising current therapy. There appears to be a 
significant unmet need for effective treatments to tackle muscle wastage and current 
practice is an imprecise approach; however the use of anabolic agents in combination 
with an exercise intervention to tackle muscle wastage was received relatively well in 
the context of a clinical trial.  
These clinician interviews have demonstrated support for a cost effective, 
individualised and adaptable exercise programme for men with CRPC which could 
improve fitness and mitigate some of the long-term effects of their cancer/cancer 
therapy. However, there exists potential and significant barriers to successful 
implementation in the NHS, which may result in this service falling outside of NHS 
provision. However, supportive programmes which promote "self-care" are lacking 
significantly in the current prostate cancer care pathway for men with CRPC; there is a 
significant gap for such programs tailored to the complex needs of this group.  Where 
there is a lack of continuity in the pathway, their successful implementation is less 
likely. In order for such a programme to be successful, there must also be a 
recruitment strategy which educates both the patient and the clinicians involved in the 
care of these men. Furthermore, it was expressed by the HCPs that there would need 
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to be consideration to the timing of the intervention, particularly when faced with 
treatments and disease related barriers.  
The described barriers and facilitators to implementing exercise interventions were 
taken into account when conducting the feasibility RCT (COMRADE). The following 
study (chapter 4) will explore the feasibility of a uniquely tailored and adaptable 
exercise programme with dietary supplementation for this group of men which will aim 
to improve outcomes including changes in LBM, bone health QoL and physical 
function.  
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Chapter 4 The feasibility and safety 
of a lifestyle intervention in men 
with castrate resistant prostate 
cancer: a randomised controlled 
trial  
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1. Introduction 
In consideration of the evidence provided in the previous chapters, the following study 
was designed to determine the feasibility of a lifestyle intervention of resistance 
exercise, dietary supplementation and dietary guidance for men with CRPC in order to 
improve outcomes in these men. In the current study, an adaptive programme of 
resistance exercise was designed to promote beneficial effects in physiological and 
psychological outcomes for men with CRPC. In addition, whey protein and creatine 
monohydrate supplementation were consumed to promote anabolic effects including 
improved LBM. Dietary advice to promote healthy eating behaviours was also 
provided. The target population were men who were inactive and mostly sedentary 
and therefore not already meeting the NICE guidelines (section 1.4.19 in CG175).  
This study aimed to be the first to explore the feasibility of such a lifestyle intervention, 
examining the use of exercise and dietary intervention specifically tailored to the needs 
of men with CRPC. The research question for the present COMRADE (A Combined 
Programme of Exercise and Dietary Advice in Men with Castrate Resistant Prostate 
Cancer) Feasibility RCT was: 
Is a RCT of a lifestyle intervention, including supervised resistance exercise training, 
whey protein and creatine supplementation, and dietary advice feasible in men with 
CRPC? 
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2. Methods 
2.1 Research design 
A phase II feasibility RCT was used as an exploratory research method to assess 
exercise in improving outcomes for men with CRPC. Phase II trials "…describe the 
constant and variable components of a replicable intervention and feasibility of the 
protocol for comparing the intervention with an appropriate alternative" (Gorard and 
Taylor 2004). The advantages of the RCT design mean that systematic differences 
between the groups in the study do not occur due to randomisation and an unbiased 
estimation of the average effect can be gained compared to non-randomised 
intervention trial design (Gorard and Taylor 2004). Such trials are also conducted in 
preparation of a definitive larger scale RCT and therefore aim to assess the clinical 
and economic viability of an intervention.  
Feasibility studies are recommended by the MRC to identify problems which may 
occur or address uncertainties in a larger scale RCT (Craig, Dieppe et al. 2013). The 
MRC suggests the aims of such studies should include the testing of procedures for 
their acceptability, estimating rates of recruitment and retention, and the determination 
of sample sizes (Craig, Dieppe et al. 2013). The current study aimed to assess these 
outcomes of feasibility for comparing the intervention to the alternative or standard 
NHS care (control). Although an RCT used alone poses its limitations in real world 
implementation, in combination with the methods used previously it could provide 
robust evidence for the feasibility of a RCT of a lifestyle intervention providing a 
potential supportive therapy for these men to combat some of the effects associated 
with treatment and disease. 
2.1.1 Aim  
To determine the feasibility of a 16-week lifestyle intervention of resistance exercise, 
whey protein and creatine supplementation and dietary guidance in men with CRPC. 
2.1.2 Primary outcomes 
1. Determine the rate of recruitment. 
2. Determine the eligibility of men among those screened to take part in the 
trial. 
3. Measure intervention adherence. 
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4. Measure study completion rate over 16-weeks (attrition rate). 
5. Measure adverse events (safety). 
6. Assess objectives 1-5 using standard methods for rates and proportions. 
2.1.3 Secondary outcomes 
1. To measure changes in physical function and fitness. 
2. To measure changes in muscle hypertrophy, lean body mass (LBM), fat 
mass (FM) and bone mineral density (BMD) assessed by dual energy x-ray 
absorptiometry (DXA) scanning and anthropometric measurements. 
3. To measure changes in prostate specific QoL and fatigue perception. 
4. To measure changes in serum biomarkers, including sex hormone binding 
globulin (SHBG), testosterone, PSA and lactate dehydrogenase. 
5. To measure changes in the dietary and nutritional status using 3-day diet 
diaries.  
2.1.4 Participants 
2.1.4.1 Inclusion criteria  
Men with CRPC, defined as men with histologically confirmed prostate cancer on long-
term ADT with either: 
 PSA>2ng/ml above nadir and a PSA level that has risen serially on at least two 
occasions (each at least 4 weeks apart) in the presence of castrate levels of 
testosterone or;  
 Evidence of symptomatic disease progression whilst undergoing first line 
androgen deprivation therapy (ADT) in the presence of castrate levels of 
testosterone or;  
 Radiographic disease progression whilst undergoing first line ADT in the 
presence of castrate levels of testosterone. 
2.1.4.2 Exclusion criteria 
 Participation in other trials which might bias the evaluation of the primary 
outcomes of the present study. 
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 Current participation in regular physical activity. This was defined as purposeful 
physical activity of a moderate intensity for 90 minutes per week for at least six 
months.  
 Unstable angina, uncontrolled hypertension, recent myocardial infarction, fitted 
with a pacemaker. 
 Uncontrolled painful or unstable bony metastatic lesions.  
 Within two months of invasive surgical treatment (transurethral surgery 
allowed). 
 Any physical, neurological or psychiatric impairment, disease or other condition, 
or non-English speakers/readers that would limit the ability to understand and 
complete the study assessments and complete the required questionnaires, 
recall and record of dietary information would be excluded. 
2.1.5 Sample size 
As this study was a feasibility RCT, a power calculation was not conducted to 
determine sample size. A target recruitment figure of 50 patients was set empirically to 
promote estimates for this feasibility study. Fifty participants can provide estimates of 
feasibility measures and of variability in secondary outcomes for use in power 
calculations with reference to the design of a subsequent larger-scale RCT (Lancaster, 
Dodd et al. 2004, Bourke, Doll et al. 2011). 
2.1.6 Study design 
Participants were randomly allocated to receive either 16 weeks of resistance exercise 
training, dietary supplementation and dietary advice, or 16 weeks of usual care. 
Repeat assessments were performed after 8 weeks (mid-point assessment) and 16 
weeks of the intervention (end-point assessment). There was also an option to partake 
in a post-study completion focus group (chapter 5). The patient pathway through the 
study is shown in the study schematic Figure 4.1. 
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Figure 4.1 A schematic of the COMRADE trial recruitment and assessment schedule  
2.1.7 Ethics approval 
This study was approved by North East - Newcastle & North Tyneside 2 Research 
Ethics committee (15/SW/0260) and in accordance with the Governance 
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Arrangements for Research Ethics Committees and complies fully with the Standard 
Operating Procedures for Research Ethics Committees in the UK. All Management 
permissions were sought from the relevant NHS organisations involved in the study in 
accordance with NHS research governance arrangements (appendix 12). 
ClinicalTrials.gov Identifier: NCT03017417. All participants gave their informed 
consent before participation in this study.  
2.1.8 Recruitment methods 
Patients were identified from treatment lists and clinic lists from urology (by a study 
research nurse or the author) and oncology outpatient clinics (by the author) in Weston 
Park Hospital and The Royal Hallamshire Hospitals in Sheffield, UK. The clinics 
consisted of clinician or nurse led follow-up clinics and treatment clinics. Patients were 
screened (by the author or study research nurse) against the inclusion and exclusion 
criteria via the electronic notes on the electronic document management system 
(EDMS) or Lorenzo  prior to attending clinic or via paper notes in the clinic where 
electronic notes were unavailable. LORENZO and EDMS are patient health record 
systems which allow access to patient details (date of birth, address, phone numbers 
etc.), dictated clinic letters as well as the results of any clinical investigations. Those 
identified as potentially eligible were approached in person in clinic by a member of the 
research team (the author or the study research nurse) and given a recruitment pack, 
consisting of a patient information sheet (PIS) and invitation letter (appendix 13).  
Patients were then given a minimum of 24 hours to read the PIS before a follow up 
phone call was made (by the author). Alternatively, a recruitment pack was posted and 
a follow up phone call followed between 3-7 days from posting (by the author). For 
transparency the data for the recruitment of men with CRPC is displayed in the 
Consolidated Standards of Reporting Trials (CONSORT) diagram (Figure 5.2). 
Recruitment posters were displayed in clinic waiting areas where prospective 
participants were given the trial contact information (appendix 14).  
2.1.9 Invitation follow-up phone call and post screening health screening 
questionnaire 
Participants were contacted by phone after a minimum of 24 hours from receiving the 
PIS. Participants who expressed an interest in the study were requested to complete a 
health screening questionnaire (HSQ) over the phone (appendix 15). Patients were re-
screened against exclusion criteria. During this phone call the participants were given 
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a chance to ask any questions and address any concerns with the member of the 
research team. The trial assessments, randomisation, intervention protocol, time 
commitment and general practicalities of the study (parking, location of rooms etc.) 
were reiterated and discussed to ensure sufficient understanding of the commitment 
required for the study. If participants still wanted to be included in the study they were 
invited to provide informed consent (appendix 16) and undergo a baseline assessment 
at Sheffield Hallam University (SHU).  
2.2 Baseline assessment and randomisation 
Prior to baseline assessment, participants completed written and verbal informed 
consent procedures on site at SHU. See figure 4.1 for the recruitment and assessment 
schedule. Assessment visit one was undertaken at baseline and repeated at 8 and 16 
weeks. Assessment visit two was undertaken at baseline and repeated at 16 weeks 
only. 
Assessment visit 1: Sheffield Hallam University 
At visit 1 the participant underwent a series of physical functioning assessments and 
muscle strength tests (conducted by the author or a research technician). In addition, 
whilst on site, a blood serum sample was taken (by RG), two questionnaires and a diet 
diary was provided for completion. In this session participants had their second 
assessment visit confirmed with the member of the research team. Outcome 
measures are described in detail in section 2.4. 
Assessment visit 2: The Clinical Research Facility, The Northern General Hospital 
During visit 2, participants underwent whole body DXA scan (conducted by 
researchers at The Clinical Research Facility) details of which are described in section 
2.4. 
Randomisation procedures 
Once castrate levels of testosterone (from blood serum analysis conducted by labs at 
STH) were confirmed, patients were randomised at an allocation ratio of 1:1 to either 
to the resistance exercise and dietary intervention arm plus usual care (intervention 
arm) or the exercise guidance plus usual care (control arm). Men randomised to the 
control arm were provided with Macmillan independent exercise advice guidelines for 
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cancer patients (Macmillan Move More Pack). The randomisation was completed by 
an independent researcher via a computer generated algorithm randomisation tool:  
(https://www.random.org/sequences/?mode=advanced).  
The sequence generation was undertaken by an academic blind to allocation who then 
kept the sequence blind to the research team. Once successfully randomised, the 
participants GP was sent two letters to notify the participants recruitment into the trial 
and to notify that the participant was required to undergo two DXA scans (appendix 
17).  
2.2.1 Intervention habituation sessions (week 1) 
Participants randomised to the intervention undertook a familiarisation week during 
week one, consisting of two separate sessions. On day one, the participants were 
introduced to the 16-week resistance exercise programme plan with an explanation of 
the design of the programme (including a whole body approach, reasons for warm-
ups/cool-downs etc.). On this day, participants were also inducted to the exercises 
(day one, phase one) of the trial. This included the correct use of the exercise 
equipment; how to perform exercises using appropriate technique and correct form 
throughout an optimal range of movement. It was explained that this was to ensure 
exercises were undertaken safely and to reduce the risk of injury. Men were also 
requested to bring their own towel, for hygiene purposes, and water was provided ad 
libitum in each session. Advice was provided on speed of concentric and eccentric 
phases of the exercises and breathing techniques. This included a 1:2/1:3 ratio in the 
velocity of concentric to eccentric phase of the exercise whilst exhaling on the 
concentric phase and in on the eccentric phase. The exercise specialist (by RG or 
research technician) also took this time to assess the individual's ability to safely 
perform exercises and adapt exercises, where necessary, with regressions or 
progressions. Participants were provided with the dietary guidance booklet which 
includes recommendations and dietary advice based on the NHS healthy eating 
guidelines (appendix 18). 
In the second session (day two, phase one), participants were again inducted to the 
exercises. Participants were also given the whey protein, creatine supplements, and a 
protein shaker (see section 2.3.3 supplementation). The protein and creatine 
supplementation, including reasons for taking the supplements and how to take the 
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supplements, was also discussed with participants in person at the session (appendix 
19, SOP).  
2.3 Lifestyle intervention 
2.3.1 Exercise sessions  
The exercise sessions took place in the exercise facilities in A205 Collegiate Hall on 
Collegiate Crescent at SHU. All sessions were supervised by an exercise specialist 
(with CQC Level 3 exercise referral qualification, the author (RG) or physiotherapist) to 
ensure safety and correct form during exercises. Sessions took approximately 45 to 60 
minutes dependant on the time taken to complete all exercises. The sessions 
consisted of a 7 to 10 minute warm up on a piece of cardiovascular equipment 
(treadmill, cross-trainer, bike or rower based on personal preference) and 6 resistance 
exercises. The cool down lasted approximately 5 to 10 minutes, which was also 
undertaken on a piece of cardiovascular equipment. Each resistance exercise was 
performed for 2-3 sets of 6-12 repetitions with a 30-90 second rest period between 
sets.  
The exercises sessions were split into three phases, each phase consisting of 5-6 
weeks and included two alternating days of exercises. The full exercise programme is 
available in appendix 20. Phase one consisted of body weight squat, seated cable 
row, bench press, body weight lunge, lateral raise, dumbbell side bends, push ups, 
glute bridge hold, single arm bent over row, farmer carries and 1-arm kneeling lateral 
pulldown. Phase two consisted of body weight sumo squat, dumbbell deadlift, leg 
raise, upright row, dumbbell shoulder press, tall plank, knee extension, back 
extension, standing bicep curl, leg press, standing tricep pulldown and sit-ups. Phase 
three consisted of body weight squat, leg press, cable row, bicep curl, cable tricep 
pulldown, tall plank, bench press, deadlift, hip abductor, lateral cable hold, kick-backs 
and dead bug. Each phase was sequential, in which phase one was weeks 1-5, phase  
two was weeks 6-10 and phase three was weeks 11-16. The exercises targeted all 
major muscle groups and the phase approach was chosen to ensure variety in the 
exercise session to encourage adherence and reduce monotony. In addition, such an 
approach helped to sedentary participants to progress (both in physical ability and in 
confidence) to more complex exercises, increasing in intensity, which recruit an 
increased number of major muscle groups or required more balance.  
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The exercise volume, frequency and intensity were based on the number of sets, 
repetitions and weight (kg) lifted. The programme was designed to increase exercise 
volume, frequency and intensity progressively, with no more than 2 reps/1 set/ 15%-
40% increase in weight (kg) if the exercise was progressed. At the beginning of a new 
phase, the initial weight, number of sets and number of repetitions was determined 
during familiarisation sessions. The familiarisation sessions also determined the 
positioning on the exercise equipment, for example if a man could not lie flat during a 
bench press, the angle of the bench where he could perform the exercise safety and 
comfortably was recorded. In this case, a further aim would be to progress to the 
proper exercise form as well as in weight, sets and repetitions. A progression would be 
made based on the ease of the last set completed, this included whether the 
participant felt they could do more than 2 additional repetitions in their last performed 
set.  
However, when necessary the exercise volume, intensity or frequency would either not 
progress or be regressed (e.g. the type of exercise or the weight reduced from the last 
recorded weight in a completed set). An example of where such regressions would be 
made included either when a man arrived at the sessions with worsened symptoms of 
disease and/or treatment or when he had some absence (due to illness for example). 
At the beginning of each session, each man was asked how he felt to ensure any 
regressions were adopted if necessary.  
In addition, participants were given a 16-week independent exercise diary in which 
they were asked to log at least one form of moderate- high intensity aerobic activity 
lasting 30 minutes or more a week (appendix 21). They were asked to undertake 
aerobic activity which was most convenient for them such as walking or cycling. The 
diary allowed participants to record the activity undertaken, the duration of the activity 
and the rate of perceived exertion (RPE) using the BORG scale and ask to undertake 
activity which was 12 or higher (Borg 1982). 
2.3.2 Dietary guidance 
Participants randomised to the intervention arm were offered a dietary guidance 
document with recipes (appendix 18). The 28 page dietary guidance document gave 
dietary advice based on the widely available national guidelines for healthy eating (Eat 
Well.NHS 2016). The dietary guidance also contained nutritionally balanced recipes 
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which were independently reviewed by two registered nutritionists from SHU (both with 
Doctorates of Professional Studies related to sports nutrition; Dr Dave Rogerson and 
Dr Trevor Simper). Dietary advice encouraged participants to adopt a diet rich in 
nutrient dense whole foods, fruit and vegetables and discouraged processed foods 
and those high in refined carbohydrates and saturated fats. Participants were asked to 
drink 6-8 glasses of fluid a day, preferably water, but inclusive of tea, coffee and sugar 
free/low sugar drinks (more when exercising) and to limit alcohol intake. The recipes 
provided encouraged a high protein, moderate fat, high fibre and low carbohydrate 
meals.  
2.3.3 Supplementation 
Whey protein: To promote muscle protein synthesis, participants were required to 
increase protein consumption via whey protein supplementation provided. Whey 
protein is rapidly digested and has a high leucine content which appears more efficient 
at muscle protein synthesis than other protein alternatives (e.g. soya protein) post-
resistance exercise (Wilkinson, Tarnopolsky et al. 2007, Villanueva, He et al. 2014). 
Participants were provided with whey protein to consume with 300-500ml of fat-free 
milk or water (Hartman, Tang et al. 2007). The recommended dosage of protein was 
1.2 g/day per kg-1 of bodyweight as previously described (Burke, Chilibeck et al. 2001). 
Creatine: The intervention group were asked to take 0.25 g·kg-1 of LBM per  day of 
creatine during the acute loading phase (the first 5 days of creatine supplementation) 
and thereafter a maintenance dose of 5 grams per day. This dosage has been 
previously described in research (Burke, Chilibeck et al. 2001, Naderi, de Oliveira et 
al. 2016). 
2.4 Outcome Measures 
Outcome measures were obtained during the assessment visits at baseline, 8 weeks 
(mid-point) and 16 weeks (end-point) for all participants. All assessments were 
undertaken by assessors blind to group allocation. Questionnaires and three day diet 
diaries were given to the participant at the assessment visits and asked to return them 
via post in a prepaid envelope. 
2.4.1 Eastern Cooperative Oncology Group and Karnofsky 
PS was assessed by the Eastern Cooperative Oncology Group (ECOG) and 
Karnofsky performance status (KPS) assessment tools (Yates, Chalmer et al. 1980, 
191 
 
Oken, Creech et al. 1982). The breakdown of the ECOG and KPS scoring is given in 
appendix 22. 
2.4.2 Functional Assessment of Cancer Therapy - fatigue 
The Functional Assessment of Cancer Therapy - fatigue (FACT-F) scale is a 13-item 
questionnaire assessing fatigue/tiredness in cancer patients and its impact on 
activities of daily living. Question items are scored from 0-4, where a higher total score 
is indicative of lower levels of fatigue (Yellen, Cella et al. 1997). The Fatigue Subscale 
is a validated brief and reliable measure of fatigue in cancer patients (Yellen, Cella et 
al. 1997). FACT-F is presented in appendix 23. 
2.4.3 Functional Assessment of Cancer Therapy - prostate 
The FACT-P scale is a 39 item questionnaire assessing the health related quality of 
life of prostate cancer patients. The FACT-P is a widely used validated tool and 
comprises of four subscales of health related quality of life (physical well-being, 
social/family well-being, emotional well-being, and functional well-being) as well as the 
prostate cancer subscale (PCS) (Esper, Mo et al. 1997). The FACT-P questionnaire 
items are scored from 0-4 and a higher overall score is indicative of a better quality of 
life.  FACT-P is available in appendix 24. 
2.4.4 Three day diet diaries 
Three day diet diaries were used to assess dietary intake over three consecutive days 
where participants would be eating a "typical" diet for themselves. Participants were 
asked to complete the diet diaries during periods were they would be eating and 
drinking as considered 'normal'. For example, a participant would be advised to avoid 
recording in the diary on days he was on holiday and would be frequently eating out. 
Open-ended food records, including the three day diet diary, have been demonstrated 
as a reliable and validated tool for dietary assessment and when compared to other 
tools such as 24-hour food recall or food frequency questionnaires are better at 
correctly placing an individual's distribution of habitual diet (Bingham, Gill et al. 1994, 
Day, McKeown et al. 2001). The three day diet diary is presented in appendix 25. Diet 
diaries were analysed using the dietary analysis software Nutritics Education (v4.315) 
by a paid student researcher experienced in using the software and in dietary analysis 
to assess the participants macro/micronutrients based on the diet data. 
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2.4.5 Dual-energy X-ray absorptiometry (DXA) Scan 
At baseline and 16 weeks, a full body DXA scan was performed to determine post-
cranial appendicular LBM and FM. DXA also allows bone health to be assessed by 
examining BMD at the lumbar spine, total hip and whole body. DXA scans were the 
chosen method to provide information on body composition as they are fast, precise 
and one of the only available measures to provide data on fat, lean and bone mass 
(Andreoli, Garaci et al. 2016). DXA scanning has become one of the most widely used 
and clinically relevant methods for determining body composition and has been 
validated in numerous studies (Ellis 2000, Norcross and Van Loan 2004, Rothney, 
Brychta et al. 2009). It is deemed a safe method since the effective radiation dose 
from DXA scans is 32μSV less than one year’s radiation dose and considered “low 
risk”. Public Health England describes a radiation exposure equivalent to a few years 
average natural background radiation as ‘Low Risk’, with between 1:10,000 and 
1:1,000 lifetime additional risk of cancer. 
Areas of previous fracture or where known bone metastasis exist were excluded from 
the region of interest to calculate BMD. Scans were performed using the Hologic 
densitometer, at The Clinical Research Facility, Northern General Hospital and 
analysed by the scan technician using standard DXA software. Participants were 
asked to lie flat in the centre of the scan table and remain still for the duration of the 
scan.  
2.4.6 Three Repetition max testing 
Three-repetition maximum (3RM) strength tests were carried out on the leg press and 
chest press at baseline, 8 weeks and 16 weeks using resistance machines in 
physiology testing suites at SHU. These exercises were chosen as measures of both 
upper and lower body strength in major muscle groups. The 3RM test was defined as 
the maximal load that could be moved through the full range of motion with proper 
form for three repetitions (Delmonico, Kostek et al. 2005, Hanson, Sheaff et al. 2013). 
Participants underwent at least one familiarisation session before to the testing 
session in which they completed the exercise with little or no resistance and instructed 
on proper warm-up, stretching, and exercise techniques to help prevent injuries and 
reduce muscle soreness after the strength testing assessment. An investigator was 
present conducting the strength tests with consistency of seat adjustment, body 
position, and level of verbal encouragement. The 3RM was achieved by gradually 
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increasing the resistance from an estimated submaximal load after each successful 
exercise repetition until the maximal load was obtained. The chest press was 
conducted on a flat or inclined bench with free-weight dumbbells and the leg press 
conducted using the leg press resistance machine (Life fitness, Insignia Series Seated 
Leg Press) present in A205 physiology suite. 3RM testing was deemed safer than one-
repetition max testing for older deconditioned adults. Sub-maximal testing is a widely 
used, inexpensive and practical test of muscle strength (Brzycki 1993, Verdijk, van 
Loon et al. 2009). 
2.4.7 Six minute walk test 
Participants walked along a marked ten meter course at their normal pace with the 
number of steps and distance recorded to the nearest second for six minutes. Steps 
were measured using a validated pedometer (Omron, Walking Style One 2.1 
Pedometer) attached to the waistband or pocket of the participant and distance was 
recorded using a tape measure (Holbrook, Barreira et al. 2009). The test was repeated 
three times, with other physical function tests performed in-between to allow for 
recovery time, and the average time and best time recorded. Data has demonstrated 
that walking distance tends to increase with repeated test administration due to 
familiarisation effects. Because the distance walked tends to plateau after 3 walks, 1 to 
2 initial walks have been performed before determining an individual’s functional 
capacity  (Wu, Sanderson et al. 2003). Walk tests are a simple and inexpensive test of 
physical function. It has been demonstrated that the inability to perform a six minute 
walk test is a reliable indicator of disability and high dependency (De Feo, Tramarin et 
al. 2011, Kim, Yabushita et al. 2012). 
2.4.8 Hand grip strength 
Measurements were made using a digital hand held dynamometer (Camry Scale, 
USA). The hand dynamometer was individually adjusted to fit the hand of the 
participant. Participants were asked, whilst standing with their hands by their side, to 
grip the dynamometer for five seconds as hard as possible. The results were recorded, 
repeated on each hand alternatively three times. The best attempt was represented as 
maximal grip strength as it has been demonstrated as a reliable surrogate 
measurement for overall muscle strength and predictive of short and long-term 
mortality and morbidity (Ling, Taekema et al. 2010, Norman, Stobäus et al. 2011). 
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2.4.9 Chair sit-to-stand 
Participants were seated in a hard-backed chair, arms folded across their chest, and 
instructed to rise as fast as possible to a full standing position and then return to a full 
sitting position as many times as they could for 30 seconds. The same chair and 
seating position was used at each assessment. The number of repetitions was 
recorded. The chair sit to stand test is a valid and inexpensive measure of lower body 
muscle strength (Jones, Rikli et al. 1999). The inability to stand from a sitting position 
is associated with disability and a poor functional status (Bohannon 1995, Jones, Rikli 
et al. 1999, Janssen, Bussmann et al. 2002). 
2.4.10 Anthropometrics 
Height (m), body mass (kg), body mass index (BMI, m.kg-2, calculated as the weight 
(kg) divided by height (m)) and mid-arm circumference were also recorded at baseline, 
8 weeks and 16 weeks. Mid-arm circumference was determined using a tape 
measure. Weight and height were determined using the same stadiometer and scales 
in each assessment period. BMI is a widely used tool which can be indicative of total 
body fat (Deurenberg, Weststrate et al. 2007). Mid-arm circumference is widely used 
as reliable and validated method predictive of nutritional status and muscle mass 
depletion (Soler-Cataluña, Sánchez-Sánchez et al. , McWhirter and Pennington 1994). 
2.4.11 Blood analysis 
At baseline, 8 and 16 weeks blood samples, for the assessment of LDH, SHBG, 
testosterone and PSA, were collected by the author, unless there was significant 
difficulty obtaining blood samples. If this was the case, the participant would be 
accompanied to the phlebotomy department for blood draws to be made from an 
experienced phlebotomist whilst chaperoned by the study research nurse. 
Approximately 20ml of venous blood was drawn. Serum samples were analysed 
according to STH laboratory standard operating procedures and reported on ICE 
(Integrated Clinical Environment, Sunquest). Blood serum LDH is a regulatory enzyme 
involved in anaerobic glycolysis activity and is correlated to muscle fatigue and tissue 
damage (Machado, Koch et al. 2011, Washington, Healey et al. 2014) as well as 
prostate cancer progression in advanced disease (Naruse, Yamada et al. 2007). 
SHBG is a glycoprotein with a high affinity binding for hormones such as testosterone 
and oestradiol and its use in combination with total testosterone provides information 
regarding the proportion of protein bound and free testosterone (Selby 1990). PSA is a 
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protein secreted by the epithelial cells of the prostate gland and was monitored as a 
surrogate biomarker for disease changes. Blood samples were sent to STH central 
laboratories for analysis. The anonymised blood results were made available for 
research staff by central laboratories according to local policy.  
2.5 Analysis and interpretation 
Outcomes including feasibility measures were assessed using descriptive statistics 
including standard methods for rates and proportions (Eldridge, Chan et al. 2016). 
Statistical analysis was performed using Statistical Package for the Social Sciences 
(SPSS) for Windows (version 24, IBM incorporated, New York, USA).  
Adherence data is provided for those who completed the 16-week intervention. Data 
on adherence were quantified in terms of number of prescribed exercise sessions 
attended as a proportion of those prescribed, which has previously been used to 
describe exercise adherence (Bourke, Homer et al. 2013). For adherence data, each 
participant's attendance was calculated based on the number of agreed sessions per 
week, i.e. 3, 2 or 1 sessions, over the 16-week intervention period. The maximum 
amount of sessions which could be attended were 48, 32 or 16 sessions for those who 
agreed to attend 3, 2 or 1 sessions of exercise sessions per week, respectively. The 
adherence was calculated as a percentage: 
Adherence (%) =  
(Number of sessions actually attended during the intervention 
Maximum number of sessions agreed to attend)  
The average attendance was then calculated for the participants who agreed to attend 
the same number of sessions e.g. all participants who agreed to 2 sessions per week. 
Average (μ) adherence per number of sessions agreed (%) =  
(Σ Attendance of participants per number of sessions agreed  
Σ Number of participants per number of sessions agreed)  
Finally total adherence was calculated: 
Total average (μ) adherence (%) = 
x 100 
 x 100 
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(Average when 3 sessions agreed (%) + Average when 2 sessions agreed (%) + 
Average when 1 session agreed (%)) 
3 
 
For the independent exercise, by totalling the minutes of moderate-high intensity 
exercise during the 16 weeks it was determined if they had reached the prescribed 30 
minutes of independent exercise per week (total 480 minutes across 16 weeks). If 480 
minutes or more were recorded in the diary 100% adherence was given, any less was 
presented as a percentage of the 480 minute target. This data was only available for 
those who had completed the independent exercise diaries.  
Average (μ) independent exercise adherence = 
Σ (Independent exercise adherence from participants with data) 
Σ (Participants with independent exercise data) 
Adherence to supplementation (whey protein and creatine) was reported as a 
percentage of the total dose initially prescribed. For example, adherence to whey 
protein would be 50% for someone who consumed half of their prescribed dose over 
the 16-week intervention period.  
Average (μ) adherence to supplementation = 
   Σ (Participant adherence to supplementation) 
   Σ (Participants with supplement data) 
Rates of recruitment and attrition were calculated as a percentage: 
Rate of recruitment  =  Σ participants recruited 
    Σ of patients approached 
 
Attrition =   Σ those randomized who dropped out from the study 
     Σ participants recruited 
 x 100 
 x 100 
 x 100 
 x 100 
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For baseline demographic data, descriptive statistics including means and standard 
deviations were used to describe both the intervention and control groups. After 
checking for normal distribution using the Shapiro-Wilk test, differences between 
groups at baseline were assessed using independent t-tests or the non-parametric 
equivalent (Mann Whitney-U) with all tests performed two-sided. Statistical 
significance was set as p <0.05. Variation in frequency distribution for demographic 
data was examined using Pearson's Chi squared test.  
For outcome data, effect sizes (ԁ) were calculated for variation between groups for the 
difference from baseline measures using Cohens d. An effect size expresses a 
difference between groups or change within groups as a fraction of the variability 
between participants, therefore it is possible to estimate the impact and clinical 
relevance of the intervention on the chosen outcome (Winter, Abt et al. 2014). As this 
study was not aimed or powered to determine significant changes in secondary 
outcomes, effect size calculation was chosen to reflect differences between groups 
(Winter, Abt et al. 2014). Thresholds were set at 0.0-0.19 for a trivial effect, 0.2-0.49 
for a small effect, 0.5-0.79 for a medium effect and 0.8 and above for a large effect 
(Cohen 1992, Sullivan and Feinn 2012). 
The change (∆) within groups observed between baseline and 16-week time-points 
were reported for participants with complete data for each outcome (i.e. no missing 
data at baseline or 16 weeks). A positive score indicated an increased change from 
baseline and a negative score indicated decrease change from baseline. Data are 
presented as mean ± standard deviation (SD) unless stated. The mean (μ) change (∆) 
and the SD for each group was then calculated and used to determine the effect size 
(ԁ). 
 μ∆ =    Σ [16-week value - Baseline value] 
         Number of participants with baseline and 16-week data  
 
 
   ԁ =   
 
[μ∆ experimental group] – [μ∆ control group] 
SDpooled 
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Microsoft Excel (version14, Microsoft Office Professional Plus, 2010) was used to 
graphically represent the means within the groups for participants with complete 
baseline, 8-week and 16-week data at a given time point.  Graphs were used to 
compare changes in the control and intervention groups over the three assessment 
points for the physical function measures.  
3. Results 
Of the 280 men identified as potentially eligible for the trial, where possible men were 
approached in clinic or contacted via letter. It was not possible to contact 54 men due 
to missing, incorrect or incomplete contact details. In total 39 men expressed an 
interest in the study. Of these men, 35 were successfully screened via the health 
screening questionnaire, three men once screened were deemed ineligible due to 
being too physically active (n =2) or it was determined that travel was a problem (n 
=1). In total 32 men underwent baseline assessment, one man then changed his mind 
about participation pre-randomisation. In total, 31 were successfully randomised into 
the trial. The mean ages of those randomised were 70 (SD:5.49) and 73 (SD:6.56),  
for control and intervention respectively.  
3.1 Baseline demographics 
Baseline demographics are summarised in table 4.1 Groups were well matched at 
baseline and there were no statistically significant differences between the group 
demographics. Table 4.2 details the baseline blood serum data for both groups. All 
participants were confirmed castrated with serum testosterone levels of less than 50 
ng/dL (1.735 nmol/L) at baseline, 8 weeks and 16 weeks (Gomella 2009).  
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Table 4.1 Baseline demographics 
  Control (n =13) Intervention (n =18) 
 μ (SD) μ (SD) 
Age (years) 70.00 (5.49) 73.00 (6.56) 
White British 13.00 (0.00) 18.00 (0.00) 
Body mass (kg) 90.00 (13.45) 97.10 (16.17) 
Height (cm2) 173.70 (5.84) 174.06 (6.55) 
BMI (kg/m2) 29.84 (4.24) 31.95 (4.35) 
Disease stage   n (%)  n (%) 
Node positive 10 (78) 11 (61) 
Metastatic  11 (85) 10 (56) 
Treatment history     
ADT μ (SD) μ (SD) 
No. of years on ADT 6.69 (4.84) 7.79 (3.95) 
No. of years castrate resistant 3.85 (3.18) 4.56 (3.21) 
 n (%) n (%) 
CAB/MAB 10 (78) 13 (72) 
Enzalutamide  4 (31) 10 (56) 
Abiraterone  5 (38) 2 (32) 
Chemotherapy μ (SD) μ (SD) 
No. of years since initiation of first 
chemotherapy regimen 
1.20 (0.72) 1.38 (0.5) 
No. of chemotherapy cycles 6.67 (1.15) 8.33 (3.21) 
 n (%) n (%) 
Docetaxel 3 (23) 3(17) 
Carbazitaxel 1 (8) 2 (11) 
Other treatments   
Dexamethasone  3 (23) 6 (33) 
Palliative RTx  3 (23) 2 (11) 
Standard RTx 3 (23) 7 (39) 
Radical prostatectomy  3 (23) 7 (39) 
Health history  n (%) n (%) 
CVD  9 (69) 11 (61) 
Family history of cancer  4 (31) 9 (50) 
Family history of CVD  10 (78) 13 (72) 
MSK comorbidity  7 (52) 9 (50) 
Metabolic comorbidity  1 (8) 2 (11) 
Registered disabled  2 (15) 6 (33) 
Lifestyle  n (%) n (%) 
Working  1 (8) 4 (22) 
Smoker  0 (0) 1 (6) 
Previous smoker  8 (62)  9 (50) 
Drinks alcohol  9 (69) 14 (78) 
BMI - Body mass index; CAB/MAB - Complete/Maximum androgen blockade; RTx - 
Radiotherapy; CVD - Cardiovascular disease, MSK - musculoskeletal.  
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Table 4.2 Baseline blood serum data 
  Control (n =13) Intervention (n =18) 
  μ SD μ SD 
LDH (IU/L) 425.77 130.14 397.39 81.53 
SHBG (nmol/L) 71.32 36.85 73.00 47.14 
Testosterone 
(nmol/L)  
0.48 0.20 0.54 0.22 
PSA(ug/L) 100.91 195.95 29.91 72.28 
LDH - Lactase dehydrogenase; SHBG - sex hormone binding globulin; PSA - prostate 
specific antigen. 
3.2 Feasibility outcomes 
3.2.1 Eligibility and recruitment  
A total of 3607 patients were screened for eligibility, of 280 deemed potentially eligible, 
229 were approached. The rate of recruitment was 13.5% from men approached to 
those who were successfully randomised (n =31). Among those screened those found 
to be potentially eligible were 6% (see figure 4.2 CONSORT diagram for further detail). 
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Patients from oncology clinics 
screened: 2088 
Patients from urology clinics 
screened: 844 
Patients from the oncology treatment 
list screened: 670 
Total: 3607 
Patients from oncology clinics 
identified as castrate resistant: 320 
Patients from urology clinics 
identified as castrate resistant: 353 
Patients from the oncology treatment 
lists identified as castrate resistant: 
481 
Total: 1154 
Men with castrate resistant prostate 
cancer identified as potentially 
eligible 
Total: 280 
Could not be contacted: 54 
Men approached  
Clinic: 95 
Letter: 134 
Total: 229 
 
 
 
 
Total number of men interested in 
participating: 39 
Total number of men HSQ: 35 
Total number of men randomised into trial: 31 
Excluded: Duplicated patients already identified 
and approached or not eligible (excluded) 
Reason: deceased, hormone sensitive, immobile, 
recent myocardial infarction, considered too ill by 
treating clinician, unstable bony metastasis. 
Total excluded: 874 
Declined to participate: 95 
Reason: location and/or travel (26), not interested 
(24), too inconvenient (13), musculoskeletal co-
morbidity (10), adverse effects from treatment 
and/or disease (7), significant disability (3), already 
fit enough (3), other co-morbidity (3), too old (3), 
moving home (1), hospital in-patient (1), going into 
a hospice (1)  
Excluded: 92 
Reason: painful and/or unstable bone metastasis 
(33), unable to give informed consent (10), needs 
full time carer/ hospital in-patient/ in hospice (9), 
hormone sensitive disease (8), on advice of 
treating clinician (7), spinal cord compression (6), 
undertaking purposeful physical activity of a 
moderate intensity for 90 minutes per week for at 
least six months (6), physically immobile (5), 
significant heart comorbidity (5), deceased (2), 
severe musculoskeletal comorbidity (1) 
Excluded: Not castrate resistant prostate patients 
Total excluded: 2453 
No longer interested: 4 
Changed mind: 4 
Figure 4.2 CONSORT diagram detailing the recruitment of men with CRPC. 
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3.2.2 Adherence and attrition 
31 men with CRPC were recruited into the trial and were successfully randomised to 
the lifestyle intervention (n =18) or control group (n =13). During the intervention period 
a total of four men dropped out from the intervention group (all within 4 weeks of 
randomisation) and one man died in the control group (due to disease progression). 
This data is summarised in figure 4.3. Therefore, the attrition rate was 22.2% and 
7.7% in the intervention group and the control group respectively. 
 
Figure 4.3 COMRADE trial recruitment diagram 
Randomised = 31  
Completed baseline assessment = 32 
Randomised to intervention = 18 
Started intervention = 17 
Randomised to control = 13 
Dropped out (n =1) 
Changed mind = 1 
Completed 8 week assessment 
= 14 
Completed 8 week assessment 
= 12 
Dropped out (n = 4) 
Could no longer commit 
time = 1 
Disease progression = 1 
Pain as a result of disease = 
1 
Psychological morbidity = 1 
Dropped out (n = 1) 
Death (not related to 
trial) = 1 
Completed 16 week 
assessment = 14 
Completed 16 week 
assessment = 12 
Dropped out (n =0) Dropped out (n =0) 
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Men randomised into the intervention group were given the choice of attending the 
university up to 3 sessions of supervised exercise a week. In total, adherence to the 
exercise sessions was 69% when combining the adherence data. A breakdown of the 
adherence at supervised exercise sessions based on number of days chosen to attend 
per week is given in table 4.3. Adherence to the exercise allocated in the exercise 
session was 100% as exercise was always adapted to the individual as described in 
section 2.3.1. Adherence to the whey protein supplementation was 68% (0-100%) and 
creatine supplementation 71% (0-100%). 
Table 4.3 Sub-group adherence to exercise in days per week training 
 
 
 
 
The adherence to the independent exercise was 78% (i.e. patients reporting at least 
30 min of aerobic exercise in their log books). With an average 117.42 minutes of 
moderate intensity exercise reported (BORG 11-14) and 42 minutes of high intensity 
exercise reported (BORG >14). Two participants failed to return their independent 
exercise diaries. 
3.2.3 Safety 
In total nine AEs were reported and six SAEs were recorded. Of the AEs, there were 
three instances of gastrointestinal discomfort associated with the supplementation and 
one instance of positional vertigo during a DXA scan. No other AEs were thought to be 
related to trial procedures. Of the SAEs there were no instances attributed to trial 
procedures. Breakdowns of the reported events are provided below. Table 4.4 
presents the AEs and Table 4.5 the SAEs 
 
 
 
  
Number of agreed days per 
week  exercise training (max 3) 
n Adherence (%) 
1 3 51.1 
2 6 63.3 
3 5 78.8 
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Table 4.4 AEs reported in the COMRADE trial 
Participant 
number 
 
Date Detail 
COMRAD0010 13/05/17 
GI discomfort from intervention supplements. 
Participant stopped taking supplements. 
COMRAD0006 27/07/17 Ankle pain. 
COMRAD0004 02/08/17 Positional vertigo during a DXA scan 
COMRAD0017 13/09/17 
Involved in road traffic accident. Fractured sternum. 
Not admitted to hospital. 
COMRAD0017 19/09/17 
Faint in bathroom. Received cardiology review and 
given all clear. 
COMRAD0018 03/10/17 
GI discomfort from supplements. Supplements 
stopped. 
COMRAD0014 04/10/17 GI discomfort from supplements. 
COMRAD0019 07/10/17 Fall in garden at home. Pain in left side. 
COMRAD0013 13/11/17 Skin rash 
 
Table 4.5 SAEs reported in the COMRADE trial 
Participant 
number 
Date SAE details Conclusion 
COMRAD0015 18/09/17 Participant admitted to hospital with 
neutropenic sepsis (resulting from 
chemotherapy). 
SAE not related 
to trial. 
COMRAD0018 21/10/17 Initially reported as a UTI (and recorded 
as an AE, not SAE due to detail 
provided by participant), after obtaining 
detail from care team, the participant 
suffered haematuria and was admitted 
to hospital. 
SAE not related 
to trial. 
COMRAD0019 08/01/18 Participant reported to A&E with a flu-
like illness. Admitted to hospital with 
pneumonia. 
SAE not related 
to trial. 
COMRAD0021 09/01/18 Participant reported to A&E with a flu-
like illness. Admitted to hospital with a 
respiratory infection. 
SAE not related 
to trial. 
COMRAD0016 18/01/18 
 
Participant died due to prostate cancer 
progression (control arm participant) 
SAE not related 
to trial. 
COMRAD0018 19/01/18 A second instance of haematuria for this 
participant. Admitted to hospital for 
treatment. 
SAE not related 
to trial. 
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3.3 Secondary outcome measures 
During assessments, some men were either unable to attend or undertake physical 
assessments, for example due to dropping out of the study, ill health or fatigue. As a 
result the number (n) of complete data for outcomes is indicated in the tables below.  
3.3.1 Fatigue and prostate cancer specific quality of life questionnaires 
Data for the FACT-F (Fatigue) and FACT-P (QoL) outcome measures are provided in 
table 4.6. Groups were well matched with no significant differences at baseline for 
FACT-P and FACT-F. There were 11 (85%) control and 13 (72%) intervention 
participants with complete data sets. 
3.3.1.1 Effect size 
There was a medium effect size for the increase in physical wellbeing domain of the 
FACT P (QoL) favouring the intervention group after 16 weeks (d = 0.602). There were 
no other notable effect sizes for all other outcome measures (d < 0.49). 
Table 4.6 The change in fatigue and prostate cancer specific QoL outcomes from baseline to 
16 weeks 
Questionnaire  Control Intervention 
  
  
 n 0 wk μ 
(SD) 
16 wk μ 
(SD) 
μ∆ (SD) n 0 wk μ 
(SD) 
16 wk μ 
(SD) 
 μ∆ (SD) d 
FACT-F 11 39.32 
(13.88) 
38.50 
(12.18) 
-1.87 
(14.23) 
13 30.70 
(12.81) 
33.92 
(12.69) 
2.75 
(10.38) 
0.37 
FP Physical 
wellbeing 
11 23.00 
(6.52) 
21.75 
(6.40) 
-1.27 
(6.93) 
13 20.00 
(6.10) 
22.15 
(6.40) 
1.77 
(4.64) 
0.60 
FP family 
wellbeing 
11 21.46 
(7.67) 
20.74 
(7.61) 
-0.24 
(11.59) 
13 20.84 
(4.98) 
22.62 
(5.09) 
1.13 
(4.04) 
0.16 
FP emotional 
wellbeing 
11 19.85 
(3.47) 
19.08 
(4.10) 
-0.02 
(4.51) 
13 17.69 
(5.68) 
17.31 
(4.96) 
0.08 
(5.44) 
0.02 
FP functional 
wellbeing 
11 22.92 
(4.42) 
20.26 
(8.34) 
-2.08 
(7.64) 
13 19.63 
(7.45) 
18.54 
(5.87) 
-0.54 
(5.65) 
0.23 
FP sub score 11 35.93 
(8.34) 
33.90 
(6.57) 
-1.95 
(8.52) 
13 29.59 
(9.97) 
30.95 
(7.67) 
0.68 
(7.02) 
0.34 
FACT-P total 11 123.49 
(22.96) 
115.73 
(24.04) 
-5.92 
(30.99) 
13 107.74 
(25.47) 
111.57 
(25.45) 
3.12 
(15.19) 
0.37 
FP - FACT-P; wk - week 
3.3.2 Physical outcomes 
Data for physical outcome measures are highlighted in table 4.7.  
The groups were well matched at baseline on physical outcomes. However, there 
were differences at baseline for leg press between groups (control μ = 99.32kg [SD = 
23.078] vs 74.56kg [41.024]).  
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All participants had Karnofsky and ECOG data (intervention n =18(100%), control n 
=13(100%)). Weight and BMI data was available for 12 (67%) intervention and 9 (69%) 
control participants.  
Some participants were unable to attend further physical assessment at 8 and 16 
weeks. Subsequently there were 10 (56%) intervention and 8 (62%) control 
participants with complete data with the exception of the chest press outcome 
(intervention n =9 (50%) and control n =7 (54%). The reasons for inability to complete 
the physical assessments were bone pain, illness and progressive disease.  
3.3.2.1 Effect sizes for physical outcomes 
A moderate effect size was observed for weight (d = 0.737) and BMI (d = 0.552) both 
of which increased in the intervention groups versus the control (table 4.7).  
A moderate effect size was also observed for the 3RM testing. Both the leg press (d = 
0.597) and the chest press (d = 0.522) increased in favour of the intervention group 
when compared to the control (table 4.7). Accordingly, changes overtime in both of the 
3RM testing showed improvements in the intervention groups vs the control (figure 4.4 
and figure 4.5).  
There were no other notable effect sizes for all other physical outcomes (d <0.49). 
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Table 4.7 The change in physical assessments from baseline to 16 weeks 
Physical 
assessments 
 Control  Intervention  
 n 0 wk μ 
(SD) 
16 wk μ 
(SD) 
μ∆ (SD) n 0 wk μ 
(SD) 
16 wk μ 
(SD) 
μ∆ (SD) d 
Weight (kg) 9 90.02 
(13.45) 
89.48 
(13.01) 
-1.13 
(1.78) 
12 97.10 
(16.17) 
97.69 
(16.23) 
0.62 
(2.85) 
0.74 
BMI (kg/m2) 9 29.84 
(4.24) 
29.57 
(4.45) 
-0.28 
(0.71) 
12 31.95 
(4.35) 
31.98 
(3.49) 
0.15 
(0.84) 
0.55 
ECOG (n) 9 0.08 
(0.28) 
0.44 
(0.53) 
0.33 
(0.50) 
12 0.22 
(0.55) 
0.83 
(0.84) 
0.50 
(0.67) 
0.28 
KPS (n) 9 96.92 
(11.09) 
92.22 
(9.72) 
-3.33 
(12.25) 
12 96.67 
(6.86) 
87.50 
(13.57) 
-7.50 
(12.15) 
0.34 
3RM Leg press 
(kg) 
8 99.32 
(23.08) 
97.50 
(43.10) 
6.25 
(17.88) 
10 74.56 
(41.02) 
93.00 
(33.10) 
21.75 
(32.06) 
0.60 
3RM Chest press 
(kg) 
7 9.83 
(2.54) 
10.14 
(1.65) 
-0.21 
(1.22) 
9 10.69 
(9.72) 
8.55 
(2.53) 
0.72 
(2.22) 
0.52 
Hand Grip Left 
(lbs) 
8 32.82 
(8.04) 
32.51 
(7.77) 
0.40 
(4.47) 
10 29.80 
(7.11) 
32.45 
(5.00) 
2.04 
(3.44) 
0.41 
Hand Grip Right 
(lbs) 
8 35.63 
(8.83) 
36.04 
(7.80) 
-0.05 
(4.86) 
10 32.16 
(6.14) 
34.03 
(6.29) 
1.19 
(4.08) 
0.28 
SMWT Average 
(m) 
8 379.90 
(103.35) 
447.00 
(215.86) 
10.30 
(23.49) 
10 375.33 
(97.79) 
361.09 
(49.32) 
5.26 
(75.43) 
0.09 
CSTS (n) 8 10.15 
(2.79) 
10.25 
(3.91) 
1.13 
(2.70) 
10 9.00 
(3.28) 
12.27 
(4.90) 
2.00 
(1.56) 
0.40 
Mid arm 
circumference 
(cm2) 
8 32.98 
(4.65) 
34.28 
(3.81) 
1.04 
(0.77) 
10 34.39 
(4.30) 
35.18 
(4.09) 
1.40 
(2.12) 
0.23 
BMI - body mass index; ECOG - Eastern Cooperative Oncology Group; KPS - 
Karnofsky performance score; 3RM - Three repetition max; SMWT - Six minute walk 
test; CSTS - Chair sit to stand 
3.3.2.2 Changes in physical outcomes at baseline, 8 and 16 weeks 
Graphical data displaying the within group results of mean change from baseline in 8-
week and 16-week physical outcomes is shown in figures 4.4 to 4.8.  
3.3.2.2.1 Leg Press 
Leg press weight was increased in the intervention group from baseline at 8 weeks (μ∆ 
from baseline 21.26 kg) and 16 weeks (μ∆ from baseline 21.75 kg), whilst men in the 
control group saw little change over the same period (μ∆ from baseline to 8-week 
assessment 3.57kg and 16-week assessment 6.25kg). 
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Figure 4.4 Leg press three repetition max testing for the intervention and control groups. Data 
is displayed as mean in groups and standard error bars.  
3.3.2.2.2 Chest Press 
For chest press weight was increased in the intervention group from baseline at 8 
weeks (μ∆ from baseline 0.23kg) and 16 weeks (μ∆ from baseline 0.72kg). Men in the 
control group saw a fall in chest press weight over the same period (μ∆ from baseline 
to 8-week assessment -0.14 and 16-week assessment -0.21kg). 
 
Figure 4.5 Chest press three repetition max testing for the intervention and control groups. 
Data is displayed as mean in groups and standard error bars. 
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3.3.2.2.3 Hand grip strength 
For hand grip strength in the left hand there was an increase in the intervention group 
from baseline at 8 weeks (μ∆ from baseline 1.70lbs) and 16 weeks (μ∆ from baseline 
2.04lbs). For the right hand there was no observable change from baseline at 8 weeks 
(μ∆ from baseline -0.10lbs) but by the 16-week assessment the handgrip strength for 
the right hand had increased (μ∆ from baseline 1.19lbs). 
However, men in the control group initially saw a larger increase in left hand grip 
strength at 8 weeks (μ∆ from baseline to 8-week assessment 5.00lbs) but this fell by 
the 16-week assessment (μ∆ from baseline 16-week assessment 0.40lbs). A similar 
result was observed for right hand grip strength with an increase at 8 weeks (μ∆ from 
baseline 6.5lbs) followed by a drop by 16 weeks to lower than the baseline result (μ∆ 
from baseline -0.05lbs). 
 
 
Figure 4.6 Hand grip strength testing for the intervention and control groups. Data is displayed 
as mean in groups and standard error bars. 
3.3.2.2.4 Six minute walk test 
For mean distance travelled  in the six minute walk test there was no notable change 
in the intervention group at the 8-week assessment (μ∆ from baseline 0.6m) but an  
improvement observed at 16 weeks (μ∆ from baseline 5.40m). However, for the 
control group, there was a slight decrease in average distance travelled at 8 weeks 
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(μ∆ from baseline -2.50m) with an improvement at 16 weeks (μ∆ from baseline 
10.30m) greater than that observed in the intervention. However, the effect size for this 
change was trivial (d = 0.090).  
  
Figure 4.7 Six minute walk testing for the intervention and control groups. Data is displayed as 
mean of the best score in groups and standard error bars. 
3.3.2.2.5 Chair sit-to-stand test 
For the chair sit to stand test results had improved from baseline for both the 8-week 
and 16-week assessments in the intervention group (μ∆ baseline to 8 week 
assessment n =1.10 and 16 weeks n =2.00). In the control group there was also an 
improvement from baseline to a similar degree to the intervention group at the 8-week 
assessment but this improved from the 8-week to the 16-week assessment with only 
marginally (μ∆ baseline to 8-week assessment n =1.00 and 16-week assessment n 
=1.13).  
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Figure 4.8 Chair sit to stand test for the intervention and control groups. Data is displayed as 
mean of the best score in groups and standard error bars. 
3.3.3 Body composition outcomes 
3.3.3.1 Lean indices 
Data for lean indices are provided in table 4.8. Groups were well matched with no 
significant differences in lean indices between groups at baseline. Complete data was 
available for 9 (69%) control and 12 (67%) intervention participants. 
A moderate effect size was observed for left arm (d = 0.740), right arm (d = 0.604), left 
leg (d = 0.702) and right leg (d = 0.604) lean mass which increased in favour of the 
intervention group when compared to controls.  A large effect size was observed for 
trunk (d = 1.124), sub-total body (d = 1.529) and whole body (d = 1.432) lean mass, 
from baseline to 16 weeks, which increased in favour of the intervention group when 
compared to control. Although, with the exclusion of head lean mass, all of the lean 
indices increased in favour of the intervention group but demonstrated no notable 
effect size (d < 0.49). 
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Table 4.8 Change in lean indices from baseline to 16 weeks. 
Lean indices  Control 
  
Intervention   
 n 0 wk μ 
(SD) 
16 wk μ 
(SD) 
μ∆ (SD) n 0 wk μ 
(SD) 
16 wk μ 
(SD) 
μ∆ (SD) d 
Head Lean 
(g) 
9 3751.22 
(332.28) 
3766.24 
(377.63) 
-25.40 
(143.30) 
12 3825.50 
(327.47) 
3773.96 
(274.33) 
-38.84 
(220.80) 
0.07 
Left arm 
lean (g) 
9 3317.32 
(447.69) 
3330.06 
(335.34) 
-62.95 
(260.31) 
12 3183.07 
(592.93) 
3289.24 
(583.34) 
104.95 
(187.86) 
0.74 
Right arm 
lean (g) 
9 3413.12 
(443.63) 
3442.40 
(437.45) 
-41.21 
(159.72) 
12 3359.56 
(605.16) 
3448.20 
(580.57) 
59.82 
(174.43) 
0.60 
Trunk lean 
(g) 
9 29243.00 
(26.62) 
29495.96 
(2773.03) 
-431.62 
(937.62) 
12 29678.68 
(3668.57) 
30332.72 
(4194.10) 
1044.41 
(1603.01) 
1.12 
Left leg 
Lean (g) 
9 8578.04 
(995.367) 
8795.27 
(1092.29) 
70.94 
(385.07) 
12 8709.50 
(1215.37) 
9199.17 
(1308.09) 
309.80 
(288.98) 
0.70 
Right leg 
lean (g) 
9 8903.35 
(1024.21) 
9026.77 
(919.75) 
-41.21 
(159.72) 
12 8840.22 
(1315.40) 
9149.63 
(1474.75) 
59.82 
(174.43) 
0.60 
Sub-total 
body lean 
(g) 
9 53454.84 
(5205.13) 
54090.46 
(5050.99) 
-497.26 
(1218.92) 
12 53771.03 
(7078.64) 
55418.96 
(7929.48) 
1685.98 
(1610.49) 
1.53 
Whole body 
lean (g) 
9 57206.06 
(5383.52) 
57856.69 
(5188.90) 
-522.67 
(1325.57) 
12 57.59.53 
(7266.34) 
59192.92 
(8138.93) 
1647.13 
(1683.73) 
1.43 
 
3.3.3.2 Fat indices 
Data for the fat indices are given in table 4.9. There were differences evident in fat 
indices at baseline between groups for right arm fat % (control 37.40[8.51] vs 
intervention 43.80[5.23]); left arm fat % (control 32.13[8.93] vs intervention 
44.19[5.23]) trunk fat % (control 34.73[8.28] vs intervention 39.74[5.32]); Right leg fat 
% (control 37.21[7.13] vs intervention 41.81[5.10]); sub total body fat % (control 
36.18[7.38] vs intervention 41.00[4.57]) and whole body fat % (control 35.63[7.09] vs 
intervention 40.27[4.40]). The other fat indices were well matched between the groups 
at baseline. 
A moderate effect size was observed for whole body fat % (d = 0.664), subtotal body 
fat % (d = 0.666), right leg fat % (d = 0.532), left leg fat % (d = 0.636) and left arm fat 
% (d = 0.644) all of which decreased in favour of the intervention group versus the 
control. A large effect size was observed for right arm fat % (d = 0.946) which 
decreased in favour of the intervention group versus the control. All other fat indices 
decreased in the intervention group relative to the control group however there were 
no other notable effects sizes (d <0.49). 
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Table 4.9 Change in fat indices from baseline to 16 weeks. 
Fat indices  Control 
  
 Intervention    
 n 0 wk μ 
(SD) 
16 wk μ 
(SD) 
μ∆(SD) n 0 wk μ 
(SD) 
16 wk μ 
(SD) 
μ∆(SD) d 
Whole 
Body fat 
(%) 
9 35.63 
(7.09) 
34.67 
(7.37) 
0.10 
(1.22) 
12 40.27 
(4.40) 
39.19 
(3.67) 
-1.08 
(2.20) 
0.66 
Whole 
Body fat 
(g) 
9 32675.60 
(9963.31) 
31755.58 
(9945.17) 
-64.52 
(1387.82) 
12 39545.64 
(9885.24) 
38652.68 
(8918.81) 
-907.87 
(3295.17) 
0.33 
Subtotal 
body fat 
(%) 
9 36.19 
(7.38) 
35.20 
(7.38) 
0.09 
(1.27) 
12 41.00 
(4.57) 
39.85 
(3.83) 
-1.14 
(2.30) 
0.67 
Subtotal 
body fat 
(g) 
9 31355.28 
(9835.67) 
30477.53 
(9845.37) 
-51.59 
(1387.86) 
12 38092.06 
(9806.42) 
37238.97 
(8866.34) 
-884.41 
(3263.33) 
0.33 
Right leg 
fat (%) 
9 37.22 
(7.13) 
35.93 
(7.63) 
0.45 
(1.80) 
12 41.81 
(5.10) 
40.74 
(5.85) 
-0.65 
(2.33) 
0.53 
Right leg 
fat (g) 
9 5450.84 
(1691.97) 
5277.77 
(1913.49) 
88.51 
(287.07) 
12 6498.05 
(1825.46) 
6450.72 
(2006.29) 
-91.09 
(589.30) 
0.39 
Left leg fat 
(%) 
9 38.29 
(6.41) 
36.59 
(6.81) 
-0.22 
(1.55) 
12 41.61 
(4.48) 
39.91 
(4.57) 
-1.23 
(1.64) 
0.64 
Left leg fat 
(g) 
9 5462.6 
(1584.02) 
5241.19 
(1742.99) 
-16.55 
(277.25) 
12 6329.34 
(1672.43) 
6257.89(
1871.70) 
-104.33 
(460.13) 
0.23 
Trunk fat 
(%) 
9 34.73 
(8.28) 
33.89 
(8.49) 
-0.07 
(1.81) 
12 39.74 
(5.32) 
38.72 
(3.79) 
-1.28 
(2.97) 
0.49 
Trunk fat 
(g) 
9 116258.0
2 
(5723.81) 
15828.82 
(5562.37) 
-143.93 
(1021.75) 
12 20002.03 
(5507.13) 
19376.95 
(4286.34) 
-546.67 
(1846.75) 
0.27 
Right arm 
fat (%) 
9 37.40 
(8.51) 
37.04 
(9.28) 
0.63 
(1.43) 
12 43.80 
(5.23) 
42.45 
(5.41) 
-1.198 
(2.33) 
0.95 
Right arm 
fat (g) 
9 2123.70 
(743.61) 
2096.88 
(689.10) 
23.19 
(152.12) 
12 2685.15 
(843.83) 
2599.16 
(765.88) 
-103.60 
(408.86) 
0.41 
Left arm 
fat (%) 
9 37.13 
(8.93) 
36.94 
(8.15) 
0.59 
(2.12) 
12 44.19 
(5.23) 
43.11 
(6.01) 
-1.11 
(3.07) 
0.64 
Left arm 
fat (g) 
9 2060.08 
(773.31) 
2032.87 
(656.29) 
-2.81 
(116.94) 
12 2577.48 
(776.58) 
254.25 
(766.58) 
-38.71 
(349.86) 
0.14 
Head fat 
(%) 
9 26.05 
(2.98) 
25.36 
(3.37) 
-0.06 
(0.22) 
12 27.46 
(1.78) 
27.22 
(2.00) 
-0.09 
(0.31) 
0.10 
Head fat 
(g) 
9 1320.32 
(179.87) 
1278.05 
(200.53) 
-12.93 
(56.29) 
12 1453.58 
(192.80) 
1413.72 
(157.71) 
-23.46 
(99.76) 
0.13 
 
3.3.3.3 Bone mineral density 
Data for BMD is highlighted in table 4.10. There were baseline differences evident 
between groups for femoral neck BMD (control .71[.08] vs intervention .90[.14]) and 
total hip BMD (control .93[.10] vs intervention 1.03[.13]). All other BMD measures were 
well-matched between groups at baseline. 
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A large effect size was observed for hip BMD (d = 1.575) which decreased in the 
intervention group versus the control from baseline to 16 weeks. All other BMD 
measures decreased in the intervention group relative to the control group however 
there were no notable effect sizes (d < 0.49) except for head lean mass which only just 
reached a moderate effect size.  
Table 4.10 Change in BMD from baseline to 16 weeks. 
Bone mineral 
density 
(g/cm2) 
 Control 
  
 Intervention 
  
  
 n 0 wk μ 
(SD) 
16 wk μ 
(SD) 
μ∆(SD) n 0 wk μ 
(SD) 
16 wk μ 
(SD) 
μ∆(SD) d 
Lumbar spine  8 0.98 
(0.11) 
1.03 
(0.13) 
0.01 
(0.04) 
12 1.01 
(0.14) 
0.94 
(0.10) 
-0.00 
(0.04) 
0.22 
Femoral Neck  8 0.71 
(0.08) 
0.71 
(0.08) 
0.00 
(0.02) 
12 0.80 
(0.14) 
0.15 
(0.12) 
-0.00 
(0.03) 
0.12 
Hip  8 0.93 
(0.10) 
0.97 
(0.12) 
0.01 
(0.01) 
12 1.03 
(0.13) 
0.97 
(0.12) 
-0.02 
(0.02) 
1.58 
Whole body  8 1.14 
(0.13) 
1.13 
(0.07) 
0.01 
(0.03) 
12 1.14 
(0.13) 
1.09 
(0.10) 
-0.00 
(0.02) 
0.47 
Subtotal body  8 1.04 
(0.13) 
1.04 
(0.08) 
0.01 
(0.03) 
12 1.03 
(0.13) 
0.98 
(0.08) 
-0.00 
(0.02) 
0.37 
Head  8 2.01 
(0.212) 
2.01 
(0.18) 
0.03 
(0.10) 
12 2.15 
(0.34) 
2.05 
(0.32) 
-0.01 
(0.05) 
0.50 
3.3.4 Blood serum outcomes 
Data for the blood serum results are given in table 4.11. No notable effect sizes were 
observed between the two groups (d<0.49).  Complete data was available for 10 
(77%) control and 14 (78%) intervention participants. 
Table 4.11 Change from baseline to 16 weeks in blood serum values  
Blood serum 
results 
Control 
 
Intervention   
nmol n 0 wk μ 
(SD) 
16 wk μ 
(SD) 
μ∆(SD) n 0 wk μ 
(SD) 
16 wk μ 
(SD) 
μ∆(SD) d 
PSA (ug/L) 10 100.91 
(195.95) 
139.34 
(385.23) 
80.29 
(266.55) 
14 29.91 
(72.28) 
14.26 
(24.83) 
0.50 
(21.40) 
0.42 
SHBG (nmol/L) 10 71.32 
(36.85) 
73.50 
(28.19) 
3.98 
(29.04) 
14 73.00 
(47.14) 
80.99 
(51.32) 
2.58 
(9.17) 
0.07 
Testosterone 
(nmol/L) 
10 0.48 
(0.20) 
0.48 
(0.22) 
-0.02 
(0.32) 
14 0.54 
(0.22) 
0.46 
(0.14) 
-0.05 
(0.17) 
0.06 
LDH (IU/L) 10 425.77 
(130.14) 
383.60 
(62.01) 
-13.40 
(41.33) 
14 397.39 
(81.52) 
400.00 
(74.92) 
0.69 
(31.71) 
0.38 
Blood serum local normal ranges: PSA ug/L (0.1-4.5)*; LDH IU/L (240-480); 
Testosterone nmol/L (6.7 - 25.7); SHBG nmol/L (20.6-76.7). * Prostate cancer risk 
management programme referral pathway PSA values are: 50-59 years 3.0 ug/L, 60-
69 years 4.0 ug/L, 70 years and older 5.0 ug/L. 
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3.3.5 Dietary outcomes 
Data for dietary intake is given in table 4.12. Groups were well matched at baseline. 
Complete dietary data was obtained from 12 (92%) control participants and 13 (72%) 
intervention participants.  
A moderate effect size was observed for calories (d = 0.555), sugars (d = 0.573) and 
fibre (d = 0.639) which all increased in favour of the intervention group compared to 
control. A large effect size was observed in protein intake (d = 1.620) which increased 
in the intervention group versus the control. No other dietary intake had a notable 
effect size (d < 0.49). 
Table 4.12. The change in dietary intake from baseline to 16 weeks. 
Average 
daily  
dietary 
intake 
Control Intervention  
 n 0 wk μ 
(SD) 
16 wk μ 
(SD) 
μ∆ 
(SD) 
n 0 wk μ 
(SD) 
16 wk 
μ(SD) 
Iμ∆(SD) d 
Calories 
(kcal) 
12 1837.00 
(665.70) 
1766.70 
(645.50) 
-111.17 
(319.70) 
13 1651.90 
(355.70) 
1782.40 
(387.40) 
77.92 
(360.56) 
0.56 
Carbohydrat
es (g) 
12 211.50 
(88.30) 
204.50 
(81.70) 
-13.17 
(32.18) 
13 189.60 
(36.40) 
181.00 
(45.00) 
-11.92 
(53.09) 
0.03 
Sugars (g) 12 97.60 
(60.70) 
82.20 
(49.60) 
-20.57 
(23.67) 
13 92.10 
(22.90) 
86.50 
(29.40) 
-4.98 
(30.30) 
0.57 
Protein (g) 12 82.70 
(19.90) 
74.30 
(20.00) 
-9.00 
14.62 
13 68.60 
(18.30) 
115.50 
(33.50) 
38.08 
(38.40) 
1.62 
Fat (g) 12 67.20 
(28.50) 
68.10 
(31.80) 
-0.08 
22.99 
13 62.40 
(23.30) 
65.90 
(22.30) 
3.12 
(19.14) 
0.15 
Saturates (g) 12 25.20 
(11.30) 
25.30 
(12.50) 
0.21 
8.93 
13 22.70 
(9.80) 
26.10 
(7.60) 
3.32 
(6.37) 
0.40 
Fibre (g) 12 21.50 
(7.00) 
21.40 
(8.90) 
-0.94 
(3.54) 
13 17.10 
(4.10) 
18.60 
(5.10) 
1.35 
(3.61) 
0.64 
Salt (g) 12 5.40 
(2.00) 
5.10 
(2.40) 
-0.23 
(2.07) 
13 4.80 
(1.50) 
5.20 
(2.00) 
0.34 
(1.63) 
0.30 
 
3.3.6 Sample size calculation 
The planning for the sample size in subsequent phase III RCTs should be based on 
clinically important changes in key health outcomes and taking into account patient 
attrition data observed in the phase II feasibility trial (Altman, Schulz et al. 2001). The 
key health outcome for men with CRPC chosen in the present study were prostate 
cancer specific QoL (FACT-P). Based on the FACT-P, the following can be calculated.  
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The power calculation to estimate sample size for a subsequent Phase III RCT was 
performed using the power calculation software (G*Power v3.0.10, Germany). A two 
independent samples test was undertaken with 95% power and 5% significance, using 
effect size (calculated from μ∆ and SD) from the intervention and control groups. 
When the mean change from baseline to 16 weeks in FACT-P (control μ∆ (SD) = -
5.92(30.99) vs. intervention 3.12(15.19)) the required phase III RCT sample size is 
estimated at 191 participants per group. Given a 16% dropout rate in the present study 
this would require a cohort of 444 in a two arm trial (222 in each group) patients in 
order to detect significance at α level of 0.05 with 95% power.  
4. Discussion 
4.1 Overview of the key findings 
The primary aims of this present study were to determine the feasibility of a combined 
programme of dietary guidance, supplementation and resistance exercise in men with 
CRPC and its effect on key health outcomes in these men. The primary outcomes 
would address the feasibility of participant recruitment and determine the design for a 
potential further larger scale trial (Phase III RCT). 
There was difficulty in recruiting this population to a feasibility exercise RCT. A 
recruitment rate of 13.5% was achieved. Of those recruited attendance was relatively 
good at 69% with the best attendance observed in those who opted to attend sessions 
three times a week. Adherence during attended sessions was 100% as exercise 
sessions were adapted per session as described in the methods (section 2.3.1)  
Adherence to independent exercise was excellent at 78.57%. Additionally, adherence 
to the supplements was relatively good at 68% for whey protein and 71% for creatine. 
As such an intervention has never previously been trialled in men with CRPC, the 
findings of this study are novel. The study showed improvements within the 
intervention group in LBM indices and a reduction in fat mass indices corresponding 
with a decline in weight and favourable changes in BMI. In addition, improvements in 
3RM testing and physical wellbeing scores were demonstrated in the intervention 
group.  
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Surprisingly, a decline in BMD was observed in the intervention group, although a 
notable effect size was only observable in the decline for hip BMD. This could be due 
to progressive disease but the reasons are unclear. 
4.2 The feasibility of the lifestyle intervention 
4.2.1 Recruitment and eligibility 
The recruitment target for this phase II feasibility study was initially set at 50 
participants which was not successfully met. A total of 31 participants were 
successfully recruited. However, a large majority of men with CRPC were deemed 
ineligible for this study due to extensive comorbidities (figure 4.2 CONSORT diagram). 
This reflects the complex nature of these patients at such an advanced stage of 
disease. A primary reason for ineligibility to this trial was unstable/painful bony 
metastasis, which is a common comorbidity that is extremely detrimental to the 
wellbeing of men with CRPC (Hotte and Saad 2010).  
Other common reasons for ineligibility involved the inability to give informed consent 
due to the presence of neurodegenerative diseases such as Alzheimer's and 
dementia. There is some data to suggest that ADT increases the risk of developing 
such neurodegenerative diseases (Nead, Gaskin et al. 2017). A proportion of those 
who declined were under full time care (either at home, in a care-home, hospice or as 
a hospital inpatient). Although these reasons might not be directly linked to the 
presence of advanced prostate cancer, many within the population of men with CRPC 
are older adults and therefore have multiple comorbidities to contend with.  
Recruitment of older participants into research studies has previously been 
demonstrated to be difficult and more challenging than younger participants (Corbie-
Smith, Viscoli et al. 2003, Murthy, Krumholz et al. 2004, Ahsan, Chen et al. 2006). 
However, despite this the average age of the study participants in this cohort was 70 
years in the control and 73 years in the intervention, an average of 72 years, a 
population often considered under-represented in clinical research (Mody, Miller et al. 
2008). This age group has previously been shown to have the lowest participation in 
cancer research studies with a 0.5% enrolment fraction in the 75 year and older 
groups (Murthy, Krumholz et al. 2004). In addition, the baseline demographics of the 
groups demonstrate the trial was able to recruit participants with multiple comorbidities 
including CVD, MSK comorbidity and metabolic disease (table 4.1).   
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In comparison to other prostate cancer and exercise studies, the men in this study 
were older (μ: 70.00 (5.49) control and 73.00 (6.56) intervention), had a higher BMI (μ: 
90.00 (13.45) control and 97.10 (16.17) intervention) and a larger proportion had 
comorbid conditions, were retired, previous CAB/MAB, previous chemotherapy and 
node positive or metastatic disease (Bourke, Doll et al. 2011, Gilbert, Tew et al. 2016, 
Taaffe, Newton et al. 2017, Dawson, Dorff et al. 2018). However, these studies 
included men on ADT at earlier stages of disease, i.e. localised of locally advanced 
disease, so this was to be expected. This is a positive indication that although there 
were difficulties from recruiting from such a complex heterogenic population, there was 
not simply a selection bias for the "healthier" patients.   The research team made a 
concerted effort to achieve a representative sample of men with CRPC undergoing 
treatment at STH. However, the men recruited into this study were all white and whilst 
this does represent the majority ethnic group in Yorkshire and the Humber (83.7%) the 
study failed to recruit any men from other ethnic minorities (Census 2011). This too is 
a problem commonly seen in the recruitment to research studies, including in prostate 
cancer trials (Murthy, Krumholz et al. 2004, Lane, Donovan et al. 2014, Hamdy, 
Donovan et al. 2016).  
Men were either identified from oncology or urology clinic lists or from oncology 
treatment lists. However, in total 3607 patients were screened in the process which 
was time consuming and labour intensive. Of those screened, only 229 men were 
considered eligible (a 6% rate of those eligible to those screened) and the rate of 
recruitment was 13.5%. The rate of recruitment is similar to that which has been 
observed in previous cancer and exercise studies, reporting between 9.5%-19% 
recruitment rates (Thomas, Alvarez-Reeves et al. 2013, Gilbert, Tew et al. 2016, 
Thomas Gwendolyn, Cartmel et al. 2016). Given that men with CRPC are a dying 
population, it could be that the eligible population to recruit into this trial was too small 
within STH alone given only 6% screened were initially considered eligible. A solution 
to this would be a multi-site study.  
4.2.2 Adherence 
Adherence to the supervised and independent exercise was relatively good at 69% 
and 78.57% respectively. For supervised exercise, participants who opted to attend 
the maximum three sessions per week had the best adherence versus those who 
opted for two or one session a week (78.8%, 63.3% and 51.1% respectively).  The 
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adherence was less than that which has been reported in other prostate cancer 
exercise trials, ranging from 69%-95% (Bourke, Doll et al. 2011, Gilbert, Tew et al. 
2016, Dawson, Dorff et al. 2018, GalvÃO, Taaffe et al. 2018).  However, a common 
reason for non-adherence to the exercise sessions was fatigue and illness. Particularly 
during the winter period, a number of participants were not able to attend due to ill 
health, which is common for a group on immunosuppressive therapies (Antonarakis 
and Armstrong 2011, Auchus, Yu et al. 2014). Furthermore, this finding is reflected in 
the high number of SAEs and AEs that occurred over the trial period, which included 
one death (control).  
Two patients in the intervention group over this period spent time in hospital due to ill 
health, one of whom had a diagnosis of pneumonia. However, adherence to the 
independent exercise was excellent at 78.57%, which includes missing data from two 
participants. This adherence rate to independent exercise is similar to that which has 
been seen in trials of combination of supervised exercise and independent exercise in 
prostate cancer patients (Bourke, Doll et al. 2011, Gilbert, Tew et al. 2016). It could be 
that for men experiencing fatigue and illness in this study, the independent exercise 
was more accessible to them where they could fit the exercise around their "good 
days" rather than a scheduled session. Complete data on the assessment outcomes 
ranged from 56-92% inclusive of drop-outs, whereby the lowest number of complete 
data available was for the physical outcome assessments, specifically the 3RM 
testing. Participants reported common reasons for the non-participation of the physical 
outcome assessments was bone pain and fatigue. Although the figures completed 
assessments seem low, previous exercise studies of advanced cancer patients 
undergoing palliative care showed completion was 69% (Oldervoll, Loge et al. 2011). 
The adherence to the whey protein supplementation was 68% and creatine 
supplementation 71% which was comparable to the only other prostate cancer and 
whey protein supplement trial (72.0 ± 22.8%) (Dawson, Dorff et al. 2018).  
4.2.3 Adverse and serious adverse events 
There were three AEs associated with taking the whey protein which were all 
gastrointestinal disturbances consisting of constipation and/or acid reflux. Other than 
this, the whey protein was well tolerated. There was one episode of vertigo in a control 
participant who had a history of vertigo problems during his DXA scan. No other AEs 
or any SAEs were associated with trial procedures. This is more reflective of the 
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complexity of these advanced cancer patients with multiple comorbidities. Overall the 
COMRADE trial was viewed as safe. 
4.2.4 Attrition 
The overall attrition rate was 16% with four drop outs and one death in the control 
group. This is similar to that which has been observed in previous prostate and 
exercise trials, which ranged from 10-15% (Bourke, Doll et al. 2011, Gilbert, Tew et al. 
2016, GalvÃO, Taaffe et al. 2018). However, the overall attrition was superior to that 
observed in the study by Taffe et al which was 34% (Taaffe, Newton et al. 2017). 
Furthermore, these figures were better than those seen in trials of advanced cancer 
patients however which have been reported to be as high as 36% (Oldervoll, Loge et 
al. 2011). Reasons for drop out were that the participant could no longer commit the 
time (n =1), disease progression (n =1), pain as a result of disease (n =1) and 
psychological morbidity (n =1). For the man that could no longer commit the time, he 
has specified that this was due to his frequent and ongoing visits to hospital. This 
again reflects the ongoing complications and burden of advanced and incurable 
cancer on these men.  
4.2.5 Summary of feasibility findings 
The feasibility data indicate that the described lifestyle intervention is feasible for men 
with CRPC. A responsive programme to the changing needs of the participant, with 
adequate duration, intensity and frequency, at such an advanced stage of disease 
would improve the programmes accessibility. It may be that for some, with a higher 
disease or comorbidity burden, a greater emphasis on home based exercise is 
warranted. In the present study, COMRADE was designed to be flexible as was 
recommended by the HCPs in Chapter 3. The exercises which were given had both 
progressions and regressions with a mixture of upper body and lower body exercises. 
Additionally, alternative exercises could be provided to minimise compressive loads to 
metastatic lesions whilst still targeting the required muscle groups. This approach was 
also adopted in the recently published study by Dawson et al (Dawson, Dorff et al. 
2018). This approach was demonstrated as being well tolerated and safe in the current 
cohort. Subsequently, although adherence to the exercise sessions was 69%, 
compliance in these sessions (i.e. the completion of the exercises) was 100% as the 
exercises were adapted to the participant on a session by session basis and therefore 
there was no refusal to perform exercises.  
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The lack of studies reporting exercise interventions in advanced cancer patients 
undergoing palliative care has been recognised (Eyigor and Akdeniz 2014, Wittry, Lam 
et al. 2018). The approach to delivering exercise intervention studies should be 
different to that typically seen for cancer patients at earlier stages of disease. 
Advanced cancer populations are more heterogeneous in nature and are less 
predictable in their natural history, where some men can experience a rapid decline in 
health. Therefore, longer term interventions are exposed to the effects of disease 
progression as has been demonstrated in the present study. The present study has 
developed our initial understanding of how to make exercise programmes for castrate 
resistant prostate cancer patients feasible and the potential complications arising 
along the way.  
4.3 Effect of intervention on secondary outcomes 
4.3.1 Quality of life and fatigue 
There were no notable changes in the FACT-P and FACT-F overall although there 
was a trend for overall improvement or maintenance of scores in the intervention 
group when compared to the control group which on average had declined. One sub 
score of the FACT-P questionnaire, physical wellbeing, showed a moderate effect in 
improvement in the intervention group (d = 0.602). Previous studies have 
demonstrated an improvement in FACT-P and FACT-F scores for men with prostate 
cancer with exercise training (Segal, Reid et al. 2003, Bourke, Doll et al. 2011, 
Dawson, Dorff et al. 2018). However, the men recruited into both of these studies were 
at much earlier stages of disease with a lower disease burden and there was a much 
larger sample size for all three studies, so it could be that the absence of these 
findings may be due to the lack of statistical power. Despite this the μ∆ in FACT F and 
FACT P was n =2.75 and n =3.12 for the intervention group which is slightly better 
than the change reported by Segal et al, 2003. 
4.3.2 Physical function  
For the physical functioning tests, a meaningful effect size was observed for the 3RM 
testing in both chest press and leg press, which was also demonstrated in the trend 
over time at 8-week and 16-week assessments (Figure 5.4 and 5.8). These findings 
are similar to those in published studies suggesting improvements with exercise in 
prostate cancer patients with chest press and leg press maximal testing (Nilsen, 
Raastad et al. 2015, Taaffe, Newton et al. 2017, GalvÃO, Taaffe et al. 2018). Nilsen et 
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al showed improvement in strength in upper and lower extremities of 0.49 kg, p <0.01 
and 0.15 kg, p <0.05, respectively (Nilsen, Raastad et al. 2015). Galvao et al showed 
significant improvement in leg press of 6.6 kg (95% CI 0.6–12.7; p =0.033) at 3 months 
(GalvÃO, Taaffe et al. 2018). Furthermore, a combination of physical functioning tests 
in the study by Taaffe et al which included 1RM testing of chest press and leg press 
showed significant improvement (p <0.001) with strength progressively increasing at 6 
months and 12 months (p <0.001) (Taaffe, Newton et al. 2017). 
The 2018 Galvao study in particular had a cohort of patients with metastatic disease, 
comparable to the cohort in the current study. In addition, Dawson et al also showed 
improvements in chest press and leg press with resistance exercise and whey protein 
supplementation in prostate cancer patients (Dawson, Dorff et al. 2018). Conversely 
the study by Sajid et al failed to showed a change in chest press repetition max testing 
(p =0.22) however this study was a home-based exercise programme (Sajid, Dale et 
al. 2016). In the present study, there were however differences at baseline in the leg 
press, this is likely due to the small sample size and the heterogenity of the CRPC 
population. 
Similar to the present study, previous research in  prostate cancer and exercise 
studies have also found no notable changes  in the walk test and chair sit to stand test 
(timed up and go) (Dawson, Dorff et al. 2018, GalvÃO, Taaffe et al. 2018). The 
Oldervoll study of exercise in advanced cancer patients undergoing palliative care also 
showed no significant change in chair sit to stand but there was a significant 
improvement in the walk test (Oldervoll, Loge et al. 2011). Nilsen et al showed 
improvements in both chair sit-to-stand and the walk test (Nilsen, Raastad et al. 2015). 
Regardless, figure 4.8 did show a trend over time for the improvement in the chair sit 
to stand testing in the intervention compared to control.  
For hand grip strength no notable changes were found which was similar in previous 
studies in prostate cancer groups (Sajid, Dale et al. 2016). However in advanced 
cancer patients undergoing palliative treatment, exercise interventions have been 
demonstrated to improve hand-grip strength (Oldervoll, Loge et al. 2011). However, 
figure 4.8 demonstrated that the change in hand grip strength in the control group 
whilst initially increasing at 8 weeks, fell to below baseline values at 16 weeks. A 
similar situation, although to a lesser degree, is observed in the control group values 
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for the 6 minute walk test. The lack of consistency in the change in mean for both 
groups may reflect problems and inconsistencies between assessors as multiple 
assessors were used in the physical function assessments or may be a result of the 
small sample size.  
No notable changes to KPS or ECOG was observed in the present study. However, 
the association between performance scoring and functional status has been debated, 
where performance scoring has been deemed insufficient to accurately depict 
functional status when compared to objective measures (Atkinson, Andreotti et al. 
2015, Kelly and Shahrokni 2016). A study in lung cancer patients suggested that 
objective measures such as V˙O2peak may be a useful in the clinical management of 
oncology patients and was superior to performance scoring such as ECOG (Roman, 
Koelwyn et al. 2014). In addition, given that the physical function assessments were 
conducted by more than one assessor, there were likely inconsistencies between the 
subjective reporting of PSs which may contribute as to why there was no observable 
change in PS despite improvements in some of the physical function outcomes.  
Due to the low numbers recruited into this trial, it is likely the study was underpowered 
to demonstrate any notable changes in physical performance outcomes. However, 
there were changes to 3RM testing in the present study. It may be beneficial in the 
future to include a more aerobic aspect to the exercise programme if the aim were to 
facilitate improvement in cardiovascular fitness and therefore potentially physical 
performance outcomes. In the present study, there was an objective to improve LBM 
and therefore resistance exercise in combination with the dietary intervention was 
chosen as guided by the literature.  However, it should be noted that compared to the 
other studies described, the present study is the only study to determine the effects of 
a resistance exercise and dietary intervention in men with CRPC who have a higher 
disease burden and have been on multiple treatments for up to two decades. 
Therefore, where this study has been unable to demonstrate a notable change in 
physical outcomes in these men, it could be that physiological changes are much 
harder to achieve over a period of 16 weeks and/or scope to achieve these changes is 
reduced given the disease burden in these men, compared to that seen in other 
studies in men at earlier stages of disease.  
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4.3.3 Body composition 
There were favourable changes in body composition in the intervention group 
demonstrated in the present study. These findings also correlated well with the 
changes in weight and BMI both of which had a large effect size (d = 2.85 and d = 0.84 
respectively).  
For the lean indices, a moderate effect size (d > 0.6) was observed for left arm, right 
arm, left leg and right leg lean mass which increased in favour of the intervention 
group when compared to controls.  In addition, a large effect size (d > 1.1) was 
observed for trunk, sub-total body and whole body lean mass which increased in 
favour of the intervention group when compared to controls. 
For the fat indices, a moderate effect size (d > 0.5) was observed for whole body fat 
percentage, subtotal body fat percentage, right leg fat percentage, left leg fat 
percentage and left arm fat percentage; all of which decreased in favour of the 
intervention group versus the control. In addition, a large effect size was observed for 
right arm fat percentage (d > 0.9) which decreased in favour of the intervention group 
versus the control. However, these results should be viewed with caution as baseline 
differences were observed between groups in fat percentage for right arm, left arm, 
trunk, right leg, sub total body and whole body. This could be down to the small 
sample size and number of available measures for the DXA scan. For all other indices 
there was a trend in the intervention group for a reduction in fat mass in comparison to 
the control group. 
There was however, no observable change in mid arm circumference which is an 
indicator for muscle hypertrophy. Previous studies of exercise in cancer patients also 
found no change in mid arm circumference or in muscle thickness observed by 
ultrasound (McKenzie and Kalda 2003, Galvao, Nosaka et al. 2006). Given that DXA 
results indicated changes in lean mass for both right and left arms, this result indicates 
the ineffectiveness of mid arm circumference in measuring changes of lean mass in 
this study. This may be due to the short time frame of the intervention but also the 
corresponding reduction in fat mass which may confound the finding of muscle 
hypertrophy.  
The changes in body composition found in the present study are an important finding. 
Multiple studies evaluating resistance exercise training or with resistance exercise 
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included as part of an exercise programme in prostate cancer patients have failed to 
show any improvements in LBM and/ or favourable changes in body fat indices (Segal, 
Reid et al. 2003, Nilsen, Raastad et al. 2015, Sajid, Dale et al. 2016, Winters-Stone, 
Lyons et al. 2016, GalvÃO, Taaffe et al. 2018). These results support the findings 
which demonstrated improvements in physical function outcomes. The present study 
was able to demonstrate that despite the long-term effects associated with ADT and 
chemotherapy these men face, favourable changes to body composition can be 
achieved with a programme of exercise, dietary guidance and supplementation.  
Dawson et al, 2018 demonstrated increases in FFM, LBM and appendicular skeletal 
mass comparable to the present study. Galvao et al which combined both aerobic and 
resistance training in prostate cancer patients also showed improvement in total body 
upper limb and lower body lean mass (Galvão, Taaffe et al. 2010). Another study, of  a 
12-week endurance training programme, whilst demonstrating a decrease in the 
intervention group for fat mass failed to demonstrate an increase in lean body mass 
(Hvid, Winding et al. 2013).  
An unexpected finding in the current study was the trend for a lower BMD in the 
intervention group compared to the control group. For hip BMD, this decline had a 
large effect size. However, there were differences at baseline between the groups 
which could account for this finding potentially due to the low sample size. Equally this 
could be due to changes in medications in the intervention group that have not been 
accounted for. It seems unlikely that the whey protein, creatine or resistance exercise 
would cause a decline in BMD due to a large body of evidence to the contrary where 
BMD is either improved or maintained (Tarnopolsky, Zimmer et al. 2007, Alves, Murai 
et al. 2012, Cheung, Zajac et al. 2014, Winters-Stone, Dobek et al. 2014, Gwendolyn, 
Brenda et al. 2017). In essence, it is not clear what may have caused this decline in 
BMD.  
4.3.4 Blood serum  
There was no notable effect observed on blood serum results in the present study. 
Although PSA was maintained in the intervention group when compared to the control 
which rose, this finding was not of a notable effect size. Similar findings have observed 
the maintenance of blood serum markers such as PSA and testosterone 
demonstrating the biochemical safety of exercise interventions in prostate cancer 
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cohorts (Galvao, Nosaka et al. 2006, Bourke, Doll et al. 2011, Taaffe, Newton et al. 
2017). A study with a longer duration might promote a more substantial change in 
blood serum markers, but it was not an aim of the present study to demonstrate 
alteration in markers of disease burden, only to ensure the study's biochemical safety.  
4.3.5 Dietary changes 
A moderate effect size (d >0.5) was observed for calories, sugars and fibre which all 
increased in favour of the intervention group compared to control. A large effect size 
was observed in protein intake (d >1.620) which increased in the intervention group 
versus the control. It should be noted that the reporting in the three day diet diaries 
was very poor and therefore was a serious limitation to the accurate analysis of diet. 
This is not an uncommon finding in research (Schoeller 1990, Subar, Freedman et al. 
2015). As a result, the author advises that these results are interpreted with caution. 
The increase in calories and protein was an expected finding due to the protein 
supplementation. Aside from this, the results did not differ from that previously 
reported in dietary analysis of prostate cancer patients undergoing an exercise 
intervention (Bourke, Doll et al. 2011). 
5. Study limitations 
As previously mentioned, the major limitation of this study was the number of 
participants. In addition, there was missing data for a number of the outcomes 
assessed. This was in the intervention group predominantly which could introduce a 
bias to the findings, where potentially the men who were less able could not perform 
the assessment and therefore an inflation of the effects in favour of the intervention 
group may exist. Alternatively, it is possible that where similar studies were able to 
demonstrate meaningful changes in outcomes where this study failed, due to the study 
being under powered. The original target for recruitment was set at 50 participants, 
which the present study failed to meet. This is despite extensive numbers of patients 
screened. As mentioned previously, this could be due to these men being in the 
terminal phase of their disease, with an average 22-24 months life expectancy upon 
the diagnosis of CRPC. This is reflected in the observation that the rate of recruitment 
was similar to that seen in other studies of exercise in cancer patients (including 
advanced cancer patients undergoing palliative care). Whilst it is clear that there is a 
group of CRPC both eligible and willing to participate in such studies, recruitment from 
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a single site is a limitation where the required numbers of these men are simply not 
there. The sample size calculation suggest a sample of n =444 for a two arm trial 
based on the findings for the FACT-P questionnaire. A phase III multi-site trial design 
could address the issues of a low recruitment rate and the lack of representation of 
ethnic minority groups. Where a multi-site trial design may also enable the recruitment 
of a more ethnically diverse cohort. 
An additional difficulty in this study was the use of multiple assessors for the physical 
assessments. This may have introduced inconsistencies where participants may have 
had more or less encouragement during physical assessments or where there were 
inconsistencies in reporting. This may explain the discrepancies in changes at eight 
and 16 weeks in the control group, where average change dramatically increased at 8 
weeks and fell at 16 weeks in hand-grip strength testing and fall at 8 weeks then 
increase at 16 weeks in the 6 minute walk test.  
The lack of availability of researchers was also a problem during the exercise 
sessions. For safety reasons, the men in this study had to be "spotted" for each 
exercise involving free-weights which meant there was a limit to how many men could 
be safely supervised during an exercise session with a single researcher. Although in 
this study, voluntary exercise instructors were adopted into the trial part way through, 
they were not dedicated researchers to this trial they were present on an ad hoc basis. 
Although they were given the study SOP (appendix 13) and briefed/ inducted as to 
how sessions should be undertaken by the man researcher (RG) for consistency, it 
would be more beneficial to more formally train all instructors to standardize 
procedures, which was not feasible in the present body of work. Furthermore, during 
the exercise sessions no data on RPE were recorded. RPE data (using the BORG 
scale) would have given a greater insight and help to quantify the intensity of the 
exercise sessions attended on an individual basis as well as preferences for exercise. 
The randomisation procedures in this study were also a logistical limitation. Simple 
randomisation was adopted, but as a result, the randomisation schedule placed 80% 
of the first ten men in the control group and 70% of the last ten men into the 
intervention group. This caused a potential bias in that the last ten men (predominantly 
intervention), when compared to the first ten (predominantly control) who were 
recruited over the summer, were in the trial over the winter months and therefore 
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experienced more AEs due to winter colds and general illness causing a degree of 
variance between the groups. In addition, this caused problems for an increased 
workload for the researchers over the winter period which resulted in significantly 
reduced time available for recruitment. A future trial might adopt a permuted block 
randomisation procedure to ensure balance across treatment groups where 
participants are randomly allocated to a group within a time frame. Each “block” of 
participants would have a specified number of randomly ordered treatment 
assignments. The example below demonstrates blocks of ten participants: 
Intervention group (A) and control group (B)  
Block 1: BAAABABBAB. 
Block 2: ABABBABABA. 
Block 3: AAABBBAABB. 
Another limitation experienced in this trial was the adherence to the supervised 
exercise, whilst the independent exercise had excellent adherence (despite two 
missing independent exercise diaries). As previously described, a major problem with 
the complex group of patients recruited into this trial was the comorbid conditions and 
ill health experienced by these men, reflected in the high number of AEs and SAEs 
particularly over the winter period. A potential solution to this would be a longer term 
study, where effects of periods of ill health and therefore a drop in trial adherence may 
be attenuated. For participants who have fallen to ill health and are therefore required 
to take time out of the study, upon their return this would also allow the time required 
to enable the study participants to regain some strength and recover. This would 
potentially provide a better indication of the changes to secondary outcomes assessed 
in the present study. 
The present study did not adopt behavioural change techniques. It has been 
recommended that behaviour change be incorporated into studies which aim to 
increase exercise in cancer patients and confer long-term behaviour change (Bourke, 
Homer et al. 2013, Roberts, Fisher et al. 2017, Bourke, Turner et al. 2018). Behaviour 
change techniques have been shown to confer improvements in moderate-vigorous 
physical activity and promoting better adherence to exercise interventions (Roberts, 
Fisher et al. 2017).  
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Furthermore, more extensive preliminary work would have benefitted the trial design 
with the addition of patient focus groups prior to the trial starting. Earlier preliminary 
work may have helped to identify the problems that were observed with patient 
recruitment and helped in defining recruitment techniques. It may also have helped to 
identify the day to day barriers to exercise patients experience related to their ill health. 
For example, it may have been possible to develop a more robust at home programme 
which participants could adopt as a substitute for supervised exercise during periods 
where their health had declined.  
In terms of study outcomes there were two main limitations to this study. The first was 
the poor reporting of the three day diet diaries. There was significant difficulty in 
analysing the diet diaries due to poor reporting of portion sizes and lack of detail on 
foods consumed. For example terms like "fish with broccoli and peas" gave no 
information on the size or type of fish, how the fish was cooked nor the portion size of 
the vegetables. As a result, many of the food reported in the diet diaries had to be 
omitted and therefore there was serious limitation in any conclusions which could be 
drawn from the dietary analysis. Problems with the underreporting in diet diaries is well 
known, however currently there exists no form of dietary recall that does is not affected 
by this limitation (Johnson Rachel 2012). An approach which may better the reporting 
in future trials would be a higher quality diet diary with a more extensive explanation 
on correct completion and additional examples given. In addition, this could be 
supported by the researchers giving a greater deal of time to go through such 
examples and instructions. Furthermore the adoption of a 7 day exercise diary would 
ensure that both weekday and weekend dietary data would further enrich the data 
giving a greater insight into dietary and nutritional changes. However, given the 
present limitation described, it would likely be more beneficial in proceeding studies to 
use the 3 day diet diary with a refined and improved approach first, as some men may 
find 7 days' worth of dietary recording cumbersome.  
The use of the DXA scan to obtain data on body composition could present as a 
limitation. DXA scans, although are able to give data on both fat, bone and muscle, are 
not the most accurate measure of lean mass changes. CT imaging allows for 
quantitative assessment of individual muscles and muscle tissue composition can be 
quantified, either by separate segmentation of muscle and adipose tissue or by 
analyzing muscle density, both of which cannot be done using the DXA scan (Buckinx, 
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Landi et al. 2018). However, the DXA scan still provides a much lower dose of 
radiation compared to CT and is less expensive (Buckinx, Landi et al. 2018). 
In addition, no record of changes in exercise behavior were recorded. Particularly for 
the control group, there is a risk of contamination due to the study being single 
blinded, a common limitation of exercise trials (Steins Bisschop, Courneya et al. 2015). 
The adoption of a measure of exercise behavior would help to quantify any 
contamination in the control group where they may have increased their exercise 
behavior as a result of being recruited into this study. Exercise behavior could be 
assessed in a future study with the use of the Godin Leisure Score Index 
questionnaire which has been adopted in other exercise trials of cancer patients 
(Bourke, Doll et al. 2011). 
6. Conclusions 
The aim of this study was to investigate the feasibility of a lifestyle intervention of 
supervised resistance exercise, dietary supplementation and dietary advice in men 
with CRPC.  The recruitment rate of the present study was similar to previous studies. 
In addition, adherence to the supervised exercise, independent exercise and 
supplementation was sufficient in the intervention group. Whilst the number of AEs 
and SAEs was high in the present study, this predominantly reflects the complex 
nature of such an advanced cancer population than being related to the study itself. 
The dropout rate in the present study was also similar to that which has been 
observed in previous exercise trials.  
In conclusion, despite the number of significant barriers these men face, compared to 
the healthier cohorts often recruited into complex lifestyle interventions of exercise, 
these men have demonstrated that a trial of exercise, dietary supplementation and 
dietary guidance for men with CRPC is both feasible and safe however the author 
suggests that for a subsequent trial changes be made to mitigate the limitations found 
in the present study.  
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Chapter 5 Participant reported 
experiences of COMRADE  
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1. Introduction 
Whilst chapter 4 has reported the quantitative findings of the COMRADE feasibility 
trial, it did not report the participant's experience of the trial. Participant insights have 
the potential to further our interpretation and understanding of the observed trial 
findings within the context of what is acceptable and meaningful to participants 
(Malterud 2001). A qualitative approach, using participant focus groups can generate 
an understanding of the processes by which the COMRADE intervention may 
influence QoL and wellbeing for men with CRPC. Understanding the importance of any 
lifestyle intervention effects within the participants own personal context by obtaining 
detailed, information data based upon participants’ interpretation of their experiences 
enables researchers to understand the meaningfulness of any benefits received. In 
addition, addressing the acceptability and tolerability of the trial procedures provides 
information for the design and planning of future studies (Moore, Carter et al. 2011).  
With this information a tailored intervention, with a superior trial design, may help to 
maximise trial adherence (Sekhon, Cartwright et al. 2017). 
In this cohort of men, who are typically under-researched in terms of supportive care 
we can only hypothesise what barriers to exercise or to the COMRADE trial they have 
experienced. Furthermore, given the limitations described in chapter 4, namely - 
difficulty with recruitment, high rate of AEs, poor reporting of diet diaries - it was 
important to explore further with the participants why they choose to take part in the 
trial and their acceptability of the intervention procedures and study design. The 
benefit of focus groups over other qualitative approaches such as interviews are that 
the participants can share and compare their experiences with each other, develop 
and generate ideas and explore issues of shared importance (Breen 2006).  The use 
of post study focus groups have been recognised as a valuable methodological 
approach for understanding participant experiences of complex social interventions 
(Mays and Pope 2000, Neuman 2013). Therefore, participants' in the COMRADE 
feasibility RCT were invited to attend post-study focus group to qualitatively share their 
experiences and views of the trial. 
 
The aim of this study was to explore the experiences, opinions and views of 
participants in the feasibility RCT to inform the design and running of a potential 
subsequent study. 
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Objectives: 
1. Determine motivations of the participants for entering the trial. 
2. Explore the previous experience of exercise training in men with CRPC prior to 
participation in COMRADE 
3. Explore the current experience of exercise training in men with CRPC within 
COMRADE (i.e. exercise intervention) and outside of COMRADE. 
4. Explore the barriers and facilitators to exercise training and physical activity of 
men with CRPC both within and outside of the COMRADE trial. 
5. Evaluate patient reported acceptability of trial procedures and trial conduct. 
2. Methods 
In complex interventions, it is crucial that attempts are made to unpick the multiple 
components effecting the implementation of an intervention. In such cases, an 
evaluation such as that of participant focus groups or interviews are a valuable 
research method to make sense of some of the findings and observations experienced 
in the study. A process evaluation in trials, as recognised by the MRC, “…can be used 
to assess fidelity and quality of implementation, clarify causal mechanisms and identify 
contextual factors associated with variation in outcomes.” (Moore, Audrey et al. 2015). 
Although an in-depth process evaluation was not conducted as part of this body of 
research, the focus groups were used as means to qualitatively explore  a detailed 
understanding of the processes' of the intervention functioning on a small scale 
(Moore, Audrey et al. 2015). The benefits of using focus groups compared to other 
research methods such as one to one interviews are the ability for focus groups to 
capitalize on communication and interactions between research participants (Mays 
and Pope 2000). The group dynamic of focus groups enable the participants to hear 
each other's lived experience and perspectives which can stimulate new thinking and 
insights; creating an environment for sharing, reflecting and refining thoughts. 
2.1 Study design 
The approach to the analysis of the data was deductive and framework analysis was 
seen as the most appropriate because the objectives of the focus groups were set in 
advance rather than emerging from a reflexive research process (Mays and Pope 
2000). The overall analytical process however, resonates with the thematic approach, 
but with the framework approach it is more explicit and informed by a priori reasoning 
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(Mays and Pope 2000). The framework approach involves familiarisation, generating 
codes and identifying a thematic framework, indexing/coding, charting and finally 
mapping and interpretation. 
2.2 Research governance 
2.2.1 Ethics and research and development approval 
This study was approved by NRES Committee South West - Cornwall & Plymouth 
(15/SW/0260) and in accordance with the Governance Arrangements for Research 
Ethics Committees and complies fully with the Standard Operating Procedures for 
Research Ethics Committees in the UK. All Management permissions were sought 
from the relevant NHS organisations involved in the study in accordance with NHS 
research governance arrangements (appendix 14). 
2.2.2 Informed consent 
Full informed written and verbal consent was obtained from each participant before the 
commencement of the focus groups (appendix 18). 
2.2.3 Confidentiality 
Focus Group transcripts were anonymised by allocating each participant a number to 
protect the identity of all participants. All data was kept on a password protected drive 
or encrypted on a password protected USB. No identifiable information was released 
into the public domain or published. No participant withdrew consent, but if they had 
chosen to their data would have been confidentially destroyed. 
2.3 Sample and setting 
2.3.1 Sampling 
Purposive sampling was used to identify 15 participants in total, from the intervention 
and control arms of COMRADE, with 4-7 participants per focus group. This included 
participants who experienced AE/SAEs during the trial, participants with trial 
completion over six months ago, participants with trial completion within the last six 
months, those who failed to complete all study trial assessments, and participants who 
had experienced the exercise sessions on a one-one or group format (where more 
than one participant in the intervention arm was also undergoing supervised exercise). 
This was done to facilitate conversation between the participants regarding differences 
and similarities in experiences.  
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Men who had dropped out of the COMRADE study were not included in the post study 
focus groups. Two of these men were not contacted as they had died before they 
could be invited to take part in the focus groups. Furthermore, two other men whom 
had dropped out very early into the trial had significant progressive disease and 
subsequently died in June 2018. The final man was not contactable after he had 
decided to drop out. All of these men were intervention participants, and two of four of 
these men did not attend a single exercise session. Furthermore, the men who 
dropped out of the study were already asked questions regarding reasons for their 
drop out which are in chapter 4.  
2.3.2 Inclusion criteria 
 Participants who had been randomly allocated to either the Control or 
Intervention trial arms of COMRADE and had completed the 16-week follow up. 
 Participants who were able to attend the date of the focus group. 
2.3.3 Exclusion criteria 
 Participants whom were not randomised as part of COMRADE 
 Participants who did not successfully complete the 16-week follow up period of 
COMRADE. 
 Participants unable to attend the date of the focus group. 
2.4 Recruitment and data collection 
2.4.1 Recruitment 
Participants were identified from the COMRADE participant log. The participants were 
initially contacted via a telephone call (by the author); if unavailable a voicemail 
message was recorded requesting a response if they had an interest in the 
participation of the focus group. After a briefing over the phone, if the participant 
expressed an interest in taking part in the focus groups the date and time of the focus 
group was confirmed to them. 
2.4.2 Data collection 
Focus groups were conducted face to face with between four and seven participants 
present and up to two researchers present (the author and a study researcher (RT)). 
Focus groups were conducted by the author and RT guided by the focus group 
interview schedule. As new insights were offered these topics were explored. The 
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focus groups were digitally recorded (encrypted Olympus DM-650 Digital Voice 
Recorder) and then anonymised.  
2.5 Focus group interview schedule 
The focus group interview schedule was semi-structured with open ended questions 
and prompts to allow the participants to express their views and opinions. The focus 
group interview schedule consisted of 43 questions for the intervention group and 28 
questions for the control group. Although all questions were intended to be asked, if 
the context of a question was addressed in the focus group during discussion then it 
was omitted. These questions covered motivations and apprehensions before taking 
part in the trial; previous experience of exercise; evaluation and acceptability of the 
general trial procedures; acceptability of the COMRADE exercise intervention; 
engaging with the dietary advice and supplements; support and present experience of 
exercise post trial. The interview schedule was designed to be inductive with some 
deductive reasoning. The detailed interview schedule can be reviewed as appendix 
28. 
2.6 Data analysis 
Data analysis using the framework approach is described previously in Chapter 3 
section 3.5, but has been summarized below. 
Digital recordings were transcribed verbatim by an independent transcription service 
(JHTS audio and transcription service, www.jhts.co.uk) and the data coded via 
Nvivo10 software (Version 1.0, by the author). Using the thematic framework analysis 
approach, familiarisation with the transcripts was first performed and then initial codes 
were generated. 
Initial codes were then related to final themes and sub-themes and analysed according 
to a thematic framework analysis (Gale, Heath et al. 2013). The analytical framework 
was then refined and codes grouped together where they were conceptually related. 
This generated a total of 99 codes in 9 categories. These categories subsequently 
formed the final three superordinate themes and nine subordinate themes (appendix 
27).  
All transcripts were double coded by a second researcher (HC) to ensure reliability 
and rigour of the data analysis. There were no discrepancies in coding between the 
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author (RG) and HC. The data were then charted into the framework matrix of 
superordinate themes mapped against verbatim quotes from each focus group. The 
analytical framework was then refined and codes grouped together where they were 
conceptually related. An example of an extract from the table is given in appendix 28. 
The framework was then verified by a third party researcher (DB).  
2.6.1 Qualitative data analysis options 
As the approach to the analysis of the data was deductive, framework was seen as the 
most appropriate form of analysis because the objectives of the focus groups were set 
in advance rather than emerging from a reflexive research process (Mays and Pope 
2000). The overall analytical process however, resonates with the thematic approach, 
but with the framework approach it is more explicit and informed by a priori reasoning 
(Mays and Pope 2000).  
2.6.2 The framework approach 
Framework analysis is a systematic analytical approach to qualitative research. It is a 
matrix based method for ordering and synthesizing qualitative data and was developed 
by Jane Ritchie and Liz Spencer in the 1980s for large scale policy research (Ritchie 
and Spencer 2002) but is now widely used in health research (Gale, Heath et al. 
2013). In the context of these focus groups framework analysis was chosen as it was 
the most pragmatic approach to systematically facilitate rigorous and transparent data 
management without losing sight of the "raw data" and enabled the classification of the 
data into key themes and sub themes, judged comprehensively.  
2.6.3 The method of the framework approach 
The analysis was carried out in a 6 step approach including familiarising with the data; 
generating initial codes; searching for themes; reviewing themes; devising and naming 
themes and producing the report (Braun and Clarke 2006).  
2.6.3.1 Familiarisation 
Before any attempt to sort through the data was made, there was a process of data 
familiarisation.  Transcripts and observational field notes were read and re-read and 
recordings were listened to in order to fully immerse oneself with the data in advance 
of any kind of analytical stage. 
238 
 
2.6.3.2 Generating initial codes and identifying a thematic framework 
After initial familiarisation, a process of "open coding" was conducted. This included 
analysis of a section of an intervention group transcript and the coding of data which 
was felt to have relevance to the research aims and objectives (such as opinions, 
attitudes, behaviours or views). Each of these initial codes was accompanied with a 
note to clarify its meaning. 
2.6.3.3 Indexing/coding 
Coding aims to classify all the data and enable a systematic comparison between the 
different data sets. Codes are grouped together in categories which are clearly defined 
to generate themes and subthemes (Gale, Heath et al. 2013). Coding was conducted 
electronically using the programme Nvivo by RG. A second researcher (HC) manually 
coded transcripts. Indexing indicated which themes in the text were being discussed. 
Once data had been coded a thematic framework was developed consisting of themes 
and subthemes. Initial themes were more descriptive rather than analytical or abstract. 
2.6.3.4 Charting 
Once the main themes and subthemes had been identified, reviewed and finalised 
between the researchers, a matrix was created to help delineate the data set. Each 
column of the matrix was headed with each theme and each row with each focus 
group number demonstrated in appendix 28. The relevant sections from each coded 
transcript were then summarised and entered into the framework matrix so the text 
can easily be navigated and comparisons can be made between the groups. For each 
focus group summary, selected information was taken from each transcript in order to 
reflect meaning without losing content. The transcription conventions were:   
 Italics - Direct quote 
 … - Quote has been abridged 
 [word] - Where the author has clarified the meaning or phrase from the 
quotation 
2.6.3.5 Mapping and interpretation 
Once charting was complete a more refined analysis of the data set was possible with 
a deeper immersion into the content of the transcripts. Summaries of each theme were 
made from identifying relationships between the quotes and links between the data as 
a whole, providing explanations for the findings and overarching themes (Ritchie and 
Spencer 2002). This included drawing comparisons between the transcripts 
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highlighting any conflict/consistencies in key terms/ phrases/ descriptions/ views or 
explanations. Explanations and conclusions were drawn from the analysis, this can be 
explicit (originating from the participants descriptive statements) or implicit (identified 
by the analyst). After the final analysis the data were categorised into a priori themes 
or new themes were constructed as appropriate (Ritchie and Spencer 2002).  
2.6.4 Ensuring quality within qualitative research 
Quality in qualitative research is multifaceted and includes consideration of the 
importance of the research question, the rigor of the research methods, the 
appropriateness and salience of the inferences, and the clarity and completeness of 
reporting. Although there is much debate about standards for methodological rigor in 
qualitative research there is widespread agreement about the need for clear and 
complete reporting. High quality research which is conducted and assessed 
systematically would enable researchers to synthesise the data, critically appraise the 
data with greater ease due to transparency and therefore subsequently ensure 
reproducibility.  
To ensure quality, this qualitative research was conducted following the guidelines for 
standards for reporting, process and methods from the Consolidated criteria for 
reporting qualitative research (COREQ) criteria (Tong, Sainsbury et al. 2007). The 
checklist was used to ensure explicit and comprehensive reporting of the final analysis 
(appendix 10). The NICE public health development guidance and MRC guidance on 
the development and evaluation of complex health interventions were used to aid the 
design of the focus groups (NICE 2012, Craig, Dieppe et al. 2013). The quality of 
qualitative research is judged fundamentally differently to that of quantitative methods 
which predominantly look for internal validity, external validity, reliability and objectivity. 
This study sought to ensure rigour by the four criteria outlined by Shenton i.e. 
credibility, transferability, dependability and confirmability (Shenton 2004).  
3. Results 
Of the 31 trial participants, 22 were contacted for their participation after meeting the 
inclusion criteria. Three focus groups in total were conducted; the first group with 
control only participants and the second and third groups with intervention only 
participants. Of the control group, nine men were contacted and of this four agreed to 
participate (FG1 control, n =4), the remaining men could not participate on the 
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proposed focus group date due to prior commitments. Of the intervention group, six 
men were contacted and of this five agreed to participate in the first focus group. Four 
men subsequently took part in the focus group as one man had been admitted into 
hospital as an inpatient (FG2 intervention, n =4). For the second intervention focus 
group seven men were contacted and all seven agreed to participate in the focus 
group (FG3 intervention, n =7). The characteristics and demographics of participants 
who took part in the focus group study are detailed in table 6.1.  
Table 6.1. Participant demographics 
 FG1 control 
(n =4) 
 
FG2 intervention 
(n =4) 
FG3 intervention 
(n =7) 
Mean age (y) 70 73 75 
Retired  3 4 6 
Current or previous 
Enzalutamide 
0 2 6 
Current or previous 
Abiraterone 
0 0 1 
Current or previous Docetaxel 2 0 1 
 
Three primary themes were identified from the data (table 6.2).These included 1) living 
with CRPC, 2) experience and opinions of the trial, 3) attitudes and experiences of 
exercise training and physical activity. Participant's verbatim quotes are provided in 
order to illustrate the findings. 
Table 6.2. Primary and secondary themes of focus groups 
Theme 1: Living with CRPC Physical health 
Psychological health 
  
Theme 2: Experience and opinions of the trial Motivations and expectations for the trial 
Acceptability of trial procedures 
Perceived benefits of the exercise and dietary 
intervention 
Critique and suggested improvements for a 
future study 
  
Theme 2: Attitudes and experience of exercise 
training and physical activity 
Barriers to exercise training and physical activity 
inside and outside the trial 
Facilitators to exercise training and physical 
activity inside and outside the trial 
Experience of exercise training outside the trial 
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3.1 Theme 1: living with castrate resistant prostate cancer 
3.1.1 Physical health 
When discussing their physical health the most commonly mentioned concern 
amongst the men was the observed decline in fitness as a result of treatment. In FG1 
(control group) this was mentioned 12 times amongst all four participants, in the two 
other intervention focus groups (FG1 and FG2) it was mentioned a further 6 times in 
total. The common worry was the inability or increased difficulty in carrying out 
activities of daily living such as walking the dog, walking to the hospital or performing 
manual jobs.  
 "Yeah, but I used to run and I’ve found that I just cannot run at all…Since I’ve 
been diagnosed with cancer…I couldn’t do five minutes and it’s just demoralising..." 
Participant 4, control group 
 "Well, I’m still working on occasion, touch wood, but when I’m carrying the tiles 
upstairs or whatever, instead of carrying a box, I carry just maybe four or five tiles 
because they’re large tiles; whereas I used to be able to carry one, maybe two boxes 
at a time." Participant 2, control group 
 "…if I had to walk, I used to get off a bus outside the Hallamshire and then walk 
up to Weston Park and there’s those steps aren’t there…I was stopping three times or 
more going up there because I just hadn’t got the energy to do it and I was almost 
crawling up the little gradient after that to get up the hill…And my feeling is that you 
can be as fit as you like at one point, but it just drops away rapidly if something goes 
wrong and you can’t do anything about it." Participant 3, control group 
These effects were reported as being associated with a combination of problems 
relating to progression of disease and the AEs of treatment. Disease related AEs, pain 
and lymphedema were the most commonly mentioned. One man, participant three in 
the control group, also spoke of the effects of spinal cord compression as a 
predominant detrimental side effect. In terms of treatment, the AEs effecting activities 
of daily living were neutropenia resulting from chemotherapy and fatigue resulting from 
Enzalutamide. For one man fatigue was a very significant problem in FG3, to the 
extent where he had been asked to be periodically taken off the drug. 
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 "…I said with my prostate reading being so low, can you not give me a break, 
can you not take me off this enzalutamide for three months and then we’ll have 
another blood test? Oh no it’s working, so you’ve got it and I said well it really is 
affecting my quality of life and he said to me well at least you’ve got a life." Participant 
15, intervention group 
Although some positive effects of steroid treatment were mentioned, such as 
reductions in pain, there were two men in the FG1 who detailed their concerns of 
excessive weight gain which was perceived to be steroid induced. 
 "… the extra weight makes it even harder to do anything...I was on steroids 
when I had chemotherapy and I clapped two stone on straightaway… I think that, that 
extra weight is affecting me as much as anything else really, especially my breathing. 
The breathlessness is the worst thing for me that really gets me down…" Participant 
4, control group 
Other negative changes to body composition as a result of ADT was mentioned, 
including weight gain and a loss in muscle, this was also described as a barrier to 
exercise (see section 6.3.2.1). 
3.1.2 Psychological health 
For two men in the control group, the detrimental effects of the disease or treatment 
for disease had had a large impact upon psychological wellbeing. This ranged from 
feeling low and a lack of motivation to do every day activities to resentment for their 
disease and their diagnosis.  
 "I’m either all right or I’m like down on the floor. In the early days I felt awful, 
terrible, both physically and mentally, I took a right knock."   Participant 4, control 
group 
The interaction between participants and their consensus is highlighted by the 
following quotes. It appeared that for one man, there was some resentment for his 
disease and his declined physical fitness. 
 "I find it just unfair, if you like. I think why me, what have I done wrong? Just 
when I ought to be enjoying life more than ever and there’s all sorts of things I want to 
do and it doesn’t seem fair." Participant 3, control group  
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 "I agree it doesn’t seem fair." Participant 4, control group 
 "I look at young people running or doing things and doing their everyday things. 
When you come here and you’re going past all the students and they’re looking all full 
of life and doing things and laughing and joking and running around and I think you 
don’t know how lucky you are. And I resent it in a way and I’m jealous of people 
because they’re fit and I’m thinking well I know I’m not that young, but there’s no 
reason why I can’t feel - I wanted to be as fit as I could be for my age, but this knocked 
it on the head, all this." Participant 3, control group 
3.2 Theme 2: experience and opinions of the trial  
3.2.1 Motivations and expectations for the trial 
The two most commonly mentioned reasons for taking part in the study were to be a 
part of a research study that could help future prostate cancer patients and to improve 
their fitness.  
 "I mean although I’ve always been relatively fit, I find it quite difficult to maintain 
the fitness level since I’ve been on medication. So that was the motivation. Basically 
that was it." Participant 8, intervention group 
 "… for me I tend to be a bit lazy and by coming to something like this because 
I’d got to a very low level of fitness and I was very worried about whether I’d ever get 
out of it and yeah, it got to me do exercise in a more formal way and if it benefits the 
other people who find themselves in the same boat in future, yeah, then great." 
Participant 13, intervention group 
 "…I felt like that, it’s payback time, got to put something back in for all the years 
and years that I’ve had treatment..." Participant 15, intervention group 
Other reasons for taking part in the trial were the encouragement of family and friends, 
to improve bone health, to improve psychological wellbeing, to simply get moving 
again and because the exercise offered was supervised The supervised aspect was 
felt to beneficial as these men would get individual tailored advice tailored to their 
needs and abilities. 
 "...but at the back of my mind I thought it would be nice if there’s somebody 
there who knows what you should be doing and possibly not be doing and what the 
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best thing is for you. Because we can all, body withstanding, go and get on machines 
and knock yourself out, but is it really doing you any good?"  Participant 4, control 
group 
 "It was just at the back end of last year, wasn’t it and I get pretty low in the 
winter, I get very low sometimes and I thought this would help pull me through the 
winter." Participant 15, intervention group 
The only apprehensions about starting the trial were in reference to being randomised 
to the control group and for one man whether the weights he would be asked to use in 
the intervention would be too heavy.  
The reasons given for regularly attending the exercise sessions were predominantly 
the camaraderie experienced with the group aspect of the exercise, the supervised 
exercise support as well as the beneficial changes to body composition.  
3.2.2 Acceptability of trial procedures 
There was overall positive feedback given regarding the trial procedures.  
Assessments were generally well received although all participants in FG3 agreed that 
the physical assessments (three repetition maximum testing, six minute walk test, 
hand grip strength and chair sit to stand test) as being "too easy". 
 "I think the thing to me was the initial test that [the author] carried out, where 
they analyse what you can do and what your physicality is. And I thought that was 
excellent because it gives you a base to work from." Participant 8, intervention 
group 
 "I thought it was handled very well... he just walked me through it in a 
straightforward way and timed me and adjusted the weights and things like that. So it 
was excellent yeah." Participant 7, intervention group 
 "I’d just think well I’ve done [the assessment], that’s been easy, I wish I could 
have gone further." Participant 9, intervention group 
For the questionnaires, there were some difficulties with completing the diet diaries, 
particularly with fresh food as opposed to packaged, in detailing portion sizes and 
remembering exactly what was eaten. In addition, there were some difficulties with 
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gauging how to interpret and complete the rating of items on the FACT-F and FACT-P 
questionnaires. 
 "I find them really difficult to judge where I’m putting it at. Am I comparing 
myself to when I was 20 years old...I’m sometimes tempted to feel that I’m 100%. But I 
don’t know how helpful that would be to you because you don’t know what I’m 
comparing it with. That’s what I meant by that, yeah." Participant 4, control group 
The dietary guidance was very well received but there were some problems for men 
who were not used to cooking for themselves implying that their lack of cooking skills 
meant they struggled to make as much of a change as they would have liked. 
The interaction between intervention participants in focus group 2 and their consensus 
is highlighted by the following quotes: 
 "I think it was a good idea putting that in, I didn’t expect that and it was 
excellent." Participant 7, intervention group 
 "Yeah, I mean it gave you an insight into what…" Participant 8, intervention 
group 
 "Alternative things to eat. Participant 7, intervention group 
  "That’s right yeah." Participant 8, intervention group 
 "Trouble is my wife has got to the age now where she doesn’t want, she’s 
always cooked for me; I’ve never cooked anything. In fact I was in catering corps in 
army and I couldn’t have boiled an egg." Participant 5, intervention group 
The duration of the trial was thought by the majority to be long enough, with the 
exception of one who voiced a preference for a longer duration of trial. The structure of 
the three phase intervention was also received very well by the intervention 
participants.  
 "It struck me that they’d been thought through. It wasn’t just, oh I’ll have a go at 
this one now, and, oh that one’s free, do this, that you had given some thought to the 
order in which, well not just a day one and day two thing but also doing each 
exercise…" Participant 6, intervention group 
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The group exercise format (which included up to 6 participants in a session) was also 
received very positively, and was an aspect enjoyed most by the participants 
particularly the camaraderie between the participants. 
 "I thought the group that we’ve got and the [instructors] that we got and all the 
rest of it, I thought it was quite a nice mix. A bit of a laugh here and there or tried to 
make it so… I think there was a certain amount of camaraderie" Participant 8, 
intervention group 
The interaction between intervention participants in focus group 2 and their consensus 
is highlighted by the following quotes: 
  "I started by myself and you suggested going into the group. I went into the 
group and I enjoyed it…But it worked well and seeing what other people could do was 
useful. And seeing how much he could do, I’m pointing at [participant 5] over here." 
Participant 7, intervention group 
 "I think he used to look up to me a little bit." Participant 5,  intervention 
group  
 "I think there were lots of times when I was with [participant 14] and I think only 
two or three occasions when there were more, maybe four and certainly the last few 
there’s just been me...I enjoyed it when there were more people in. Now, it’s difficult 
for you to manage that when we’re all doing different exercises, but if that could be 
part of it, so that camaraderie, if that’s the right word, the banter, because for me that 
was an important part of it." Participant 10, intervention group 
The rapport with the trainers and assessors was also an aspect enjoyed by the 
participants. It was felt that they were effective at communicating the trial procedures; 
providing enough information, guidance and support; and adequately contactable 
when needed (with an appropriate level of contact).  
 "I found the guys there really helpful and that. And they let you push you as 
much as you wanted to. And I kept trying to do more of, you know the leg push thing." 
Participant 4, control group 
For one participant, it was felt to be of benefit that the trainers were researchers and 
"scientifically trained" where that would not be the case in a commercial gym 
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environment. In addition, the participants perceived that the trainers in the study had a 
genuine interest in coaching participants to improve their strength and fitness 
capability. Overall, the feedback from the participants who took part in the focus 
groups reported the trial be a very positive experience. 
3.2.3 Perceived benefits of the exercise and dietary intervention 
The physical benefit arising from the COMRADE exercise intervention most commonly 
mentioned was perceived improvements in muscle strength and fitness, mentioned by 
9 intervention participants. Other physical benefits included improvements in the 
activities of daily living (mentioned by two), improvements in pain (mentioned by four) 
and the maintenance of physical fitness. These physical outcomes were felt to be 
declining prior to the intervention.  
 "…I certainly feel a lot stronger. I can do things that I couldn’t do before." 
Participant 7, intervention group 
 "But compared to last year, we had to have professional gardeners in to go out 
to do our garden. Yesterday I mowed the lawn and it’s a big lawn. So yeah, I’m a 
whole lot fitter than I was a year ago. I even did a charity job, a charity auction; I went 
and chopped somebody’s trees down with a chainsaw...Yeah, I’m a whole lot fitter and 
it’s worked for me." Participant 9, intervention group 
 "I wanted to give it a go to see what it was like. Like I said it’s been a success 
up to now. I don’t get no pain in bottom of my spine now and I’ve gone back to gym 
where I was." Participant 8, intervention group 
 "I realised that when I was first diagnosed 26th of June 2015, I went to the gym 
and I tested myself on every bit of equipment that I’ve ever used and I’d been going 
downhill.... I think now is that I’ve stopped the decline…on the two occasions I’ve been 
to the gym since, I think I was moving fairly close to what had previously been the 
maximum and they were one rep maxima and, you know, you’ve been getting me to 
do between eight and 12 three times. So you were a reminder that I actually have got 
stronger." Participant 14, intervention group 
The social and psychological benefits were mentioned by 7 of the intervention 
participants. Improvements in wellbeing and QoL were mentioned. If seemed from the 
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conversations that the trial enabled the men to open up about their disease with others 
who are in a similar situation and therefore were able to support each other. 
The interaction between intervention participants in focus group 2 and their consensus 
is highlighted in the group dynamic demonstrated below. This highlights the 
commonalities amongst the participants. 
 "The wellbeing factor. Setting aside the purpose of your project which was bone 
density and things like that. The wellbeing is overwhelmingly good." Participant 7, 
intervention group 
 "It’s markedly better isn’t it?" Participant 8, intervention group 
 "…but a lot of people are in the same boat and coping with it 15 years, 12 years 
or whatever. When you’re first diagnosed and you find, you ask the question, well, if I 
don’t have any treatment what are we talking about and the guy says 12 months, that’s 
a good laxative! And the fact that we’ve got through that …I’m not one personally for 
support groups in that way - but indirectly this is one to some degree, the fact that 
you’re doing the exercises and then just chatting to people who have been through 
what you’ve been through…that’s helpful." Participant 10, intervention group 
 "… I think the idea of almost whether or not it works because we don’t know 
whether or not the scans and that will show growth or whatever it might be but the fact 
that it stops you lying around doing bugger all, actually gets you out of the house and 
provides that motivation, that in itself, and it’s quality of life. Now, whether or not the 
quality of life, how long we’ve got is shortened, increased or whatever, the fact that it 
actually makes you get out of bed when you might not, I think that’s beneficial in itself." 
Participant 10, intervention group 
One man in the intervention group spoke about how his own progression in the trial, 
and improvements in physical ability, had inspired others who had also been 
diagnosed with prostate cancer. 
 "I’m very conscious that in the last six months I’ve improved both mentally and 
physically. But three of my friends in the last eight weeks have been diagnosed with 
prostate cancer and I can say to them, look, I’ve had it for 15 years and I’m still there 
and you’ve got lots of hope because I’m still there and feeling better than I was…I’m a 
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bit of an example to a number of people just suddenly having the shock, you’ve got 
prostate cancer and I can talk to them about it and not everybody can talk about it. 
And if they can see you coming back then they’re thinking well hey, there’s hope for 
me…so it’s giving them a hope for the future, I hope, so there are quite a few positives 
coming out of all this." Participant 13, intervention group 
3.2.4 Critique and suggested improvements for a future study 
As mentioned previously, some participants experienced difficulties completing the 
questionnaires, as a result, it was suggested that further and more in depth 
explanation of how to complete them would be of benefit in a future study.  
Unfortunately, for some of the men randomised to the control, there was great 
disappointment that they would not be receiving any diet and supervised exercise 
support.  
 "I was devastated. I was gutted, absolutely gutted. I nearly didn’t come to the 
control! I just fancied the idea of somebody telling me what I should and shouldn’t be 
doing and the diet as well just to give something a try, you know, but it is what it is. It’s 
a lottery, isn’t it, but yeah, I felt really disappointed. You weren’t my friend that day!" 
Participant 4, control group 
In the intervention group, problems reported that affected attendance to exercise 
sessions were illness (3), a family bereavement (1) and poor weather (3). Other 
problems during the trial included constipation as a result of consuming the whey 
protein (2), difficulty with travel and parking (8) and the lack of accessible showers (1).  
Regarding the intensity of the exercise session, there was a mix of opinion. Some of 
the men reported that the overall session was not as difficult as they had wanted 
however there were also some who had difficulty with individual exercises. 
 " I think you know what I’m going to say. There was one exercise which I found 
very difficult and I found it very disheartening and I’d been managing everything until 
then." Participant 7, intervention group 
 "Now in my opinion the [exercise] I do now [at the gym is] harder than when I 
came here…I took a towel [to the trial exercise sessions] because I was expecting 
250 
 
coming out sweating and sometimes I didn’t come out sweating at all " Participant 5, 
intervention group 
Although the group format was overwhelmingly preferred and enjoyed by the 
intervention participants, there was some concern over the number of available 
instructors present in the sessions. It was felt that sessions would benefit from more 
instructors to adequately ensure the safe and timely running of the sessions, 
 "If you’ve got two or three of you." Participant 5, intervention group 
 "Yeah, if there’s more. But sometimes it depended on how many there were. 
Sometimes there were too many." Participant 8, intervention group 
 "Too many for [the instructor] weren’t there?" Participant 5, intervention 
group 
 "Yeah." Participant 8, intervention group 
In addition, it was felt the most benefit would be gained from consistently seeing the 
same trainer during the intervention period.  
 "I’m the same with the doctor, I like to see the same doctor because he knows 
what the criteria is for me, he knows what the situation is. And I think you’re better off 
staying with the same [instructor] whichever one it was...I do think it would be more 
beneficial for the individual." Participant 8, intervention group 
One participant had also spoken at how he would have preferred for their to have been 
a longer duration of the intervention. 
 "I think the duration of it ought to be six months. Seriously because I think it 
gives you a wider span and a greater depth of knowledge. I mean I understand the 
cost is going to be substantially more, but I think you would probably find that after six 
months you would see a substantial improvement in the individual performance. Or 
when I say performance I’m talking about readings, PSA and all that....But I do think 
that if you extended it over six months it would eradicate the holidays." Participant 8, 
intervention group 
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3.3 Theme 3: attitudes and experiences of exercise training and physical 
activity  
3.3.1 Barriers to exercise training and physical activity inside and outside the 
COMRADE trial 
The most commonly mentioned barrier to exercise training outside of the trial (both pre 
and post study) was lack of motivation followed by fatigue and lack of support and/or 
advice from treating clinician. Lack of personal motivation was mentioned by 11 
participants.  
 "The motivation to go and do it [exercise], it’s just too easy to put it off and say 
oh, I’ll do it in a bit…it’s just really hard to make you do things that are quite tedious 
and boring aren’t they?" Participant 4, control group 
The lack of endorsement to exercise from a clinician or a lack of information which was 
tailored to men with prostate cancer was a significant concern for three participants. 
 "...but it’s just knowing what the right thing to do is. My wife reads everything, 
absolutely everything, internet, all the books, we’ve got every booklet that’s ever been 
published and that. And I find a lot of those things would hold you back rather than 
encourage you to do anything. So I think it’s the degree that you’re at. But you don’t 
know what’s right and what’s wrong, are you doing any harm or are you not, and when 
your oncologist goes don’t do that, and you think…Yeah, that’s what she said to me, 
yeah, don’t go on any weights or anything like that." Participant 4, control group 
 "I think I’ve found when I’ve talked to them and mentioned exercise and also the 
cancer support place, they talk to you as if you can’t do anything. And I don’t think they 
recognise the difference between being almost an invalid and being reasonably active. 
My oncologist told me don’t go to the gym, don’t do this, don’t do that, try some 
Pilates." Participant 4, control group 
Other barriers mentioned were the gym environment being perceived as too boring, 
existing co-morbidities (cardiovascular and musculoskeletal), poor mobility, being too 
old and interfering with holidays. 
The barriers specifically associated with prostate cancer and its treatments were 
reported as fatigue associated with ADT (mentioned by five of the men), disease 
progression, and side effects of chemotherapy. In addition, body changes associated 
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with ADT appeared to have significant effects on the body image of four of the men, to 
the extent where they would not partake in exercise. There was mutual support offered 
in acknowledging the problem of gynaecomastia amongst the participants, where men 
shared their common experience and expressed their joint concerns.  
 "I used to swim, but I won’t go in a swimming pool now because, well, I look like 
a woman because of the treatment. The hormones, the female hormones I’m 
practically wearing my wife’s bra, so I won’t go swimming." Participant 1, control 
group 
 "I don’t go in swimming pool now; it’s embarrassing a bit isn’t it?" Participants 
5, intervention group 
 "…I’ve got quite noticeable boobs." Participants 8, intervention group  
 "Don’t worry about that, I could do with a bra."  Participants 5, intervention 
group 
 "…this fatigue problem, you said well exercise, well that’s the wrong thing to say 
to somebody like us if you’re really fatigued to say go and do some exercise because 
that’s the last thing you want." Participant 15, intervention group 
   
3.3.2 Facilitators to exercise training and physical activity inside and outside the 
trial 
The most common facilitator to exercise as mentioned in the focus groups was 
encouragement or advice received from their clinical team. Of the 15 men who took 
part in the focus groups, only three had received support for exercise behaviour from 
their clinicians. In addition, many of the men felt that exercise should form part of 
overall care because of its associated health benefits. 
 "Well my doctor and at Weston Park, they’ve always said that, when they found 
out I go to a gym they always said it’s a good thing. It’s a very good thing to go to a 
gym while you’ve got, well you’ll always have this." Participant 4, intervention group 
 "I think there should be some link up. I think it ought to be possible to say look 
you’re going to benefit if you can keep fit and do this and we’d like to keep an eye on it 
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and this sort of thing. But I think the oncologists at the Weston Park Hospital just 
haven’t got time. They’ve got so many people." Participant 3, control group 
Alongside the participants desire for clinician input and guidance, was the feeling that 
supervised exercise would not only be the safest option for men who were unsure of 
the type and intensity of exercise to do but also help the men to understand which 
exercises would benefit them the most. This perception was reflected on from their 
recent experience of supervised exercise in the COMRADE trial 
 "…particularly as we were trying to go up the weights, I think if we’d have done 
that left to our own devices we might have either taken the easy way out or tried to do 
something too much to do that. So I think it was necessary to [be supervised] to know 
what our own, if you like, for you to manage our limitations." Participant 10, 
intervention group 
3.3.3 Experience of exercise outside the trial 
In the intervention group, there was a higher prevalence of men who had chosen to 
continue with exercise in a gym environment post-study. For three men, they felt that 
the study had given them the encouragement and confidence to translate their 
motivation and competence to exercise post participation in the trial. In the control 
group, there were some negative perceptions of commercial gyms including them 
being too busy, but also a lack of trust with personal trainers who may not have the 
empathy or awareness of the clinical condition to achieve the best outcomes for these 
men. In contrast, the COMRADE trial was perceived as being specifically tailored to 
achieving benefits in health outcomes relevant to their disease and the related needs 
of men with CRPC. 
 "Yeah, it encouraged me to join the gym doing this. And the main difference I 
think is expense, it’s quite expensive if you include the trainer as well. I’m going three 
times a week for about an hour." Participant 7, intervention group  
The interaction between participants and their consensus is highlighted by the 
following quotes: 
 "I joined a gym once and it was just like chucking money away. I had a personal 
trainer who just walked around with us and that were that. All they wanted was that. 
Participant 1, control group 
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 "I would say when you’re talking about other gyms you’ve got to question, not 
the motivation of people there, motivation of the trainers, what they’re after and 
obviously the people here know what you’re trying to achieve, don’t they?" Participant 
4, control group 
Other activities mentioned were home based exercise with the help of equipment such 
as bikes and rowers and a community based group for cancer patients (Macmillan 
Active Everyday) which helped to facilitate and encourage exercise.  
4. Discussion 
4.1 The adverse effects of treatment and disease 
It is clear from the findings of this study that the participants who participated in the 
qualitative focus groups experience a tirade of AEs which are detrimental to both 
physical and psychological health.  
The overall effects leading to a decline in physical fitness was of primary concern for 
these men, likely leading (in part) to the decline in psychological health that some men 
experienced. An interesting finding was that this concern was more prevalent in the 
control group than in the intervention focus groups, despite their being more than 
double the number of intervention to control participants. Given the perceived benefits 
described from those in the intervention, it could be that at the time the men engaged 
in the focus groups there was a perceived mitigation of the decline in physical fitness 
when compared to the control participants. The perception of this decrease in physical 
fitness was predominantly perceived as a lesser ability to carry out activities of daily 
living. A decreased ability to carry out activities of daily living has been shown to have 
profound effects on QoL in cancer patients, and therefore likely to impact on overall 
wellbeing (Ulander, Jeppsson et al. 1997). This is compounded by the presence of 
advanced prostate cancer and the AEs of its associated treatments. Problems like 
fatigue and lymphedema (which were described in these focus groups) can 
significantly impede physical function and exercise tolerance in cancer patients and 
older adults (Stolldorf, Dietrich et al. 2016, Kogure, Hara et al. 2017).  
For one man, fatigue brought about by enzalutamide had affected his QoL to the 
extent where he had asked to be periodically abstain from taking the drug, on this 
occasion he felt that the impact on his QoL had outweighed the perceived benefits. 
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This was surprising in light of the findings of chapter 3 where the HCPs interviewed 
emphasized the importance of balancing QoL and treatment for disease as well as 
discussions with patients regarding treatment decisions. The fatigue described by this 
man had affected his functional capacity and ability to carry out everyday activities. 
This further reflects that which was previously described in chapter 3 where 
maintaining physical performance and therefore "fitness for treatment" is pivotal.  
The psychological health of advanced cancer patients is of significant clinical impact. 
Low mood, lack of motivation for everyday activities and resentment for the disease 
and associated effects were all described by these men. In prostate cancer, men with 
advanced disease and those who have received ADT are much more likely to report 
greater number of effects which impede QoL (Kornblith Alice, Herr Harry et al. 1994). 
4.2 Evaluating the trial experience 
The two most common reasons for taking part in the study were to potentially help by 
contributing to evidence from which informed decisions about therapeutic support for 
future CRPC patients can be made; and to improve fitness. Similarly, the study by 
Bourke et al (2012) also reported a motivation for participation in an exercise trial was 
to contribute to improved treatment for future patients (Bourke, Sohanpal et al. 2012).  
As described earlier, the decline in physical fitness is of primary concern for these men 
and the combination of both the effects of their cancer and the side-effects of drugs 
can result in a reduced ability to undertake activities of daily living. Improvements in 
fitness were therefore clearly a priority and motivator to take part in COMRADE for 
these men. This has also been described  as a significant motivator to increase 
exercise behavior in a previous qualitative study of men with prostate cancer (Bruun, 
Krustrup et al. 2014). Therefore, a programme which adopts and records continuous 
progression in exercise training is an important motivator, where men are able to see 
how they have improved physically over the course of the programme. 
Other reasons such as the encouragement of family and friends further reflect the 
need for support and guidance, not just from their clinical team, but also from their 
close social circles. It has previously been recognised that the support of family and 
friends is an important factor the decision making of cancer patients (Hobbs, Landrum 
et al. 2015, Al-Bahri, Al-Moundhri et al. 2017). In addition, the camaraderie and social 
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interaction with others due to the group based format of the intervention was an 
important reason for men to continue to attend sessions. 
The group format and social aspect of the intervention was mentioned numerous times 
in the focus groups. Not only did it bring about peer to peer encouragement, but it also 
acted as a support network, where the men felt comfortable to talk about their disease 
openly, which was agreed between the focus groups participants. A previous 
qualitative study of prostate cancer patients has also demonstrated the value of 
creating opportunities to share experiences as a psychosocial exercise (McCaughan, 
McKenna et al. 2015). Whilst the exercise in the COMRADE intervention group was 
providing meaningful physical health benefits to participants it appeared the social 
interaction with others and research staff had a valued impact on their psychological 
health. Wellbeing improvements were described as improvements in quality of life and 
the ability to do activities of daily living. Such terms were similarly described in the 
study by (Adamsen, Rasmussen et al. 2001). In addition, the improvements 
experienced by the men on the trail did not only act as motivators for those also within 
the study, but one man had also described how his experience had inspired friends 
outside the study, helping them to have a more positive outlook upon the diagnosis of 
prostate cancer. Similar findings have also been demonstrated in qualitative analysis 
of exercise based interventions, demonstrating the group aspect brought both 
camaraderie and served as a motivational driver in sessions (Adamsen, Rasmussen et 
al. 2001, Bourke, Sohanpal et al. 2012, Bruun, Krustrup et al. 2014). 
These findings suggest that psychosocial support is pivotal for future exercise 
programmes. Group based formats as well as family and friend encouragement are 
clear motivators. Furthermore, confidence and support for exercise from treating 
clinicians is warranted. Future programmes should therefore encourage clinician 
involvement which is also a key finding in chapter 3. This too would help facilitate 
exercise in the prostate cancer care pathway, where clinicians who are clinical 
champions for exercise are able to encourage and advise their patients on exercise 
and physical activity but also have the knowledge to refer them to local schemes 
where available. Furthermore, it is important to have family support, this could include 
the presence of a partner or family member in the initial consultation regarding an 
exercise programme so they can be a part of the decision making process. In 
COMRADE it was often the case where men were approached in clinic they were 
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accompanied by a partner or family member and it was often the case that they were 
encouraging and in favor of the recruited men to participate in the study. Partners were 
also receptive and helpful in aspects such as the adoption of a healthy diet, cooking 
some of the meals suggested in the dietary guidance for their family. 
There was a range of benefits experienced by those men who had undertaken the 
exercise intervention. The most commonly mentioned improvements were physical 
fitness, muscle strength and ability to undertake activities of daily living. Previous 
qualitative studies of exercise interventions in prostate cancer patients had also 
described the positive changes to strength and capacity to do everyday activities 
(Bruun, Krustrup et al. 2014). An outcome of the COMRADE trial was to determine the 
effects of the intervention on LBM and physical performance, with the overall aim to 
improve outcomes in men with CRPC. The findings from the focus groups are 
encouraging that men in the intervention had reported both physical and benefits 
including increases in muscle strength. More importantly however, was the unanimous 
finding of the intervention participants that there were improvements in wellbeing and 
quality of life.   
Despite the barrier to exercise associated with long-term ADT, these men still were still 
able to undertake exercise training and observed significant benefit from doing so. 
Although none of these men were on chemotherapy during the trial, two in the 
intervention had had a previous chemotherapy regimen. This does lead to questions 
regarding the HCPs perception of physical fitness, given the doubts expressed in 
chapter 3, where these men have been able to undertake exercise despite significant 
previous treatment and comorbidity. Despite the significant barriers described in 
chapter 3, these men were still able to undertake the exercise intervention safely 
regardless of their comorbidity and physical ability. This demonstrates the intervention 
was well tolerated, which is further reflected in the lack of SAEs/AEs associated with 
the trial procedures (with the exception of whey protein causing gastrointestinal 
problems) in addition to the good adherence described in chapter 3.  
The findings from this study and that demonstrated in chapter 5 suggest a need for 
such supportive interventions for men with CRPC and that with tailored and 
individualised advice, with supervision initially, can ensure that exercise interventions 
can be undertaken safely. This includes those burdened by the adverse effects of 
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treatment and disease. The tolerability of the exercise intervention, despite this, shows 
how exercise could benefit these men if offered in the care pathway. 
4.3 Attitudes and experience of exercise 
Personal motivation was the most commonly described barrier to exercise. Although 
behavior change techniques were not implemented as part of this study, it is 
recognised they are a key part of improving motivation for increased exercise in 
cancer patients (Bourke, Homer et al. 2013, Roberts, Fisher et al. 2017). 
In addition, lack of support from the clinical care team, was the second most 
commonly mentioned barrier to engaging in exercise. As previously mentioned, 
clinicians input and recommendation is an important factor in patient decision making 
in prostate cancer patients (Blanchard, Labrecque et al. 1988, Ferrante, Shaw et al. 
2011). Similar to Bourke et al 2012, none of the men had received specific guidance 
from their clinical team regards lifestyle changes such as exercise advice, although 
three of the participant's clinicians had supported the concept of exercise (Bourke, 
Sohanpal et al. 2012). A study by Koutoukidis et al (2018) showed that whilst HCP's 
do have the desire to support lifestyle advice, this is not necessarily substantiated with 
action (Koutoukidis, Lopes et al. 2018). Koutoukidis et al report that HCP's knowledge 
of healthy lifestyle guidelines, feeling that they were not the ‘right person’ to provide 
advice, and lack of time and resources are barriers to engaging cancer patients in 
discussions about exercise; these findings are similarly reflected in chapter 3 of this 
thesis (Koutoukidis, Lopes et al. 2018). However, given that for some of these men, no 
advice on physical activity was ever given, it could be that even the most modest 
discussion regarding increasing physical activity and exercise during routine 
appointments may improve exercise behavior. This could, in the least, open up 
conversation for men who may not be aware that such positive lifestyle changes can 
have a profound effect on their physical and psychological health.  
Other barriers included those relating to treatment AEs. A significant barrier relating to 
the adverse effects of body composition was poor body image. The cessation of 
activities, such as swimming, was mentioned in two separate focus groups due to 
effects such as gynecomastia and weight gain. A qualitative study exploring the impact 
of the AEs of ADT also found that men who suffered gynecomastia avoided "revealing 
situations" (Grunfeld, Halliday et al. 2012). For these reasons, when considering the 
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accessibility of exercise for men with CRPC, the type of exercise especially in a public 
or group environment must be taken into account. For some men who have had 
unfavorable changes in body composition due to ADT, they may be less likely to 
participate in exercise programme which may involve activities like swimming. Equally, 
this could indicate the benefit of exercising in groups who are at a similar stage of 
treatment, where men may not feel as self-conscious around those in a similar 
situation. This is prevalent by the fact these men spoke openly with each other about 
this barrier, even in the presence of two female researchers. This may further indicate 
that these men felt the researchers were understanding of these types of long-term 
effects associated with ADT, and therefore were comfortable to talk about it.  
Facilitators to exercise most commonly mentioned were advice from the clinical team, 
this finding has also been previously described in qualitative studies evaluating 
exercise intervention in prostate cancer patients (Bruun, Krustrup et al. 2014). The 
participants in this study felt that positive lifestyle behaviors should be an aspect of 
their "usual care" provided by their clinical care team, indicating it should be integrated 
into the care pathway. This was in part due to these men having a desire to be 
informed of how exercise might benefit them as well as guidance on how to safely 
exercise. In a previous qualitative study of an intervention facilitating prostate cancer 
patient and clinician decision making, it was recognised that patients welcomed a 
preference-sensitive and personalised support approach to treatment  decision making 
(Hacking, Scott et al. 2014). The present study highlighted further the need for tailored 
advice and guidance, which included the need for a supervised aspect to help at least 
in the initial stages of undertaking exercise which may be unfamiliar. The supervised 
and tailored aspect of the intervention was in part what motivated some of these men 
to take part in the trial, where guidance on exercise participation was provided.  This 
motivation has also been described in previous qualitative research in men with 
prostate cancer who have taken part in an exercise intervention (Adamsen, 
Rasmussen et al. 2001). Furthermore, for the men who had been randomised to the 
intervention, it was reported that the trial had provided them with the encouragement 
and knowledge required to exercise independently post trial, a finding which has also 
been the case in previous studies (Bourke, Sohanpal et al. 2012).  Therefore, the 
findings suggest that in order to sustain (improve) exercise behavior in these men, a 
holistic approach to addressing patients health and wellbeing is needed. Such an 
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approach would allow the clinician to tailor exercise and lifestyle advice relative to the 
patient's disease history and status. As mentioned in chapter 3, this approach is 
considered imperative to managing symptoms of disease, treatment related AEs and 
promoting positive health outcomes (Cockle-Hearne and Faithfull 2010). As one 
participant commented, when talking of exercise as a supportive therapy as part of 
their usual care, 
"I class it as one really. I think it’s all, me personally I think it’s all one, all connected." 
Participant 11, intervention group.  
Some negative experiences at commercial gyms were described by a few of the men, 
in particular distrust in the motivations of personal trainers. It is likely that trainers who 
are qualified and had specific expertise in exercise referral would be the most 
successful in helping to improve exercise behaviour in these men. This was further 
reflected in a later comments made by the intervention participants regarding the 
researchers who were "scientifically trained" which was seen as a specific benefit of 
COMRADE. Similarly, a previous study in men with prostate cancer found that 
combination of the training facility and the professional expertise was crucial to the 
men's faith in an exercise intervention (Adamsen, Rasmussen et al. 2001). 
Furthermore, having a good rapport with the trainers was a facilitator to exercise for 
those in the intervention group, by motivating and encouraging them to keep 
progressing their exercise capacity where they may not have been confident in their 
physical ability. 
4.4 Critique and suggested improvements for a future study 
Overall, the procedures in the trial were well received. However, there were a few 
problems experienced by some participants and some suggestions for improvement in 
a future trial.  
Randomisation to the control arm was a significant set-back for one man. In exercise 
studies, where it is not possible to double blind, there are ongoing problems where 
participants are aware they are randomized to the control, and in some studies this 
has resulted in drop-outs (Bourke, Doll et al. 2011). One possible solution to this is a 
multi-site study, where the sites are randomised to intervention or control as opposed 
to individual participants. Not only does this reduce the risk of control contamination, 
but also of disappointment and subsequent drop outs. 
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There was some difficulty when completing the questionnaires, such as determining 
portion sizes in the three day diet diary and determining how to correctly rate the 
FACT-F and FACT-P questionnaires. For the three day diet diaries, the lack of detail 
and underreporting during their analysis was a significant problem, as described in the 
previous chapter. As a result for a lot of the men on this study, accurate detail on 
dietary intake was not available.  In the future, it was agreed with the participants that 
better guidance on how to fill these out, including better instruction with the diet diaries 
was warranted for clarity. 
With the assessments, some described the assessments as being "too easy" and felt 
"they could have done more". Particularly with the three repetition max testing, the 
predominant concern was safety. Although the aim would be to push these men in 
such physical assessments, with the blinding of the researchers conducting the 
assessments, it would not have been clear who is deconditioned and in fact who may 
have been in the intervention and therefore more capable of "pushing further" safely 
when weights were getting heavier. The best recommendation would therefore be to 
ensure that the same single researcher is conducting each of the participant 
assessments, and can therefore become more accustomed to the individuals ability. In 
addition, establishing a protocol and logistical operations would help stratify by 
complexity of patient needs.  
 
Although the format of the intervention was well received, some men described 
wanting a more intense session, whilst others described difficulty during certain 
exercises. This reflects further the heterogenic of the CRPC population and the 
difficulty in modifying interventions based on the individual. Given that this study was a 
feasibility study, it is expected that there would be some men who perhaps did not 
have a perfectly adapted intervention. Furthermore, as this was the first exercise 
intervention conducted by the author and that the intensity was determined by the 
author, more experienced exercise instructors would potentially be able to determine 
the correct intensity for each participant. Experienced instructors would potentially be 
able to stratify the intervention better according to disease and physical capability. 
In addition, the lack of instructors in a single session to supervise the participants was 
mentioned as a problem as well as being supervised by different trainers on some 
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days. Whilst this study lacked the resources to have multiple trainers involved in 
delivering the intervention, in a future subsequent study if more exercise trainers were 
adopted this could not only help with achieving the right amount of intensity (or dose) 
of the exercise suited to the individual as the trainer gets used to the participants own 
ability but also to track progress and ensure adequate progression and regression 
where necessary.   
The duration of the study was sufficient for the majority of the focus group participants. 
However, for one participant he had described how a longer study (6 months) would 
be of greater benefit to achieve the physical improvements and mitigate the effects of 
absence. As these men are a very complex and heterogeneous group, there were 
problems with absence relating to ill health. Although not described in the focus 
groups, for some of the participants in the intervention group, it was very disappointing 
that they had lost time on the trial and had asked for their intervention period to be 
extended. Although there was not the resources or time to conduct a study with a 
longer intervention period, a future study, with a 6 month intervention period would 
reduce the feelings of "time lost" on the trial due to ill health but equally give men a 
greater chance of regaining fitness or strength lost due to absence. In addition, an at 
home programme which could be substituted in periods of absence could offer a 
pragmatic approach to maintaining adherence and preventing feelings of "time lost" 
Despite this, these findings are very encouraging not only that it is feasible to conduct 
an exercise intervention in men with CRPC safety, but that they are very willing to 
undertake such interventions for a longer duration of time. It can be said that given no 
such intervention has been trialed before in men with CRPC and given the limited 
resources and time available as a PhD study, it is not a surprising finding that there 
were some difficulty with addressing the right intensity for each individual. However, all 
sessions were conducted safely. Furthermore, these findings suggest that despite the 
lack of research surrounding exercise interventions for cancer patients with advanced 
disease and the exclusion of men with additional comorbidity or those with bone 
metastasis in previous prostate cancer exercise studies, these men are indeed able to 
benefit from such interventions. Despite limitations associated with advanced disease 
and adverse effects of treatment, these men were capable of exercise and had 
numerous benefits from undertaking the intervention provided in COMRADE. 
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5. Study limitations 
The study included only 15 participants who had taken part in the feasibility RCT and 
for this reason is limited in its generalizability of the findings not relating to trial 
procedures. There was a limitation for the available dates for focus group participation, 
which meant two of the control participants who were invited to take part in the 
interview could not attend and therefore their views and opinions could not be explored 
in this study. The interviews included the opinions of only white British men from the 
South Yorkshire and Humber area under STH care, as this was from the available 
cohort recruited into the feasibility RCT. The data is therefore biased to the 
perspectives of this particular group. Due to the nature of how these participants were 
recruited into the feasibility RCT, it is acknowledged that a self-selection bias may also 
exist where the opinions of the men who could not participate were not explored. As 
before, the thematic framework approach to analysing the data was used, although 
commonly used in healthcare research; this form of analysis is more deductive and 
therefore stays strongly informed by a priori reasoning (Mays and Pope 2000). It was 
not pragmatic or feasible to have the focus group participants validate the findings of 
these focus groups in the context of this PhD, however this does mean the findings are 
under the interpretation of the author and second researcher (HC) who double coded.  
Finally, these were the first focus groups and the second piece of qualitative work 
undertaken by the author. For this reason, a lack of experience must be taken into 
account. It must also be noted however that these focus groups contract in both 
richness and quality of findings compared to the HCP interviews described in chapter 
3. This is likely to be due to a difference in set up (i.e. focus groups vs 1:1 interviews), 
power dynamic (patients vs senior clinicians) and rapport of the interviewer with the 
participants (given that these men were part of the trial and knew the researchers for 
over 16 weeks). 
6. Conclusions 
Overall the feasibility study procedures were well received by the participants, 
including the assessments, duration and format of the intervention.  
Despite the potential barriers associated with advancing disease, long-term side 
effects of treatment, declining physical fitness and comorbidity, this complex and 
heterogeneous group were able to undertake the COMRADE study. The study was 
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well tolerated and despite the high number of SAEs and AEs, none of these were 
related to the exercise aspect of the intervention, although some where associated 
with whey protein. Furthermore, these men experienced exceptional physical and 
psychological benefits. 
The group exercise format in particular was very well received bringing about peer to 
peer support, camaraderie and physical and psychological health. Valuable insights 
were gained in respect of implementing future exercise intervention studies - 
participants noted that clinician support, adaptability and supervision of an exercise 
programme are key processes from a participant perspective that underpin the 
success of a lifestyle behaviour study such as COMRADE. There are significant 
physical and psychological problems experienced by men with CRPC due to both the 
presence of advanced cancer and its associated treatments. As a result there is a 
need for adequate support and guidance for exercise behaviour from the clinical team, 
and this a significant facilitator to improvement in the participation of exercise. This 
includes information specifically tailored to the unique needs of these men due to a 
currently unmet need for supportive interventions which is of meaningful benefit to 
men with CRPC. Participant reported experiences here suggest that exercise training 
for men with CRPC in a supportive, professionally supervised setting, endorsed by 
clinical team are both feasible and highly valued by patients. Integrating such 
programmes into NHS cancer care pathways for this group of patients although likely 
challenging to implement are arguably both valuable and worthwhile means to 
enhance QoL during the terminal phase of illness. 
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Chapter 6 General discussion 
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1. Summary and key findings 
1.1 Chapter 1: Introduction 
1.1.1 Castrate resistant prostate cancer: treatments and the disease 
In the UK, prostate cancer is the most common cancer in men with 47,151 new cases 
reported in 2015 (Office of National Statistics 2015). CRPC remains the terminal 
phase of the disease, where patients are typically older, have more comorbidity and 
can remain on treatments for their disease for over a decade. As a result, these men 
experience the long-term AEs of ADT, chemotherapy and the presence of their 
disease as it progresses.  
Extensive and detrimental effects of ADT including sexual dysfunction, fatigue, 
cardiotoxicity, increased FM, decreased LBM, declines in BMD and metabolic 
comorbidity results in significant morbidity in men with CRPC, effecting QoL (Bagrodia, 
DiBlasio et al. 2009, Walker, Tran et al. 2013, Bourke, Turner et al. 2018, Dawson, 
Dorff et al. 2018). In addition, the presence of advanced cancer may exacerbate some 
of these effects, such as ADT associated LBM loss and development of cachexia. 
Cachexia can necessitate suboptimal chemotherapy dosage, exacerbating treatment 
toxicity and at refractory stages ultimately results in death (Suzuki, Asakawa et al. 
2013).  
1.1.2 Androgens and prostate cancer 
The use of ADT as a treatment for prostate cancer results in significant AEs 
associated with hypogonadism impacting on the QoL in these men. There is emerging 
data demonstrating the therapeutic effects of testosterone therapy for men with 
prostate cancer without exacerbating disease progression, contradictory to the 
"androgen hypothesis" (Agarwal and Oefelein 2005, Morgentaler 2008, Morgentaler 
and Traish 2009). Studies have highlighted the administration of testosterone as a 
therapy in men with prostate cancer has failed to initiate tumour progression, and on 
the contrary showed a drop in PSA (Rhoden and Morgentaler 2003, Agarwal and 
Oefelein 2005, Balbontin, Moreno et al. 2014). This suggests that treatments which 
have the potential to promote anabolic changes may not have tumour progressive 
effects in prostate cancer patients (Morgentaler and Traish 2009, Morgentaler, 
Lipshultz et al. 2011). These findings indicate that anabolic agents may have a 
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therapeutic place in treating the AEs associated hypogonadism due to long-term ADT, 
which may be of significant benefit for men with CRPC with a long history of disease.  
1.1.3 Treating lean body mass loss 
Pharmacological agents used to address LBM loss and/or cachexia include 
testosterone, corticosteroids, SARMs, SERMs and supplements promoting anabolic 
effects such as eicosapentanoic acid and whey protein (Burckart, Beca et al. 2010, 
Dalton, Barnette et al. 2011, Madeddu, Maccio et al. 2012). Some of these agents 
have demonstrated beneficial effects in improving LBM and have proven to be safe in 
preclinical and clinical studies of prostate cancer. In addition, whey protein 
supplementation has been used to improve LBM in prostate cancer patients with or 
without resistance exercise (Hanson, Nelson et al. 2017, Dawson, Dorff et al. 2018). 
Creatine monohydrate has also shown to promote the effect of resistance exercise by 
improving body composition and improving muscle strength (Brose, Parise et al. 2003, 
Tarnopolsky, Zimmer et al. 2007). 
1.2 Chapter 2: A literature review of exercise and dietary interventions as a 
supportive therapy for cancer 
Supportive programmes which promote "self-care" are lacking in the current prostate 
cancer care pathway. For men with CRPC, there is a significant need for such 
programmes tailored to the complex needs of this group.  
As men with CRPC are faced with the effects of long-term castration, there is a 
rationale for the use of exercise and dietary interventions to improve outcomes in 
these men. Despite data demonstrating the success of diet and exercise interventions 
in prostate cancer patients in improving prostate cancer specific outcomes such as 
sexual function, fatigue and QoL, there has been no published RCT data on the effect 
of such interventions in men with CRPC (Bourke, Doll et al. 2011, Baumann, Zopf et 
al. 2012, Bourke, Smith et al. 2016).  
Although there is an ongoing study underway for men with CRPC (INTERVAL-GAP4), 
this study, like previous studies of exercise for men with prostate cancer, has 
neglected to include those men who are more complex. This includes excluding those 
who have experienced disease progression despite previous treatment whilst receiving 
therapies such as abiraterone, no previous chemotherapy and a PS of ≤1 (Newton, 
Kenfield et al. 2018). This potentially, excludes a large proportion of men with CRPC. 
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In addition, the study adopts a high intensity training approach to exercise. It is likely 
therefore that this study too risks selecting the "healthiest" or "fittest" within the 
population and neglects what could be a large proportion of men with CRPC that stand 
to gain a great deal from such lifestyle interventions. It could be however, that given 
the study adopts a high intensity exercise programme, it was deemed that not only 
would the programme appeal to those who are fitter but also could be conducted 
safely in this cohort. However, this again raises questions on the real world 
applicability of the study, where it may not be suitable, or appealing, to a large majority 
of men with CRPC. 
1.2.1 A lifestyle intervention in castrate resistant prostate cancer patients: Thesis 
Overview  
Given the evidence, a programme of resistance exercise, whey protein and creatine 
supplementation, with dietary advice presents an attractive supportive adjunct to the 
usual care of men with CRPC, where there is a significant clinical need for such 
interventions. Whilst the prospect of an anabolic drug along-side an exercise 
intervention was initially an attractive idea, an anabolic drug was not obtainable for the 
feasibility RCT (due to financial constraints and lack of time), and so whey protein and 
creatine monohydrate were considered excellent substitutes which were feasible for 
this study and still promoted anabolic effects on muscle mass.  
Given the heterogeneity of men with CRPC whom are older, experience multiple 
comorbidity and have often been on long-term ADT for a number of years (sometimes 
over a decade), these men stand to gain a great deal from a supportive therapy aimed 
at improving outcomes related to their disease and treatment. Despite these men 
being in the terminal phase of their disease, it's the responsibility of the NHS, as with 
any advanced disease, to ensure these men live well during this period. The RCT of a 
lifestyle intervention conducted as part of this PhD was undertaken to provide some 
evidence for such a supportive therapy. 
1.3 Chapter 3: UK healthcare professional opinions regarding exercise 
provision for prostate cancer patients 
The findings of this chapter demonstrated variability within trusts offering 
chemohormonal therapy. In addition and irrespective of the 2014 NICE guidelines 
(section 1.4.19 in CG175), it was clear there were significant inconsistencies in the 
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NHS in how men initiating or undergoing ADT are offered supervised resistance and 
aerobic exercise if at all.  
The survey demonstrated inconsistencies in delivering exercise recommendations 
amongst all 79 trusts identified. There was also variation in the delivery of exercise 
recommendations across the 47 sites determined as having an exercise programme or 
exercise referral scheme which had potential to meet the NICE guidelines. The 
findings from this study suggested that there is a need to standardise exercise 
programmes which can be fully integrated into the cancer care pathway for all men 
initiating or undergoing ADT regardless of the stage of disease.  
The views and opinions of HCPs highlighted a lack of current supportive therapies for 
men with CRPC where such programmes could improve fitness and mitigate some of 
the long-term effects of their cancer/cancer therapy. The interviews demonstrated the 
need for an individualised and adaptable lifestyle intervention which employs a self-
care approach to empower these men to be an active part of their own health 
management. In addition, muscle wastage is of significant clinical impact, affecting 
fitness for treatment and in some cases compromises current therapy. The HCPs were 
receptive to the idea of anabolic agents being consumed whilst completing a 
programme of exercise to reduce LBM loss in the context of a clinical trial. 
Furthermore, fitness for treatment in advanced prostate cancer remains a significant 
barrier for access to available therapies in those with a poor PS. Given the effects of 
long-term therapy and competing comorbidity in CRPC patients effecting PS, 
considerations into the timing of an exercise intervention must be made. This includes 
considerations into the safety of an intervention during chemotherapy due to the risk of 
neutropenia. Although generally it was felt that exercise throughout the prostate 
cancer care pathway would benefit patients.  
Despite the lack of available exercise programmes for prostate cancer patients in the 
UK, the HCP survey and interviews suggest there is support for such intervention 
amongst the clinical community. However, considerations into the timing of such 
interventions must be made, such as the stage of disease and treatment. Although the 
HCP interviews revealed the need and the support for, a cost effective, individualised 
and adaptable exercise programme for men with CRPC, one HCP did express some 
concern over the "unfair allocation of resources" to cancer and another considered it 
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more of a luxury. Overall, the findings suggest that HCPs perceived advocating a self-
care approach would empower these men to be an active part of their own health 
management. In order for such a programme to be successful it was concluded that 
education of both patient and clinicians would be essential.  
1.4 Chapter 4: The feasibility study - COMRADE 
The aim of COMRADE was to investigate the feasibility of a lifestyle intervention of 
supervised resistance exercise, dietary supplementation and dietary advice in men 
with CRPC. Recruiting this population was difficult with a recruitment rate of 13.5%.  
However, this was similar to previous exercise studies in cancer cohorts (Thomas, 
Alvarez-Reeves et al. 2013, Gilbert, Tew et al. 2016, Thomas Gwendolyn, Cartmel et 
al. 2016). Of those successfully recruited, adherence was less than that observed in 
other prostate cancer trials at 69%, with the best adherence observed in those who 
opted to attend sessions three times a week  (Bourke, Doll et al. 2011, Gilbert, Tew et 
al. 2016, Dawson, Dorff et al. 2018, GalvÃO, Taaffe et al. 2018). Adherence to 
independent exercise was 78%. Additionally, adherence to the supplements was 68% 
for whey protein and 71% for creatine. Whilst the number of AEs and SAEs was high 
in the present study, this predominantly reflects the complex nature of such an 
advanced cancer population than being related to the study itself. The dropout rate in 
the present study was also similar to that which has been observed in previous 
exercise trials (Bourke, Doll et al. 2011, Gilbert, Tew et al. 2016, GalvÃO, Taaffe et al. 
2018).  
The study demonstrated improvements in LBM indices and a reduction in FM indices 
with the intervention corresponding with a decline in body mass and favourable 
changes in BMI. Previous studies have failed to show beneficial changes in body 
composition with exercise interventions in prostate cancer patients (Segal, Reid et al. 
2003, Nilsen, Raastad et al. 2015, Sajid, Dale et al. 2016, Winters-Stone, Lyons et al. 
2016, GalvÃO, Taaffe et al. 2018). In addition, improvements in 3RM testing and 
physical wellbeing scores were demonstrated, which is similar to findings in previous 
studies (Nilsen, Raastad et al. 2015, Taaffe, Newton et al. 2017, GalvÃO, Taaffe et al. 
2018). Surprisingly, a decline in BMD was observed in the intervention group, although 
a notable effect size was only observable for hip BMD, but the reason for this decline 
was not determined.  
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The favourable changes in LBM suggest that resistance exercise with dietary guidance 
and supplementation has the potential to reduce the associated effects of LBM loss 
with ADT. Compared to healthier cohorts often recruited into complex lifestyle 
interventions of exercise, a trial of exercise, dietary supplementation and dietary 
guidance for men with CRPC was both feasible and safe. However, it is to be 
expected that there will be non-trial related SAE's and AE's due to the age and 
comorbidity profile of the participants. 
1.5 Chapter 5: Participant focus groups 
The focus groups demonstrated that the feasibility study procedures were well 
received. Improvements in the instruction and design of questionnaires, continuity of 
instructors and assessors throughout the trial, and an increased duration of exercise 
intervention programme were recommended. 
The exercise programme was well tolerated overall. However, where some men had 
felt the programme was not physically challenging enough, others struggled with some 
of the exercises. This finding was also observed by the exercise instructor and author 
(RG). Some men appeared to progress in the exercises more rapidly than others and 
also tolerate changes in intensity much better, and others progressed much slower 
and struggled with increased intensity or starting new exercises as part of a new 
phase. However, the men perceived themselves as fitter and stronger, which reflects 
and is supported by the increased LBM and muscle strength discussed in chapter 4. 
The supplements were not tolerated as well as the exercise programme in the 
intervention group, with some men completely ceasing the whey and some reducing 
their dosage as shown in chapter 4. This was also reflected in the discussion during 
the focus group intervention participants.  
Similar to previous exercise studies for men with prostate cancer, the camaraderie of 
the group exercise environment was considered very important by the participants and 
was of significant psychosocial benefit (Adamsen, Rasmussen et al. 2001, Bourke, 
Sohanpal et al. 2012, Bruun, Krustrup et al. 2014). Although the men did not explicitly 
state that the lifestyle intervention should be considered a treatment, it was felt to be a 
part of their overall care and the QoL and physical wellbeing benefits were highly 
valued. The physical changes described by these men were a contributing factor to 
their continued motivation and participation in the trial. Furthermore, the guidance from 
272 
 
trained individuals with the expertise and knowledge of their disease was another 
motivator to initial and continued participation in the trial. 
The focus groups also showed that these men experienced significant physical and 
psychological problems due to both the presence of advanced cancer and its 
associated treatments. This included fatigue, gynecomastia, lymphodema, spinal cord 
compression and bone pain as well as the associated detrimental effects to wellbeing 
and QoL. Many of these effects were also associated as barriers to the participation in 
exercise and have been previous described as barriers in other studies (Grunfeld, 
Halliday et al. 2012, Stolldorf, Dietrich et al. 2016, Kogure, Hara et al. 2017). Other 
barriers included lack motivation and lack of clinician support for exercise behaviour. 
The findings indicated there is a need for adequate support and guidance for exercise 
behaviour from the clinical team, and this is likely to be a significant facilitator in 
supporting men with CRPC to initiate and sustain exercise. Previous studies have also 
described a lack of support for exercise from a patients clinical team and the 
importance of such conversations in promoting exercise behaviours (Bourke, 
Sohanpal et al. 2012, Koutoukidis, Lopes et al. 2018). In particular, information 
specifically tailored to the unique needs of these men, taking into account the 
individuals needs and abilities to achieve the best health outcomes was 
recommended. 
Overall the men's experience of the trial was a positive one, one participant 
summarised his experience in the quote below: 
 "… I think the idea of almost whether or not it works because we don’t know 
whether or not the scans and that will show growth or whatever it might be but the fact 
that it stops you lying around doing bugger all, actually gets you out of the house and 
provides that motivation, that in itself, and it’s quality of life. Now, whether or not the 
quality of life, how long we’ve got is shortened, increased or whatever, the fact that it 
actually makes you get out of bed when you might not, I think that’s beneficial in itself." 
Participant 10, intervention group 
2. Implications for practice 
The findings from these studies have added valuable evidence to the current data 
regarding exercise and dietary interventions for men with prostate cancer. The studies 
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in this thesis demonstrate the feasibility of an exercise and dietary intervention for men 
with CRPC. The patient reported experience demonstrated that patients are willing 
and receptive to exercise behaviour support. Despite this and the NICE guidelines 
(section 1.4.19 in CG175), there remains a lack of national implementation of exercise 
programmes for men with prostate cancer. The evidence accrued in the studies 
undertaken as part of this thesis has made a contribution to identifying some of the 
barriers as to why exercise is not routinely implemented in prostate cancer care and 
how such interventions may be conducted alongside standard clinical care. This 
evidence has the potential to be translated into addressing these barriers in clinical 
practice and provide some context as to how lifestyle interventions such as 
COMRADE can be implemented alongside standard care. 
The barriers to exercise training in men with CRPC identified in this thesis can be 
summarised: 
 Pathways: Structural and organisational barriers as a result of pathway changes 
in the NHS. 
 Accessibility: The lack of available exercise programmes nationally which are 
accessible and appropriate for these men. 
 Attitudes: Both of patients and HCPs involved in the care of these men. This 
predominantly surrounds the perceived ability to undertake exercise, with 
concerns over safety from HCPs, a lack of data supporting exercise 
interventions, and also in the motivation of patients to take part. 
 Availability of exercise specialists: The need for instructors who have vital 
knowledge on the disease and how to correctly "prescribe" the correct 
exercises and intensity of exercise. 
 Adverse effects of treatments and disease: The adverse effect of treatments 
impacting men's physical and psychological (attitudinal) ability to conduct 
exercise training. Disease progression can also result in changes in treatment 
and physical ability due to adverse effects such as pain or bone metastasis. 
 Comorbidity: Increased disability as a result of other health ailments related or 
not related to their cancer, such as neurodegenerative disease. 
From the evidence in the HCP survey and interviews, it is evident that in order for 
exercise interventions to be most effective, there is a significant need to embed them 
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into usual care for men with prostate cancer. The NICE guidance talks about the use 
of exercise interventions in the context of improving symptoms of fatigue, the evidence 
presented in the present study suggest that further benefits specific to men with CRPC 
may be possible with a tailored programme of exercise with supplementation.   
The pathway changes related to the introduction of treatments and therefore changes 
in treatment sequencing can result in inconsistencies in patient care and also 
uncertainties regarding the long-term effects of these treatments. For these reasons, 
the introduction of an exercise programme should be considered as early as possible, 
but continued throughout a man's disease, to ensure the maintenance of an active 
lifestyle and therefore best possible physical and psychological health outcomes.  
Furthermore, the HCP survey findings indicated that there are limited exercise 
interventions accessible for all cancer patients not just for prostate cancer patients. 
Patients with a poor performance status related to any cancer type have been 
neglected in exercise interventions. The findings from the studies presented in this 
thesis could be translated to highlight the potential opportunities to support other 
advanced cancer patients where LBM loss and cachexia are of clinical significance, 
such as pancreatic cancer and lung cancer via exercise and dietary intervention (Tan 
and Fearon 2008, Tan, Birdsell et al. 2009, Baracos, Reiman et al. 2010). 
The findings demonstrate that supportive therapies for men with prostate cancer are 
necessary and exercise programmes present a potential therapeutic option as 
reflected by a participant in the intervention group.  
 "…but a lot of people are in the same boat and coping with it 15 years, 12 years 
or whatever…I’m not one personally for support groups in that way - but indirectly this 
is one to some degree, the fact that you’re doing the exercises and then just chatting 
to people who have been through what you’ve been through…that’s helpful." 
Participant 10, intervention group 
If a programme was introduced, it would require consideration to the current NHS 
treatment pathway, the barriers described by the HCPs in chapter 3 and the patient 
reported barriers described in chapter 5 to determine a strategy for successful 
implementation. This should include training of HCPs involved in the care for men for 
prostate cancer all the way from diagnosis to the terminal phase of the disease. This 
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training package would need to discuss concerns regarding the safety of exercise for 
the more complicated patients and stress the importance of exercise and physical 
activity as part of standard care, in achieving best outcomes for disease and 
treatment. Furthermore, where men may ask their clinician for advice on how to safely 
exercise, such training would prepare clinicians with the information and or tools they 
need to advise accordingly, with the confidence that the information they are giving 
their patients is backed up by high quality research evidence. Where it is possible, 
professionals with a background in an exercise or health specialism should deliver 
such training working with clinicians to establish appropriate exercise advice. 
It is vital that the clinical care team are advocates for exercise as part of a "self-care" 
approach to enable patients to benefit in both their treatments and disease. 
Furthermore, assessment of a patient's physical activity level could in the future be an 
integral part of a comprehensive medical history. It is the clinical teams responsibility 
to deliver the highest quality healthcare for these men, and therefore to initiate 
important conversations regarding improving and maintaining physical activity and 
exercise during routine care. Whilst it may not be feasible for oncologists or urologists 
to lead an in depth conversation regarding physical activity and exercise, given the 
time constraints described in chapter 3, where possible they should recommend 
increasing activity and refer to an appropriate available programme or to another 
trained member of the clinical team (such as a CNS) for further information.  
A clear referral pathway to exercise programmes needs to be established nationally 
within Trusts, ideally supported by all members of the patient's MDT. What is less clear 
is who should provide such a programme which these men can access, the NHS or 
local authority. This could be determined through a robust economical evaluation of 
such programmes, which warrants further research. As part of an implementable 
programme, exercise professionals such as gym instructors and personal trainers, 
would also need the necessary training to understand some of the barriers which 
these men may be faced with due to their cancer, both treatment and disease related. 
This would ensure an understanding and empathetic approach as well as ensuring the 
participants in the programme feel the professionals have the appropriate experience 
and qualifications and understand their physical challenges and needs. This would 
include an understanding of the barriers faced regarding poor body image, debilitating 
fatigue and bone metastasis for example. Where instructors or trainers are adequately 
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trained this is likely to instil confidence in the participants. Exercise instructors who are 
trained in at least the level 3 exercise referral diploma would be recommended to 
undertake the programme sessions. 
Prior to this study, there has been no published RCT data which has demonstrated the 
benefit of exercise training / physical activity in these men. Not only do the findings 
from this thesis demonstrate it is possible for men with CRPC to undertake exercise 
safely but also that patients report this kind of supportive therapy is needed and 
valued. The findings from the present body of work, with confirmatory evidence from 
future studies, could provide the impetus for clinicians to discuss exercise as a self-
care approach with their more advanced patients and encourage patients to be 
receptive to support in improving or maintaining levels of activity. Considerations 
should be made when designing an exercise programme for these men, such as 
ensuring flexibility in the programme around current therapies, competing 
comorbidities and symptoms of disease. By tailoring exercise specific to the needs of 
men with CRPC, it may be possible to potentially manage LBM loss and slow the 
trajectory toward poor PS. Where men are able to tolerate treatments better due to 
superior PS and therefore fitness, we can aim to potentially improve OS.  
The choice of the design of the resistance exercise aspect of the intervention was not 
only to utilise multiple muscle groups ensuring a full body approach was adopted but 
also to allow for regressions and progressions dependant on the individual. As was 
evident in the focus groups, some men were better at certain exercises than others 
and therefore responded better to certain exercises. As men with CRPC are a very 
heterogeneous group, there will be some physical variability of these men at baseline. 
An adapted approach to exercise training would enable men to adhere to the 
exercises and confer physical improvements (in weights and repetitions).  For this 
reason, when developing future exercise programmes for men with CRPC (or other 
advanced cancer patients) it will be important to ensure the exercises chosen are 
adapted to suit the needs of the individual. As these men have complex needs due to 
their long history of disease, the approach should be different to that of earlier stage 
disease. It is therefore vital that those conducting the exercise programmes are 
adequately trained. Ensuring this will not only instil confidence in the clinical team 
when referring to the programme, but also in the individuals taking part. Such trained 
individuals would be able to sufficiently adapt exercise sessions, have an 
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understanding of the disease and treatment related barriers and facilitate exercise 
sessions safely. 
3. Future research recommendations 
3.1 Evidence for successful implementation of exercise in the prostate cancer 
care pathway 
Despite an aim of COMRADE being to inform a larger scale trial, considering the 
findings of this thesis in its entirety, the immediate logical next steps for research may 
not be scaling up COMRADE to a larger RCT. Although the findings of these studies 
have given an insight into the value of lifestyle interventions for men with CRPC, there 
remain a number of broader questions to be answered. These specifically surround 
the successful implementation of future exercise programmes. 
There have been a number of studies which have evaluated exercise interventions in 
cancer patients, however as demonstrated in the findings, a lack of implementation 
evidence has led to failures in research translating to clinical practice. Without such 
data there are potential risks involved in implementing future programmes. These can 
include equity harms, where exercise programmes may benefit those who need it least 
such as those who already partake in exercise or had the intention to do so (Bonell, 
Jamal et al. 2014). This also encompasses inequities in the intervention benefits, 
where although all men may benefit, some benefit much more than others, which 
could arguably be the case in COMRADE where some men progressed much better 
than others (Bonell, Jamal et al. 2014). Finally, opportunity harms where ineffective 
interventions may take the place of those which are more effective (Bonell, Jamal et al. 
2014). Therefore, it is important to better understand the mechanisms of 
implementation but also of pathways of potential harm to optimise future interventions. 
Future research should evaluate the differential effects of using different professional 
roles in exercise programme implementation. As highlighted in the HCP interviews, 
there is uncertainty as to who should deliver exercise advice and/or the programme 
itself. Although it was concluded that each member of the clinical team should play a 
part, to what degree is less clear. Furthermore, it is unclear if the intervention itself 
should be a community or NHS commissioned programme, where there lacks 
comparative data of the two. We do not know the differential effects of using different 
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professional groups in different settings, and this question will surely need to be 
answered for national implementation to be feasible.  
In absence of such information, cost comparisons cannot be made and whether such 
interventions are even deemed viable at all in light of the financial restrictions in the 
NHS and local authorities.  This also poses the question as to how cost effective a 
tailored prostate cancer specific programme compares to a programme that may 
include multiple cancer types. It may be that given the economical restrictions, a 
tailored programme is not justifiable and, as put by one of the clinicians in the HCP 
interviews, considered "more of a luxury". Regardless of what the most cost effective 
approach to implementing a programme is, these programmes need to be accessible 
enough to enable the NHS to signpost men appropriately.  
The findings from the HCP interviews suggest that men are offered exercise 
programmes throughout their patient journey. Considerations should be made as to 
how these programmes may be positioned in the context of other guidelines/ 
programmes and initiatives, such as activity in older adults or other cancer types. If a 
prostate cancer specific programme is to be run separately, what is the justification for 
doing so and how is this more effective?  
A significant limitation of these studies was the small sample sizes which limited the 
scope of the findings to select populations. Future considerations should be taken into 
how we may approach interventions to populations of different race, ethnicity, 
socioeconomic status, sexual orientation, religion/belief or other characteristics. Such 
considerations are fundamental to health equality, a key component of NICE 
recommendations and guidelines, and therefore for successful national 
implementation. Future research should consider how the characteristics of different 
populations can alter the effectiveness of a prescribed intervention.  
Finally, the findings in this body of work have raised some questions on what benefits 
we should aim to achieve with such interventions for men with CRPC. There is some 
suggestion from the focus groups that the most valued outcome of the intervention 
were the psychological benefits, with men describing benefits in mental wellbeing. 
Future studies should address the outcomes that are most meaningful to these men; 
the physical, the psychological, or both and to what degree? Pre-study focus groups 
with CRPC patients would have been valuable in addressing this, but was not viable in 
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the time constraints of this body of work. Perhaps if these men consider wellbeing as a 
factor they would most like to improve, then the design of an intervention may look 
different to that of COMRADE. The intervention may focus less on a regimented 
exercise training programme and encompass a more casual group based aspect, 
where men can choose the type of activity for example with a focus on more social 
factors such as team orientated activity; particularly as the group format of the 
intervention was valued highly by the men in COMRADE. A less regimented and 
flexible approach may also encourage men who feel they are less physically capable 
or struggle with motivation or accessibility to still participate. As mentioned previously, 
the key component must be that the exercise is tailored to the individual, but this 
should also encompass individual goals. Future research should question what these 
men would like to achieve, what is clinically meaningful to them, and how do we 
achieve this with an intervention. Throughout the disease trajectory of prostate cancer, 
from diagnosis to death, the outcomes these men consider most important will likely 
change. For men with CRPC, improvements and maintenance of QoL is imperative 
and future interventions should strive to reflect that.  
3.2 Future trials 
The findings of this body of work indicate that a supportive lifestyle intervention for 
men with CRPC are both needed and have the potential to be of therapeutic benefit. 
Despite the lack of implementation data as described in the previous section, further 
research into the specific impact that resistance exercise and dietary interventions in 
men with CRPC is recommended given the findings in COMRADE.  
3.2.1 Optimising the exercise dose 
The findings of this thesis suggest a fundamental need for more robust mechanistic 
evidence. Primarily, this type of research and evidence could enhance greater clinician 
"buy in". Clinicians rely on plausible physiological rationales in addition to empirical 
data. This was highlighted by medical oncologist 2 in the HCP interviews who stated a 
lack of data surrounding exercise as a therapeutic for men with prostate cancer. The 
data surrounding exercise interventions in cancer groups thus far has predominantly 
been single dose exercise interventions with a progressive increase in intensity and a 
one size fits all approach (Buffart, Galvao et al. 2014, van der Leeden, Huijsmans et 
al. 2018). Such an approach is unlikely to confer a robust effect in outcomes as cancer 
in itself is heterogenic in nature and numerous studies have shown individual 
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differences to exercise stimuli (Buffart, Galvao et al. 2014). Patients are therefore likely 
to respond to a relative intensity/ exercise stimulus differently and what works well for 
one, might not for another. This further corresponds with the HCP interviews where 
they had voiced a need for an adaptable programme, and particularly for the advanced 
cancer patients where they are contending with multiple health ailments.  
Future research considerations may like to explore quantifiable data at the molecular 
level demonstrating a dose response relationship between the optimal type and 
intensity of exercise for cancer cohorts to promote physiological changes (Friedenreich 
and Orenstein 2002, Courneya 2003, Buffart, Galvao et al. 2014). The mechanisms 
which underlie the observable improvements in health outcomes with exercise in 
cancer patients are not established. For example, there is no established mechanism 
for why exercise reduces pain or fatigue (Twomey, Martin et al. 2018). Furthermore, in 
the present trial it is not clear why this was a finding for some men and not others. 
Without a deeper understanding of the molecular and physiological changes resulting 
from exercise training in cancer patients, questions regarding the causal relationship 
will remain unanswered. As a result we are no closer to determining the optimal dose 
(intensity, duration and method) and type of exercise to confer the greatest benefit for 
individuals (Courneya 2003, Buffart, Galvao et al. 2014). A personalised approach to 
exercise prescription might confer the greatest beneficial effect and therefore the most 
robust evidence for exercise as a supportive therapy.  
3.2.2 A trial to deliver the prescribed dose 
Previous studies adopting an adapted exercise programme approach have also shown 
improvements in advanced cancer patients with complex needs (Touillaud, Foucaut et 
al. 2013, Twomey, Martin et al. 2018, van der Leeden, Huijsmans et al. 2018). 
Evidence which described the optimal exercise dose adapted to the individual would 
also be encouraging for clinicians, where the observable effects of the RCT data can 
be underpinned with basic science mechanistic data which suggests a causal 
relationship. In addition, such an approach would likely confer an even larger effect 
size on health outcomes of interest, perhaps beyond that which has been observed in 
the current literature. Questions on optimal implementation of exercise programmes 
for greater efficacy and efficiency can then be adequately addressed (Buffart, Galvao 
et al. 2014). In this case, it may be more appropriate to conduct a small (n ≤100) single 
arm trial with a more robust real-time evaluation which could therefore respond to the 
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continually evolving cancer pathways, as demonstrated by the HCP survey and 
interviews. In addition, such an approach would allow for flexibility and adaptive doses 
of exercise to be implemented at a relatively low cost compared to a large scale phase 
III study. 
Although RCTs remain the gold standard study design for pharmaceutical research, 
there is significant criticism for their use in other areas of medicine and they have been 
considered inappropriate for more complex long-term highly individualised studies  
(Bothwell, Greene et al. 2016). RCTs have their challenges, from establishing 
appropriate inclusion criteria to standardising interventions and determining the most 
relevant outcomes in addition to being both expensive and time consuming, with these 
limitations being well documented (Bothwell, Greene et al. 2016). The proposed study 
design would evaluate the effectiveness of the intervention and provide an ongoing 
timely narrative to the data. Issues arising in the study such as lack of efficacy, poor 
adherence, or study failings would be addressed and allow for programme 
improvement from formative evaluations of intermediary results (Ling 2012). In 
addition, the removal of the control arm would remove the prospect of contamination 
and the disappointment experienced by those who are subsequently not offered the 
intervention. The purpose of such a study design would be to observe the molecular 
and physiological changes observed with a prescribed adapted programme of exercise 
training. For example, the relationship between increased LBM and inflammatory 
cytokines with a prescribed exercise dose for an individual. Although this data would 
not directly demonstrate efficacy of the dose of exercise prescribed for each 
participant as the trial is not controlled and randomised, it could provide indicators to 
potential mechanisms underpinning exercise and the corresponding clinical outcomes. 
Furthermore, the flexibility in the trial would allow for changes to be made (real-time) 
for best implementation and participant adherence.  
The combination of the data regarding optimal exercise prescription underpinned by 
findings at the molecular level could therefore be used to inform the design of a further 
study, which would likely be a larger scale RCT (Friedenreich and Orenstein 2002, 
Courneya 2003, Buffart, Galvao et al. 2014). This study would address the 
implementation of an individualised exercise programme, with a prescribed dose 
underpinned by mechanistic findings, for men with prostate cancer. The findings could 
be used to educate clinicians prior to study recruitment, increasing clinician "buy in" 
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and helping them to advocate individualised exercise training for their patients. This 
subsequent study would also draw on the suggested improvements which have been 
discussed in the present body of work such as a multi-site study, increased 
intervention duration, adequate numbers of trainers and trainer/assessor continuity, 
improved instruction for filing out questionnaires, permuted block randomisation and a 
four arm trial for example. 
5. Research evaluation 
The research question for the body of work was can a lifestyle intervention of 
resistance exercise, dietary supplementation and dietary guidance improve outcomes 
in men with CRPC? This body of work has demonstrated that a lifestyle intervention of 
resistance exercise, dietary supplementation and guidance can improve outcomes of 
wellbeing, muscle strength, LBM and body fat.  
The first aim of this body of work was to describe exercise in the usual care pathway 
for men in the UK with prostate cancer who have undergone ADT; including if, how 
and in which trusts exercise is part of "usual care". The findings determined that 
nationally supervised exercise for men with advanced prostate cancer undergoing or 
initiating long-term ADT is not routinely offered in UK trusts and not a part of "usual 
care". Furthermore, there is a significant lack of available exercise programmes which 
men with prostate cancer can access. 
The second aim was to explore the perspectives of HCPs on the use of exercise 
training for the management of CRPC. The findings show that HCPs are supportive of 
exercise as a supportive adjunct to standard care to improve outcomes in these men. 
However, such a programme would need to be adequately tailored to the needs of the 
individual taking into consideration comorbidities, disease burden and current and 
previous treatments and their associated AEs.  
The final aim was to determine the feasibility and participant acceptability of a 16-week 
programme of resistance exercise training, dietary supplementation and dietary 
guidance as a novel supportive therapy in men with CRPC. There were significant 
problems with recruitment in the RCT were the study was unable to make its target 
recruitment of 50 participants; there were a high number of AEs/SAEs; and the 
adherence to supervised exercise was lower than that seen in previous exercise 
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studies. However, the advances stage of disease of these men must be taken into 
account, and with the suggested adaptations to a future trial, it is likely that some of 
these feasibility outcomes could be improved. Furthermore, the focus groups have 
established that the study procedures were very well received by the participants.  
5.1 Dissemination of findings 
The HCP survey and interview findings have been published in two peer reviewed 
journals (Bourke, Turner et al. 2018, Greasley, Turner et al. 2018). The findings of the 
COMRADE RCT and focus groups have been accepted for poster presentation at the 
2018 National Cancer Research Institute conference and will be published as a full 
manuscript in due course. 
4. Summary 
The studies contained within this thesis are a novel contribution to knowledge and 
provide data on the feasibility of a programme of exercise, dietary guidance and 
supplementation for men with CRPC. The findings of the studies indicate that whilst it 
was safe and feasible to conduct such an intervention in these men, significant 
barriers exist to the implementation of exercise programmes for men with prostate 
cancer within the NHS and there is a lack of data underpinning the associated 
physiological changes associated with exercise training in men with prostate cancer. 
Further research, should address problems associated with national implementation of 
exercise programmes. This includes creating an NHS culture whereby exercise is 
seen as a therapeutic adjunct to standard care, whereby it is endorsed by the entire 
care team. It is likely that this will need to include training HCPs and upskilling the 
NHS workforce to enable the conversation of exercise with patients but also to refer to 
appropriate programmes. In order for a referral to be made, there must be available 
programmes accessible to these men that are facilitated by trained individuals, aware 
of the unique challenges these men face related to their treatment and disease.  
To encourage clinician "buy in" for exercise as part of standard care, future research 
should also look to determine the optimal "dose" of exercise to warrant the best clinical 
outcomes in each individual. Part of this may encompass a future study with an 
adapted trial design, underpinned by the investigation of mechanistic outcomes to 
further the literature and aid in the successful implementation of exercise programmes 
in the NHS. With such evidence, we can develop a future prostate cancer care 
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pathway where exercise is a fundamental aspect of care, ensuring continuity between 
trusts and exercise programmes across the country which is accessible by all men 
affected by the disease.  
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1. Preamble 
 
This report describes the invitation, collection and analysis of data from respondents 
invited by Clinvivo, on behalf of the STAMINA investigators, to participate in a 
survey to explore issues around delivering prostate cancer care in NHS practice. 
 
2. Methods 
 
 
2.1  Sampling, recruitment and material 
 
The STAMINA Investigators provided Clinvivo with the text of the questionnaire along 
with a list of invitees and wording of the e-mail invitation (Appendix). Clinvivo sent the 
invitation email to the invitees along with personalised links to the questionnaire presented 
on the Clinvivo platform. Clinvivo also prepared and sent customised links to contacts in 
professional organisations to be circulated to their members, and one link to be shared by 
the investigators to their Twitter followers. 
 
Individual e-mail invitations were sent out to 392 invitees on 26th November 2015, and 
invitations for members of four professional organisations were sent to their contacts 
on 1st December 2015. A Twitter link was shared with the investigators on 11th 
December 2015. The first reminders to the emailed invitees were sent on 10th 
December 2015 and the final reminders on 22nd December 2015. 
 
Panellists were invited to comment on the availability and management of exercise 
therapy for men with prostate cancer on Androgen Deprivation Therapy (ADT) in the 
NHS. 
 
2.2  Statistical analysis 
 
Descriptive statistics were used to report all responses. The proportions and 
denominators of categorical variables, and the means and ranges of continuous 
responses are presented in this report. Graphical categorical proportions have been 
presented graphically, using pie charts for mutually exclusive categorical data and bar 
graphs for responses where selection of multiple outcomes was allowed. All analyses 
were conducted in Stata v13. 
 
3. Results 
 
A total of 95 practitioners agreed to participate in the survey. The individual email 
invitations contributed to 44.2% of responses, and the the emails to professional 
6 
 
organisations elicited 47.4% of responses. The remaining 8.2% of responses were 
elicited via Twitter. 
Table 1: Mode of invitation of respondents to the survey 
 
Referrer n % 
   
BAUN 13 13.68 
   
BAUS 24 25.26 
   
BUG 4 4.21 
   
E-mail 42 44.21 
   
PCUS 4 4.21 
   
Twitter 8 8.42 
   
Total 95 100 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Mode of invitation of respondents to the survey 
 
 
 
Most of the respondents were urologists (36.8%) perhaps reflecting the subject area of 
the survey. Nurses were the next largest group (21.1%), while 16.8% of respondents 
did not fall under any of the listed professions. 
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Table 2: Professional roles of respondents 
 
Profession n % 
   
Allied Health Care Professional 3 3.16 
   
Cancer Care Commissioner 3 3.16 
   
Exercise Physiologist 3 3.16 
   
General Care Commissioner 1 1.05 
   
General Practitioner (GP) 7 7.37 
   
Nurse 20 21.05 
   
Oncologist 4 4.21 
   
Physiotherapist 3 3.16 
   
Urologist 35 36.84 
   
Other 16 16.84 
   
Total 95 100 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Professional roles of respondents 
 
 
 
Respondents were reminded of the recent findings of the CHAARTED and STAMPEDE 
studies which showed a survival advantage for hormone-naive men with metastatic 
prostate cancer on chemohormonal therapy (Taxane based chemotherapy plus ADT) 
rather than ADT alone. Respondents indicated that on average 23.3% of men currently 
commencing long-term ADT were 
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also receiving Docetaxel or a similar agent at initiation of ADT, although this 
ranged from 0% to 87%. 
 
The commonest reasons given by the 39 respondents who indicated that men were not 
receiving chemohormonal therapy were that the patient was unfit for it (48.7%) and lack of 
funding (43.59%) 
 
 
Table 3: Reasons for not giving chemohormonal therapy 
 
Reason n % 
   
No funding 17 43.59 
   
Unconvincing evidence 3 7.69 
   
Updating guidelines 8 20.51 
   
Clinician resistance 5 12.82 
   
Patient resistance 5 12.82 
   
Patient unfit 19 48.72 
   
Other 10 25.64 
   
Number of responses (multiple selection allowed) 39  
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Reasons for not giving chemohormonal therapy 
 
 
Respondents were asked to indicate the proportion of men on long-term ADT receiving 
treatment in primary care in their area. A total of 64 respondents reported a mean 
percentage of 84.5%, ranging from zero to 100%.
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In most of the local prostate cancer pathways staffed by the respondents, urologists 
(93.9%), oncologists (77.2%) and clinical nurse specialists (63.6%) were involved in 
initiating ADT. General practitioners were involved to a lesser extent (19.7%) and 
practice nurses were barely involved (4.6%). However, a wider range of specialities 
were involved in delivering ADT. 
 
 
 
Table 4: Healthcare professionals involved in initiating ADT 
 
Profession n % 
   
Oncologist 51 77.21 
   
Urologist 62 93.94 
   
Clinical Nurse Specialist 42 63.64 
   
General Practitioner (GP) 13 19.70 
   
Outpatient Nurse 0 0.00 
   
Practice Nurse 3 4.55 
   
District Nurse 0 0.00 
   
Other 0 0.00 
   
Number of responses (multiple selection allowed) 66  
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Healthcare professionals involved in initiating ADT 
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Table 5: Healthcare professionals involved in delivering ADT 
 
Profession n % 
   
Oncologist 19 28.79 
   
Urologist 24 36.36 
   
Clinical Nurse Specialist 46 69.70 
   
General Practitioner (GP) 56 84.85 
   
Outpatient Nurse 10 15.15 
   
Practice Nurse 49 74.24 
   
District Nurse 24 36.36 
   
Other 1 1.52 
   
Number of responses (multiple selection allowed) 66  
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Healthcare professionals involved in delivering ADT 
 
 
 
A total of 70 out of 95 respondents (73.6%) stated that they were aware of the new 
NICE guidelines on Prostate cancer (cg175). Slightly fewer, 58 respondents (61.1%) 
said they were aware of NICE recommendation 1.4.19 which states that men who are 
starting or having androgen deprivation therapy should be offered supervised resistance 
and aerobic exercise at least twice a week for 12 weeks to reduce fatigue and improve 
quality of life. Asked to rate on a scale of 10 their ability to deliver this 
recommendation in their locality, the mean response was 4.87. 
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Figure 6: Respondents' awareness of NICE guidelines on prostate cancer 
(cg175)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Respondents' awareness of NICE recommendation 1.4.19 
 
About half of respondents were aware of current exercise referral or prescription 
schemes for patients with cancer in their locality. 
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Table 6: Respondents' awareness of current local exercise referral/prescription 
schemes for patients with cancer 
 
Aware n % 
   
Yes 47 49.47 
   
No 37 38.95 
   
Unsure 11 11.58 
   
Total 95  
   
 
Among those who were aware of the existence of an exercise programme, 80.6% 
reported that there were schemes accessible to men with prostate cancer on ADT. 
 
 
Table 7: Accessibility of the available exercise referral/prescription schemes to men 
with prostate cancer on ADT 
 
Accessible n % 
   
Yes 38 80.85 
   
No 8 17.02 
   
Unsure 1 2.13 
   
Total 47  
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Respondents' awareness of current local exercise referral/prescription 
schemes for patients with cancer 
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Most of the exercise referral schemes were available in the community (53.2%), 
local authority (34.0%) and hospital (21.3%). 
 
 
Table 8: Where the exercise referral schemes are based 
 
Location n % 
   
Not applicable – these services are not available in my area 0 0.00 
   
Unsure 6 12.77 
   
Hospital 10 21.28 
   
Community 25 53.19 
   
Both hospital and community 6 12.77 
   
Charity sector 3 6.38 
   
Local authority 16 34.04 
   
Other 3 6.38 
   
Number of responses (multiple selection allowed) 47  
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Where the exercise referral schemes are based 
 
 
 
Nurses, GPs, physiotherapists and hospital consultants were the clinical specialists most 
commonly reported to be involved in the exercise referral pathways. Non-clinical 
specialists, including gym instructors (44.7%) and personal trainers (25.5%) were also 
involved in the referral pathway. 
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However, it was the non-clinical professionals, chiefly gym instructors who were 
reported to be responsible for setting the frequency, intensity and duration of the 
exercise programme (66.0%), and for supervising the delivery of exercise and tailoring 
and monitoring individuals' programmes (68.1%). Majority of exercise programmes 
were offered in group sessions (59.6%). 
 
 
Table 9: Healthcare professionals involved in exercise referral pathway 
 
Healthcare professional n % 
   
Hospital consultant 16 34.04 
   
Nurse 28 59.57 
   
GP 20 42.55 
   
Physiotherapist 18 38.30 
   
Clinical Exercise Physiologist 8 17.02 
   
Other 6 12.77 
   
Number of responses (multiple selection allowed) 47  
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Healthcare professionals involved in exercise referral pathway 
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Table 10: Non-clinical professionals involved in exercise referral pathway 
 
Non-clinical professional n % 
   
Gym Instructor 21 44.68 
   
Personal Trainer 12 25.53 
   
Other 23 48.94 
   
Number of responses (multiple selection allowed) 47  
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Non-clinical professionals involved in exercise referral pathwa
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Table 11: Professionals responsible for setting frequency, intensity and 
duration of exercise programmes 
 
Professional n % 
   
Consultant 0 0.00 
   
Nurse 5 10.64 
   
GP 3 6.38 
   
Physiotherapist 11 23.40 
   
Clinical Exercise Physiologist 13 27.66 
   
Gym Instructor 31 65.96 
   
Other 8 17.02 
   
Number of responses (multiple selection allowed) 47  
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Professionals responsible for setting frequency, intensity and duration of 
exercise programmes 
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Table 12: Professionals responsible for supervised exercise delivery, tailoring and 
monitoring of an individual's programme 
 
Professional n % 
   
Consultant 0 0.00 
   
Nurse 1 2.13 
   
GP 1 2.13 
   
Physiotherapist 11 23.40 
   
Clinical Exercise Physiologist 12 25.53 
   
Gym Instructor 32 68.09 
   
Other 8 17.02 
   
Number of responses (multiple selection allowed) 47  
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Professionals responsible for supervised exercise delivery, tailoring and 
monitoring of an individual's programme 
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Table 13: How the exercise sessions are offered 
 
Session type n % 
   
Group 28 59.57 
   
One-to-one 14 29.79 
   
Both group and one-to-one 1 2.13 
   
Other 1 8.51 
   
Total 47 100 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: How the exercise sessions are offered 
 
 
 
Over half – 72.3% – of the 47 respondents who knew about exercise referral 
programmes were not aware or were unsure of the existence of training schemes in their 
organisations for staff on exercise interventions in cancer populations. A third of these 
respondents (32.4%) reported that instead these facilities were based in the community 
or local authority, just under 20% reported that they were available in primary care, 
secondary care, charities or private sector, while most (44.1%) reported that these 
facilities were based in other places. 
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Table 14: Respondents' awareness of training schemes in their organisations for 
staff on exercise interventions in cancer populations 
 
Aware n % 
   
Yes 13 27.66 
   
No 25 53.19 
   
Unsure 9 19.15 
   
Total 47 100 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Respondents' awareness of training schemes in their organisations for staff 
on exercise interventions in cancer populations 
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Table 15: Where training facilities (not located in respondents organisations) are based 
 
Location n % 
   
Community/local authority 11 32.35 
   
Primary care 1 2.94 
   
Secondary care 1 2.94 
   
Charitable organisation 5 14.71 
   
Private sector 0 0.00 
   
Other 15 44.12 
   
Number of responses (multiple selection allowed) 34  
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Where training facilities (not located in respondents organisations) are 
based 
 
 
 
A majority of respondents were aware of current (55.3%) or future (63.8%) local 
service evaluations around exercise programmes for men with prostate cancer. Only 
45.3% of respondents were aware of behaviour change support services available to 
their local population to promote active lifestyle; of these 79.1% of respondents 
indicated that these services were available to men with prostate cancer. 
 
 
 
 
 
21 
 
Table 16: Respondents' awareness of current local service evaluations around exercise 
programmes for men with prostate cancer 
 
Aware n % 
   
Yes 12 25.53 
   
No 26 55.32 
   
Unsure 9 19.15 
   
Total 47 100 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Respondents' awareness of current local service evaluations around 
exercise programmes for men with prostate cancer 
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Table 17: Respondents' awareness of future local service evaluations around exercise 
programmes for men with prostate cancer 
 
Aware n % 
   
Yes 6 12.77 
   
No 30 63.83 
   
Unsure 11 23.40 
   
Total 47 100 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: Respondents' awareness of future local service evaluations around exercise 
programmes for men with prostate cancer 
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Table 18: Respondents' awareness of behaviour change support services available 
to their local Awarepopulations to promote active lifestyle 
 
Aware n % 
   
Yes 43 45.26 
   
No 36 37.87 
   
Unsure 16 16.84 
   
Total 95 100 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: Respondents' awareness of behaviour change support services available to 
their local populations to promote active lifestyle 
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Table 19: Availability of behaviour change support services to men with prostate cancer 
 
Available n % 
   
Yes 34 79.07 
   
No 9 20.93 
   
Total 43 100 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: Availability of behaviour change support services to men with prostate 
cancer 
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Just over half – 50.3% – of respondents do not believe that charity services for lifestyle 
support without NHS resources would fulfil the NICE guidelines on exercise for men with 
prostate cancer. 
 
 
Table 20: Respondents' opinion on whether charity services for lifestyle support 
without NHS resources would fulfil NICE guidelines on exercise 
 
Charity services sufficient n % 
   
Yes 24 25.26 
   
No 48 50.53 
   
Unsure 23 24.21 
   
Total 95 100 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: Respondents' opinion on whether charity services for lifestyle support 
without NHS resources would fulfil NICE guidelines on exercise 
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About half of the respondents agreed to take part in a future interview. 
 
 
 
 
Table 21: Respondents' willingness to take part in interview to explore issues in detail 
 
Willing n % 
   
Yes 48 50.53 
   
No 47 49.47 
   
Total 95 100 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22: Respondents' willingness to take part in interview to explore issues in detail 
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4. Transfer of files and data 
 
All items referred to in this report may be found in a Dropbox folder using the 
following link. The files will be available for 30 days (or longer on request) 
 
https://www.dropbox.com/sh/ddox7t7jb9bxk0o/AAAFcPyRzDbZy5sNmH76Z52xa 
 
 
 
 
It has been a pleasure working with you on this project, we trust that the data, results 
and report that we have provided are useful. 
 
5. Appendix 
 
 
5.1  Text of invitation email provided to Clinvivo 
 
 
Dear [Name] [Surname], 
 
This is to let you know that you have been invited by the University of Sheffield to 
participate in STAMINA - NIHR programme development grant evaluating 
exercise therapy for men with prostate cancer on Androgen Deprivation Therapy 
(ADT) in the NHS within England. 
 
You can access the questionnaire by going to https://www.clinvivo.co.uk/stamina/auth/ 
[redacted]. 
 
The questionnaire will be available until 23rd December 2015. 
 
Kind Regards, 
 
The Clinvivo Team. 
 
 
5.2  Text of reminder email provided to Clinvivo 
 
Dear [Name] [Surname], 
 
This is to let you know that we have yet to receive your response to our NIHR survey being 
carried out by the University of Sheffield, regarding the recent NICE guidelines on prostate 
cancer (CG175) with specific reference to supervised exercise, and its implementation 
throughout England. 
 
This survey will close on 23rd December 2015. 
 
I hope you would agree this is quite an important piece of work, and we would 
really appreciate your professional input on this. Thank you! 
 
Please click the following link to be taken directly to the survey: 
https://www.clinvivo.co.uk/stamina/auth/ [redacted]. 
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Kind regards, 
 
Rebecca Turner, Liam Bourke and Derek Rosario 
On behalf of The STAMINA Study Team at the University of Sheffiel 
 
5.3  Text of invitation emails to professional organisations provided to 
Clinvivo 
 
[Name of Professional Organisation] 
[Name of Contact Person] 
 
Dear [Name], 
 
Thank you for agreeing to distribute the questionnaire for STAMINA, NIHR 
programme development grant to members of BUG as discussed previously, it is 
greatly appreciated. It would also be very helpful if you could provide us with a figure 
of the number of people this is distributed to - the reason we ask this is so we can 
calculate a response rate. 
Please find the wording and link below ready to distribute to your BUG members. 
Thank you. 
 
___ 
 
Dear Members of [Organisation acronym], 
 
 
At the University of Sheffield we are carrying out a national survey on behalf of the 
National Institute for Health Research, NIHR (STAMINA programme development 
grant). We are looking to see how the recent NICE guidelines on prostate cancer 
(CG175), with specific reference to supervised exercise, are being implemented 
throughout England. 
 
You have been invited to participate in the survey. You can access the 
questionnaire by going to https://www.clinvivo.co.uk/stamina/ [redacted]. 
 
The questionnaire will be available until 23rd December 2015. 
 
 
Kind regards, 
 
Rebecca Turner, Liam Bourke and Derek Rosario 
On behalf of The STAMINA Study Team at the University of Sheffield  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
29 
 
5.4  Content of the survey as viewed by participants  
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Appendix 2 STAMINA ethics approval  
 
NRES Committee South West - Cornwall & Plymouth 
Level 3 Block B Whitefriars Lewins Mead 
Bristol BS1 2NT
 
 
24 August 2015 
 
Mr Derek J Rosario 
Senior Lecturer and Hon. Consultant 
Urological Surgeon University of Sheffield 
Department of Oncology School of Medicine 
Royal Hallshire Hospital, Sheffield S10 2JF 
 
Dear Mr Rosario 
Telephone: 
01173421390 
Fax:01173420445
Study title: Sustained exercise TrAining for Men wIth prostate 
caNcer on Androgen deprivation: the STAMINA 
programme 
REC reference: 15/SW/0260 
Protocol number: STH18391 
IRAS project ID: 178340 
39 
 
 
The Proportionate Review Sub-committee of the NRES Committee South West - 
Cornwall & Plymouth reviewed the above application on 24 August 2015. 
We plan to publish your research summary wording for the above study on the HRA 
website, together with your contact details. Publication will be no earlier than three 
months from the date of this favourable opinion letter. The expectation is that this 
information will be published for all studies that receive an ethical opinion but should 
you wish to provide a substitute contact point, wish to make a request to defer, or 
require further information, please contact the REC Manager Miss Georgina 
Castledine, nrescommittee.southwest-cornwall-plymouth@nhs.net. Under very limited 
circumstances (e.g. for student research which has received an unfavourable opinion), 
it may be possible to grant an exemption to the publication of the study. 
Ethical opinion 
On behalf of the Committee, the sub-committee gave a favourable ethical opinion of 
the above research on the basis described in the application form, protocol and 
supporting documentation, subject to the conditions specified below.Management 
permission or approval must be obtained from each host organisation prior to the start 
of the study at the site concerned. 
Management permission (“R&D approval”) should be sought from all NHS 
organisations involved in the study in accordance with NHS research governance 
arrangements. 
Guidance on applying for NHS permission for research is available in the Integrated 
Research Application System or at http://www.rdforum.nhs.uk. 
Where a NHS organisation’s role in the study is limited to identifying and referring 
potential participants to research sites (“participant identification centre”), guidance 
should be sought from the R&D office on the information it requires to give permission 
for this activity. 
For non-NHS sites, site management permission should be obtained in accordance 
with the procedures of the relevant host organisation. 
Sponsors are not required to notify the Committee of approvals from host 
organisations. 
Registration of Clinical Trials 
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All clinical trials (defined as the first four categories on the IRAS filter page) must be 
registered on a publically accessible database. This should be before the first 
participant is recruited but no later than 6 weeks after recruitment of the first 
participant. 
There is no requirement to separately notify the REC but you should do so at the 
earliest opportunity e.g. when submitting an amendment. We will audit the registration 
details as part of the annual progress reporting process. 
To ensure transparency in research, we strongly recommend that all research is 
registered but for non-clinical trials this is not currently mandatory. 
If a sponsor wishes to request a deferral for study registration within the required 
timeframe, they should contact hra.studyregistration@nhs.net. The expectation is that 
all clinical trials will be registered, however, in exceptional circumstances non 
registration may be permissible with prior agreement from NRES. Guidance on where 
to register is provided on the HRA website. 
It is the responsibility of the sponsor to ensure that all the conditions are 
complied with before the start of the study or its initiation at a particular site (as 
applicable). 
Ethical review of research sites 
The favourable opinion applies to all NHS sites taking part in the study, subject to 
management permission being obtained from the NHS/HSC R&D office prior to the 
start of the study (see “Conditions of the favourable opinion”). 
Approved documents 
The documents reviewed and approved were: 
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Copies of advertisement materials for research 
participants [POSTER (WS2)] 
1 29 July 2015 
Copies of advertisement materials for research 
participants [POSTER (WS3)] 
1 29 July 2015 
Covering letter on headed paper [Covering letter]  29 July 2015 
IRAS Checklist XML [Checklist_13082015]  13 August 2015 
Letter from funder [funding letter] 1 31 July 2014 
Letters of invitation to participant [Invitation letter (WS2)] 1 15 July 2015 
Letters of invitation to participant [Invitation letter (WS3)] 1 15 July 2015 
Other [Email from Sponsor]  13 August 2015 
Other [Response to validation queries]  13 August 2015 
Participant consent form [Informed consent (WS2)] 1 15 July 2015 
Participant consent form [Informed consent (WS3)] 1 27 May 2015 
Participant information sheet (PIS) [Health Professionals] 1.1 21 August 2015 
Participant information sheet (PIS) 1.2 21 August 2015 
REC Application Form [REC_Form_13082015]  13 August 2015 
Referee's report or other scientific critique report 
[Feedback report] 
1 31 July 2014 
Research protocol or project proposal [Protocol] 1 11 June 2015 
Summary CV for Chief Investigator (CI) [CI CV]  29 July 2015 
 
Membership of the Proportionate Review Sub-Committee 
The members of the Sub-Committee who took part in the review are listed on the 
attached sheet. 
There were no declarations of interest. 
Document Version Date 
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Statement of compliance 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK. 
After ethical review 
Reporting requirements 
The attached document “After ethical review – guidance for researchers” gives 
detailed guidance on reporting requirements for studies with a favourable opinion, 
including: 
 Notifying substantial amendments 
 Adding new sites and investigators 
 Notification of serious breaches of the protocol 
 Progress and safety reports 
 Notifying the end of the study 
 
The HRA website also provides guidance on these topics, which is updated in the light 
of changes in reporting requirements or procedures. 
User Feedback 
The Health Research Authority is continually striving to provide a high quality service 
to all applicants and sponsors. You are invited to give your view of the service you 
have received and the application procedure. If you wish to make your views known 
please use the feedback form available on the HRA website: 
http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/ 
HRA Training 
We are pleased to welcome researchers and R&D staff at our training days – see 
details at http://www.hra.nhs.uk/hra-training/ 
With the Committee’s best wishes for the success of this project. 
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15/SW/0260 Please quote this number on all correspondence 
Yours sincerely 
Canon Ian Ainsworth-Smith Chair 
Email: nrescommittee.southwest-cornwall-plymouth@nhs.net 
Enclosures: List of names and professions of members who took part in the review 
 
“After ethical review – guidance for researchers” [SL-AR2] 
 
Copy to: Ms Jemima Clarke, Sheffield Teaching Hospitals NHS Foundation Trust 
 
NRES Committee South West - Cornwall & Plymouth Attendance at PRS Sub-
Committee of the REC meeting on 24 August 2015 
Committee Members: 
Name Profession Present Notes 
Canon Ian Ainsworth-Smith Retired Hospital 
Chaplain 
Yes  
Dr Hilary Sanders Retired Senior 
Lecturer in Statistics 
Yes  
Miss Rosalyn Squire Research Nurse Yes  
Also in attendance: 
Name Position (or reason for attending) 
Miss Georgina Castledine REC Manager 
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South West - Cornwall & Plymouth Research Ethics Committee 
Level 3 Block B Whitefriars Lewins Mead 
Bristol BS1 2NT 
29 February 2016 
 
Mr Derek J Rosario 
Senior Lecturer and Hon. Consultant Urological Surgeon University of Sheffield 
Department of Oncology School of Medicine 
Royal Hallshire Hospital, Sheffield S10 2JF 
 
Dear Mr Rosario 
Study title: Sustained exercise TrAining for Men wIth prostate 
caNcer 
on Androgen deprivation: the STAMINA programme 
REC reference: 15/SW/0260 
Protocol number: STH18391 
Amendment number: 2 
Amendment date: 18 February 2016 
IRAS project ID: 178340 
The above amendment was reviewed by the Sub-Committee in correspondence. 
Ethical opinion 
The members of the Committee taking part in the review gave a favourable ethical 
opinion of the amendment on the basis described in the notice of amendment form 
and supporting documentation. 
The Sub-Committee reviewed the following amendment: 
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1. Added questions to semi-structured interview schedule. 
Approved documents 
The documents reviewed and approved at the meeting were: 
Document Version Date 
Interview schedules or topic guides for participants [WS2 
SSI 100216 v3] 
3 10 February 
2016 
Notice of Substantial Amendment (non-CTIMP) 2 18 February 
2016 
[AmendmentForm_ReadyForSubmission]   
 
Membership of the Committee 
The members of the Committee who took part in the review are listed on the 
attached sheet. 
R&D approval 
All investigators and research collaborators in the NHS should notify the R&D office 
for the relevant NHS care organisation of this amendment and check whether it 
affects R&D approval of the research. 
Statement of compliance 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK. 
We are pleased to welcome researchers and R & D staff at our NRES committee 
members’ training days – see details at http://www.hra.nhs.uk/hra-training/ 
Yours sincerely 
pp.  
Canon Ian Ainsworth-Smith Chair 
E-mail: nrescommittee.southwest-cornwall-plymouth@nhs.net 
Copy to: Ms Jemima Clarke, Sheffield Teaching Hospitals NHS Foundation 
Trust 
15/SW/0260: Please quote this number on all correspondence 
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South West - Cornwall & Plymouth Research Ethics Committee Attendance at 
Sub-Committee of the REC meeting via correspondence 
Committee Members: 
Name Profession Present Notes 
Canon Ian Ainsworth-Smith Retired Hospital 
Chaplain 
Yes  
Mrs Sheila Bullard Clinical Research 
Project Manager 
Yes  
 
Also in attendance: 
Name Position (or reason for attending) 
Miss Lucy Roberts REC Assistant 
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Appendix 3 HCP interview consent form 
 
  
 
 
 
PARTICIPANT CONSENT FORM:  
HEALTH PROFESSIONAL INTERVIEWS  
Version 3: 29/02/2016 
Sustained exercise TrAining for Men with prostate caNcer on Androgen 
deprivation: 
the STAMINA programme 
 
                                                                                              Please initial                                                                                             
   
1 I confirm that I have read and understood the information sheet (Version 3) for the above study, I 
have had the opportunity to consider the information, ask questions and have had these 
answered satisfactorily. 
 
2 I understand that my participation is voluntary and that I am free to withdraw at any time.  
 
 
3 
I understand that information collected during the study may be looked at by authorised 
individuals from this NHS Trust or regulatory bodies in order to confirm that the study is being 
carried out correctly. Responsible representatives of the sponsor may also have access to this 
information for the purposes of monitoring and auditing. I give permission for these individuals 
to have access to my records. 
 
4 I understand that the information I provide will be confidential and that my identity will not be 
used in any outputs from the research.  
 
5 I give permission for research personnel to retain my personal details only for the purposes of 
participation in the research study. I understand these details will not be passed on to third 
parties under any circumstances. I understand that my identifiable data will be kept securely 
by the study co-ordinating centre in hard copy only. 
 
6 I agree that my anonymised responses may be used for research purposes and publication.  
 
 
7 I agree to the interview being digitally recorded.  
 
 
8 I agree to take part in the above study. 
 
 
9 I understand if I withdraw from the study, all data taken from my participation in the study will 
be retained for analysis.  
 
 
Name of participant (PRINT) 
 
Date Signature 
Name of individual taking 
consent (PRINT) 
 
Date Signature 
2 copies to be kept; original for site file; 1 for participant 
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Appendix 4 HCP interviews participant invitation letter 
 
 
 
 
 
 
Department of Oncology & Metabolism 
The Medical School 
Beech Hill road 
Sheffield 
S10 2RX 
 
Dear [name] 
 
I am writing to inform you about a new research study to explore the potential of 
delivering exercise training for men with prostate cancer on androgen deprivation 
therapy (ADT).   
 
We would like to invite you to take part in an interview with a member of the research 
team, lasting approximately 30-40 minutes. This can happen at a time and place 
convenient to you, or over the phone. 
 
We will discuss your perspectives on roles and responsibilities in primary and 
secondary care in regards to referral and provision of supervised exercise 
programmes as part of cancer care for men on ADT.  
 
Please find enclosed a participant information sheet, which describes the study in 
detail and answers the most frequently asked questions.  
 
If you are interested in participating in this study, or wish to discuss it further please 
contact the research team using the details below. One of the study researchers will 
gladly answer any further questions you may have.  
  
 
Yours sincerely, 
 
 
Mr Derek Rosario (Consultant Urologist and study Chief Investigator)  
 
Ms Rosa Greasley via email stamina@sth.nhs.uk or R.Greasley@shu.ac.uk  
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Appendix 5 HCP interview participant information sheet 
 
PARTICIPANT INFORMATION SHEET: HEALTH PROFESSIONAL INTERVIEWS 
 
Version 3 29/02/2016 
Sustained exercise TrAining for Men with prostate caNcer on Androgen 
deprivation:  
the STAMINA programme  
 
We would like to invite you to take part in a research study.  Before you decide, you 
need to understand why the research is being done and what it will involve for you.  
Please take time to read the following information carefully.   
 
What is the purpose of the study? 
In July 2014, NICE published updated guidelines for the diagnosis and treatment of 
prostate cancer. This included a recommendation that men with prostate cancer on 
androgen deprivation therapy (ADT) should be offered 12 weeks of supervised 
resistance and aerobic exercise at least twice a week, to reduce fatigue and improve 
quality of life.  
 
The aim of this study is to understand the perspectives of different health care 
professionals in primary and secondary care regarding their role in providing supervised 
exercise programmes as part of cancer care for men on ADT. This will be done using 
semi-structured interviews. 
 
What are the possible benefits of taking part? 
We cannot promise that taking part in this study will help you personally, but the 
information you provide will be very useful to the research team in terms of evaluating if 
exercise training can be part of improving cancer care in the NHS.  
 
What are the possible disadvantages of taking part? 
We will ask you to give up your time to take part in the interview. We hope not to take 
more than 40 minutes.  
 
Why have I been invited to take part? 
You have been invited to participate because of your role as a health professional and 
your expertise in cancer, exercise or primary care.   
 
Do I have to take part? 
It is up to you to decide whether or not to take part in this research.  If you agree to be 
interviewed you will be asked to sign a consent form to show that you have read this 
information sheet and agreed to take part. You are free to withdraw from the study at 
any time, without giving a reason. Taking part in this study will not affect your legal 
rights.  
 
What will happen to me if I take part? 
If you decide to take part in the study, one of the research staff will ask you to let us 
know when we can visit you to perform the interview or tell us when you could be 
interviewed over the phone. The discussion will last around 30-40 minutes and will take 
place at a time and date convenient to you.  
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The topics to be discussed will include your current role in treating or supporting men 
with prostate cancer on ADT and your perceptions of how their quality of life can be 
positively or negatively affected, as well as your views regarding the role of exercise 
within treatment and support.  
You do not have to answer or comment on anything that you would prefer not to. You 
will be asked to agree to the discussion being audio recorded by signing the consent 
form.     
    
What if I change my mind during the study? 
You are free to withdraw from the study at any time. 
 
Will my involvement in the study be kept confidential? 
Yes. We will follow legal and ethical practice and all information about you will be 
handled in strict confidence.   
 
We will transcribe the recordings of the interviews and will be writing up a report of the 
findings but we will not use your real name anywhere in the report. When we are 
analysing the data it will only be seen by the research team and it will be stored 
securely according to the Data Protection Act.  
 
What will happen to the information from the study? 
The results of the study will be used to develop research which will test if we can 
effectively deliver exercise training for men on ADT as a brand new supportive cancer 
therapy. The overall (and anonymised) results will be written up for publication in 
scientific journals, will be fed back to patient groups, charities and also be fed back to 
national bodies such as the National Cancer Research Institute. We will be able to 
provide you with the overall results on request. You can request a copy of your interview 
transcript and let us know if you would like to amend anything you said. 
 
What action will be taken if the interviews find that the NICE guidelines are not 
being followed? 
All the results from these interviews will be anonymised and fed back to the clinical 
team providing care for men with prostate cancer in your area. No specific action will be 
taken by the research team. 
 
Who has reviewed this study? 
This study has been reviewed by the South West – Cornwall and Plymouth Research 
Ethics committee. 
 
Who is funding the study? 
This study has been funded by the National Institute for Health Research.  
 
Who has checked the ethical implications of this study?  
The South West – Cornwall and Plymouth Research Ethics committee has reviewed 
and approved this study. 
 
What if I have further questions or would like more information about the study? 
If you would like more information about the study you are invited to contact:- 
 
Dr Liam Bourke  Project Supervisor                        Tel: 0114 225 5396 
Mr Derek Rosario  Chief Investigator                 Tel: 0114 271 3223 
 
What happens if I have a complaint? 
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If you have any cause to complain about any aspect of the way in which you have been 
approached or treated during the course of this study, please contact the project 
supervisor Dr Liam Bourke 0114 2255396.  
 
THANK YOU FOR TAKING THE TIME TO CONSIDER PARTICIPATING IN THIS 
STUDY 
MR DEREK ROSARIO 
Appendix 6 HCP interview schedule 
Health Care professional semi-structured interview questions 
 
Introduction 
Thank you for your time in taking part in this interview.  We are interested in your 
perspective regarding roles, responsibilities and training needs associated with 
providing supervised exercise programmes for men with metastatic castrate 
resistant prostate cancer (mCRPC).  By supervised exercise, we mean a structured 
programme of exercise training delivered and overseen by a professional. We are 
also interested to establish the views and opinions of such interventions in 
combination with pharmacological agents with the aim to improve outcomes of a 
structured exercise programme.  
We would like to audio record the interviews but these will be completely confidential 
and all data will be anonymised in transcription and analysis.  Can you please 
confirm you have read, understood and signed the informed consent form and are 
happy to proceed? 
Questions 
STAMPEDE trial data 
 The standard of care for advanced hormone sensitive prostate cancer is long 
term-androgen deprivation therapy. How much do you agree with this 
statement? 
 Recent data from the STAMPEDE and CHAARTED trial suggest there to be a 
survival benefit in initiating chemotherapy earlier in the hormone sensitive 
advanced PCa pathway. Do you feel the recent findings of the trials will change 
the standard of care, and to what extent? 
 [PROBE] 
- How might you change your own practice? 
 
The HCPs role and current pathway for men with metastatic castrate resistant 
prostate cancer (mCRPC) 
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 What is your role within the care pathway for men whose cancer has relapsed 
(i.e. become castrate resistant)? 
[PROBE] 
- Involved in the treatment of these men: How do you typically sequence 
treatment for men with mCRPC? [Chemotherapy first? 2nd line ADT 
first? Other?] 
- Will this change based on the STAMPEDE and CHAARTED trial data? 
 
 For these men (mCRPC), what are the most common reasons that effect not 
only the initiation of 2nd line treatment but also the duration? 
 [PROBE] 
- Fitness - How might you assess these men for fitness to initiate 2nd line 
treatment and what specifically might you find that would prevent you 
in prescribing such treatment? 
- Impact on QoL - What specifically may result in a poorer QoL? 
- Clinician's advice - What specifically may influence the clinician? 
 
 In your experience what do you consider to be the most important outcome for 
men with mCRPC? 
 What supportive and/or palliative programmes for men with mCRPC do you 
know of?  
[PROBE] 
- Would you refer routinely into such programmes and if so what factors 
might prompt you to? 
- Local / National? 
- In your opinion how successful have they been? 
 
 
Muscle loss and cachexia in mCRPC 
 In your experience, what adverse effects do you consider to have the most 
impact on men with mCRPC?  
[PROBE] 
- Treatment specific? 
- Disease specific? 
 
 What impact does muscle wastage have on these men? 
[PROBE] 
- Do you consider it to be clinically important? 
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 What do you do currently to address muscle wastage in men with mCRPC? 
[PROBE] 
- Do you consider the cause of muscle wastage? (do you distinguish 
between muscle wastage associated with ADT and inactivity or cachexia 
and sarcopenia) - is there any merit to that? 
- How do you assess? 
- What treatments might you implement? 
- How successful have you found these? Adverse effects? 
- What might prompt you to initiate such treatments? 
- Are there any barriers to addressing muscle wastage? 
 
 Are there any specific therapies you might offer for a man with mCRPC with 
suspected cachexia or early onset cachexia? (different to treatment strategies 
for muscle wastage) 
 
[PROBE] 
- What therapies? 
- How successful have you found these therapies? 
 
Prostate cancer and exercise interventions 
 What do you know about the role of exercise in treating men with PCa?  
[PROBE] 
- Could you describe any guidance or recommendations you are aware 
of for these men?  
 
 What is your organisation already doing with regards to exercise for men with 
prostate cancer on ADT?  
 How beneficial do you think exercise/exercise programmes would be for your 
patients with mCRPC? 
[PROBE] 
- Would you be prepared to directly advocate and be personally involved 
in exercise programmes for men in your clinics? 
- Where do you think exercise should fit in the treatment pathway for men 
with mCRPC? (Before initiation of chemotherapy/2nd line ADT, during 
or after?) 
- Are there any additional behavioural change strategies you feel might 
complement exercise programmes? 
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 Which health care professional do you feel should be responsible for referring 
and following up exercise interventions in men with mCRPC? 
[PROMPT] Urologist/Oncologist/GP/other? 
 What are the barriers you foresee for men with mCRPC in enrolling in a 12-
week exercise programme? 
[PROBE]  
- Practical/resource (Is there currently capacity?) 
- From staff, patients, systems? 
- Patient related personal barriers? 
 
Novel pharmacological agents in combination with exercise 
 How would you feel about allowing your patients take novel pharmaceutical 
agents with anabolic effects that might improve the response to exercise? 
[PROBE] 
- Would you be concerned with androgenic effects? (Which ones and 
why?) 
- [Dependant on response] What anabolic agents do you have specific 
knowledge of to make you feel this way?  
 
 If there was an evidence based intervention that clearly improved patient 
outcomes, do you think there is a place for such a combination of therapies 
in the NHS? 
Our research team are hoping to evaluate how a 12-week supervised exercise 
programme, potentially in combination with a pharmaceutical agent to 
improve response, can be delivered in the NHS for men initiating 2nd line 
treatment for mCRPC. This will require professionals in your role to support 
this process.   
 How would you feel about referring your mCRPC men to a study which would 
investigate: 
a) An exercise intervention alone 
b) An exercise intervention in combination with a SARM (describe if not 
known) 
c) An exercise intervention in combination with an anabolic steroid 
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 Given what we have spoken about today, how would you move forward to 
improve outcomes in men with mCRPC? 
[PROBE] 
- What would be the best approach? 
- Where should research be focussed? 
 
 Is there anything else you would like to add? 
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Appendix 7 Initial codes from familiarisation for HCP interviews 
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Appendix 8 Indexing and coding of transcripts in Nvivo 
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Appendix 9 A section of the frame work matrix  
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Appendix 10 COREQ (COnsolidated criteria for REporting Qualitative 
research) Checklist 
A checklist of items that should be included in reports of qualitative research. You 
must report the page number in your manuscript where you consider each of the 
items listed in this checklist. If you have not included this information, either revise 
your manuscript accordingly before submitting or note N/A. 
 Topic  
Item 
No.   Guide Questions/Description  Reported on  
 
        Page No.  
 
 Domain 1: Research team         
 
 and reflexivity         
 
           
 Personal characteristics         
 
 Interviewer/facilitator  1   Which author/s conducted the interview or focus group?    
 
           
 Credentials  2   What were the researcher’s credentials? E.g. PhD, MD    
 
           
 
Occupation 
 
3 
  
What was their occupation at the time of the study? 
    
     -  
 
 
Gender 
 
4 
  
Was the researcher male or female? 
    
       
 
           
 Experience and training  5   What experience or training did the researcher have?    
 
           
 
Relationship with 
         
         
 
 participants         
 
 Relationship established  6   
Was a relationship established prior to study 
commencement?    
 
           
 
Participant knowledge of 
 
7 
  
What did the participants know about the researcher? 
e.g. personal 
    
        
       
 
 the interviewer     goals, reasons for doing the research     
         
           
 
Interviewer characteristics 
 
8 
  What characteristics were reported about the inter 
viewer/facilitator? 
   
 
       
 
      e.g. Bias, assumptions, reasons and interests in the 
research topic 
   
 
          
           
 Domain 2: Study design         
 
           
 Theoretical framework         
 
           
 Methodological orientation  9   
What methodological orientation was stated to underpin the 
study? e.g.    
 
 and Theory     
grounded theory, discourse analysis, ethnography, 
phenomenology,    
 
      content analysis    
 
           
 Participant selection         
 
           
 
Sampling 
 
10 
  How were participants selected? e.g. purposive, 
convenience, 
   
 
       
 
      consecutive, snowball    
 
          
 
 
Method of approach 
 
11 
  
How were participants approached? e.g. face-to-face, 
telephone, mail, 
   
 
       
 
      
email 
   
 
         
 
 Sample size  12   How many participants were in the study?    
 
 
Non-participation 
 
13 
  
How many people refused to participate or dropped out? 
Reasons? 
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 Setting         
 
 Setting of data collection  14   
Where was the data collected? e.g. home, clinic, 
workplace    
 
           
 
Presence of non- 
 
15 
  Was anyone else present besides the participants and 
researchers? 
   
 
       
 
 participants         
 
          
 
 
Description of sample 
 
16 
  What are the important characteristics of the sample? 
e.g. demographic 
   
 
       
 
      data, date     
          
           
 Data collection         
 
         
 
 Interview guide  17   
Were questions, prompts, guides provided by the authors? Was it 
pilot    
 
      tested?     
          
           
 Repeat interviews  18   Were repeat inter views carried out? If yes, how many?    
 
           
 Audio/visual recording  19   
Did the research use audio or visual recording to collect 
the data?    
 
           
 Field notes  20   
Were field notes made during and/or after the inter view or 
focus group?    
 
          
 
 Duration  21   What was the duration of the inter views or focus group?    
 
           
 Data saturation  22   Was data saturation discussed?    
 
           
 Transcripts returned  23   
Were transcripts returned to participants for comment 
and/or    
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Appendix 11 Trusts identified from the survey 
B 
Barts Health NHS Trust 
Bedford Hospital NHS Trust 
Bolton NHS foundation Trust 
Bradford Teaching Hospitals NHS Foundation Trust 
Burton Hospitals NHS Foundation Trust 
Buckinghamshire Healthcare NHS Trust 
NHS Bury and Bury Leisure 
C 
Calderdale and Huddersfield NHS Foundation Trust 
Cambridge University Hospitals NHS Foundation trust 
Chelsea and Westminster Hospital NHS Foundation Trust 
The Cheltenham NHS Trust 
The Christie NHS Foundation Trust 
City Hospitals Sunderland NHS Foundation Trust 
Cornwall Partnership Trust 
County Durham and Darlington NHS Foundation Trust 
D 
Dorset County Hospital NHS Foundation Trust 
The Dudley Group NHS Foundation Trust 
E 
East and North Herts NHS Trust 
East Kent Hospitals University NHS Foundation Trust  
F 
NHS Frimley Health Foundation Trust 
Frimley Park Hospital Trust 
G 
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Gloucestershire Hospitals NHS Foundation Trust 
Guy's and St Thomas' NHS Foundation Trust 
Gwent Healthcare NHS Trust 
H 
Hampshire Hospitals NHS Foundation Trust  
Harrogate and District NHS Foundation Trust 
Hertfordshire Partnership University NHS Foundation Trust 
Homerton University Hospital Foundation Trust 
Hull and East Yorkshire Hospitals NHS Trust 
I 
Imperial College Healthcare NHS Trust  
Ipswich Hospital NHS Trust 
Isle of Man (Nobles Hospital) 
L 
Lancashire Teaching Hospitals NHS Trust 
Leeds Teaching Hospitals NHS Trust 
M 
Maidstone and Tunbridge Wells NHS Trust 
Medway NHS Foundation Trust 
Mid Cheshire Hospitals NHS Foundation Trust. 
Mid Yorkshire Hospitals NHS Trust 
Milton Keynes University Hospital NHS Foundation Trust 
University Hospitals of Morecambe Bay NHS Foundation Trust 
N 
Newcastle upon Tyne Hospitals NHS Foundation Trust  
Norfolk and Norwich University Hospitals NHS Foundation Trust 
North Bristol NHS Trust 
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North Cumbria University Hospitals NHS Trust 
Northern Health and Social Care NHS Trust 
The North Herts NHS Trust 
Northern Lincolnshire and Goole NHS Foundation Trust 
Northwick Park and St Mark's Hospitals NHS Trust 
Nottingham University Hospitals NHS Trust  
O 
Oxford Health NHS Foundation Trust 
P 
Pennine Acute Hospitals NHS Trust 
Peterborough and Stamford Hospitals NHS Foundation Trust  
Plymouth Hospitals Acute Trust 
Portsmouth Hospitals NHS trust 
R 
Rotherham NHS foundation Trust 
The Royal Bournemouth and Christchurch Hospitals NHS Trust 
Royal Devon & Exeter NHS Foundation Trust 
The Royal Free NHS Foundation Trust 
Royal Liverpool and Broadgreen University Hospitals NHS Trust 
The Royal Marsden NHS Foundation Trust 
Royal United Hospitals Bath NHS Foundation Trust. 
The Royal Wolverhampton Hospitals NHS Trust 
S 
Salford Royal NHS Foundation Trust 
Sheffield Teaching Hospitals NHS Trust 
Shropshire community health NHS Trust 
Somerset Partnership NHS Foundation Trust 
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Surrey and Borders Partnership NHS Trust 
Surrey & Sussex NHS Trust 
South Devon Healthcare NHS Foundation Trust  
South London and  Maudsley NHS foundation Trust 
Southwark NHS Foundation Trust  
St George's Healthcare NHS Foundation Trust 
Stockport NHS Foundation Trust 
T 
NHS Tayside 
Torbay and South Devon NHS Foundation Trust  
W 
Wakefield Council and Mid Yorkshire Hospitals NHS Trust 
Wye Valley NHS Trust 
NHS West Hampshire CCG 
Y 
York Teaching Hospital NHS Foundation Trust 
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Appendix 12  Ethics approval documentation  
 
Dr Liam Bourke 
Collegiate Hall, Collegiate Crescent 
Collegiate Campus, Sheffield 
Hallam University Sheffield 
S10 2BP 
 
Email: hra.approval@nhs.net 
 
18 January 2017  
Dear Dr Bourke 
 
 
Study title: A COMbined progRamme of exercise and dietary ADvice in 
mEn with castrate resistant prostate cancer - COMRADE trial 
IRAS project ID: 215735 
Protocol number: 2 
REC reference: 16/NE/0382 
Sponsor Sheffield Teaching Hospitals NHS FT 
 
 
I am pleased to confirm that HRA Approval has been given for the above 
referenced study, on the basis described in the application form, protocol, 
supporting documentation and any clarifications noted in this letter. 
 
Participation of NHS Organisations in England 
The sponsor should now provide a copy of this letter to all participating NHS 
organisations in England. 
 
Appendix B provides important information for sponsors and participating NHS 
organisations in England for arranging and confirming capacity and capability. 
Please read Appendix B carefully, in particular the following sections: 
 Participating NHS organisations in England – this clarifies the types of 
participating organisations in the study and whether or not all organisations 
will be undertaking the same activities 
 Confirmation of capacity and capability - this confirms whether or not each 
type of participating NHS organisation in England is expected to give formal 
confirmation of capacity and capability. Where formal confirmation is not 
expected, the section also provides details on the time limit given to 
participating organisations to opt out of the study, or request additional time, 
before their participation is assumed. 
Letter of HRA Approval 
 66 
 
 Allocation of responsibilities and rights are agreed and documented (4.1 of 
HRA assessment criteria) - this provides detail on the form of agreement to 
be used in the study to confirm capacity and capability, where applicable. 
Further information on funding, HR processes, and compliance with HRA criteria and 
standards is also provided. 
 
It is critical that you involve both the research management function (e.g. R&D office) 
supporting each organisation and the local research team (where there is one) in 
setting up your study. Contact details and further information about working with the 
research management function for each organisation can be accessed from 
www.hra.nhs.uk/hra-approval. 
 
Appendices 
The HRA Approval letter contains the following appendices: 
 A – List of documents reviewed during HRA assessment 
 B – Summary of HRA assessment 
 
After HRA Approval 
The document “After Ethical Review – guidance for sponsors and investigators”, 
issued with your REC favourable opinion, gives detailed guidance on reporting 
expectations for studies, including: 
 Registration of research 
 Notifying amendments 
 Notifying the end of the study 
The HRA website also provides guidance on these topics, and is updated in the 
light of changes in reporting expectations or procedures. 
 
In addition to the guidance in the above, please note the following: 
 HRA Approval applies for the duration of your REC favourable opinion, 
unless otherwise notified in writing by the HRA. 
 Substantial amendments should be submitted directly to the Research Ethics 
Committee, as detailed in the After Ethical Review document. Non-
substantial amendments should be submitted for review by the HRA using 
the form provided on the HRA website, and emailed to 
hra.amendments@nhs.net. 
 The HRA will categorise amendments (substantial and non-substantial) and 
issue confirmation of continued HRA Approval. Further details can be found 
on the HRA website. 
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Scope 
HRA Approval provides an approval for research involving patients or staff in NHS 
organisations in England. 
 
If your study involves NHS organisations in other countries in the UK, please 
contact the relevant national coordinating functions for support and advice. 
Further information can be found at http://www.hra.nhs.uk/resources/applying-
for-reviews/nhs-hsc-rd-review/. 
 
If there are participating non-NHS organisations, local agreement should be 
obtained in accordance with the procedures of the local participating non-NHS 
organisation. 
 
User Feedback 
The Health Research Authority is continually striving to provide a high quality 
service to all applicants and sponsors. You are invited to give your view of the 
service you have received and the application 
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procedure. If you wish to make your views known please email the HRA at 
hra.approval@nhs.net. Additionally, one of our staff would be happy to call and 
discuss your experience of HRA Approval. 
 
HRA Training 
We are pleased to welcome researchers and research management staff at our 
training days – see details at http://www.hra.nhs.uk/hra-training/ 
 
Your IRAS project ID is 215735. Please quote this on all correspondence. Yours 
sincerely 
Michael Pate  
Assessor 
 
Email: hra.approval@nhs.net 
 
 
 
 
 
Copy to: Mr Luke Barron - Sheffield Teaching Hospitals NHS FT – Sponsor contact and 
lead NHS R&D contact 
NIHRN CRN Portfolio Applications Team. 
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Appendix A - List of Documents 
 
The final document set assessed and approved by HRA Approval is listed below. 
 
 
Document Version Date 
Copies of advertisement materials for research participants [Poster] 1 25 October 2016 
Covering letter on headed paper [response to rec]   
Evidence of Sponsor insurance or indemnity (non NHS Sponsors 
only) [Sheffield Hallam employer's liability and public liability] 
2016-17 29 July 2016 
GP/consultant information sheets or letters [GP Letter] 1 25 October 2016 
Interview schedules or topic guides for participants [focus group 
topic guide] 
1 14 December 2016 
IRAS Application Form [IRAS_Form_19122016]  19 December 2016 
Letter from funder [funding award]   
Letters of invitation to participant [participant invitation letter] 1 06 December 2016 
Non-validated questionnaire [Screening questionnaire] 1 25 October 2016 
Other [healthy eating and dietary guidance] 2 06 December 2016 
Other [CCTC approval letter]   
Participant consent form [Participant consent form] 3 18 January 2017 
Participant information sheet (PIS) [Participant information sheet] 3 18 January 2017 
Referee's report or other scientific critique report [Independent 
scientific review] 
  
Research protocol or project proposal [research protocol] 2 14 December 2016 
Sample diary card/patient card [3 day diet diary] 1 06 September 2016 
Sample diary card/patient card [exercise diary] 2 12 December 2016 
Summary CV for Chief Investigator (CI) [CV for CI]   
Summary CV for student [CV for student]   
Summary CV for supervisor (student research) [CV for supervisor]   
Validated questionnaire [FACIT-F]   
Validated questionnaire [FACIT-P]   
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Appendix B - Summary of HRA Assessment 
This appendix provides assurance to you, the sponsor and the NHS in England 
that the study, as reviewed for HRA Approval, is compliant with relevant standards. 
It also provides information and clarification, where appropriate, to participating 
NHS organisations in England to assist in assessing and arranging capacity and 
capability. 
For information on how the sponsor should be working with participating NHS 
organisations in England, please refer to the, participating NHS organisations, 
capacity and capability and Allocation of responsibilities and rights are agreed 
and documented (4.1 of HRA assessment criteria) sections in this appendix. 
The following person is the sponsor contact for the purpose of addressing 
participating organisation questions relating to the study: 
 
 
Name: Mr Luke 
Barron Tel: 0114 
226 5943 
Email: Luke.Barron@sth.nhs.uk 
 
HRA assessment criteria 
 
Sectio
n 
HRA Assessment Criteria Compliant with 
Standards 
Comments 
1.1 IRAS application 
completed correctly 
Yes No comments 
    
2.1 Participant 
information/consent 
documents and consent 
process 
Yes Following REC favourable 
opinion, the information sheet and 
consent form were updated via a 
non-substantial amendment to 
bring them in line with HRA 
assessment standards. 
    
3.1 Protocol assessment Yes No comments 
    
4.1 Allocation of 
responsibilities and 
rights are agreed and 
documented 
Yes This is a single site study where 
that site is also the NHS sponsor; 
therefore, no agreement is 
expected. 
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4.2 Insurance/indemnity 
arrangements 
assessed 
Yes Where applicable, independent 
contractors (e.g. General 
Practitioners) should ensure that 
the professional indemnity 
provided by their medical defence 
organisation covers the 
activities expected of them for this 
 
 
Section 
HRA Assessment 
Criteria 
Compliant 
with 
Standards 
Comm
ents 
   research study 
4.3 Financial 
arrangements 
assessed 
Yes The study is funded through an 
NIHR programme grant for the 
STAMINA study. It is expected 
that the research costs of the 
single site will be covered by this 
grant. 
    
5.1 Compliance with the 
Data Protection Act 
and data security 
issues assessed 
Yes No comments 
5.2 CTIMPS – Arrangements 
for compliance with the 
Clinical Trials 
Regulations assessed 
Not Applicable No comments 
5.3 Compliance with any 
applicable laws or 
regulations 
Yes No comments 
    
6.1 NHS Research Ethics 
Committee favourable 
opinion received for 
applicable studies 
Yes No comments 
6.2 CTIMPS – Clinical 
Trials Authorisation 
(CTA) letter received 
Not Applicable No comments 
6.3 Devices – MHRA notice of 
no objection received 
Not Applicable No comments 
6.4 Other regulatory 
approvals and 
authorisations received 
Not Applicable No comments 
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Participating NHS Organisations in England 
 
This provides detail on the types of participating NHS organisations in the study and a statement as to 
whether the activities at all organisations are the same or different. 
This is a single site study where that site is also the NHS Sponsor; therefore, one site type. 
 
If this study is subsequently extended to other NHS organisation(s) in England, an 
amendment should be submitted to the HRA, with a Statement of Activities and Schedule 
of Events for the newly participating NHS organisation(s) in England. 
 
The Chief Investigator or sponsor should share relevant study documents with participating 
NHS organisations in England in order to put arrangements in place to deliver the study. The 
documents should be sent to both the local study team, where applicable, and the office 
providing the research management function at the participating organisation. For NIHR 
CRN Portfolio studies, the Local LCRN contact should also be copied into this 
correspondence. For further guidance on working with participating NHS organisations 
please see the HRA website. 
 
If chief investigators, sponsors or principal investigators are asked to complete site level 
forms for participating NHS organisations in England which are not provided in IRAS or on 
the HRA website, the chief investigator, sponsor or principal investigator should notify the 
HRA immediately at hra.approval@nhs.net. The HRA will work with these organisations to 
achieve a consistent approach to information provision. 
 
Confirmation of Capacity and Capability 
 
This describes whether formal confirmation of capacity and capability is expected from participating 
NHS organisations in England. 
This is a single site study sponsored by the site. The R&D office will confirm to the CI when 
the study can start. 
 
 
Principal Investigator Suitability 
 
This confirms whether the sponsor position on whether a PI, LC or neither should be in place is 
correct for each 
type of participating NHS organisation in England and the minimum expectations for education, 
training and experience that PIs should meet (where applicable). 
A local Principal Investigator should be in place at the single participating site, and this 
person has been identified. 
 
GCP training is not a generic training expectation, in line with the HRA statement 
on training expectations. 
COMRADE Dietary guidance version 2 06/12/2016 STH19598 
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HR Good Practice Resource Pack Expectations 
 
This confirms the HR Good Practice Resource Pack expectations for the study and the pre-
engagement checks that should and should not be undertaken 
The direct clinical team will identify potential participants; therefore will already hold a 
contract with the NHS site. For radiographers conducting DXA scans, who do not already 
hold a contract with the participating site, an Honorary Research Contract would be 
required. Evidence of enhanced DBS, the appropriate barred list check and occupational 
health clearance would be expected. Analysis of blood samples will be conducted by staff 
employed at the participating site, therefore no LOAs or HRCs are required for these staff. 
 
Other Information to Aid Study Set-up 
 
This details any other information that may be helpful to sponsors and participating NHS organisations 
in England to aid study set-up. 
 
 The applicant has indicated that they intend to apply for inclusion on the NIHR CRN 
Portfolio. 
 HRA approval does not extend to research activities at non-NHS organisations. 
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North East - Newcastle & North Tyneside 2 Research 
Ethics Committee 
Jarrow Business Centre Rolling Mill Road 
Jarrow NE32 3DT  
Telephone: 02071048152 
 
06 January 2017 
 
Dr Liam Bourke 
Collegiate Hall, Collegiate Crescent 
Collegiate Campus, Sheffield Hallam University Shefifeld 
S10 2BP 
 
Dear Dr Bourke 
 
Study title: A COMbined progRamme of exercise and dietary ADvice in 
mEn with castrate resistant prostate cancer - COMRADE trial 
REC reference: 16/NE/0382 
Protocol number: 1 
IRAS project ID: 215735 
 
Thank you for your letter of 20th December 2016, responding to the 
Committee’s request for further information on the above research and 
submitting revised documentation. 
 
The further information has been considered on behalf of the Committee by 
the Chair. 
 
We plan to publish your research summary wording for the above study on 
the HRA website, together with your contact details. Publication will be no 
earlier than three months from the date of this opinion letter. Should you wish 
Please note: This is the 
favourable opinion of the REC 
only and does not allow 
you to start your study at NHS 
sites in England until you receive 
HRA Approval 
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to provide a substitute contact point, require further information, or wish to 
make a request to postpone publication, please contact 
hra.studyregistration@nhs.net outlining the reasons for your request. 
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical 
opinion for the above research on the basis described in the application form, 
protocol and supporting documentation as revised, subject to the conditions 
specified below. 
 
Conditions of the favourable opinion 
 
The REC favourable opinion is subject to the following conditions being met 
prior to the start of the study. 
 
Management permission must be obtained from each host organisation prior 
to the start of the study at the site concerned. 
 
Management permission should be sought from all NHS organisations involved in 
the study in accordance with NHS research governance arrangements. Each NHS 
organisation must confirm through the signing of agreements and/or other 
documents that it has given permission for the research to proceed (except where 
explicitly specified otherwise). 
Guidance on applying for NHS permission for research is available in the Integrated 
Research Application System, www.hra.nhs.uk or at http://www.rdforum.nhs.uk. 
 
Where a NHS organisation’s role in the study is limited to identifying and referring 
potential participants to research sites ("participant identification centre"), guidance 
should be sought from the R&D office on the information it requires to give 
permission for this activity. 
 
For non-NHS sites, site management permission should be obtained in accordance 
with the procedures of the relevant host organisation. 
 
Sponsors are not required to notify the Committee of management permissions from 
host organisations 
 
Registration of Clinical Trials 
 
All clinical trials (defined as the first four categories on the IRAS filter page) 
must be registered on a publically accessible database within 6 weeks of 
recruitment of the first participant (for medical device studies, within the 
timeline determined by the current registration and publication trees). 
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There is no requirement to separately notify the REC but you should do so at 
the earliest opportunity e.g. when submitting an amendment. We will audit 
the registration details as part of the annual progress reporting process. 
 
To ensure transparency in research, we strongly recommend that all 
research is registered but for non-clinical trials this is not currently 
mandatory. 
If a sponsor wishes to request a deferral for study registration within the 
required timeframe, they should contact hra.studyregistration@nhs.net. The 
expectation is that all clinical trials will be registered, however, in exceptional 
circumstances non registration may be permissible with prior agreement from 
the HRA. Guidance on where to register is provided on the HRA website. 
 
It is the responsibility of the sponsor to ensure that all the conditions are 
complied with before the start of the study or its initiation at a particular site 
(as applicable). 
 
Ethical review of research sites 
 
NHS sites 
 
The favourable opinion applies to all NHS sites taking part in the study, 
subject to management permission being obtained from the NHS/HSC R&D 
office prior to the start of the study (see "Conditions of the favourable 
opinion" below). 
 
Non-NHS sites 
 
The Committee has not yet completed any site-specific assessment (SSA) 
for the non-NHS research site(s) taking part in this study. The favourable 
opinion does not therefore apply to any non-NHS site at present. We will 
write to you again as soon as an SSA application(s) has been reviewed. In 
the meantime no study procedures should be initiated at non-NHS sites. 
 
 
 
 
 
 
 
 
 
Approved documents 
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The final list of documents reviewed and approved by the Committee is as 
follows: 
Document Version Date 
Copies of advertisement materials for research participants [Poster] 1 25 October 2016 
Covering letter on headed paper [response to rec]   
GP/consultant information sheets or letters [GP Letter] 1 25 October 2016 
Interview schedules or topic guides for participants [focus group 
topic guide] 
1 14 December 2016 
IRAS Application Form [IRAS_Form_19122016]  19 December 2016 
IRAS Application Form XML file [IRAS_Form_19122016]  19 December 2016 
IRAS Checklist XML [Checklist_19122016]  19 December 2016 
Letter from funder [funding award]   
Letters of invitation to participant [participant invitation letter] 1 06 December 2016 
Non-validated questionnaire [Screening questionnaire] 1 25 October 2016 
Other [healthy eating and dietary guidance] 2 06 December 2016 
Other [CCTC approval letter]   
Participant consent form [participant consent form] 2 14 December 2016 
Participant information sheet (PIS) [Participant Information Sheet] 2 14 December 2016 
Referee's report or other scientific critique report [Independent 
scientific review] 
  
Research protocol or project proposal [research protocol] 2 14 December 2016 
Sample diary card/patient card [3 day diet diary] 1 06 September 2016 
Sample diary card/patient card [exercise diary] 2 12 December 2016 
Summary CV for Chief Investigator (CI) [CV for CI]   
Summary CV for student [CV for student]   
Summary CV for supervisor (student research) [CV for supervisor]   
Validated questionnaire [FACIT-F]   
Validated questionnaire [FACIT-P]   
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance 
Arrangements for Research Ethics Committees and complies fully with the 
Standard Operating Procedures for Research Ethics Committees in the UK. 
 
After ethical review 
 
Reporting requirements 
 
The attached document “After ethical review – guidance for researchers” gives 
detailed guidance on reporting requirements for studies with a favourable opinion, 
including: 
 
Notifying substantial amendments 
Adding new sites and investigators 
Notification of serious breaches of the protocol 
Progress and safety reports 
 
 
78 
 
 
Notifying the end of the study 
 
The HRA website also provides guidance on these topics, which is updated 
in the light of changes in reporting requirements or procedures. 
 
 
User Feedback 
 
The Health Research Authority is continually striving to provide a high quality 
service to all applicants and sponsors. You are invited to give your view of 
the service you have received and the application procedure. If you wish to 
make your views known please use the feedback form available on the HRA 
website: 
http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/ 
 
HRA Training 
 
We are pleased to welcome researchers and R&D staff at our training days – 
see details at http://www.hra.nhs.uk/hra-training/ 
 
 
With the Committee’s best wishes for the success of this project. 
 
Yours sincerely 
 
 
pp 
 
Dr Alasdair MacSween Chair 
 
Email:nrescommittee.northeast-newcastleandnorthtyneside2@nhs.net Enclosures:
 “After ethical review – guidance for researchers” [SL-AR2] Copy to: 
 Mr Luke Barron, Sheffield Teaching Hospitals NHS FT 
  
16/NE/0382 Please quote this number on all correspondence 
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Appendix 13 Patient invitation letter and information sheet 
 
 
Collegiate Hall 
Collegiate Crescent 
Centre for Sport and Exercise Science 
Sheffield Hallam University 
National Centre for Sport and Exercise Medicine  
S10 2BP 
                                                                                            Date:  
 
(Participant address)  
Dear sir, 
 
I am writing to inform you about a new research study for men with advanced 
prostate cancer. Scientists from Sheffield are working with clinical consultants 
from the NHS in Yorkshire to understand the role of exercise training and 
dietary supplements and how it may improve muscle mass, fitness and overall 
men’s health.   
 
In this feasibility study men will be allocated at random (randomised) to one of 
two groups. There is equal chance of being in either group.   Please find 
enclosed a patient information sheet, which describes the study in detail and 
answers the most frequently asked questions.  
 
If you are interested in participating in this study, or wish to discuss it further 
please contact Rosa Greasley or Dr Bourke using the details below. One of 
the study researchers will then speak to you and will gladly answer any further 
questions you may have.  
  
Yours sincerely, 
 
Mr Derek Rosario (Consultant Urologist)  
Contact: Rosa Greasley xxx-xxxx-xxxx Dr Liam Bourke 0114 225 4654 (Chief 
investigator) 
Patient Information Sheet 
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A COMbined progRamme of exercise and dietary ADvice in mEn with 
castrate resistant prostate cancer (COMRADE trial) 
You are being invited to take part in a research study. Before you decide if you 
want to take part it is important for you to understand why the research is being 
done and what it will involve. Please take time to read the following information 
carefully. You may also wish to talk to others about the study. Ask us if there 
is anything that is not clear or if you would like more information. Take time to 
decide whether or not you wish to take part. 
What is the purpose of this study? 
The aim of this study is to see whether men with advanced prostate cancer 
might benefit from a supervised programme of exercise and dietary advice 
over sixteen weeks. We would like to assess the effects of regular exercise 
and dietary changes on physical fitness, muscle mass and quality of life. 
Why have I been invited to participate? 
Because according to our information, you satisfy the requirements for our 
study. 
Do I have to take part? 
No. It is up to you to decide whether or not to take part in this research. After 
we have described the study and go through this information sheet, which we will 
then give to you, we will then ask you to sign a consent form to show you have 
agreed to take part. If you do decide to take part, you will be free to withdraw at 
any time and do not have to provide a reason for doing so. This would not affect 
the standard of care that you receive. You will keep this information sheet. 
What will happen to me if I take part? 
If you are interested in participating, a member of the study team will speak to 
you (usually over the telephone) about what the study involves, and take a 
brief medical history from you to check that you are likely to be eligible to 
participate.  
Your involvement in the study will last for sixteen weeks. During the first week 
you will undertake two assessment visits. You will then be assigned at random 
(i.e. there is a 50:50 chance) to an exercise training and dietary advice 
(intervention) group or a usual care (control) group. If you are in the 
intervention group, you will receive supervised exercise training three times a 
week for sixteen weeks and provided with healthy diet and nutrition advice. 
We will also ask you to take part in some exercise in your own time and give 
you supplements to take home. The supplements we ask you to taker home 
are whey protein and creatine, both which have been demonstrated to have 
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beneficial effects on muscle mass. You will be required to take these 
supplements daily, the quantity of which will depend on your current weight.  If 
you are in the control group, you will receive no supervised or structured 
exercise training, dietary advice or supplements. Men allocated to this group 
will receive usual best care from their treating doctor and also we will give you 
the Macmillan physical activity pack ("Move more"). At the end of the trial, 
some men will be asked to do a short group interview about their experiences 
of the exercise and diet programme. This will only happen once. You can still 
be part of the main study even if you do not want to consent to taking part in 
these group interviews. 
If you have consented to taking part in the interviews, we will contact you by 
phone to invite you to Sheffield Hallam University were the interviews will take 
place. The interviews will be recorded using a digital Dictaphone and later 
written out as a word processor document (we called this process 
‘transcribing’) which will be anonymised and you will not be individually 
identified. You can ask for a copy of the transcribed document which you can 
check and you can inform us of any edits that you feel should be made to your 
comments. Direct quotes from the interviews, which may be used in 
publication, will not be identifiable outside of those which were present in the 
group interview, even whilst you may recognise your own words. Equally, we 
ask all participants in the group interview to keep all that is said confidential to 
protect all who participated in the discussion.  
If I am assigned to the exercise group, where will my exercise sessions 
take place? 
Supervised exercise will take place at the Centre for Sport and Exercise 
Science at Sheffield Hallam University.  
What will the study assessment visits involve?  
Men in Yorkshire will visit a physiology testing laboratory at Sheffield Hallam 
University (assessment day 1) and the Clinical Research Facility (CRF) at 
Northern General Hospital (assessment day 2).  
Before you attend any assessment visits you will be sent details of these visits 
via post as well as a three day diet diary via post to log your food and drink 
intake over the course of three days which we will then ask you to return in 
day 1 of your first assessment visit.  
In day 1 of your assessment visit you will be invited to the physiology testing 
laboratory at Sheffield Hallam University where you will be met by one of the 
clinical team to undertake assessments of your muscle function and some 
blood tests. This will require a blood draw with a needle. This assessment will 
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be required three times during the course of the trial: at the beginning of the 
trial, 8 weeks into the trial and at the end of the trial (post 16 weeks). 
Day 1 assessment visit (Sheffield Hallam University): 
 When you arrive a member of staff will go through the study procedures 
with you and will answer any questions you may have. If you are still 
happy to participate you will be asked to sign a consent form and hand 
over your three day diet diary. 
 After you have signed the consent form you will have a blood sample 
taken. 
 A member of staff will then take you through some questionnaires 
regarding your health and wellbeing and you may be asked questions 
regarding any other medical conditions you may have and medications 
you are taking. 
 We will ask you to fill in some questionnaires about your exercise and 
diet habits as well as your overall quality of life.  
 
 You will be asked to perform three muscle strength tests to assess 
upper and lower body muscle strength overseen by an exercise 
specialist. These include knee extension, leg press and shoulder press. 
You will be familiarized with these exercises and shown the proper 
technique by the exercise specialist. 
 
 You will then be asked to perform a hand-grip test which is a digital 
pressure device which measures the strength in your hand. 
 
 You will be asked to perform a chair sit to stand test in which we will 
count the number of times you can rise as fast as possible to a full 
standing position and then return to a full sitting position in 30 seconds. 
 
 The final test is a six minute walk test in which a member of staff will 
ask you to walk between two marked points ten meters apart at a 
comfortable pace and in a straight line for six minutes. 
 
Day 2 of your assessment visit will be held at the Clinical Research Facility 
(CRF) at Northern General Hospital for a scan, details of which will be sent to 
you via post. You will be required to undergo this assessment twice during the 
course of the trial: at the beginning of the trial and at the end of the trial (post 
16 weeks). On the morning of the assessment visit you can eat and drink as 
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normal and should take any medications as usual. The study visit will take 
place on a weekday and is anticipated to take no longer than 90 minutes   
Day 2 assessment visit (Northern general hospital): 
 Your height and weight will be measured and you will then be asked to 
have what is called a DEXA (Dual energy x-ray absorptiometry) scan 
which will assess your bone density and body composition giving us 
information on your bone and muscle health. A DEXA scan takes a few 
minutes. During the DXA scan you will lie on a table. The scan is 
completely painless and there are no tunnels involved. 
What checks take place before I exercise?  
All men will be checked for medical suitability to exercise by the research team 
before they undergo any assessments or partake in any exercise which will 
include a health screening questionnaire. Following this, a letter will be sent to 
your GP informing them of your participation in this study, where they will have 
the opputunity to contact the team regarding any questions or concerns. This 
information will be treated in the strictest confidence. 
What are the benefits of taking part in this study? 
Previous studies have shown that exercise training improves fitness, strength, 
cardiovascular health, quality of life, whilst reducing anxiety, fatigue and helps 
weight loss. There is some evidence that it can also help slow the progress of 
cancer. Men randomized to the intervention will undergo an individually 
tailored exercise programme at no cost for 16 weeks. Studies have also shown 
that diets low in carbohydrate and high in protein and fibre may confer a benefit 
for cancer patients. Men taking part in the experimental intervention will also 
receive dietary advice and guidance. Men will also receive some supplements 
including whey protein and creatine. Creatine is commonly found in the diet in 
foods like fish and meat. The whey protein is derived from milk; therefore it is 
important to notify us if you cannot take whey protein due to dietary 
restrictions. 
Men who are randomised to the control arm of this study will also receive a 
free bespoke cancer survivorship guide, the Macmillan "Move More" guide.  
By taking part in the study all participants will also receive the benefits of bone 
and muscle health screening which you would not otherwise receive (DXA 
scan). Two scans of your bones and muscle will be taken during the study, 
one at the beginning of the trial and one at the end of the trial after 16 weeks, 
and reviewed by a clinician. You will also receive benefits from blood tests 
where we look at specific proteins that will provide us with information on the 
condition of your muscle and well as tests measuring the strength and function 
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of your muscles. If there is a problem with your bone or muscle health, we will 
refer you to appropriate specialists if further tests or treatment are needed.  
Currently, there is no evidence which exists that demonstrates either the risks 
or benefits of this intervention in men like you. But, if this study does 
demonstrate a benefit for men like you, we hope that the information from this 
study will help us to plan future studies and help improve the care of prostate 
cancer patients.  
What are the possible disadvantages of taking part in this study? 
The procedures that we are using in this research are all well-established 
techniques which have been used in other patient groups in numerous 
research studies without any significant side effects being reported. The major 
drawbacks are that you will have to give up you your free time to attend 
assessments and possibly exercise classes. 
The risks involved in having a DXA scan are very low as the radiation exposure 
of these scans is minimal, less than that of normal background radiation you 
are exposed to over the course of a year. There are also small risks from 
having blood samples taken. For most people, taking a blood sample using a 
small needle to puncture the skin does not cause serious problems but you 
may develop a bruise or experience a small amount of bleeding or pain at the 
needle site. Some people may also feel faint. In very rare cases infection may 
occur. 
The diet supplements we ask you to take are very safe and most side effects 
which are associated with these supplements occur when taken in excessive 
amounts. However, you may experience some symptoms such as mild GI 
discomfort (such as abdominal cramps) at the doses which you will be 
provided with.  
What if there is a problem? 
Any complaint about any aspect of the way in which you have been approached 
or treated during the course of this study will be addressed. If you have a concern 
about any aspect of this study, you should ask to speak with the researchers who 
will do their best to answer your questions. You can also contact the study chief 
investigator Dr Liam Bourke. The normal National Health Service complaints 
mechanisms are available to you which are not compromised because you have 
taken part in a research study. Alternately you can use Patient Advisory Liaison 
Service if you have any concerns regarding the care you have received, or as an 
initial point of contact if you have a compliant, via telephone on 0114 271 2400 or 
via email on PST@sth.nhs.uk. 
Will my taking part in this study be kept confidential? 
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Yes. All information you provide will be anonymised and kept confidential. Nothing 
which could reveal your identity will be disclosed outside of the research study 
site. Once you have consented to take part in the research study all of your data 
will be anonymised using a study code including any blood samples which you 
give. 
Involvement of your General/Family doctor (GP) 
With your consent, your GP will be informed that you have taken part in this 
research study and be given the results of your bone scans. Your oncologist 
or urologist will also be informed.  We may also contact your GP if we need to 
clarify anything in relation to your medical information. 
What will happen to the results of this research? 
The results of this research may be presented at scientific meetings in the UK and 
overseas. Results will be written up for publication in scientific journals, will be fed 
back to patient groups, charities and also be fed back to national bodies. It will not 
be possible to identify you or your measurements from any of the information that 
will be presented. We will feed back the results to all participants of the study. 
Who is funding the study? 
This study has been funded internally by Sheffield Hallam University  
Who has reviewed and approved the study? 
The study will not take place without independent scientific review , ethical, 
research governance and Health research authority approval.  
Contact details 
If you would like more information about the study you are invited to contact: 
Rosa Greasley         Tel: *Insert telephone number* 
Dr Liam Bourke Tel: 0114 225 5396 
Mr Derek Rosario Tel: 0114 271 3223 
Thank you for reading this information sheet and considering taking part 
in the study. 
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Appendix 14 Recruitment poster 
Are you interested in taking part in a study which 
may help improve your fitness and wellbeing and 
may help treatment for advanced prostate cancer 
in the future? 
 
If you are you may be interested in joining our study. 
A COMbined progRamme of exercise and dietary 
ADvice in mEn with castrate resistant prostate cancer 
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Appendix 15 Health screening questionnaire  
  
COMRADE trial: 
Health Screening Questionnaire 
Version 1 25.10.2016 IRAS ID 215735  
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Personal details 
Name:   
Occupation:    
Date of Birth:     Age:  Ethnicity: 
 
Medical History 
a. Please answer the following 
Past History  Family History  Present Symptoms 
              
Have you ever had ? Y  N  Have any immediate 
family had? 
Y  N  Have you recently 
had? 
Y  N 
              
High blood pressure     Heart attacks     Chest pain/discomfort    
              
Any heart trouble     High blood pressure     Shortness of breath    
              
Arterial disease     High Cholesterol     Heart palpitations    
              
Lung disease     Stroke     Dizzy spells    
              
Asthma     Diabetes     Frequent headaches    
              
Diabetes     Early death     Frequent colds    
              
Epilepsy     Other family illness     Back pain    
              
Arthritis          Orthopaedic problems    
 
Renal disease 
 
 
 
 
            
 
b. If you answered yes to any of the above, please give brief details: 
 
 
 
 
c. Are you registered disabled? (Please circle) Yes / No 
d. Other than your prostate cancer, please give details on any medical 
conditions you have: 
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e. Do you currently have any form of muscle or joint injury? (Please circle) 
Yes/ No 
If yes please give brief details: 
 
 
f. Please give details on all current medications below: 
Medication  Dose and frequency Date started Date stopped 
(if applicable) 
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g. Is there any other issue you are aware of that might prevent you from 
completing the 16 week trial? (Please circle) Yes/ No 
If yes, please give details: 
 
 
 
 
Lifestyle 
Smoking 
a. Do you currently Smoke? (Please circle) Yes/ No  
If yes, how much per day  
 
b. Are you a previous smoker? (Please circle) Yes/ No  
If yes, how long is it since you stopped and how much did you smoke?  
 
 
Drinking 
a.i. Do you drink alcohol? (Please circle) Yes/ No 
If yes, how often?  (Please circle)   
Daily  Weekly Monthly Less than  A few           
Never     once a month times a year 
a.ii. How many units?  
(Examples: A small glass of wine = 1.5 units; a large glass of wine = 3 units; 
a pint of lager/beer/cider ABV 3.2% = 2 units or ABV 5.2% = 3 units; can of 
lager/beer/cider = 2 units; single shot of spirits ABV 40% = 1 unit) 
1-3  4-8  8-12  More than 12 
b. In the last week, how many consecutive days have you drank alcohol? 
(Example: If you drank Friday and Saturday, this counts as 2 consecutive 
days) 
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0 2 3 4  5 6 7 
 
Physical Activity 
a. How would you describe your current level of fitness? (Please circle) 
Very unfit  Unfit  Moderately fit Fit  Very fit 
 
Examples:  
Very unfit: Get in and out of an armchair unaided 
Unfit: Leave the house on your own to carry out daily activities 
Moderately fit: Climb three flights of stairs unaided without stopping. Walk 
100 yards without stopping. 
Fit: Walk for 1 mile without stopping. Jog for 100 yards without stopping. 
Very Fit: Jog a mile without stopping. 
 
b. How would you describe your occupational activity level? (Please circle)
    
Sedentary  Light  Moderate  Heavy 
 
c.i Do you currently engage in any physical activity? (Please circle) Yes/ No
  
If yes, what type?  
 
c.ii Are you currently doing more than 90 minutes of moderate intensity 
exercise per week regularly? Moderate intensity requires a consistent high 
heart rate, a consistent high breathing rate and for you to work up a sweat. 
(Please circle) Yes / No 
c.iii On average:  
How often do engage in physical activity? Times / week:   
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For how long do you engage in physical activity? Time/session: 
 
 
Is there any other issue you are aware of which might prevent you from 
completing the trial assessments over 16 weeks? If yes please give details 
below. 
 
 
 
 
 
Name of person completing form: 
 
Signature of person completing form: 
 
Date: 
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Appendix 16 COMRADE Consent form  
 
  
 
PARTICIPANT CONSENT 
FORM:  
  Version 3: 18/01/2017 
A COMbined progRamme of exercise and dietary ADvice in mEn with 
castrate resistant prostate cancer (COMRADE trial)                                                                                          
Please initial                                                                                                                       
   
1 I confirm that I have read and understood the information sheet (Version 3.0) for the 
above study, I have had the opportunity to consider the information, ask questions 
and have had these answered satisfactorily. 
 
2 I understand that my participation is voluntary and that I am free to withdraw at any 
time without my medical rights or legal rights being affected.  
 
 
3 
I understand that my medical records and information collected during the study 
may be looked at by authorised individuals from this NHS Trust or regulatory bodies 
in order to confirm that the study is being carried out correctly. Responsible 
representatives of the sponsor may also have access to this information for the 
purposes of monitoring and auditing. I give permission for these individuals to have 
access to my records. 
 
4 I understand that I will be required to give blood samples which will be tested in the 
local hospital central laboratories and undergo a dual energy x-ray absorptiometry 
(DEXA) scan at Northern General Hospital. 
 
5 I give permission for research personnel to retain my personal details only for the 
purposes of participation in the research study. I understand these details will not 
be passed on to third parties under any circumstances. I understand that my 
identifiable data will be kept securely by the study co-ordinating centre (Sheffield 
Hallam University). I understand my contact details will be retained for up to 6 
months after the end of the study.  
 
6 I agree that my anonymised responses from health questionnaires may be used for 
research purposes and publication.  
 
 
7 I agree to my G.P. being informed of my participation in the study. 
 
 
8 I agree that if I take part in a recorded post-intervention focus group, my 
anonymised responses may be used for research purposes and publication. 
 
 
9 I understand if I withdraw from the study, all data taken from my participation in the 
study will be retained for analysis.  
 
1
0 
I agree to take part in the COMRADE trial 
 
 
 
Name of participant (PRINT) Date Signature 
Name of individual taking 
consent (PRINT) 
Date Signature 
Three copies to be kept; original for site file; 1 for participant, 1 to go in 
medical notes 
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Appendix 17 COMRADE GP letters  
 
 
A COMbined progRamme of exercise and dietary ADvice in mEn with 
castrate resistant prostate cancer - COMRADE trial 
 
 
[GP NAME] 
 
[GP ADDRESS] 
 
 
[DATE] 
 
 
Dear Dr [NAME] 
 
Re: [NAME, D.O.B, ADDRESS] 
 
 
Your patient (named above) recently attended the Clinical Research Facility, Northern 
General Hospital, Sheffield as a participant in a clinical research study entitled: 
 
‘A COMbined progRamme of exercise and dietary ADvice in mEn with castrate 
resistant prostate cancer - COMRADE trial’ 
 
As part of this study your patient is required to undertake two dual energy X-ray 
absorptiometry (DEXA) scans approximately 16 weeks apart. We shall analyse both 
of these scans at the end of the study and provide you with a formal report. 
 
No action is required from you at this stage. 
 
If you have any queries regarding the study, please do not hesitate to contact me on 
0114 271 3223. 
 
Thank you for your help. 
Yours sincerely, 
 
Mr Derek Rosario (Consultant Urologist and Principal Investigator)  
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Appendix 18 Healthy eating and dietary guidance booklet  
 
COMRADE: 
HEALTHY 
EATING 
AND 
DIETARY 
GUIDANCE 
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ABOUT THIS GUIDANCE  
As part of the COMRADE study, we are asking our participants to make 
positive changes in their diet. This is not only for your own health and 
wellbeing but also as we feel this will help compliment the effects of the 
exercise intervention you are taking part in. You may already feel like you 
have taken some steps toward a healthy diet but please continue to read 
this information for further guidance as you may still find this helpful.  
We understand that whilst receiving treatment for cancer making the 
best food choices can be very challenging. You may find it easier to make 
changes to your diet gradually, at a budget you can afford, and when you 
feel ready. The diet diaries we ask you to fill out are also a good 
opportunity for you to see what you are currently eating and compare it 
with this information, to help you decide whether you wish to make 
healthier choices.   
This dietary advice doesn’t have to be restricted to just you, getting your 
spouse, family members and friends  on board will help to keep you on 
track and make it a much more enjoyable experience.  
The treatment that you are undergoing can be very trying on your body 
and therefore on your appetite. A loss of appetite on chemotherapy is a 
common side effect, in this case you may find it beneficial to eat little 
and often as opposed to three meals a day. Whilst we may talk about 
restricting high calorie high sugar foods in this guidance, you must also 
make sure you are maintaining a sufficient calorie intake.  Every 
individual is different and therefore it is important to follow any 
information and advice given to you by your healthcare team (like your 
dietician, GP or specialist nurse) and inform them of any changes to your 
diet.  Additionally, if you have an allergies or intolerances then speaking 
to your healthcare team before making any changes to your diet will help 
you to choose suitable and healthy alternatives. Also informing the 
research team is important; we can also help to offer some advice and 
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knowing your specific dietary requirements helps us monitor your 
progress. 
Care has been taken in these dietary guidelines to take into account any 
special dietary requirements and needs, including religious and cultural 
requirements. This includes both vegetarian and vegan alternatives. In 
addition, if you should chose to try any of the recipes in this dietary 
guidance, we encourage you to still source your ingredients from your 
regular supermarket in compliance with any religious or cultural beliefs. 
This is to ensure that you are able to continue to follow any required 
religious or cultural practices without compromise.  
If there is anything you are unsure of in these guidelines please speak to 
a member of the research team who will be more than happy to talk you 
through any questions you may have.  
We are here to help guide you and want to help you make the best 
choices you can. 
 
PLAN YOUR MEALS AS OFTEN AS POSSIBLE 
Some people turn to food when life is stressful, known as comfort eating. 
For others being busy means that they often turn to convenience food 
such as microwave meals or take-always. For this reason we ask you to 
plan your meals daily, generating a meal plan often helps. It is not always 
possible to plan your meals (if you are visiting family members or going 
on holiday) and sometimes it may not be possible to plan what you are 
going to eat. But if you make efforts as often as possible you may often 
find you will save money in the process and actually spend less time 
preparing food than you thought, whilst achieving a healthy diet. For 
example, a big batch of homemade chilli made on a Sunday can be split 
into several meals, frozen and defrosted when necessary. Making use of 
your microwave also means that on those days you are just too tired to 
cook or don’t have time, you have a portion of ready and waiting in the 
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fridge or freezer; which is much easier than ordering and waiting for a 
takeaway, and easier on your wallet too. 
 
READ THE LABELS 
You may have seen a lot in the news recently about hidden sugars in 
everyday foods. Some of the worst offenders for this are cereals 
(including cereal bars), bread, sauces and soups, yogurts, dressings and 
baked beans. Low fat or “diet” foods can often have added sugars to 
make the taste more palatable. Nutritionally fats do have higher calorie 
content, but some fat in the diet is essential. Fats from more nutrient 
dense foods such as nuts, seeds and fish provide essentially fatty acids 
(including omega-3). It is always important to read labels to check for 
any added sugars. Additionally, fruit juices and smoothies should be 
consumed within moderation. They are still high in fruit sugars and 
nutritionally offer much less fibre than the fruit in its natural form.  
 
WE ARE NOT SAYING YOU CAN’T ENJOY THAT 
FRIDAY NIGHT TAKE-AWAY  
A main point we want to make in this guidance is moderation. That 
means that we are not asking you to give up your Friday night rituals of 
a take-away or to stop drinking at your local pub with friends. Ultimately 
you will decide whether you want to eat more healthily not us and the 
argument we are making here is one we've all heard before that is: 
Moderation is key! One idea to improve your diet is that you eat as best 
and healthy as possible 90% of the time allowing for 2-3 meals each 
week as "treats" – meaning meals which don’t necessarily follow the 
dietary guidance, say for example a meal out with friends and family. This 
will help you to be more flexible and realistic with your healthy eating 
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plan, but ensuring you continue to enjoy a healthy lifestyle. The 
important thing is not to binge eat when you do decide to have a treat. 
Be mindful, but don’t feel guilty if you have that chocolate bar after a 
week of healthy eating! 
 
ALCOHOL 
The government suggests that men should not regularly drink more 
than three to four units of alcohol a day. We consider this to be an 
absolute maximum and ask that you minimise your alcohol intake as 
much as possible. Good advice seems to be if you are a drinker focus in 
having some drink free days, again like the diet diary I suggest below 
recording what you drink and when you drink may help you keep track 
and control your alcohol consumption. i.e. 
 
 
 
SOME SUGGESTIONS  
1. Wholewheat or whole grain foods rather than the white versions 
where possible (e.g. breads, cereals, crackers, pastry, pasta and 
How many units of alcohol are in a drink?1 
• A pint of lager, beer or cider contains 2-3 units. 
• A 175ml glass of wine contains about 2 units. 
• A 25ml measure of 40 per cent single spirit with mixer contains 1 unit 
1Information taken from prostatecanceruk.org/prostateinformation  
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grains like rice and couscous). If you struggle to have wholegrain 
and high fibre foods, speak to your dietician for advice on how best 
to control this whilst maintaining a healthy diet.  
 
2. Aim for at least 5 portions of fruit and vegetables each day, they 
can be fresh, tinned, frozen or dried (check the portion sizes with 
dried fruit however as you need a lot less than the natural 
versions). Try to have a range of different colours of fruit and 
vegetables to give you a variety of vitamins and minerals. Here are 
a few examples of a portion: 
 
3. Drink plenty of water. Particularly as your activity level is going to 
increase you will be losing more fluid as you sweat and it is 
important to replace this and remain hydrated but avoid high 
sugar soft drinks. A good test for checking hydration is to 
maintaining a fairly clear "straw" coloured urine whereas smelly, 
dark urine usually signifies dehydration. You should aim to drink 
six to eight glasses of fluid a day to day and more if you are 
exercising or if it is particularly warm weather (water, lower fat milk 
and sugar-free drinks including tea and coffee all count). Water is 
really important for many bodily processes including the removal 
of toxins, (NB some medicines and water soluble vitamins also 
affect the colour if our urine). 
 
4. Regular meal patterns might work well for helping you maintain  a 
healthy weight some people find that when they miss meals, for 
 Fruit juice counts (150ml or a small glass) but only once a day  
 Roughly a handful of veg is a portion  
 An average sized banana or apple is a portion 
 One portion is two or more small fruit, for example 2 plums, 2 
satsumas or 14 cherries. 
 Three heaped tablespoons of beans e.g. baked beans, chickpeas, 
kidney beans or cannellini beans count as one portion each. Remember, 
however much you eat, beans and pulses count as a maximum of one 
portion a day. 
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example breakfast, they make up for this later in the day by over-
eating as they become so hungry 
 
5. Keep a food diary- this seems to help for many people as the diary 
raises self-awareness over what we are consuming. We give you a 
three day food diary at the start of this intervention but you may 
want to continue your own diary to keep track of your healthy 
eating. Give it a try you may be surprised by the effects! 
 
PROTEIN 
As part of the exercise programme you are undergoing we are offering 
you a whey protein supplement to help you achieve a diet high in 
protein. Please speak to our research team if you cannot consume 
dairy/milk products. A diet high in protein is also important in helping to 
enhance the effects of the exercise programme you will be undertaking. 
We ask that you avoid protein sources such as red meat and processed 
meat and opt for fish, nuts, legumes, beans and poultry as alternatives. 
Pulses such as beans, lentils and peas, they are a low fat alternative to 
meat and a good source of protein as well as being suitable for a 
vegetarian and vegan diet. Other non-meat high protein sources include: 
tofu, tempeh, quinoa, amaranth, soy milk and seeds (hemp, chia and 
pumpkin are best). If you do chose to have a meal with red meat then 
opt for the leanest cuts and trim any excess fat.  
 
SOME STORE CUPBOARD FAVOURITES 
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These are a few things we think would be helpful to have in your 
cupboards regularly. We are not suggesting you go and purchase 
everything now. But you may find as you are trying new recipes you pick 
up a few of these products anyway and then they naturally become a 
regular staple in your cupboards.   
 
BEANS, PULSES, LEGUMES AND GRAINS 
 
 A selection of beans and pulses for example chickpeas, 
kidney beans, black beans, butter beans 
 Brown rice 
 Bulgur wheat 
 Pearl barley 
 Oats 
 Couscous (wholegrain) 
 Quinoa 
 Dried legumes like lentils (green, red, yellow, brown which 
ever you prefer) and split peas  
 
NUTS, SEEDS AND DRIED FRUITS 
 
A selection of dried fruit and nut (these are great for snacking but avoid 
too much as they can have a high calorie content, especially dried fruits 
in comparison to their natural undried versions.  As they are much 
smaller it’s a lot easier to get carried away, so be mindful). As a general 
rule opt for the non-peanut natural variety. Roasted and flavoured 
versions (like BBQ flavouring) can have added ingredients like sugar or 
be high in salt so always check the packets. If you can, avoid sweetened 
dried fruit as these can have added sugars. They can be a bit harder to 
spot so just make sure you read the labels when you get to the super 
market. 
 
 Almonds 
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 Cashews 
 Dried cranberries 
 Dried apricots 
 Brazil nuts 
 Anything goes really 
 
OILS ANF FATS 
 
We recommend that you try to grill, steam or poach food where you can 
but when you do choose to fry foods try to do it in fats which have had 
minimal processing such as: 
 
 Extra virgin olive oil (this can be quite expensive so you can 
also opt for regular olive oil) 
 Coconut oil 
 Sesame oil 
 Nut oils (like groundnut and walnut) 
 
TOMATO PRODUCTS 
 
 Avoid any products with any added sugar or salt.   
 Chopped/plum tomatoes 
 Passata 
 Tomato puree 
 
DRIED HERBS AND SPICES 
 
Always keep you favourites in to add a little flavour to your vegetables. 
An even easier way is to add spice mixes to your food but do check there 
are no hidden sugars. A few more suggestions are given below: 
 
 Bay leaves 
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 Oregano  
 Thyme 
 Basil  
 Rosemary 
 Smoked paprika 
 Chilli flakes 
 Cayenne pepper 
 Chinese five spice 
 Cajun spice 
 Ground cinnamon 
 Garlic granules 
 Curry powder 
 
FLOUR 
 
Stick to wholemeal or wholegrain varieties.  
 Wholemeal plain and self-raising 
 Brown rice flour 
 Buckwheat flour 
 Spelt 
 Gram flour (also known as chickpea flour) 
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RECIPES 
 
The recipes in this booklet are a few suggestions we have given you to get you 
started. Feel free to adapt them as you see fit. If there is an ingredient you dislike 
then feel confident to swap it to something else and seems like it would fit the recipe.  
Vegetarian and vegan options are given for all the recipes (excluding the salmon fish 
cakes and chicken Kiev). All of the recipes can be made gluten free too; swap oats, 
wholemeal breads and breadcrumbs for their gluten free versions available in major 
supermarkets. 
 
BREAKFAST ................................................................................ 
MAIN MEALS ........................ ERROR! BOOKMARK NOT DEFINED.  
HEALTHY SWAPS ................... ERROR! BOOKMARK NOT DEFINED.  
SNACKS ................................ ERROR! BOOKMARK NOT DEFINED.  
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BREAKFAST 
 
STUFFED BREAKFAST MUSHROOM ON WHOLEMEAL BREAD – 
SERVES 2 
 
4 Portobello 
mushrooms 
50g of goat's cheese*  
1 tbsp of olive oil plus 
extra for brushing 
1 leek finely chopped 
3 garlic cloves, finely 
chopped 
100g spinach 
½ tsp of nutmeg 
A pinch of cayenne 
pepper 
¼ tsp of Dijon 
mustard  
4 slices of wholemeal 
bread 
Preheat the oven to 200C/ gas mark 6. 
Rinse the mushrooms and pat dry with a little kitchen 
roll.  
With a knife, remove the stalks and brush the 
underside of the mushroom with olive oil. Place the 
mushrooms on a baking try lightly brushed with olive 
oil 
Heat the olive oil in a pan at a medium heat and add 
the leek, fry until soft, then add the garlic. Gently fry 
for a few minutes. 
Stir in the spinach, nutmeg, cayenne pepper and heat 
through until the spinach wilts then stir in the 
mustard. 
Fill each mushroom with the leek filling and crumble 
over the goats cheese. Bake in the oven for around 
25-30 minutes. 
Serve immediately on toasted wholemeal bread or 
rye. 
 
 
 
 
 
  
*For a non-dairy version 
leave out the goats cheese 
and sprinkle with 
pumpkin/sunflower seeds. 
 
 
107 
 
 
BANANA PANCAKES – SERVES 2 
 
2 bananas 
2 eggs* 
50g porridge 
oats 
½ teaspoon 
baking powder 
½ teaspoon of 
cinnamon 
Pinch of salt 
Greek yogurt* 
Flaked or whole 
almonds, to 
serve (optional) 
Fresh fruit, to 
serve
In a food processor add the banana, eggs, oats, baking 
powder, cinnamon and salt and blend until smooth. If you 
don’t have a food processor, mash the banana thoroughly 
first with a fork then mix in the whisked eggs, oats, baking 
powder, cinnamon and salt. If the mixture looks too thick, 
add a splash of milk to loosen the mixture. 
Heat a non-stick frying pan over medium heat. If you are 
using a regular pan melt a ½ tsp of coconut oil to the pan 
first and melt. 
Fry tablespoons of the batter until golden brown on both 
sides. 
Serve with a dollop of Greek yogurt, fresh fruit of your 
choice and scatter a handful of flaked or whole almonds 
over the top. 
*For a non-dairy version 
substitute each egg with 1 
tablespoon of ground flax 
seed with 3 tablespoons of 
water and substitute out the 
Greek yogurt for a soy or 
coconut alternative. 
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HEALTHY SIMPLE BREAKFAST BOWL – SERVES 2 
 
3 pine nuts 
1 ripe avocado, 
sliced 
10 cherry 
tomatoes, halved 
1 large carrot, 
grated 
150g of spinach, 
washed 
200g of smoked 
salmon* 
1 tbsp of whole 
grain mustard 
2 tblsp olive oil 
2 eggs*
Toast the pine nuts in a pan on a medium heat until they 
begin to go golden brown. Take off the heat and set to one 
side. 
Serve the avocado, tomatoes, carrot, spinach and salmon 
in two bowls.  
Combine the mustard and olive oil in a small bowl or mug 
and stir well. 
Poach or soft boil the eggs in a pan then serve immediately 
over the salad and salmon. Spoon over the mustard 
dressing and sprinkle the pine nuts. 
 
 
 
  
*For a vegetarian and vegan 
version substitute the smoked 
salmon for vegetarian/vegan 
sausages and omit the eggs 
for a handful of edamame 
beans 
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NUTTY GRANOLA – SERVES 8-10  
 
1 tbsp sunflower or 
coconut oil 
100ml of maple 
syrup or honey 
1 tsp of vanilla 
extract (plus 1 tsp 
of almond essence, 
optional) 
250g of porridge 
oats 
50g of whole 
almonds 
50g of seeds 
(pumpkin, 
sunflower, poppy 
all go well) 
100g of mixed 
nuts, whichever 
you prefer like 
hazelnuts (without 
skins), brazil nuts 
or walnuts 
50g of dried fruit 
(like cranberries, 
chopped dates, 
satsumas, apricots) 
1 tsp of ground 
cinnamon 
Greek yogurt* 
 Fresh fruit 
Preheat the oven to 150C/ gas mark 2 and line a 
relatively deep baking tray with baking parchment. 
Heat the oil and maple syrup together on a low heat in a 
large saucepan. Place the oats in the pan, add the vanilla 
essence and stir to coat thoroughly. 
Spread the oats out in an even layer onto the baking tray 
and bake for 10 minutes. 
Remove from the oven and add all of the nuts, try to 
distribute them as easily as possible. Place back into the 
oven and bake for a further 10-15 minutes.  
Remove from the oven and add the dried fruit and 
cinnamon then stir through 
Serve with Greek yogurt and fresh fruit like blueberries. 
 
  
Store the remaining in 
an airtight container; it 
will keep for a couple 
of weeks 
*For a non-dairy version 
substitute the Greek yogurt 
for unsweetened soy yogurt 
or coconut yogurt 
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MAIN MEALS 
 
AVOCADO AND SALMON CAKES – SERVES 4 
 
340g of tinned 
salmon or tuna 
2 eggs 
80ml of milk  
75g of 
breadcrumbs 
1 shredded 
courgette or 
carrot (a cheese 
grated works well 
if you don’t have a 
food processor) 
2bsp of curry 
powder or 2tblsp 
of Thai green 
curry paste 
Avocado  
120g Plain Greek 
yogurt 
Juice of one lime 
1 tsp of wasabi 
paste 
1 small bag of 
spinach or mixed 
salad, washed
Pre-heat the oven to 180C/gas mark 4 and grease 
8 muffin cups of a muffin tray. 
Mix by hand or put all the ingredients in a food 
processor. Once combined, using a spoon scoop 
out and distribute evenly in the 8 greased muffin 
cups.  
Place in the oven and bake for around 25-30 
minutes.  
Whilst the salmon cakes are baking, blend a large 
avocado with the Greek yogurt, lime juice and 
wasabi until smooth.  
Serve on the side with a big portion of spinach.  
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BAKED SWEET POTATO WITH SMOKY BLACK BEANS AND SPICY 
AVOCADO QUINOA SALAD– SERVES 2 
 
2 large sweet potatoes, 
washed 
100g of quinoa 
250g of tomatoes, washed 
and roughly chopped 
1 large avocado, roughly 
chopped 
2 spring onions, thinly 
sliced 
Juice of one lime 
1 small red or green chilli  
1 handful of fresh 
coriander (more if you like) 
1 red onion, peeled and 
chopped  
Olive oil 
1 tsp of cumin seeds 
1 tbsp of chipotle paste (if 
you can’t find this a chilli 
and paprika paste or 
alternative Mexican paste 
is fine) 
1 x 400g tin of black beans  
2 heaped teaspoons of low 
fat cottage cheese 
(optional) 
Preheat the oven to 180C/gas mark 4.  
Pierce a cross through the sweet 
potatoes wrap in a little tin foil and just 
before you close the top up drizzle a little 
olive oil and season lightly with salt and 
pepper. 
Roast for 45 minutes to an hour (when 
they are soft in the middle they are 
ready). 
After about 25 minutes of the sweet 
potatoes roasting, rinse the quinoa well 
before cooking to the packet instructions 
(this removes the slight bitter taste 
quinoa can get when exposed to air).  
Place the tomatoes, avocado and spring 
onions in a bowl. Finely chop the 
coriander leaves and the chilli and place 
in the bowl. Drizzle over the lime juice, 
give it a quick stir then mix the whole 
thing together with the quinoa and place 
to one side.  
Put a pan on a medium heat with a 
teaspoon of olive oil and add the cumin 
seeds. After about 30 seconds, or when 
they start to smell a little fragrant, add a 
splash of water and stir it through the 
seeds before adding the onion. Cook until 
softened and then add the chipotle paste 
and stir through.  
Continued… 
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Continued… 
Add the beans with all of their juice. 
Reduce the heat and cook for a further 5 
minutes until the sauce becomes thick,  
add a little more water if necessary. 
Season with a pinch of salt and pepper. 
Divide the beans and quinoa salad evenly 
between two plates and slice open the 
sweet potatoes. Add a dollop of cottage 
cheese to the centre of each sweet 
potato and serve.  
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SESAME SEED SALMON WITH SUMMER VEG STEW AND 
WHOLEWHEAT COUSCOUS – SERVES 2 
 
2 fillets of 
salmon* 
4 teaspoons of 
sesame seeds 
1 packet of baby 
corn, halved 
1 tbsp olive oil 
2 large carrots, 
grated 
1 red pepper 
deseeded and 
roughly chopped 
1 celery stick, 
roughly chopped 
1 small red onion, 
peeled and diced 
1 avocado, 
roughly chopped 
The juice of 1 
lemon/lime 
150g of whole 
wheat 
couscous/quinoa/
wild rice  
30g basil leaves, 
torn  
4 sundried 
tomatoes in oil, 
drained and 
roughly chopped 
Preheat a pan to a medium heat.  
Lay out the sesame seeds on a flat surface and 
gently press the sides salmon lengthways into the 
seeds (not the skin side). Leave to one side.  
Add the olive oil to the pan and throw in the 
sweetcorn and fry for around 4 minutes. Then add 
the red pepper, celery and red onion and toss in 
the pan for a further 4 minutes.  
Take off the heat and combine the veg with the 
avocado and carrot and leave covered to one side.  
Turn the heat up and fry the salmon on one side 
for four minutes or until the seeds go golden 
brown. Turn the salmon over and cook for a 
further minute then take off the heat and transfer 
to plates.  
Add the basil and sundried tomatoes to the 
cooked couscous and stir through. Serve the 
couscous and veg alongside the salmon and 
drizzle with a little lemon juice.  
*For a vegetarian and vegan 
version substitute firm tofu 
for salmon and try coating 
cubes in sesame seeds and 
follow the instructions as 
normal. 
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FIERY PRAWN STEW- SERVES 4 
 
450g peeled 
prawns * 
4 tbsp olive oil  
1 tsp smoked 
paprika 
3 garlic cloves 
1 – 1 ½ tsp chilli 
flakes 
1 bay leaf 
400g chopped 
tomatoes 
2 x 410g cannellini 
beans, drained 
1 tbsp tomato 
puree 
240ml of chicken 
or vegetable stock 
(low salt variety) 
2 tbsp fresh 
parsley or 1 ½  tsp 
of dried 
Pinch of salt 
4 large wholemeal 
flat bread 
Greek yogurt 
(optional)
Toss the prawns with 1 tbsp of olive oil and the 
paprika then transfer to a heated pan and cook 
for 2 minutes.  
Add half of the garlic and cook for 30 seconds 
then set the prawns aside in a bowl.  
Return the pan to the heat and add a further 2 
tbsp of olive oil, the chilli flakes, the bay leaf and 
the remaining garlic. 
Cook until the garlic is lightly golden and then add 
the chopped tomatoes.  
Continue to simmer until most of the liquid 
evaporates and then add the tomato puree, beans 
and stock.  
Simmer for 10 minutes. Stir in the prawns and 
parsley and season with a pinch of salt and 
pepper.  
Serve in bowls alongside warm flat breads. Add a 
dollop of Greek yogurt too if desired.  
 
 
  
* For a vegetarian and vegan 
version roast some roughly 
chopped butternut squash in 
the oven until just soft (but 
not too mushy) and follow 
the same steps you would for 
the prawns. 
 
 
115 
 
HARISSA BAKED AUBERGINE WITH MOROCCAN QUINOA – 
SERVES 2 
 
2 tsp harissa  
Olive oil 
1 large aubergine 
1 cup quinoa, rinsed * 
¼ cup raisins 
2 cups boiling vegetable stock 
(low salt variety) 
3 tablespoons extra virgin olive 
oil 
2 tablespoons lemon juice 
1 clove garlic, finely chopped 
1 teaspoon ground cumin 
1 teaspoon ground coriander 
½ teaspoon ground ginger 
1 teaspoon salt 
1 carrot, grated 
1 red pepper, diced 
1 red onion, diced 
1 cup canned chickpeas, rinsed 
and drained 
2 tablespoons finely chopped 
flat-leaf parsley 
Greek Yogurt (optional) 
 
Pre heat the oven to 180/ gas mark 4. 
Half the aubergine lengthways and 
crisscross the flesh. 
Put the harissa in a bowl and lengthen 
with a splash of olive oil, mix well. Brush 
the harissa mix onto the aubergine and 
place on the baking tray.  
Bake for around 20-30 minutes or until it 
becomes soft in the middle. If the top 
begins to brown too quickly cover with a 
little foil and place back in the oven.  
Meanwhile, cook the quinoa according 
to packet instructions in the vegetable 
stock.  
Mix the oil lemon juice and spices in a 
bowl. Fluff the quinoa with a fork to 
separate the grains and add the raisins, 
carrot red pepper, onion, chickpeas and 
parsley and stir through. 
Add the olive oil and spice mix, stir 
through and serve the quinoa with the 
aubergine placed on top.  
Add a dollop of Greek yogurt if desired.  
 
*If you don’t like quinoa then this 
recipe can be done with 
wholewheat couscous, just cook to 
packet instructions and add the rest 
of the ingredients as normal. 
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HEALTHY SWAPS 
 
Take everyday comfort food and make it more nutritious with simple swaps
BANGERS AND MASH- SERVES 2 
 
4 Lean sausages 
like venison or 
turkey (or 
vegetarian/vegan 
ones) 
2 sweet potatoes 
(or try 1 sweet 
potato and 1 large 
carrot), peeled 
and roughly 
chopped 
2 tsp of dried 
rosemary 
A pinch of salt 
2 tsp of 
butter/olive oil 
A splash of milk 
1 leek thinly sliced  
1 tbsp of olive oil 
(or 2 tsp of butter) 
100g of kale 
(washed) 
60g of toasted pine nuts 
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 Pre heat the grill 
on a medium 
heat.  
Add a splash of oil 
to a large pan and 
sauté the sweet 
potatoes for 
around 3 minutes 
before adding 
water to just 
cover the 
potatoes and a 
little salt.   
Bring to the boil 
and then turn it 
down to a simmer 
for around 20 
minutes or until 
soft. You can take 
it off the heat but 
keep the lid on to keep it warm. 
Add the olive oil to another saucepan on a 
medium heat and throw in the sliced leek.  Sweat 
the sliced leek for about 20 minutes.  
Add the kale and stir through then leave for 
another 5- 10 minutes, keep it covered if you take 
it off the heat. 
In the meantime grill the sausages according to 
the packet instructions, usually around 8-10 
minutes.  
Drain the potatoes and mash with a potato 
masher or hand blender (if you prefer it 
smoother) and stir through the butter and 
rosemary.  
Serve up the sausages over the mash and top with 
the leek kale mix. Sprinkle with the toasted pine 
nuts.  
 
TURMERIC CHICKEN PITTAS (THINK HEALTHY KEBAB) – SERVES 2 
 
2 sprigs of fresh 
oregano or 2 tsp 
of dried 
1 level tsp of 
turmeric 
2 tbsp olive oil 
2 large skinless 
chicken breasts * 
200g of baby 
spinach/Swiss 
chard/kale 
2 large wholewheat pitta breads 
1 lemon 
1 aubergine sliced into half centre meter thick 
pieces. 
1 sliced avocado (optional) 
2 heaped tbsp of low fat hummus 
Salt and pepper 
Your favourite chilli sauce (optional)
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Pre heat the oven 
to 200C /gas 
mark 6.  
Take a large bowl 
and add the 
oregano, turmeric 
and olive oil and 
mix to make the 
marinade.  
Toss the chicken 
in the marinade 
and coat evenly 
then leave to one 
side.  
Lay the aubergine 
flat on a baking 
tray and drizzle 
with a little olive 
oil. Season the 
aubergine with a 
pinch of salt and 
pepper and place in the oven.  
After ten minutes turn the slices of aubergine 
over and place them back in the oven for another 
10-15 minutes or until they are tender. 
Once done, take the aubergine out of the oven 
and leave to one side.  
In the meantime, blanch the greens until just 
tender and drain well (if you are using spinach you 
can eat it raw or just place them in a colander and 
pour over a kettle of boiled water).   
Heat some olive oil in a frying pan on a high heat 
and cook the chicken for 4 minutes on each side 
or until cooked through. 
Reheat the greens if needed and serve up the 
chicken, aubergine, greens and hummus on warm 
pitta bread with the avocado and a lemon wedge 
on the side. Drizzle over some hot chilli sauce if 
desired.  
 
  
*For a vegetarian/vegan 
version you can sub the 
chicken for Quorn/Frys 
(vegan) pieces or cubes of 
firm tofu. 
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SIMPLE THAI RED CURRY – SERVES 4 
 
2 tblsp olive oil 
1 red onion 
peeled and 
chopped 
900g skinless 
chicken breast 
sliced * 
1 tblsp of Thai 
red curry paste 
400ml of light 
coconut milk (if 
this is too heavy 
try half coconut 
milk and half low 
salt chicken or 
vegetable stock) 
3-4 dried lime 
leaves 
340g spinach 
handful of fresh 
coriander 
(optional) 
4 portions of 
cooked brown 
rice according to 
packet 
instructions
Heat the olive oil in a large non-stick pan and sweat 
the onion for 3-5 minutes.  
Add the chicken to the pan and cook, stirring for 5 
minutes.  
Stir in the curry paste and cook for a further minute 
before adding the coconut milk (and stock if using) 
and reduce the heat.  
Add the lime leaves and simmer for 7 minutes.  
Add the spinach and stir through, leave for a 
further minute then serve with the cooked rice in 
bowls and sprinkle with the fresh coriander 
. 
 
 
 
  
*You can also try a fish 
version. Any white fillet fish 
works best and cook until 
flaky although times may 
differ slightly between fish. 
Prawns also work great too. 
For a vegetarian /vegan 
version use firm tofu or 
Quorn/Frys chicken pieces 
instead. 
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SMOKEY BAKED BEANS ON RYE- SERVES 2 (WITH 4 SERVING OF 
BEANS LEFT OVER TO FREEZE) 
 
6 tins of cannellini 
beans, drained and 
rinsed 
2 bay leaves 
1 tbsp of olive oil 
2 onions, diced 
4 garlic cloves, finely 
chopped 
2 tsp of chipotle paste 
(if you can’t find this a 
chilli and paprika paste 
or alternative Mexican 
paste is fine) 
1 ½ tsp dried oregano  
1 ½ tsp dried thyme 
2 tbsp of tomato 
puree 
2 tins of tomatoes  
1-2 tbsp of maple 
syrup 
1 litre of vegetable 
stock (low salt variety) 
2 eggs (optional) 
2 slices of good quality rye bread or a 
wholemeal alternative 
In a large pan, heat the olive oil on a medium 
heat and fry the onion for 10 minutes or until 
soft.  
Add the bay leaf, celery, garlic, chipotle paste 
and herbs.  
Stir and cook for a further five minutes. Add 
the tomato puree, tined tomatoes, maple 
syrup and veg stock and cook at a medium 
simmer for 20 minutes.  
Add the cannellini beans and simmer for a 
further 30 minutes.  
Remove the lid of the pan if necessary to 
allow the excess water to evaporate and get a 
thicker consistency towards the end.  
Butter the rye bread and serve with the beans 
on top. 
Poach the eggs and serve immediately on top 
of the beans and rye bread. 
 
This recipe also 
works for a hearty 
filling breakfast. 
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CHICKEN KIEV WITH SPRING VEG- SERVES 
For the garlic butter:  
3 garlic cloves, crushed or 
diced 
50g of butter 
1 handful of fresh parsley 
finely chopped 
1 tsp of lemon juice 
 
For the kiev: 
100g bread crumbs  
½ tsp of cayenne pepper or 
smoked paprika 
1 egg 
2 skinless boneless chicken 
breasts 
Salt and pepper 
 
For the spring veg: 
1 bunch of asparagus 
100g frozen broad beans 
100g of frozen peas 
1 bunch of mint, chopped 
Olive oil 
Continued… 
Pre heat the oven to 200C/ gas mark 6 
and line a baking tray with baking 
parchment.  
Mix all the ingredients for the garlic 
butter together using a fork and season 
with pepper to taste.  
Roll in baking parchment or cling film into 
a sausage shape about 2cm in diameter. 
Leave in the freezer for 30 minutes.  
Put the breadcrumbs into a bowl with the 
cayenne pepper/paprika with a pinch of 
salt and pepper. Tip: you can make your 
own breadcrumbs with stale bread 
blitzed in a food processor. 
Beat the egg in a separate bowl.  
Push a sharp knife into the fat end of the 
chicken breast to create a pocket.  
Half the garlic butter and place one half 
inside each of the breast. Seal the pocket 
closed with your hands.  
Dip the chicken breasts in egg first then 
roll around in the breadcrumbs.  
Pat down and place on the prepared 
baking tray. Bake for 25-30 minutes.  
In the meantime heat a pan on a high 
heat and half fill it with boiling water.  
Trim the woody ends off the asparagus 
then slice the stalks to 1cm think pieces. 
Leave the tips whole.  
Continued… 
Feta cheese 
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1 Lemon 
2 slices of rye bread (or a 
wholemeal alternative), 
optional 
Cook in the water with the beans and 
peas for just 3 minutes.   
Drain and place back in the pan drizzle 
over some olive oil, toss in the mint and 
serve alongside the chicken.  
Crumble over the feta cheese and a 
squeeze of lemon.  
Serve with warm rye or wholemeal 
bread.  
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SNACKS 
 
 
There are lots of healthy options out there to help you through the day between 
meals. Although we don’t like to encourage snacking too often, it is important to 
have some healthy options when you need it between meals to help you through 
the day. The exception to this is if you are struggling with your appetite due to 
treatment or have concerns about too much weight loss. It is always important to 
consult your treating clinician or dietician first. However, you may still find these 
suggestions for small snacks helpful if not just for ideas. 
Some options for snacks are listed below: 
 A portion of fruit 
 A handful of nuts 
 A slice of rye bread or two rice cakes with nut butter 
 Low calorie popcorn (be mindful of sugars) 
 A boiled egg 
 Raw sliced veg like carrots, cucumber, celery, peppers with hummus or 
tzatziki 
 A fruit and nut bar with no added sugar 
 
  
We have also given 
you a couple of 
recipes for further 
inspiration. 
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OAT-Y NUT COOKIES 
 
4 medium 
bananas 
5 heaped tbsp of 
nut butter (chose 
varieties with no 
added sugar) 
1½ tbsp of 
coconut oil or 
sunflower oil, 
plus extra for 
greasing 
4 tbsp of honey 
or maple syrup 
1 tsp of mixed 
spice or 
cinnamon 
1 tsp of vanilla 
essence 
200g of porridge 
oats
Preheat the oven to 200C/ gas mark 6 and grease a baking 
tray lightly with coconut or sunflower oil. 
Peel and place the bananas in a food processor and blitz 
until smooth. If you down have a food processor place in a 
large mixing bowl and mash with a fork.  
Add the nut butter, oil, honey/maple syrup, spice, vanilla 
essence and oats to the banana and thoroughly mix. 
Scoop out heaped tablespoons of the sticky mixture 
spaced evenly on to the baking tray. Press them out into a 
thin cookie shape.  
Place the tray in the oven and bake for 15 – 20 minutes 
until they begin to turn golden brown. 
Remove the cookies and allow to cool on a wire rack. Store 
in an airtight container.  
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SPICY CHICKPEAS  
 
1 tbsp of olive oil  
2 cans of chickpeas, 
drained and rinsed 
2 tbsp of lemon juice 
1 tsp of maple syrup 
1 tsp of soy sauce/ tamari 
(gluten free) 
1 tsp of harissa spice (dry 
version) If you can’t find 
this try another Mexican 
spice mix. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Preheat the oven at 220C/ gas mark 7 and line a 
baking tray with baking paper. 
Heat the oil in a wok at a medium-high heat and 
add the chickpeas. Fry for around 3-5 minutes.  
In the meantime add the lemon juice maple 
syrup, soy and harissa spice to a mug and mix 
throrougly.  
Pour in the mix and over the chickpeas and coat 
evenly.  
Spread the chickpeas out evenly on the baking 
tray and place in the oven for 30-35 minutes or 
until crispy. 
Remove and allow to cool for 5-10 minutes 
before enjoying. 
Store in an airtight container.
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Abbreviations 
  
 
SOP Standard operating procedure 
HRM Heart rate monitor 
LBM Lean body mass 
OS Overall survival 
QoL Quality of life 
CV Cardiovascular 
RPE Rate of perceived exertion 
RM Rep max 
CRF Case report form 
AE/SAE Adverse event/ serious adverse event 
 
  
 
 
Glossary (add as necessary)  
 
Case Report Form 
A printed, optical or electronic document designed to record all of the protocol required 
information. 
 
1. Objective 
 
This SOP describes the intervention for the clinical trial, which consists of exercise 
training and dietary guidance. This will be undertaken by participants for 16 weeks, 
combining supervised resistance exercise session, dietary guidance and 
supplementation, and encouragement to do independent aerobic exercise. It covers 
procedures that should be in place to ensure participants perform resistance exercise 
and independent exercise in a safe and effective manner as well as encouragement to 
maintain a high protein healthy diet. 
2. Scope 
 
This SOP applies to the trial exercise specialist who will be guiding the participants 
through the complex intervention. 
3. Background  
 
Cancer patients of lower performance status and a reduced LBM have repeatedly been 
shown to have more dose limiting toxicity, a poorer chemotherapy completion rate, a 
higher risk of neutropenia and poorer OS. The metabolic benefits in LBM gain 
associated with exercise is thought to be the key determinant in risk reduction of 
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numerous chronic diseases such as cardiovascular disease, cancer, neurological 
conditions and diabetes (1). 
The beneficial effects of exercise training for improving LBM are also well established 
(2). Studies investigating the effectiveness of resistance training and cancer have 
shown positive effects demonstrating an increase in chemotherapy completion rate (3-
6). There is also level one evidence specific to improving outcomes in men with prostate 
cancer from a 2015 systematic review and meta-analysis of randomised controlled trials 
supporting exercise interventions. Interventions involving a combination of aerobic and 
resistance exercise can improve fitness, physical function, exercise capacity, cancer 
specific fatigue and prostate cancer specific QoL (7). 
In general cancer, multiple pre-clinical and clinical studies, including observational 
cohort studies, have demonstrated anti-tumour effects of a low carbohydrate and high 
protein diet (8-12). 
Resistance exercise will be prescribed and monitored throughout the study along with 
dietary intake using 3 day diet diaries. As with any intervention it is essential that it is 
conducted in a safe and effective manner in line with GCP standards. 
4. Individual responsibilities 
 
The exercise specialist is responsible for delivering the exercise and dietary guidance 
intervention throughout the study. It is their responsibility to protect the rights, safety, 
and welfare of subjects under their care during a clinical trial.  
5. Procedure 
5.1 Exercise intervention 
5.1.1 Program overview 
Resistance exercise training will be undertaken every week for 16 weeks, combining 
supervised and independent aerobic exercise training. Participants randomised to the 
exercise group will be asked to attend up to three (at least two) group based supervised 
exercise sessions per week, a total of 32-48 sessions. These sessions will ideally be 
booked in advance with each participant either via a telephone call or during their 
previous exercise session. They will take place at dedicated exercise rehabilitation 
suites (A205) at Sheffield Hallam University. Supervised sessions will take place during 
the daytime and evenings and will be flexible to work around participant's commitments. 
Participants will also be expected to undertake at least one self-directed aerobic 
exercise episode of at least 30 minutes per week.  
5.2 Session contents 
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5.2.1 Supervised Exercise 
 
Preceding any exercise sessions, men will attend a one to one consultation (1 hr) with 
the exercise specialist for a tailored exercise induction. Supervised exercise sessions 
will comprise of up to 45-60 minutes of a warm up, a resistance exercise main session 
and a cool down. The cardiovascular (CV) component of the warm up and cool down 
will include aerobic exercise, using standard ergometers e.g. stationary cycles, rowing 
ergometers, treadmills and cross-trainers. Participants will be monitored using Polar 
heart rate monitors (HRM) during the session.  
In each session, participants will perform 3-4 sets of 6-12 repetitions of 6 resistance 
exercises at 60% 3 RM initially. Free weights, body weight and cable machine exercises 
will form the resistance exercise component of each session. Exercises will be 
regressed or progressed dependant on the participant's abilities under the supervision 
of the exercise specialist. Exercises will also be tailored to participant's comorbidities 
and alternative offered or exercises omitted where necessary. Sessions will be 
conducted in a group format where possible. Participants will be asked to undertake and 
log (in a record book provided) at least one independent 30 minute aerobic activity at 
home during this period. The activity chosen will be based on that most convenient for 
the participant (such as walking or making use of community exercise facilities). In the 
record book participants will be asked to record the time of activity, duration and 
exercise intensity based on the Borg rating of perceived exertion scale, details of which 
will be provided in the booklet (12). The participant logged activity will be documented 
when participants attend supervised exercise sessions and further encouraged to 
undertake aerobic exercise through goal setting and self-regulation. 
A heart rate monitor chest strap will need to be worn by the participants with the middle 
of the strap being aligned with the bottom of the patient's sternum. HRM will be cleaned 
at the end of each session to adhere with local health and safety procedures. Heart rate 
& RPE will be monitored by the exercise specialist throughout the supervised sessions, 
if the exercise intensity falls outside of safe parameters, then it will be altered 
accordingly.  
5.2.2 Session guidance and documentation 
All supervised exercise sessions will be guided by the study exercise specialist. During 
the supervised sessions the exercise specialist will provide ongoing feedback on 
exercise technique and intensity guidance. The following information will need to be 
written on the exercise CRF: Trial ID number, medications, co-morbidities, date & time 
of session and resting/maximum heart rate. The type of exercise and HR will be 
recorded by the exercise specialist and will be monitored during the exercise sessions. 
If an adverse event or serious adverse event occurs, it will be noted on the exercise 
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CRF and the corresponding appropriate AE/SAE form will be completed by the exercise 
specialist according to the trial protocol. The exercise CRF will be stored in the secure 
trail filing cabinet in the co-ordinating centre (Sheffield Hallam University). 
5.2.3 Self-directed exercise 
 
In addition to the supervised sessions, men are required to undertake at least one self-
directed exercise episode of at least 30 minutes per week, recorded in an exercise log 
book. Independent exercise sessions are purposefully designed to be flexible in terms 
of where and when they are undertaken by intervention participants. These can be 
undertaken at home, in local council facilities, local sports clubs, parks etc. The 
participants will be expected to record type of exercise, duration and average RPE on 
their exercise log book. Once the study has been completed, the exercise log book will 
be stored in the trial master file at the co-ordinating centre.  
5.3 Dietary guidance 
5.3.1 Dietary guidance  
Participants randomised to the intervention arm will also be offered dietary advice in the 
form of a short seminar in a small group format on healthy eating and an information 
booklet with weekly meal plans and recipes. A dietary guidance information booklet will 
encourage participants to adopt a diet rich in nutrient dense whole foods, fruit and 
vegetables and discourage processed foods and those high in refined carbohydrates 
and saturated fats. Participants will also be asked to limit alcohol intake. Recipes 
provided will encourage high protein, moderate fat, high fibre and low carbohydrate 
meals.  
5.3.1 Dietary supplementation 
Whey protein: To promote muscle protein synthesis, participants will be required to 
increase protein consumption via whey protein supplementation provided. Participants 
will be provided with whey protein post-supervised exercise sessions and to take home 
where they will be advised to consume with 300-500ml of fat-free milk or water (13). 
The recommended dosage of protein will be bodyweight (kg-1)* 1.2 g/day as previously 
described (14). 
Creatine: Studies have shown that a combination of whey protein and creatine promote 
increases in LBM (14). The intervention group in our trial will be asked to take 0.25 
g·kg-1 of LBM a day of creatine during the acute loading phase (the first 5 days of 
creatine supplementation) and thereafter a maintenance dose of 5 grams per day. 
Adverse effects associated with doses are likely to be minimal.  
5.4 Non attendance 
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Patients who do not attend scheduled visits will be contacted by phone to re-schedule.  
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Study sites 
Recruitment, laboratories and/or technical departments: Sheffield Teaching Hospitals 
(STH); Royal Hallamshire hospital Sheffield, Northern General Hospital, Sheffield, 
Collegiate Hall, Sheffield Hallam University, Sheffield.. 
Sponsors: Sheffield Teaching hospitals 
 
Version 2.0 date: 05/12/2016 
Trial summary 
Methodology: Feasibility randomised controlled trial 
Research sites: Sheffield Hallam University (SHU), Sheffield Teaching Hospitals (STH) 
Aim: To determine the feasibility of a 16 week programme of exercise training and 
dietary advice in men with castrate resistant prostate cancer (CRPC). 
Objectives:  
1. To investigate the feasibility of a 16 week combined programme of exercise 
training and dietary advice in CRPC patients.  
2. To investigate the changes in physical function, fitness, body composition, 
including lean body mass (LBM) and fat mass (FM), serum markers, quality of life 
(QoL) and fatigue in men with CRPC as a result of a combined programme of 
exercise training and dietary advice.  
Number of participants/patients: 50 
Main inclusion criteria:  
Men with CRPC. 
Statistical methodology and analysis:  
Feasibility outcomes will be assessed using standard methods for rates and 
proportions. Changes in secondary outcomes will be assessed using an analysis of co-
variance with adjustment for baseline variants. 
Proposed start date: 01/01/16 
Proposed end date: 01/06/18 
Study duration: 18 Months 
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1. Introduction 
Since Huggins and Hodges demonstrated that hormone manipulation was effective in 
treating prostate cancer more than 70 years ago, androgen deprivation therapy (ADT) 
has been the cornerstone of prostate cancer treatment (Huggins, Stevens et al. 1941). 
However, patients with metastatic prostate cancer eventually relapse despite castrate 
levels of serum androgens and at this stage the disease is considered castrate resistant 
prostate cancer (CRPC). Until 2010, docetaxel was the only agent which had 
demonstrated an overall survival (OS) benefit in CRPC (Petrylak, Tangen et al. 2004, 
Berthold, Pond et al. 2008). Since, then the introduction of five other therapeutic options 
have shown a survival benefit in phase III trials: carbazitaxel, sipuleucel-T, radium-223, 
abiraterone and enzalutamide,(Kantoff, Higano et al. 2010, de Bono, Logothetis et al. 
2011, Oudard 2011, Scher, Fizazi et al. 2012, Parker, Nilsson et al. 2013). However, 
CRPC is still the terminal phase of the disease and those with metastatic disease 
(mCRPC) are expected to live <19 months (Heidenreich, Pfister et al. 2013). 
Regardless of this ever expanding era of therapeutic options for CRPC, therapies are 
not curative and therefore essentially palliative for these men.  
Improvements in survival of men with the use of cytotoxic chemotherapy at earlier 
stages of PCa have been demonstrated in the recent STAMPEDE and CHAARTED 
studies (James, Sydes et al. 2012, James, Spears et al. 2015, Sweeney, Chen et al. 
2015). Consequentially, changes in clinical practice have followed and an increasing 
number of men receive chemotherapy earlier in their treatment pathway. With this 
change in treatment paradigm for PCa, patients as well as urologists and oncologists 
are presented with new set of challenges concerning adverse effects of cytotoxic 
agents, the impact on QoL, sequencing and adherence to subsequent treatment 
regimens.  
Given the earlier introduction of chemotherapy in the standard care pathway for 
advanced prostate cancer, fitness for such treatment has become of increasing 
importance in order to achieve best possible outcomes. Cancer patients of a poorer 
performance status and a reduced lean body mass have repeatedly been shown to 
have more dose limiting toxicity, subsequently affecting survival (Antoun, Baracos et al. 
2010, Massicotte, Borget et al. 2013, Timilshina, Breunis et al. 2014, Tan, Brammer et 
al. 2015). Further, retrospective data has positively associated better overall survival in 
men with metastatic prostate cancer receiving docetaxel with skeletal muscle mass 
(Wu, Liu et al. 2015). 
There is sound theoretical rationale and increasing evidence demonstrating that 
exercise may represent a useful stand alone or combination therapy for the treatment of 
cancer, improving physiological and psychosocial outcomes (14-19).  The beneficial 
effects of exercise training for improving lean body mass (LBM) are also well 
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established (13). Studies investigating the effectiveness of resistance training and 
cancer have shown positive effects demonstrating an increase in chemotherapy 
completion rate and improvements in fatigue and quality of life (QoL)(14-17). 
There is level 1 evidence supporting the improvement of health-related outcomes in 
men with prostate cancer from a 2015 systematic review and meta-analysis of 
randomised controlled trials (RCT) supporting exercise interventions. Interventions 
involving a combination of aerobic and resistance exercise can improve fitness, physical 
function, exercise capacity, cancer specific fatigue and prostate cancer specific quality 
of life (Bourke, Smith et al. 2015). Furthermore, observational data and early pilot trials 
have consistently linked exercise behaviour after diagnosis to favourable disease 
progression and cancer specific mortality outcomes in men with prostate cancer 
(Ornish, Weidner et al. 2005, Frattaroli, Weidner et al. 2008, Kenfield, Stampfer et al. 
2011, Richman, Kenfield et al. 2011, Magbanua, Richman et al. 2014). 
However, to date there has been limited investigation of the effects of exercise training 
in men with castrate resistant prostate cancer (CRPC). Furthermore, no study has 
attempted to investigate the impact of both an exercise and dietary intervention with 
regard to physical fitness and the effect upon LBM of CRPC patients. Therefore the aim 
of this study is to investigate the feasibility of a 16 week combined programme of 
exercise training and dietary advice in CRPC patients.  
2. Trial objectives 
Hypothesis: 
1) Exercise therapy in men with CRPC will be feasible in terms of recruitment rate and 
willingness of the participants to be randomized, intervention adherence, compliance to 
the exercise prescription, attrition due to the intervention, and reporting on secondary 
outcome standard deviations (variance in the data) to assist in sample size estimates 
for a larger-scale trial. 
2) Secondary outcomes including physical function, body composition, fitness, fatigue 
and quality of life will favour the intervention group, following the combined exercise and 
dietary intervention  
 
Primary objectives 
1. To determine the rate of recruitment 
2. To determine the eligibility of men among those screened to take part in the trial 
3. To measure intervention adherence 
4. To measure study completion rate   
5. To measure adverse events 
6. Assess objectives 1-5 using standard methods for rates and proportions 
7. Use objectives 1-6 to inform the design of a definitive RCT. 
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Secondary objectives 
1. To investigate changes in physical function and fitness. 
2. To quantify changes in muscle hypertrophy, lean body mass (LBM), fat mass 
(FM) and bone mineral density (BMD) assessed by dual energy x-ray 
absorptiometry (DXA) scanning and anthropometric measurements. 
3. To assess changes in prostate specific quality of life and fatigue perception. 
4. To assess changes in serum biomarkers, including sex hormone binding globulin 
(SHBG), testosterone, prostate specific antigen (PSA) and lactate 
dehydrogenase. 
5. To assess changes in the dietary and nutritional status using 3-day diet diaries.  
3. Methodology 
Study design: The study is a two arm feasibility RCT (randomisation ratio 1:1) 
comparing a resistance exercise training intervention plus dietary advice and usual care 
to usual care plus exercise advice.  Purposive sampling of men identified as having 
CRPC and under the care of STH will be used to identify the study cohort. 
Inclusion criteria:  
Men with CRPC 
Men with histologically confirmed PCa on long-term ADT with either  
 PSA>2ng/ml above nadir or PSA level that has risen serially on at least two 
occasions (each at least 4 weeks apart) in the presence of castrate levels of 
testosterone or;  
 Evidence of symptomatic disease progression whilst undergoing first line 
androgen deprivation therapy (ADT) in the presence of castrate levels of 
testosterone or;  
 Radiographic disease progression whilst undergoing first line ADT in the 
presence of castrate levels of testosterone 
Exclusion criteria:  
 Participation in other trials which might bias the evaluation of the primary 
objectives of the present study. 
 Current participation in regular physical activity (defined as purposeful physical 
activity of a moderate intensity for 90 minutes per week for at least six months). 
 Unstable angina, uncontrolled hypertension, recent myocardial infarction, 
pacemakers. 
 Uncontrolled painful or unstable bony metastatic lesions.  
 Within two months of invasive surgical treatment (transurethral surgery allowed). 
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 Any physical, neurological or psychiatric impairment or disease or other condition 
that would limit the ability to understand and complete the study assessments 
and complete the required questionnaires, recall and record of dietary 
information would be excluded.  
 
Recruitment: Men will be recruited from routine urology/oncology clinics at Sheffield 
Teaching Hospitals (STH). Men will be recruited in one of the following ways: 
1. Identify men in Urology outpatient clinics who are attending as part of ADT follow-up 
clinics. First approach will be done by the clinical team. 
2. Identified during routine clinical follow-up as part of 2nd line treatment for prostate 
cancer. First approach will be done by the clinical team. 
3. Identify men as part of oncology treatment and follow-up clinics at Weston Park 
Hospital.  First approach will be done by the clinical team. 
4. If a man is identified but is not due for a clinical follow-up visit for some time, a study 
pack (participant invitation letter, participant information sheet and informed consent 
form) will be sent to his home address for consideration. First approach will be the 
participant invitation letter, signed by the PI. 
5. In addition, posters in treatment clinics will advertise the study and invite men to 
contact the study team for more details about how to participate. 
4. Outcome measures 
The primary outcome will be the feasibility of the intervention including recruitment rate, 
adherence and attrition due to the intervention, loss to follow-up and adverse event rate 
(Arain, Campbell et al. 2010). These will be assessed by extracting data from screening 
and recruitment logs, attendance at supervised exercise training sessions and 
independent exercise log book records and a review of adverse events. Blinded 
assessors will perform the outcome testing. Feasibility outcomes will be assessed using 
standard methods for rates and proportions. 
Secondary outcomes will be assessed at baseline, 8 and at 16 weeks (apart from DEXA 
scans which will only take place at baseline and 16 weeks). Where possible, patient 
visits will be harmonised with participant routine clinic visits. The assessments will 
include: 
 Physical function assessment: Chair sit to stand, 6 minute walk test and grip 
strength test.  
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 DEXA scan (Smith, Finkelstein et al. 2002): appendicular LBM (kg), FM (kg) and 
BMD. 
 Muscle hypertrophy assessment: anthropometric measurements of muscle 
circumference. 
 Muscle Strength assessment: 1RM testing  
 Performance status scoring: ECOG (Oken, Creech et al. 1982) and Karnofsky 
(Yates, Chalmer et al. 1980). 
 Biochemical assessment: Lactate dehydrogenase, SHBG, testosterone and PSA 
 Quality of life assessed by the FACT-P (The Functional Assessment of Cancer 
Therapy-Prostate) (Esper, Mo et al. 1997) and FACT-F (The Functional 
Assessment of Cancer Therapy-Fatigue) (Yellen, Cella et al. 1997) 
questionnaire. 
 Diet and nutrition assessment: 3 day diet diaries analysed using the dietary 
analysis software package Nutritics. 
 Anthropometrics and demographics including height, weight, age, stage of 
disease, current and previous treatment for disease, co-morbidities and ethnicity. 
5. Study procedures 
Hospital recruitment and screening: Potential participants will be screened against the 
study inclusion criteria. Men who meet the criteria will either be approached in clinic by 
the clinical team during routine follow-up visits or have study details (participant 
invitation letter, participant information sheet and informed consent form) sent via the 
post to their home address, on behalf of the treating clinician. A follow-up phone call will 
be made to men who have details sent via post, to ensure contact address is up to date. 
Men who are interested in taking part in the study will be invited to contact the research 
team via phone or email. The men are then screened against the study exclusion 
criteria (described in section 3). Men who are not excluded, and are still interested, will 
be asked to provide informed consent to participate in the trial which will be conducted 
before their trial study assessments. 
A log of all patients screened for the study, excluding those who then enter into the 
study will be kept in the STH urology research office.  
Informed Consent Procedures: All men will be provided with the participant information 
sheet to consider for a minimum of 24 hours before informed consent is obtained for 
participation. 
Randomisation procedures: Patients will be randomised at an allocation ratio of 1:1 to 
either the exercise and dietary intervention arm plus usual care (intervention arm) or the 
exercise guidance advice plus usual care (control arm). A computer algorithm 
randomisation tool will administer the randomisation allocation procedure.  
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Usual care: All men will continue to be followed up in clinic as normal by their 
oncology/urology team.  
Specimens to be collected outside of routine care: At baseline, 8 and 16 weeks, 
fasting blood samples, for the assessment of lactate dehydrogenase, SHBG, 
testosterone and PSA will be collected by a trained member of the research team. Men 
will have approximately 20ml of venous blood drawn. Serum samples will be analysed 
according to local hospital laboratory standard operating procedures. Blood serum 
lactate dehydrogenase is a regulatory enzyme involved in anaerobic glycolysis activity 
is correlated to muscle fatigue and tissue damage (Machado, Koch et al. 2011, 
Washington, Healey et al. 2014) as well as prostate cancer progression in advanced 
disease (Naruse, Yamada et al. 2007). 
SHBG is a glycoprotein with a high affinity binding for hormones such as testosterone 
and oestradiol and its use in combination with total testosterone will provide us with 
information regarding the proportion of protein bound and free testosterone (Selby 
1990). 
PSA is a protein secreted by the epithelial cells of the prostate gland and will be 
monitored to monitor any biochemical disease changes. 
All participants will have blood samples sent to STH central laboratories for analysis. 
Anonymised blood results will be made available for research staff by central 
laboratories according to local policy. Results will be manually entered directly onto the 
secure research database according to participant trial number by the study team. 
Radiographic assessment outside of routine care: At baseline and 16 weeks a DEXA 
scan will collect data on via a full body scan to determine post-cranial appendicular 
whole body LM, whole body fat free mass (FFM) and whole body FM. Bone health 
assessed by BMD assessment at the lumbar spine, total hip and whole body. Areas of 
previous fracture or where known bone metastasis exist will be excluded from the 
region of interest to calculate BMD. Scans will be performed using the Hologic 
densitometer, at the clinical Research Facility, Northern General Hospital and analysed 
by the scan technician using the standard DXA software. Participants will be asked to lie 
flat in the centre of the scan table and remain still for the duration of the scan. 
Participants found to be osteoporotic on baseline scanning (i.e. high risk of fracture and 
requiring osteoporosis treatment) will be referred to the metabolic bone centre in 
Sheffield for further assessment and treatment.  
Muscle function measures outside of routine care: 
Muscle Strength assessment  
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One-repetition maximum (1 RM) strength tests will be carried out on knee extension, leg 
press and chest press at baseline and 16 weeks using resistance machines in 
physiology testing suites at Sheffield Hallam University. The 1 RM test was defined as 
the maximal load that could be moved through the full range of motion with proper form 
for one repetition(Delmonico, Kostek et al. 2005, Hanson, Sheaff et al. 2013). 
Participants will undergo at least one familiarization session preceding the testing 
session in which they will complete the exercise with little or no resistance and 
instructed on proper warm-up, stretching, and exercise techniques to help prevent 
injuries and reduce muscle soreness after the strength testing assessment. The same 
blinded investigator will be present conducting the strength tests for each subject both 
at baseline and 16 weeks using standardized procedures with consistency of seat 
adjustment, body position, and level of vocal encouragement. The 1 RM will be 
achieved by gradually increasing the resistance from an estimated submaximal load 
after each successful exercise repetition until the maximal load was obtained.  
Physical performance assessment outside of routine care: 
Physical function assessment 
Chair-sit to stand, hand grip strength and 6 minute walk test (shuttle walk test) to be 
performed in Sheffield Hallam physiology suits alongside muscle strength assessment 
under guidance of the blinded investigator at baseline, 8 and at 16 weeks. Even small 
changes in muscle mass can have significant effects on physical function testing 
(Argilés, López-Soriano et al. 2011). The grip strength, 6 minute walk test and chair sit 
to stand are markers of disability, high dependency, nutritional status, survival in elderly 
people and short and long-term mortality and morbidity (Ling, Taekema et al. 2010, De 
Feo, Tramarin et al. 2011, Norman, Stobäus et al. 2011, Kim, Yabushita et al. 2012). 
Chair-sit to stand: Participants will be seated in a hard-backed chair, arms folded across 
their chest, and instructed to rise as fast as possible to a full standing position and then 
return to a full sitting position as many times as they can within 30s. (Galvão and Taaffe 
2005, Galvao, Nosaka et al. 2006). Their number of repetitions will be recorded 
(Bourke, Doll et al. 2011). 
Grip strength test: Measurements will be made using a digital hand dynamometer. 
Participants are asked to grip the dynamometer for five seconds and the results are 
recorded, repeated on each hand three times. The maximal grip strength will be used 
for analysis. 
6 minute walk test (shuttle test): The participant will walk along a marked ten meter 
course at their normal pace with the number of steps and time recorded to the nearest 
second for six minutes. The test will be repeated three times and the average time 
calculated.  
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Performance status outcomes  
Performance status will be assessed by the Eastern Cooperative Oncology Group 
(ECOG) and Karnofsky performance status (KPS) assessment tools at baseline, 8 and 
at 16 weeks.(Yates, Chalmer et al. 1980, Oken, Creech et al. 1982) 
Questionnaires and diet diaries: Participants will be asked to complete quality of life 
assessed by the FACT-P and FACT-F questionnaires at baseline and at 16 
weeks.(Esper, Mo et al. 1997, Yellen, Cella et al. 1997, Cella, Nichol et al. 2009) At 
baseline and 16 weeks participants will be asked to complete and return three day diet 
diaries. Individual feedback will be given on diet diaries with the aim of facilitating 
optimal nutritional intake. A dietary analysis software package (Nutritics) will be used to 
assess nutritional intake. 
End of Study Definition: Once all participants have completed 16 week follow-up, study 
feasibility analysis and fidelity measures are completed, the research ethics committee 
will be informed of study end. 
Post intervention participants will be invited to attend a focus group to share their 
experiences of the exercise intervention. The experiences and views of participants in 
this pilot study will be used to inform the strategy for the design and running of a 
subsequent larger study. 
Current medications and comorbidity: Current medications will be recorded during 
study assessments as well as any other known co-morbidities. 
Criteria for discontinuation/withdrawal: exit criteria would be patient choice. Data 
from participants who have withdrawn from the study (see Criteria for 
discontinuation/withdrawal above) will be retained up until the point of withdrawal on the 
study database and will be included in the overall study analysis. 
Subject withdrawal: (including data collection / retention for withdrawn participants): 
Data from participants who have withdrawn from the study (see Criteria for 
discontinuation/withdrawal above) will be retained up until the point of withdrawal on the 
study database and will be included in the overall study analysis. 
Procedure for collecting data: hard copies of case report forms will be used during 
study assessments and then stored in Collegiate Hall (Sheffield Hallam University), in a 
locked cabinet which only the trial team have access to.  
Participant evaluation of the intervention: post intervention, participants will be invited 
to attend a respective focus group to share their experiences of the exercise 
intervention, dietary supplements and overall participation in the trial. The experiences 
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and views of participants in this study will be used to inform the strategy for the design 
of a definitive phase III/IV trial.  
 
 
Figure 1: Study schematic 
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6. The Intervention and control group. 
Exercise and dietary intervention arm: 
Exercise sessions will take place at The Centre for Sport and Exercise Science at 
Sheffield Hallam University in a dedicated exercise facility with an experienced exercise 
specialist.  
 
Structure and content of supervised exercise and dietary intervention 
Men randomised to the exercise intervention arm will undergo a 16 week programme of 
exercise involving three supervised exercise sessions a week and encouragement to 
undertake home-based independent exercise. Preceding any exercise sessions, men 
will attend a one to one consultation (1 hr) with the exercise specialist for a tailored 
exercise induction.  
In each session, participants will perform 3-4 sets of 6-12 repetitions of 6 resistance 
exercises. Sessions will be conducted in a group format where possible. Participants 
will be asked to undertake and log (in a record book provided) at least one independent 
30 minute aerobic activity at home during this period. The activity chosen will be based 
on that most convenient for the participant (such as walking or making use of 
community exercise facilities). In the record book participants will be asked to record the 
time of activity, duration and exercise intensity based on the Borg rating of perceived 
exertion scale, details of which will be provided in the booklet (Borg 1982). The 
participant logged activity will be documented when participants attend supervised 
exercise sessions and further encouraged to undertake aerobic exercise through goal 
setting and self-regulation.  
Dietary advice 
Participants randomised to the intervention arm will also be offered dietary advice in the 
form of a short seminar in a small group format on healthy eating and an information 
booklet with weekly meal plans and recipes. Multiple pre-clinical and clinical studies, 
including observational cohort studies, have demonstrated anti-tumour effects of a low 
carbohydrate and high protein diet (Slattery, Benson et al. 1997, Terry, Jain et al. 2003, 
Fung, Hu et al. 2011, Ho, Leung et al. 2011, Fokidis, Yieng Chin et al. 2015). In 
addition, a high fibre diet has been associated with chemoprotective effects, lowering 
the risk of colorectal cancer (Bingham, Day et al. 2003, Peters, Sinha et al. 2003). 
Dietary advice will encourage participants to adopt a diet rich in nutrient dense whole 
foods, fruit and vegetables and discourage processed foods and those high in refined 
carbohydrates and saturated fats. Participants will also be asked to limit alcohol intake. 
Recipes provided will encourage high protein, moderate fat, high fibre and low 
carbohydrate meals.  
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Dietary supplementation 
Whey protein: To promote muscle protein synthesis, participants will be required to 
increase protein consumption via whey protein supplementation provided. Whey protein 
is rapidly digested and has a high leucine content which appears more efficient at 
muscle protein synthesis than other protein alternatives (e.g. soya protein) post-
resistance exercise (Wilkinson, Tarnopolsky et al. 2007). Participants will be provided 
with whey protein post-supervised exercise sessions and to take home where they will 
be advised to consume with 300-500ml of fat-free milk or water (Hartman, Tang et al. 
2007). The recommended dosage of protein will be bodyweight (kg-1)* 1.2 g/day as 
previously described (Burke, Chilibeck et al. 2001). 
Creatine: Studies have shown that a combination of whey protein and creatine promote 
increases in LBM (Burke, Chilibeck et al. 2001). Additionally, there is a body of evidence 
to indicate that creatine supplementation during resistance training is more effective at 
increasing muscle strength and weightlifting performance than resistance training alone 
(Rawson and Volek 2003) including its use in older adults (Brose, Parise et al. 2003). 
Participants will require a dosage of 0.25 g·kg-1 of LBM a day of creatine during the 
acute loading phase (the first 5 days of creatine supplementation) and thereafter a 
maintenance dose of 5 grams per day (Burke, Chilibeck et al. 2003). 
Control arm: Men randomised to this arm of the trial will receive usual care from their 
oncology/urology team, will be provided with Macmillan exercise advice guidelines and 
signposted to local exercise programmes for cancer patients (e.g. Move more 
Sheffield).   
7. Statistical considerations 
Sample size and power calculation: A target recruitment figure of 50 patients can 
provide estimates of feasibility measures and of variability in secondary outcomes for 
use in power calculations with reference to the design of a subsequent larger-scale RCT 
(Lancaster, Dodd et al. 2004, Bourke, Doll et al. 2011).  In addition a sample size of 50 
men is sufficient to detect preliminary improvements in physical performance (chair sit 
to-stand test) similar to those reported in an earlier feasibility trial of men with advanced 
prostate cancer undergoing androgen deprivation therapy. Assuming an improvement of 
4 reps in the performance test, and a standard deviation of 4 reps (providing an effect 
size of 1.0) at an alpha level of 0.05 and with 80% power, this would require 19 men per 
arm, allowing for a 20% drop-out rate over 16 weeks, (Bourke, Doll et al. 2011) 
 
Analysis: Feasibility outcomes will be assessed using standard methods for rates and 
proportions. Secondary outcomes will also be compared at each follow-up point using 
ANCOVA procedures, with baseline values being used as the covariate. Asscoaitions 
between physical activity dose and other outcome variables will be analysed using 
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bivariate correlation and regression analysis. Statistical significance will be set at p 
<0.05.  Data will be analysed using the SPSS statistical package (SPSS U.K. Ltd, 
Woking U.K.). The data will be analysed on an intention to treat basis. 
A Mann-Whitney U test will be used for non-normally distributed data. Statistical 
considerations will be made for potential effects of medications or comorbidities on 
blood serum markers if necessary. 
A thematic ‘framework’ approach will be used for the analysis of post-intervention focus 
groups.(Bourke, Sohanpal et al. 2012) 
8. Ethics 
Full local ethical and research governance approval will be obtained before study 
recruitment begins. All men will be provided with the participant information sheet to 
consider for a minimum of 24 hours before written informed consent is obtained for 
participation. 
9. Safety 
All recruited men will continue to be under the care of their treating cancer clinician who 
will be aware of their participation in the trial and will follow current best practice 
standard of care. A formal risk assessment has been carried out (see Appendix 1) 
Study adverse events will be recorded and addressed according to the criteria below. 
Any new pain (e.g. bone pain) will be discussed with the participant’s cancer clinician 
and referred to the patient’s GP or individuals own oncologist as advised by clinician. 
Any other medical complication e.g. cardiovascular, will be referred directly to the study 
participants GP. Immediate life support facilities will be available in the exercise suite. 
The risks of the exercise programme will be fully apparent at the end of the trial, but are 
likely to be minimal. 
Adverse Events (AE)  
Notification and reporting Adverse Events or Reactions  
Non-serious adverse events: the AE is recorded in the study file and the participant will 
be followed up by the research team. The AE is documented in the participants’ medical 
notes (where appropriate).  
Serious incidents/ serious untoward incidents (SI/SUI) 
A SI/SUI defined as an untoward occurrence that:  
(a) results in death;  
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(b) is life-threatening;  
(c) requires hospitalisation or prolongation of existing hospitalisation;  
(d) results in persistent or significant disability or incapacity;  
(e) is otherwise considered medically significant by the investigator.  
A SI/SUI occurring to a research participant will be reported to the study REC where in 
the opinion of the Chief Investigator the event was:  
• Related – that is, it resulted from administration of any of the research procedures, 
and  
• Unexpected – that is, the type of event is not listed in the protocol as an expected 
occurrence.  
SI/SUIs that are considered to be ‘related’ and ‘unexpected’ will be reported within 7 
working days of learning of the event. 
10. Data handling and record keeping 
All data will be stored according to the 1998 Data protection Act. Participant data will be 
anonymised before entered into a password protected study database. Participant 
identifiable data collected during screening assessments and contact details will be 
retained in the study co-ordinating centre (Collegiate Hall, Sheffield Hallam University 
and Royal Hallamshire hospital) in restircted access research offices in locked filing 
cabinets. Data from paper case report forms will be entered by the coordinating centre 
(Sheffield Hallam University, SHU), onto a secure, password protected, encrypted hard 
drives. Copies of paper CRFs received at the coordinating centre will be stored in the 
Trial Master File (TMF) for source data verification purposes, in a locked cabinet which 
is protected by security code doors which only authorised personnel can gain entry to. 
11. Laboratories 
Exercise intervention and physical function assessments 
 The physiology research facilities at Sheffield Hallam University will be used to 
carry out the exercise intervention, the muscle function measures and physical 
performance assessments. 
Radiographical imaging (DXA scans) 
 DXA scans will be performed in the Clinical Research Facility (CRF), Northern 
General Hospital, Herries Road, Sheffield S5 7AU. 
Data Preparation and Collection  
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 Samples will be labelled with participant identification numbers, time & date 
collected and analysis to be carried out (PSA etc).  
 Samples will be sent to local hospitals central laboratories for analysis and 
results will be uploaded to the NHS STH Integrated Clinical Environment (ICE) 
system.  
12. Dissemination and research findings 
The study results will be published and broadcasted via papers, conference, feedback 
to patients and charities. Trial feasibility analysis will be written up for publication in 
scientific peer-reviewed journals. 
Appendix  
Safety and risk assessment  
Radiation dose: The effective radiation dose from DEXA scans is 32μSV less than one 
year’s radiation dose and considered “low risk”. Public Health England describe a 
radiation exposure equivalent to a few years average natural background radiation as 
‘Low Risk’, with between 1:10,000 and 1:1,000 lifetime additional risk of cancer.  
Venepuncture: Blood samples will be taken by an appropriately trained trial staff 
member. Consent to use and store the samples will be obtained according to the 
Human Tissue Act 2004. Risks include a small amount of bruising, bleeding or pain at 
the needle site. Some may feel faint and on very rare occasion infection can occur.  
Exercise intervention: Exercise in men for prostate cancer has been demonstrated to 
be of low risk in a recent meta-analysis of 16 RCTs. Minor musculo-skeletal issues such 
as cramps and or low grade strains can occur but are very infrequent.  Serious averse 
events such as MI, are very seldom indeed and there is no difference in the rate of 
cardiac serious adverse events in men undertaking exercise interventions compared 
with comparison control groups.  
Supplementation guidelines  
Whey protein: Participants will be provided with whey protein post-supervised exercise 
sessions within the sports labs and to take home where they will be advised to consume 
with 300-500ml of fat-free milk or water. The recommended dosage of protein is 
bodyweight (kg-1)* 1.2 g/day. Participants will be asked to take 4.5 scoops of whey 
protein a day, amounting to 90g of protein, and asked to make up the rest with diet. 
Dietary guidelines will be provided to aid in the required protein consumption. 
Participants will be provided with protein shakers.  
Creatine: Participants will require a dosage of 0.25 g·kg-1 of LBM a day of creatine 
during the acute loading phase (the first 5 days of creatine supplementation) and 
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thereafter a maintenance dose of 5 grams per day. One and a half scoops equates to 
5g. Participants will be encouraged to take the creatine supplement alongside the whey 
supplement.  
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Appendix 20 The COMRADE three phase exercise programme 
 
  
COMRADE trial  
16 week supervised exercise 
case report form 
 
Participant:     Date:   
 
Participant comorbidities and medications:  
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Phase one  
DAY ONE 
WEEK 1 
Session 1 
WEEK 1 
Session 2 
WEEK 2 
Session 1 
WEEK 3 
Session 1 
Warm-up Date Date Date Date 
CV machine: Tread/XT/Bike (10-15m) 
Intensity (incline/speed/resistance)  
 
    
Main session  Regressions and progressions  Set 1 Set 2 Set 3 Set 1 Set 2 Set 3 Set 1 Set 2 Set 3 Set 1 Set 2 Set 3 
Body weight squat 
 
R - Chair placed behind client/ swiss ball  
P - Goblet squat 
Reps 
Weight 
            
Seated cable row 
 
R – Standing cable row/ reduce weight 
P- increase weight/ bent over row 
Reps 
Weight 
            
Bench press 
 
R - Reduce weight/ single arm press (floor) 
P - Increase weight 
Reps 
Weight 
            
Body weight lunge 
(single leg)  
R - Reduce repetitions/ chair assisted 
P - Weighted lunge 
Reps 
Weight 
            
Lat raise R – Seated lat raise/ single arm/ reduce 
ROM (bend elbows) 
P – increase weight 
Reps 
Weight 
            
Dumbbell side bends R - Reduce weight/ reps 
P – Increase weight/ Pallof press (cable) 
Reps 
Weight 
            
Cool down Notes Notes Notes Notes 
CV machine: Tread/ XT/ bike 
Intensity (incline/speed/resistance) 
    
Additional notes on session (e.g regressions, fatigue, difficulty with completing sets, AE/SAE [must also fill out AE/SAE form]) 
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Phase one  
DAY ONE 
WEEK 3 
Session 2 
WEEK 4 
Session 1 
WEEK 5 
Session 1 
WEEK 5 
Session 2 
Warm-up Date Date Date Date 
CV machine: Tread/XT/Bike (10-15m) 
Intensity (incline/speed/resistance) 
    
Main session  Regressions and progressions  Set 1 Set 2 Set 3 Set 1 Set 2 Set 3 Set 1 Set 2 Set 3 Set 1 Set 2 Set 3 
Body weight squat 
 
R - Chair placed behind client/ swiss ball  
P - Goblet squat 
Reps 
Weight 
            
Seated cable row 
 
R – Standing cable row/ reduce weight 
P- increase weight/ bent over row 
Reps 
Weight 
            
Bench press 
 
R - Reduce weight/ single arm press (floor) 
P - Increase weight 
Reps 
Weight 
            
Body weight lunge 
(single leg)  
R - Reduce repetitions/ chair assisted 
P - Weighted lunge 
Reps 
Weight 
            
Lat raise R – Seated lat raise/ single arm/ reduce 
ROM (bend elbows) 
P – increase weight 
Reps 
Weight 
            
Dumbbell side bends R - Reduce weight/ reps 
P – Increase weight/ Pallof press (cable) 
Reps 
Weight 
            
Cool down Notes Notes Notes Notes 
CV machine: Tread/ XT/ bike 
Intensity (incline/speed/resistance) 
    
Additional notes on session (e.g regressions, fatigue, difficulty with completing sets, AE/SAE [must also fill out AE/SAE form]) 
 
Phase one  WEEK 1 WEEK 2 WEEK 2 WEEK 3 
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DAY TWO Session 1 Session 1 Session 2 Session 1 
Warm-up Date Date Date Date 
CV machine: Tread/XT/Bike (10-15m) 
Intensity (incline/speed/resistance) 
    
Main session  Regressions and progressions  Set 1 Set 2 Set 3 Set 1 Set 2 Set 3 Set 1 Set 2 Set 3 Set 1 Set 2 Set 3 
Body weight squat 
 
R - Chair placed behind client/ swiss ball  
P - Goblet squat 
Reps 
Weight 
            
Push ups 
 
R – Wall/bench/bent knees push ups 
P – 
Reps 
Weight 
            
Glute bridge hold
  
R -  
P – Barbell weighted/ feet on bench 
Reps 
Weight 
            
Single arm bent over 
row 
R – Standing cable row/ resistance band  
P- increase weight 
Reps 
Weight 
            
Farmer carries R – reduce weight/distance 
P –increase weight 
Reps 
Weight 
            
1-arm kneeling lat 
pulldown 
R – resistance band 
P – increase weight 
Reps 
Weight 
            
Cool down Notes Notes Notes Notes 
CV machine: Tread/ XT/ bike 
Intensity (incline/speed/resistance) 
    
Additional notes on session (e.g regressions, fatigue, difficulty with completing sets, AE/SAE [must also fill out AE/SAE form]) 
 
 
Phase one  WEEK 4 WEEK 4 WEEK 5 
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DAY TWO Session 1 Session 2 Session 1 
Warm-up Notes Notes Notes 
CV machine: Tread/XT/Bike (10-15m) 
Intensity (incline/speed/resistance) 
   
Main session  Regressions and progressions  Set 1 Set 2 Set 3 Set 1 Set 2 Set 3 Set 1 Set 2 Set 3 
Body weight squat 
 
R - Chair placed behind client/ swiss ball  
P - Goblet squat 
Reps 
Weight 
         
Push ups 
 
R – Wall/bench/bent knees push ups 
P – 
Reps 
Weight 
         
Glute bridge hold
  
R -  
P – Barbell weighted/ feet on bench 
Reps 
Weight 
         
Single arm bent over 
row 
R – Standing cable row/ resistance band  
P- increase weight 
Reps 
Weight 
         
Farmer carries R – reduce weight/distance 
P –increase weight 
Reps 
Weight 
         
1-arm kneeling lat 
pulldown 
R – resistance band 
P – increase weight 
Reps 
Weight 
         
Cool down Notes Notes Notes 
CV machine: Tread/ XT/ bike 
Intensity (incline/speed/resistance) 
   
Additional notes on session (e.g regressions, fatigue, difficulty with completing sets, AE/SAE [must also fill out AE/SAE form]) 
 
Phase two 
DAY ONE 
WEEK 1 
Session 1 
WEEK 1 
Session 2 
WEEK 2 
Session 1 
WEEK 3 
Session 1 
 
 
155 
 
 
Warm-up Date Date Date Date 
CV machine: Tread/XT/Bike (10-15m) 
Intensity (incline/speed/resistance) 
    
Main session  Regressions and progressions  Set 1 Set 2 Set 3 Set 1 Set 2 Set 3 Set 1 Set 2 Set 3 Set 1 Set 2 Set 3 
Body weight sumo 
squat 
 
R - Chair placed behind client/ swiss ball  
P - weighted sumo squat 
Reps 
Weight 
            
Dumbbell Deadlift R – Resistance band deadlift/ hip hinge  
P – Barbell Romanian deadlift 
Reps 
Weight 
            
Leg raise (bench) R – Floor based bent knee leg raise 
P - Floor based V-snap 
Reps 
Weight 
            
Upright row 
(dumbbell/barbell) 
R – seated row/resistance band 
P- increase weight 
Reps 
Weight 
            
Dumbbell shoulder 
press 
R – Seated/ single arm press 
P - Increase weight 
Reps 
Weight 
            
Tall plank R – reduce angle with bench or bosu 
P – Low plank 
Reps 
Weight 
            
Cool down Notes Notes Notes Notes 
CV machine: Tread/ XT/ bike 
Intensity (incline/speed/resistance) 
    
Additional notes on session (e.g regressions, fatigue, difficulty with completing sets, AE/SAE [must also fill out AE/SAE form]) 
 
Phase two 
DAY ONE 
WEEK 3 
Session 2 
WEEK 4 
Session 1 
WEEK 5 
Session 1 
WEEK 5 
Session 1 
Warm-up Date Date Date Date 
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CV machine: Tread/XT/Bike (10-15m) 
Intensity (incline/speed/resistance) 
    
Main session  Regressions and progressions  Set 1 Set 2 Set 3 Set 1 Set 2 Set 3 Set 1 Set 2 Set 3 Set 1 Set 2 Set 3 
Body weight sumo 
squat 
 
R - Chair placed behind client/ swiss ball  
P - weighted sumo squat 
Reps 
Weight 
            
Dumbbell Deadlift R – Resistance band deadlift/ hip hinge  
P – Barbell Romanian deadlift 
Reps 
Weight 
            
Leg raise (bench) R – Floor based bent knee leg raise 
P - Floor based V-snap 
Reps 
Weight 
            
Upright row 
(dumbbell/barbell) 
R – seated row/resistance band 
P- increase weight 
Reps 
Weight 
            
Dumbbell shoulder 
press 
R – Seated/ single arm press 
P - Increase weight 
Reps 
Weight 
            
Tall plank R – reduce angle with bench or bosu 
P – Low plank 
Reps 
Weight 
            
Cool down Notes Notes Notes Notes 
CV machine: Tread/ XT/ bike 
Intensity (incline/speed/resistance) 
    
Additional notes on session (e.g regressions, fatigue, difficulty with completing sets, AE/SAE [must also fill out AE/SAE form]) 
 
 
Phase two 
DAY TWO 
WEEK 1 
Session 1 
WEEK 2 
Session 1 
WEEK 2 
Session 2 
WEEK 3 
Session 1 
Warm-up Date Date Date Date 
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CV machine: Tread/XT/Bike (10-15m) 
Intensity (incline/speed/resistance) 
    
Main session  Regressions and progressions  Set 1 Set 2 Set 3 Set 1 Set 2 Set 3 Set 1 Set 2 Set 3 Set 1 Set 2 Set 3 
Knee extension R – reduce weight  
P – increase weight 
Reps 
Weight 
            
Back extension R – Seated lat raise/ single arm 
P – increase weight 
Reps 
Weight 
            
Standing bicep curl 
(low pulley) 
R - Reduce weight 
P – Dumbbell/barbell standing bicep curl 
Reps 
Weight 
            
Leg press R - Reduce weight 
P – Increase weight 
Reps 
Weight 
            
Standing tricep 
pulldown 
R – Reduce weight 
P- increase weight/ seated tricep extension 
Reps 
Weight 
            
Sit-ups R – Reduce reps/ leg raises (bench) 
P – Hands above head 
Reps 
Weight 
            
Cool down Notes Notes Notes Notes 
CV machine: Tread/ XT/ bike 
Intensity (incline/speed/resistance) 
    
Additional notes on session (e.g regressions, fatigue, difficulty with completing sets, AE/SAE [must also fill out AE/SAE form]) 
 
Phase two 
DAY TWO 
WEEK 4 
Session 1 
WEEK 4 
Session 2 
WEEK 5 
Session 1 
Warm-up Date Date Date 
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CV machine: Tread/XT/Bike (10-15m) 
Intensity (incline/speed/resistance) 
   
Main session  Regressions and progressions  Set 1 Set 2 Set 3 Set 1 Set 2 Set 3 Set 1 Set 2 Set 3 
Knee extension R – reduce weight  
P – increase weight 
Reps 
Weight 
         
Back extension R – Seated lat raise/ single arm 
P – increase weight 
Reps 
Weight 
         
Standing bicep curl 
(low pulley) 
R - Reduce weight 
P – Dumbbell/barbell standing bicep curl 
Reps 
Weight 
         
Leg press R - Reduce weight 
P – Increase weight 
Reps 
Weight 
         
Standing tricep 
pulldown 
R – Reduce weight 
P- increase weight/ seated tricep extension 
Reps 
Weight 
         
Sit-ups R – Reduce reps/ leg raises (bench) 
P – Hands above head 
Reps 
Weight 
         
Cool down Notes Notes Notes 
CV machine: Tread/ XT/ bike 
Intensity (incline/speed/resistance) 
   
Additional notes on session (e.g regressions, fatigue, difficulty with completing sets, AE/SAE [must also fill out AE/SAE form]) 
 
Phase three 
DAY ONE 
WEEK 1 
Session 1 
WEEK 1 
Session 2 
WEEK 2 
Session 1 
WEEK 3 
Session 1 
Warm-up Date Date Date Date 
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CV machine: Tread/XT/Bike (10-15m) 
Intensity (incline/speed/resistance) 
    
Main session  Regressions and progressions  Set 1 Set 2 Set 3 Set 1 Set 2 Set 3 Set 1 Set 2 Set 3 Set 1 Set 2 Set 3 
Body weight squat 
 
R - Chair placed behind client/ swiss ball  
P - weighted sumo squat 
Reps 
Weight 
            
Leg press R – reduce weight  
P – increase weight 
Reps 
Weight 
            
Cable row R – reduce weight  
P – increase weight 
Reps 
Weight 
            
Bicep curl R – reduce weight  
P – increase weight 
Reps 
Weight 
            
Cable tricep pull 
down 
R – underarm tricep 
P - Increase weight 
Reps 
Weight 
            
Tall plank R – reduce angle with bench or bosu 
P – Low plank 
Reps 
Weight 
            
Cool down Notes Notes Notes Notes 
CV machine: Tread/ XT/ bike 
Intensity (incline/speed/resistance) 
    
Additional notes on session (e.g regressions, fatigue, difficulty with completing sets, AE/SAE [must also fill out AE/SAE form]) 
 
Phase three 
DAY ONE 
WEEK 3 
Session 2 
WEEK 4 
Session 1 
WEEK 5 
Session 1 
WEEK 5 
Session 1 
Warm-up Date Date Date Date 
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CV machine: Tread/XT/Bike (10-15m) 
Intensity (incline/speed/resistance) 
    
Main session  Regressions and progressions  Set 1 Set 2 Set 3 Set 1 Set 2 Set 3 Set 1 Set 2 Set 3 Set 1 Set 2 Set 3 
Body weight squat 
 
R - Chair placed behind client/ swiss ball  
P - weighted sumo squat 
Reps 
Weight 
            
Leg press R – reduce weight  
P – increase weight 
Reps 
Weight 
            
Cable row R – reduce weight  
P – increase weight 
Reps 
Weight 
            
Bicep curl R – reduce weight  
P – increase weight 
Reps 
Weight 
            
Cable tricep 
pulldown 
R – underarm tricep 
P - Increase weight 
Reps 
Weight 
            
Tall plank R – reduce angle with bench or bosu 
P – Low plank 
Reps 
Weight 
            
Cool down Notes Notes Notes Notes 
CV machine: Tread/ XT/ bike 
Intensity (incline/speed/resistance) 
    
Additional notes on session (e.g regressions, fatigue, difficulty with completing sets, AE/SAE [must also fill out AE/SAE form]) 
 
Phase three 
DAY ONE 
FINAL WEEK 6 
Session 1 
Warm-up Date 
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CV machine: Tread/XT/Bike (10-15m) 
Intensity (incline/speed/resistance) 
 
Main session  Regressions and progressions  Set 1 Set 2 Set 3 
Body weight squat 
 
R - Chair placed behind client/ swiss ball  
P - weighted sumo squat 
Reps 
Weight 
   
Leg press R – reduce weight  
P – increase weight 
Reps 
Weight 
   
Cable row R – reduce weight  
P – increase weight 
Reps 
Weight 
   
Bicep curl  R – reduce weight  
P – increase weight 
Reps 
Weight 
   
Cable tricep 
pulldown 
R – underarm tricep 
P - Increase weight 
Reps 
Weight 
   
Tall plank R – reduce angle with bench or bosu 
P – Low plank 
Reps 
Weight 
   
Cool down Notes 
CV machine: Tread/ XT/ bike 
Intensity (incline/speed/resistance) 
 
 
 
Phase three 
DAY TWO 
WEEK 1 
Session 1 
WEEK 2 
Session 1 
WEEK 2 
Session 2 
WEEK 3 
Session 1 
Warm-up Date Date Date Date 
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CV machine: Tread/XT/Bike (10-15m) 
Intensity (incline/speed/resistance) 
    
Main session  Regressions and progressions  Set 1 Set 2 Set 3 Set 1 Set 2 Set 3 Set 1 Set 2 Set 3 Set 1 Set 2 Set 3 
Bench press R – reduce weight/reduce angle  
P – increase weight 
Reps 
Weight 
            
Deadlift R – Resistance band deadlift/ hip hinge  
P – Barbell Romanian deadlift 
Reps 
Weight 
            
Hip abbductor R – reduce weight  
P – increase weight 
Reps 
Weight 
            
Lateral cable hold R – reduce weight  
P – increase weight 
Reps 
Weight 
            
kick backs R – reduce weight  
P – increase weight 
Reps 
Weight 
            
Dead bug R – reduce angle with bench 
P – walking plank 
Reps 
Weight 
            
Cool down Notes Notes Notes Notes 
CV machine: Tread/ XT/ bike 
Intensity (incline/speed/resistance) 
    
Additional notes on session (e.g regressions, fatigue, difficulty with completing sets, AE/SAE [must also fill out AE/SAE form]) 
 
 
Phase three 
DAY TWO 
WEEK 4 
Session 1 
WEEK 4 
Session 2 
WEEK 5 
Session 1 
FINAL WEEK 6 
Session 1 
Warm-up Date Date Date Date 
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CV machine: Tread/XT/Bike (10-15m) 
Intensity (incline/speed/resistance) 
    
Main session  Regressions and progressions  Set 1 Set 2 Set 3 Set 1 Set 2 Set 3 Set 1 Set 2 Set 3 Set 1 Set 2 Set 3 
Bench Press 
 
R – reduce weight/reduce angle  
P – increase weight 
Reps 
Weight 
            
Deadlift R – Resistance band deadlift/ hip hinge  
P – Barbell Romanian deadlift 
Reps 
Weight 
            
Hip abbductor R – reduce weight  
P – increase weight 
Reps 
Weight 
            
Lateral cable hold R – reduce weight  
P – increase weight 
Reps 
Weight 
            
kick backs R – reduce weight  
P – increase weight 
Reps 
Weight 
            
Dead bug R – reduce angle with bench 
P – walking plank 
Reps 
Weight 
            
Cool down Notes Notes Notes Notes 
CV machine: Tread/ XT/ bike 
Intensity (incline/speed/resistance) 
    
Additional notes on session (e.g regressions, fatigue, difficulty with completing sets, AE/SAE [must also fill out AE/SAE form]) 
 
 
Phase three 
DAY TWO 
FINAL WEEK 6 
Session 2 
Warm-up Date 
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CV machine: Tread/XT/Bike (10-15m) 
Intensity (incline/speed/resistance) 
 
Main session  Regressions and progressions  Set 1 Set 2 Set 3 
Bench press 
 
R – reduce weight/reduce angle  
P – increase weight 
Reps 
Weight 
   
Deadlift R – Resistance band deadlift/ hip hinge  
P – Barbell Romanian deadlift 
Reps 
Weight 
   
Hip abbductor R – reduce weight  
P – increase weight 
Reps 
Weight 
   
Lateral cable hold R – reduce weight  
P – increase weight 
Reps 
Weight 
   
kick backs R – reduce weight  
P – increase weight 
Reps 
Weight 
   
Dead bug R – reduce angle with bench 
P – walking plank 
Reps 
Weight 
   
Cool down Notes 
CV machine: Tread/ XT/ bike 
Intensity (incline/speed/resistance) 
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Appendix 21 Independent exercise diary  
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Appendix 22 ECOG and Karnofsky performance scoring 
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Appendix 23 FACT-F questionnaire and FACT-F scoring  
 
COMRADE FACIT Fatigue Scale (Version 4) 25/10/2016 STH19598 
 
Below is a list of statements that other people with your illness have said are important. 
Please circle or mark one number per line to indicate your response as it applies to 
the past 7 days. 
 
 
  Not 
at all 
A little 
bit 
Some-
what 
Quite 
a bit 
Very 
much 
 
HI7 I feel 
fatigued
 ...............................................................  
0 1 2 3 4 
HI12 I feel weak all 
over
 ...............................................................  
0 1 2 3 4 
An1 I feel listless (“washed 
out”)
 ...............................................................  
0 1 2 3 4 
An2 I feel 
tired
 ...............................................................  
0 1 2 3 4 
An3 I have trouble starting things because I 
am 
tired
 ...............................................................  
0 1 2 3 4 
An4 I have trouble finishing things because I 
am 
tired
 ...............................................................  
0 1 2 3 4 
An5 I have 
energy
 ...............................................................  
0 1 2 3 4 
An7 I am able to do my usual 
activities
 ...............................................................  
0 1 2 3 4 
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An8 I need to sleep during the 
day
 ...............................................................  
0 1 2 3 4 
An12 I am too tired to 
eat
 ...............................................................  
0 1 2 3 4 
An14 I need help doing my usual 
activities
 ...............................................................  
0 1 2 3 4 
An15 I am frustrated by being too tired to do 
the things I want to 
do
 ...............................................................  
 
0 
 
1 
 
2 
 
3 
 
4 
An16 I have to limit my social activity because 
I am 
tired
 ...............................................................  
0 1 2 3 4 
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FACIT-Fatigue Subscale Scoring Guidelines (Version 4) – Page 1 
 
Instructions:* 1. Record answers in "item response" column. If missing, mark with an X 
    2. Perform reversals as indicated, and sum individual items to obtain a score. 
3. Multiply the sum of the item scores by the number of items in the subscale, then divide by the   
    number of items answered.  This produces the subscale score. 
4. The higher the score, the better the QOL. 
 
 
 
Subscale          Item Code       Reverse item?            Item response          Item Score  
 
FATIGUE  HI7       4 - ________  =________ 
SUBSCALE  HI12  4 - ________  =________ 
      An1  4 - ________  =________ 
An2  4 - ________  =________ 
An3  4 - ________  =________ 
An4  4 - ________  =________ 
An5  0 + ________  =________ 
An7  0 + ________  =________ 
An8  4 - ________  =________ 
An12  4 - ________  =________ 
An14  4 - ________  =________ 
An15  4 - ________  =________ 
An16  4 - ________  =________ 
 
              Sum individual item scores:________   
                      Multiply by 13: ________ 
            Divide by number of items answered: ________=Fatigue 
Subscale score 
 
*For guidelines on handling missing data and scoring options, please refer to the Administration and Scoring 
Guidelines in the manual or on-line at www.facit.org. 
  
Score range: 0-52 
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Appendix 24 FACT-P and FACT-P scoring 
COMRADE FACT-P version 1 25/10/2016 STH19598 
Below is a list of statements that other people with your illness have said are 
important. Please circle or mark one number per line to indicate your 
response as it applies to the past 7 days. 
 
 
 
PHYSICAL WELL-BEING 
 
Not at 
all 
A little 
bit 
Some-
what 
Quitea 
bit 
Very 
much 
 
GP1 I have a lack of 
energy
 .......................................................  
0 1 2 3 4 
GP2 I have 
nausea
 .......................................................  
0 1 2 3 4 
GP3 Because of my physical condition, I 
have trouble meeting the needs of 
my 
family
 .......................................................  
 
0 
 
1 
 
2 
 
3 
 
4 
GP4 I have 
pain
 .......................................................  
0 1 2 3 4 
GP5 I am bothered by side effects of 
treatment
 .......................................................  
0 1 2 3 4 
GP6 I feel 
ill
 .......................................................  
0 1 2 3 4 
GP7 I am forced to spend time in 
bed
 .......................................................  
0 1 2 3 4 
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Please circle or mark one number per line to indicate your response as it 
applies to the past 7 days. 
 
 SOCIAL/FAMILY WELL-
BEING 
 
Not at 
all 
A little 
bit 
Some-
what 
Quitea 
bit 
Very 
much 
 
GS1 I feel close to my 
friends
 .......................................................  
0 1 2 3 4 
GS2 I get emotional support from my 
family
 .......................................................  
0 1 2 3 4 
GS3 I get support from my 
friends
 .......................................................  
0 1 2 3 4 
GS4 My family has accepted my 
illness
 .......................................................  
0 1 2 3 4 
GS5 I am satisfied with family 
communication about my 
illness
 .......................................................  
 
0 
 
1 
 
2 
 
3 
 
4 
GS6 I feel close to my partner (or the 
person who is my main 
support)
 .......................................................  
 
0 
 
1 
 
2 
 
3 
 
4 
Q1 Regardless of your current level of sexual 
activity, please answer the following question. 
If you prefer not to answer it, please mark this 
box           and go to the next section. 
     
GS7 I am satisfied with my sex 
life
 ......................................................................  
0 1 2 3 4 
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 EMOTIONAL WELL-
BEING 
Not at 
all 
A little 
bit 
Some-
what 
Quitea 
bit 
Very 
much 
 
GE
1 
I feel 
sad
 .................................................... 
0 1 2 3 4 
GE
2 
I am satisfied with how I am 
coping with my 
illness
 .................................................... 
0 1 2 3 4 
GE
3 
I am losing hope in the fight 
against my 
illness
 .................................................... 
0 1 2 3 4 
GE
4 
I feel 
nervous
 .................................................... 
0 1 2 3 4 
GE
5 
I worry about 
dying
 .................................................... 
0 1 2 3 4 
GE
6 
I worry that my condition will get 
worse
 .................................................... 
0 1 2 3 4 
 
 
 
 FUNCTIONAL WELL-
BEING 
 
Not at 
all 
A little 
bit 
Some-
what 
Quitea 
bit 
Very 
much 
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GF1 I am able to work (include work 
at 
home)
 ................................................... 
0 1 2 3 4 
GF2 My work (include work at home) 
is 
fulfilling
 ................................................... 
0 1 2 3 4 
GF3 I am able to enjoy 
life
 ................................................... 
0 1 2 3 4 
GF4 I have accepted my 
illness
 ................................................... 
0 1 2 3 4 
GF5 I am sleeping 
well
 ................................................... 
0 1 2 3 4 
GF6 I am enjoying the things I 
usually do for 
fun
 ................................................... 
0 1 2 3 4 
GF7 I am content with the quality of 
my life right 
now
 ................................................... 
0 1 2 3 4 
 
  
 
 
186 
 
 
Please circle or mark one number per line to indicate your response as it 
applies to the past 7 days. 
 ADDITIONAL CONCERNS 
 
Not at 
all 
A little 
bit 
Some
-what 
Quite 
a bit 
Very 
much 
 
C2 I am losing 
weight
 ........................................................  
0 1 2 3 4 
C6 I have a good 
appetite
 ........................................................  
0 1 2 3 4 
P1 I have aches and pains that bother 
me
 ........................................................  
0 1 2 3 4 
P2 I have certain parts of my body 
where I experience 
pain
 ........................................................  
0 1 2 3 4 
P3 My pain keeps me from doing 
things I want to 
do
 ........................................................  
0 1 2 3 4 
P4 I am satisfied with my present 
comfort 
level
 ........................................................  
0 1 2 3 4 
P5 I am able to feel like a 
man
 ........................................................  
0 1 2 3 4 
P6 I have trouble moving my 
bowels
 ........................................................  
0 1 2 3 4 
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P7 I have difficulty 
urinating
 ........................................................  
0 1 2 3 4 
BL2 I urinate more frequently than 
usual
 ........................................................  
0 1 2 3 4 
P8 My problems with urinating limit my 
activities
 ........................................................  
0 1 2 3 4 
BL5 I am able to have and maintain an 
erection
 ........................................................  
0 1 2 3 4 
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FACT-P Scoring Guidelines (Version 4) – Page 1 
 
Instructions:* 1. Record answers in "item response" column. If missing, mark with an X 
    2. Perform reversals as indicated, and sum individual items to obtain a score. 
3. Multiply the sum of the item scores by the number of items in the subscale, then 
divide by the   
    number of items answered.  This produces the subscale score. 
4. Add subscale scores to derive total scores (TOI, FACT-G & FACT-P).  
5. The higher the score, the better the QOL. 
 
 
Subscale    Item Code    Reverse item?       Item response         Item Score  
 
PHYSICAL GP1  4 - ________  =________ 
WELL-BEING GP2  4 - ________  =________ 
   (PWB) GP3  4 - ________  =________ 
       GP4  4 - ________  =________ 
       GP5  4 - ________  =________ 
       GP6  4 - ________  =________ 
       GP7  4 - ________  =________ 
 
              Sum individual item scores: ________   
                         Multiply by 7: ________ 
             Divide by number of items answered: ________=PWB 
subscale score 
 
SOCIAL/FAMILY GS1  0 + ________  =________ 
WELL-BEING GS2  0 + ________  =________ 
    (SWB) GS3  0 + ________  =________ 
       GS4  0 + ________  =________ 
       GS5  0 + ________  =________ 
Score range: 0-28 
Score range: 0-28 
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    GS6  0 + ________  =________ 
       GS7  0 + ________  =________ 
 
             Sum individual item scores: ________   
                        Multiply by 7: ________ 
            Divide by number of items answered: ________=SWB 
subscale score 
 
EMOTIONAL GE1 4 - ________  =________ 
WELL-BEING GE2 0 + ________  =________ 
    (EWB) GE3 4 - ________  =________ 
       GE4 4 - ________  =________ 
      GE5 4 - ________  =________  
  
 GE6 4 - ________  =________ 
 
             Sum individual item scores: ________   
                        Multiply by 6: ________ 
            Divide by number of items answered: ________=EWB 
subscale score 
 
FUNCTIONAL   GF1  0 + ________  =________ 
WELL-BEING  GF2  0 + ________  =________ 
     (FWB) GF3  0 + ________  =________ 
       GF4  0 + ________  =________ 
       GF5  0 + ________  =________ 
       GF6  0 + ________  =________ 
       GF7  0 + ________  =________ 
 
             Sum individual item scores: ________   
                        Multiply by 7: ________ 
Score range: 0-24 
Score range: 0-28 
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            Divide by number of items answered: ________=FWB 
subscale score 
 
 
 
 
FACT-P Scoring Guidelines (Version 4) – Page 2 
 
 
Subscale          Item Code       Reverse item?            Item response          Item Score  
 
PROSTATE  C2  4 - ________  =________ 
CANCER  C6  0 + ________  =________ 
SUBSCALE  P1  4 - ________  =________ 
    (PCS)   P2  4 - ________  =________ 
P3  4 - ________  =________ 
P4  0 + ________  =________ 
P5  0 + ________  =________ 
P6  4 - ________  =________ 
P7  4 - ________  =________ 
BL2  4 - ________  =________ 
P8  4 - ________  =________ 
BL5  0 + ________  =________ 
 
              Sum individual item scores:________   
                      Multiply by 12: ________ 
            Divide by number of items answered: ________=PC 
Subscale score 
 
 
To derive a FACT-P Trial Outcome Index (TOI): 
Score range: 0-104 
Score range: 0-48 
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  __________ + __________ + __________ =________=FACT-P 
TOI 
  (PWB score)   (FWB score)   (PCS score)   
 
 
To Derive a FACT-G total score: 
 
        __________ + __________ + __________ + __________=________=FACT-G Total score 
        (PWB score)    (SWB score)   (EWB score)  (FWB score) 
 
 
 
To Derive a FACT-P total score: 
 
 
              _________ + __________ + __________ + __________ + __________ =________=FACT-P 
Total score 
                            (PWB score)  (SWB score)   (EWB score)  (FWB score)   (PCS score) 
 
 
*For guidelines on handling missing data and scoring options, please refer to the Administration and 
Scoring Guidelines in the manual or on-line at www.facit.org
Score range: 0-108 
Score range: 0-156 
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Appendix 25 COMRADE Three Day Diet Diary  
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Appendix 26 The COMRADE participant focus group interview schedule 
Version 2: Patient focus group questions  
Questions 
 
 Have any of you previously taken part in any other research trials?  
[PROBE] 
- Yes: Which ones? 
- Yes: Were any of these exercise trials? 
Motivations and apprehension before taking part in the trial 
 Why did you chose to participate in the COMRADE trial what 
particularly attracted you? 
[PROBE] 
- Did you receive any support in choosing to participate in the study? 
- Did your clinician ever speak to you about exercise, or encourage you 
to participate? 
- Family/ spouse/ peers? 
 Did any of you speak to your GP/consultant about the study?  
[PROBE] 
- Yes: what did they say?  
- Yes: Did this affect your participation in the study?  
 
 What was your perception of your clinical team's involvement in the study? 
[PROBE] 
- Do you have any view or experience of your clinical team liaising with 
the research team on COMRADE? 
- Did you differentiate between the clinical team and the research team? 
- Did your clinical team discuss the trial with you, or your progress?  
 What expectations did you have of the study? 
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 What benefits did you think you might get from participation in the study, if 
any? 
 Were you apprehensive about any aspects of the trial before starting?  
[PROBE] 
- Yes: what were you apprehensive about? 
 Did you feel there might be any barriers to you taking part in the study / 
signing up for the study?  
 
Previous experience of exercise 
 Throughout life, did you consider yourself physically active? 
[PROBE] 
- What activities did you do? 
- Did anything change (post-diagnosis)? 
 Did your GP/consultant previously recommend exercise to you prior to 
hearing about the trial?  
[PROBE] 
- Yes: Did you take their advice? Why/why not?  
- Yes: what did they say? Did this affect your participation in the study?  
-  
Evaluation and acceptability of the general trial procedures 
 
 How did it feel when you were allocated the (control/intervention) arm? 
 How did you find the trial assessments? 
- Duration/content 
 How did you find the overall duration of the study? 
- What would have been your preferred duration of the study? 
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 Was the location of the study convenient for you? Did you have any issues 
with the location/parking?  
[PROBE] 
- Yes: Did this ever affect your attendance? 
 
 Did you feel there was any changes to your health during the study? 
 
Exercise Arm Participant Questions  
Acceptability of the exercise intervention  
 Did you enjoy the experience? 
[PROBE] 
- Yes: What did you like about it most of all? 
 
 How did you feel about the structure of the exercise sessions? 
 Was the intensity of the sessions OK for you?  
- Duration and frequency 
 Did you have any physical limitations (side effects of treatments/prostate 
cancer) that meant you needed to change/adapt the exercises? 
[PROBE]  
- Yes: did you feel the exercises were sufficiently adapted to suit your 
needs? 
 What encouraged you to attend the sessions each week?  
 Did anything stop any of you from attending the sessions? 
- Prostate cancer/ treatments/ comorbidity/ fitness/ age 
[PROBE] 
- Yes: Do you feel anything could have been done to help with these 
barriers either by the research team or by someone else? 
 Did you ever feel you did not want to attend?  
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[PROBE] 
- Yes: What stopped you or what made you decide to still go? 
 Was there anything else that would have helped you to attend the sessions? 
 Do you feel you had or have experienced any physical benefits from taking 
part in the exercise sessions?  
- Activities of daily living (e.g. walking further/upstairs/ less out of breath 
playing with grandkids); feeling stronger/ fitter 
 Were there any other mental wellbeing benefits? 
- Feeling more positive, getting out of the house, distraction, confidence 
 
 How did you find exercising as a group (for those that did)? 
 [PROBE]  
- Is it useful to exercise with others?  
- Do you prefer to exercise in a group or alone?  
 
 Did you have any negative experiences whilst on the trial? 
- Fatigue, was too intense, wasn't aware how hard it would be, did not 
like the environment/setting, did not like the supplements/dietary 
guidance, did not like seeing younger/fitter men OR older/more 
advanced men, should have had  more experienced staff 
(physiotherapist) 
[PROBE] 
- Did these improve at all during the trial? 
- Do you feel you received adequate support/ information from the 
research staff for this? 
 
 Did you experience any adverse effects as a result of the trial?  
- Fatigue, stiff muscles/joints 
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[PROBE] 
- Did these improve at all during the trial? 
- Do you feel you received adequate support/ information from the 
research staff for this? 
Exercise Arm Participant Questions  
Engaging with the dietary advice and supplements 
 Was the information given to you on the dietary guidance and 
supplementation enough and clear? 
- No: what could be done to improve it? 
 What was your experience with the dietary guidance given? Were you able to 
adhere to the guidance?  
- No: why? What would help you adhere? 
 What was your experience with the supplements given?  
[PROBE] 
- Do you think they helped, if so why? 
- Did you experience any adverse effects? 
- Did any of you have to reduce the dose of supplements? If you did 
why, and by how much?  
Support 
 Do you feel you were adequately supported by the research team during the 
trial? 
[PROBE] 
- No: What could the staff have done to better support you?  
- Yes: What did they do specifically to support your needs? 
 Did you feel you had sufficient contact with the research team? 
 Did you develop good rapport with the research team?  
 [Intervention participants] Over time do you think you needed less help 
from the research team?  
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 [Intervention participants] How is it useful to have a staff member always 
there?  
- reassurance, company, motivation, safety, adaptations 
 Do you think if you were asked to exercise at home - that would work for you?  
 [PROBE] 
- Yes: Do you feel that is because you have become more confident to 
exercise independently since the trial? Do you feel it could be as 
effective as exercising in a supervised format? 
- No: What do you feel may help you to exercise independently? 
Present experience of exercise 
 Would you say you are physically active now? 
 Who of you have continued with exercise since completing the trial?/ Do you 
feel like you can continue with exercise since the trial? 
 Have any of you had previous experience within a gym environment? (before 
or after the trial) 
[PROBE]  
- [intervention participants] Yes: How do you feel COMRADE 
compares to your previous experience with gyms? 
- No: How do you feel now with using a commercial gym since 
completing the intervention? Has anything changed? 
 How comfortable would you feel participating in exercise unsupervised or 
exercising with supervision? Do you have a preference? 
Other Comments 
 Do any of you have any recommendations for the design of future exercise 
studies? 
 Is there anything else that you have not had chance to discuss relating to the 
trial that any of you would like to tell me about? 
Thank you for your time 
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Appendix 27 Focus groups initial codes  
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Appendix 28 Charting for the focus group analysis 
